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Abstract 
Background: Psychiatric  disorders  are  common  in  patients  with  autoimmune 
diseases such as rheumatoid arthritis. These disorders are poorly understood and 
are an important co morbidity. They may occur as a consequence of the effects 
of  the  autoimmune  inflammation  on  the  central  nervous  system.  Peripheral 
inflammation  inducing  central  cytokine  production  in  the  CNS  has  been 
documented in acute inflammatory models such as after systemic LPS challenge, 
and cytokine administration has been shown to induce cognitive impairment and 
mood disorders. These disorders may be due to the central action of cytokines 
on neurogenesis and reduced hippocampal neurogenesis has been implicated in 
depression  and  cognitive  decline.  Peripheral  inflammation  and  some  specific 
cytokines have been reported to inhibit hippocampal neurogenesis, resulting in 
cognition impairment and depressive like behaviour in animal models.  
Hypothesis:  Based  on  this  evidence,  we  hypothesized  that  peripheral 
inflammation  associated  with  arthritis  can  induce  central  production  of 
inflammatory mediators in the brain contributing to reduction in hippocampal 
neurogenesis thereby offering a mechanism and potential therapeutic targets for 
RA associated psychiatric disorders.  
Aims  and  Methods:  The  aim  of  this  project  is  1)  to  investigate  whether 
peripheral immune/inflammatory responses during arthritis can induce changes 
in  inflammatory  mediators  in  brains  of  collagen  induced  arthritis  (CIA)  mice, 
using  this  as  a  model  for  an  adaptive  immune  response  contributing  to 
neurological  disease  development  similar  to  the  human  disease.  We  used 
Luminex bead based screening assays to determine a wide range of inflammatory 
mediator  proteins  in single  small  volume  samples  obtained  from  mouse  brain 
tissues.  In  the  same tissues,  the  transcription  levels  of  genes encoding  these 
inflammatory mediators were also quantified using real time PCR and quantified 
as  absolute  copy  numbers.  2)  To  investigate  whether  peripheral 
immune/inflammatory  responses  during  arthritis  can  induce  changes  in 
hippocampal neurogenesis in brains of collagen induced arthritis (CIA) mice, we 
also measure changes in hippocampal neurogenesis in CII immunized mice using 
the immunohistochemistry of neuronal marker doublecortin (DCX). In order to 
confirm  that  changes  in  both  inflammatory  mediators  and  hippocampal 3 
neurogenesis  were  due  to  peripheral  inflammation,  CII  immunized  mice  were 
given  peripheral  anti  TNF α  etanercept  treatment.  Inflammatory  mediator 
profiles  and  hippocampal  neurogenesis  in  brains  of  etanercept treated  CII 
immunized mice were compared to PBS  treated CII immunized mice and naive 
control mice. 
Results:  Systemic  etanercept  treatment  attenuated  arthritis  in  CII 
immunized  mice.  IL 1β,  IL 5,  CXCL1  and  FGF2  protein  were  increased  in  the 
serum of CII immunized mice. In addition, we found up regulation of protein and 
gene concentrations of IL 1β, IL 1 α, TNF α, IL 6, IFN γ, IL 2, IL 12, IL 4, IL 5, 
CXCL1,  CXCL0  and  CCL2,  VEGF  and  FGF2  in  brains  of  CII  immunized  mice 
compared  to  those  in  naive  control  mice.  The  reduction  in  number  of  DCX 
positive neurons in the dentate gurus of CII immunized mice compared to those 
in naive control mice, suggesting the impairment in hippocampus neurogenesis in 
CII immunized mice. In addition, reduction of inflammatory mediators, including 
IL 1β,  TNF α,  IL 12,  CXCL1,  and  increases  of  IL 6,  IL 2  and  VEGF  and  FGF2 
protein  concentrations  were  observed  in  brains  of  etanercept treated  CII 
immunized  mice  compared  to  those  in  untreated  CII  immunized  mice.  In 
addition,  the  impairment  in  hippocampal  neurogenesis  was  reversed  by 
peripheral etanercept treatment in CII immunized mice. In conclusion, the data 
of  this  thesis  shows  that  peripheral  inflammation  during  arthritis  potentially 
induces production of inflammatory mediators in brains of CII immunized mice. 
Up regulation of these inflammatory mediators in the brain may be associated 
with  the  impairment  in  hippocampal  neurogenesis  of  CII  immunized  mice.  In 
addition,  peripheral  etanercept  treatment  seems  to  have  protective  effect 
against  peripheral induced  brain  inflammation  and  the  impairment  in 
hippocampal neurogenesis in CII immunized mice.  
In  summary,  we  demonstrated  that  peripheral  inflammation  resulting  from 
arthritis  may induce brain inflammation and contribute to the  impairment  of 
hippocampal neurogenesis. Systemic etanercept treatment not only attenuated 
joint  inflammation,  but  also  reduced  brain  inflammation  and  reversed  the 
impairment in hippocampal neurogenesis resulting from peripheral inflammation 
in CII immunized mice. 4 
Conclusion and prospect: These data provide an important new insight into a 
potential  mechanism  underlying  psychiatric  disorders  in  chronic  inflammatory 
disease. We suggest that when considering management of chronic disorders, the 
potential physiological effects on the brain should also be considered. This may 
be  difficult  to  quantify  for  example  when  assessing  reduced  hippocampal 
neurogenesis.  Therefore  we  propose  some  experimental  studies  that  could 
follow from this thesis might include a search for a systemic biomarker such as 
BDNF that might provide information of CNS changes, perhaps by a comparative 
transcriptional analysis of normal and inflamed brain. The experimental model in 
our study did not include a cognitive or memory end point as an index of brain 
function,  and  this  aspect  could  also  be  included  in  future  experiments  to 
complete the link from systemic inflammation to psychological changes. We also 
noted that there may be neurological changes that occur in immunized mice that 
do not yet show signs of arthritis, and if so perhaps depression may occasionally 
reflect a pre clinical chronic condition.  
However, we feel we have provided sufficient evidence that there is a 
strong  link  between  systemic  inflammation  with  physiological  changes  in  the 
brain  that  might  suggest  that  therapeutic  choices  for  RA  could  reduce 
inflammation as well as attenuate depression associated with arthritis. 
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Introduction Chapter 1    28 
 
1.1  Immune system 
1.1.1  Overview of immune system 
The  immune  system  is  a  complex  network  of  cells  and  molecules  that  has  a 
fundamental role in homeostasis and in defending against infection and cancer. 
The  immune  system  can  be  functionally  divided  into  two  categories,  namely 
innate  immunity  and  adaptive  immunity,  which  usually  work  together  to 
eliminate pathogens (Delves and Roitt, 2000a). Innate immunity is the first line 
of  nonspecific  immune  defence,  which  involves  phagocytic  cells,  including 
macrophages, neutrophils, basophils, mast cells, eosinophils, and natural killer 
(NK) cells. These cells bind to invading microorganisms using pattern recognized 
receptors  (PRRs),  which  recognize  a  large  number  of  molecules  that  share  a 
common  structural  motif  or  pattern  (Medzhitov,  2007).  There  are  two  main 
families of PRRs, which are the toll like receptors (TLRs) and the neucleotide 
binding  oligomerization  domains  (NODs)  (Martinon  and  Tschopp,  2005).  The 
ligands  of  PPRs  on  phagocytes  are  pathogen associated  molecular  patterns 
(PAMPs), which are usually conserved microbial structures with repeat sugar or 
amino acid  motifs  that  do  not  occur  on  mammalian  cells.  Constituents  of 
bacterial walls, including lipopolysaccharide (LPS), peptidoglycan, lipoteichoic 
acids and cell wall lipoproteins are common bacterial PAMPs (Medzhitov, 2007). 
Phagocytes  internalize  and  destroy  pathogens  by  the  process  including 
phagocytosis followed by fusion of the phagosome with a lysosome containing 
proteolytic  enzyme  resulting  in  microbial lysis.  The  molecular  components  of 
innate  immunity  include  complement,  acute phase  proteins  and  cytokines 
including interferon (Medzhitov and Janeway, 2000).  
Adaptive immunity, by contrast, is a highly specific response that can recognise 
any antigenic epitopes on a particular pathogen. The adaptive immune response 
involves antigen recognition by lymphocytes, which are T cells and B cells. The 
main subsets of T cells function either as effector or cytotoxic T (Tc) cells that 
directly attack the pathogens, or as helper T (Th) cells that enhance immune 
response.  B cells function mainly to produce antibodies that are stimulated by, 
are  conditioned  by  and  can  bind  to  antigens.  When  antibodies  bind  to  a 
pathogen, the antibody can cause the activation of the complement system and Chapter 1    29 
assist phagocytosis by innate cells to internalize the pathogen and destroy this 
by enzyme lysis. Both T cells and B cells originate from pluripotent stem cells in 
the fetal liver and in the bone marrow. The bone marrow resident stem cells 
develop to be B cells, while those that travel to the thymus develop into T cells 
(Delves and Roitt, 2000b).  
The  activation  and  the  proliferation  of  antigen specific  T  and  B  cells  (clonal 
expansion) occur in the secondary lymphoid tissues such as lymph nodes, spleen, 
and  mucosa associated  lymphoid  tissue.  B  cells  migrate  to  germinal  centre, 
where B cells hyper mutate the variable region of their immunoglobulin genes 
and undergo class switching, leading to the production of diversity of specific 
antibodies. Each B cell has a unique antigen receptor, called the B cell receptor 
(BCR), which is activated by its specific antigen in the context of an antigen 
presenting cell. This leads to a differentiation and maturation of B cells into 
plasma cells that secrete specific antibodies with the same specificity as their 
antigen receptor (Kuppers, 2005) . 
The clonal expansion of T cells occurs in the peri arteriolar lymphoid sheaths of 
the lymph node (Delves and Roitt, 2000b).  The professional antigen presenting 
cells (APCs), including dendritic cells, B cells and macrophages present antigen 
to naïve T cells in the context of the major histocompatibility complex (MHC) 
(Carter,  2000).  B  cells  present  antigens  to  T  cells  via  their  membrane bound 
antibodies,  while  dendritic  cells  and  macrophages  pinocytose  antigens  and 
process  them  internally  by  combining  antigen  fragments  into  an  assembling 
major histo compatibility complex (MHC) and present to T cells in that context. 
These APC cells, particularly dendritic cells, express co stimulatory molecules 
such  as  CD28  (the  B7  ligand),  CD154  (the  CD40  ligand),  and  CD2  (the  CD58 
ligand).  These  co stimulatory  molecules  that  bind  to  the  appropriate  ligands 
expressed  on  T  cells  generate  signals  that  are  essential  for  T  cell  activation 
(Delves and Roitt, 2000b). T cells express T cell receptors (TCRs) that recognize 
specific  antigen.  T  cell  antigen  recognition,  in  the  context  of  the  MHC 
presentation, results in clonal proliferation of T cells expressing the same TCR 
that target the specific antigen. T cells expressing the CD4 molecule recognize 
antigens presented by MHC class II, and usually act as helper T cells. CD4 T cells 
can be divided in 2 major types (Mosmann and Sad, 1996). Type 1 (Th1) helper T 
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macrophages  by  producing  cytokines  such  as  interleukin 2,  interferon  gamma 
(IFNγ). Type 2 (Th2) helper T cells function to help B cell differentiation and the 
production of antibodies by releasing growth and differentiation cytokines such 
as interleukin 4 (IL 4), interleukin 5 (IL 5), interleukin 6 (IL 6), and interleukin 
(IL 10).  There  are  further  subdivisions  of  T  helper  cell  subsets  characterised 
largely by the function of the characteristic cytokine they produce, for example 
Th 17 cells produce interleukin 17 (IL 17) that promotes autoimmunity.  T cells 
expressing  CD8  molecule  recognize  antigens  presented  by  MHC  class  I,  and 
usually  function  as  cytotoxic  killer  T  cells.  CD8
+  cytotoxic  T  (Tc) cells  that 
recognize and directly bind and destroy cells that are infected with viruses, and 
CD3/56/16
+  NKT cells  that  recognise  conserved  microbial  and  cancer related 
glycolipid structures presented in the context of CD1 (Delves and Roitt, 2000b).  
Antigen presentation to naïve lymphocytes during the primary immune response 
also generates memory T and B cells, which are characterized by the expression 
of CD45RO on their cell surface. After a subsequent encounter with the same 
antigen,  the  secondary  immune  response  initiated  by  memory  lymphocytes  is 
more  rapid  than  the  primary  immune  response.  In  addition,  the  secondary 
immune response is quantitatively and qualitatively more sophisticated than the 
primary  immune  response.  For  example,  memory  lymphocytes  enhance 
proliferation of specific T cells in larger numbers, and B cells to produced higher 
concentrations  and  producing  higher  affinity  antibodies  during  the  secondary 
immune response compared to those in the primary immune response (Parkin 
and Cohen, 2001).  
1.1.2   Cytokines 
 
Cytokines  are  a  group  of  small  peptides  that  are  responsible  for  the 
communication between cells of the immune system. Cytokines are secreted by 
all cell types, especially lymphocytes and monocytes/macrophages, for example 
in response to pathogens (Marshall, 1992), and are recognised by cells that have 
cell membrane receptors for that cytokine in order to respond. Cytokines are 
structurally  varied,  but  may  share  several  characteristics.  For  example,  the 
same  cytokine  may  be  generated  from  various  cell  types,  and  have  differing 
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isolation.  They  tend  to  work  in  networks  and  can  function  synergistically  or 
antagonistically,  which  regulate  positively  and  negatively  other  cytokine 
production or function. Most cytokines function locally in the tissue where they 
were produced, either affecting the function of the cell type that produced it 
(autocrine  action),  or  binds  to  its  receptor  in  nearby  cells  and  affects  their 
function (paracrine action). In addition, each set of immune cells synthesise a 
particular group of cytokines, depending on the type of cell and whether, and 
how,  it  has  been  stimulated  (Tayal  and  Kalra,  2008).  Pro inflammatory 
cytokines,  including  interleukin  1beta  (IL 1β),  interleukin  6  (IL 6),  tumour 
necrosis factor   alpha (TNF α), are produced from mononuclear cells such as 
macrophages in response to infection, inflammation and tissue damage (Haddad, 
2002). TNF α is one of the most potent cytokines because it up regulates other 
cytokines, such as IL 1, IL 6, and some chemokines which can direct the cellular 
and  behavioural  signs  of  infection  and  inflammation,  including  fever  and 
increasing the serum acute phase protein concentrations. TNF α also stimulates 
the cell surface expression of the major histocompatibility antigens.  
The TNF α receptor consists of two cell surface receptor proteins (p55, p75). 
This receptor complex can be shed from the cells surface and in this soluble 
form can bind TNF α and prevent its inflammatory function. This observation has 
been developed for translational purposes, and the use of a recombinant form of 
the  soluble  tumour  necrosis  factor  receptor  as  a  TNF α  antagonist  is  now  an 
effective  therapeutic  for  autoimmune  disease  such  as  rheumatoid  arthritis 
(O'Shea et al., 2002).  
Cytokines  produced  from  lymphocytes  are  sometimes  called  lymphokines. 
They  are  non immunoglobulin  polypeptide  substance  produced  by  T  cells  and 
natural  killer  cells  that  regulate  the  functions  of  other  cells.  Lymphokines, 
including  IL 2,  interferon gamma  (IFN γ),  interleukin 12  (IL 12)  and  tumor 
necrosis  factor  beta  (TNF β)  are  produced  from  Th1  cells  (Tayal  and  Kalra, 
2008). IFN α is produced by phagocytes (monocyte and granulocyte), while IFN β 
is  produced  mainly  by  stromal  cells  fibroblasts  and  epithelial  cells.  IFNs  are 
produced in response to viral infection and function to inhibit viral replication 
and destroy cancer cells. IFNs, particularly interferon alpha (IFN α), are used 
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Th2 cells produce IL 4, IL 5, IL 6, IL 10, and IL 13, and the production of these 
Th2 cytokines is inhibited by Th1 cytokines such as IL 12 and IFN γ. IL 4 and IL 
10 promote humoral immunity by stimulating the growth and activation of mast 
cells and eosinophils, and the differentiation of B cells into antibody secreting B 
cells. In addition, IL 4 and IL 10 are considered to be major anti inflammatory 
cytokines since they inhibit macrophage activation, T cell proliferation and the 
production of pro inflammatory cytokines (Opal and DePalo, 2000).  
1.1.3  Chemokines 
 
Chemokines are a large family of structurally homologous cytokines that regulate 
trafficking of various types of leukocytes from the blood to tissue by recognition 
of a concentration gradient. They are small (8–10 kDa) secreted proteins that are 
divided into four groups, namely XC, CC, CXC and CX3C, based on the number 
and  location  of  the  two  N terminal  cysteine  residues  (Fernandez  and  Lolis, 
2002).  There  are  approximately  50  chemokines  recently  identified  and  all  of 
them can regulate leukocyte migration. Leukocytes are the major source of CC 
and CXC chemokines, but these are also produced by various cell types, such as 
endothelial  cells,  epithelial  cells,  and  fibroblasts.  Various  CC  chemokines  are 
also  produced  by  antigen  activated  T  cells,  acting  as  a  connection  between 
adaptive immunity and recruitment of inflammatory leukocytes (Slettenaar and 
Wilson,  2006).  Chemokine  production  is  mainly  induced  by  pro inflammatory 
cytokines IL 1, IL 2, TNF α, γ interferon and the bacterial product LPS, while 
TGF β,  IL 4,  IL 10  can  inhibit  chemokine  production  (Rottman,  1999a). 
Chemokines  are divided  functionally  into two  major  categories;  housekeeping 
chemokines and inflammatory chemokines. Housekeeping chemokines, including 
CCL25,  CCL17,  CCL  27,  CCL19,  CCL21  and  CXCL12,  are  homeostatic  and 
constitutively  produced  and  secreted.  They  regulate  the  trafficking  of 
lymphocytes and dendritic cells to the lymphoid tissues (Graham, 2009). They 
also function to co localize B and T cells with antigen on the surface of antigen 
presenting  cells  in  the  lymphatic  system  (Fernandez  and  Lolis,  2002). 
Inflammatory chemokines, including CCL1, CCL2, CCL3, CCL4, CCL5 and CXCL1, 
CXCL2,  CXCL3,  CXCL4,  CXCL5,  CXCL6,  CXCL7,  CXCL8,  CXCL9,  CXCL10  and 
CXCL11, are produced by various cells in response to inflammatory stimuli and 
induce  the  migration  of  leukocytes  to  these  sites  of  inflammation.  In  the Chapter 1    33 
inflammatory  process,  CXCL1,  CXCL2,  CXCL3,  CXCL4,  CXCL5,  CXCL6,  CXCL7, 
CXCL8  regulates  neutrophil  trafficking  and  CXCL9,  CXCL10,  CXCL11  regulate 
activated T cell trafficking (Graham, 2009). The CC chemokines function mainly 
on monocytes, macrophages, lymphocytes, and eosinophils (Adams and Lloyd, 
1997).  Chemokines function by interacting with chemokine receptors containing 
seven transmembrane  α helical  domains,  which  belongs  to  the  family  of  G 
protein  couple  receptors  (GPCRs).  These  consist  of  single  polypeptide  chains 
with three extracellular and three intracellular loops, an acidic amino terminal 
domain  involved  in  ligand  binding,  and  a  serine/threonine rich  intracellular 
carboxy  terminal  domain  (Mantovani  et  al.,  2006).  The  amino  acid  sequence 
DRYLAIV  in  the  second  intracellular  loop  domain  is  the  unique  structure 
characteristic  of  chemokine  receptors  (Rottman,  1999b).  Ten  signalling 
receptors for the CC chemokines (CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, 
CCR8, CCR9, CCR10), seven CXCR chemokine receptors (CXCR1, CXCR2, CXCR3, 
CXCR4, CXCR5, CXCR6, CXCR7) and single receptor for XC and CX3C families are 
identified so far (Graham, 2009). Multiple chemokine ligands can bind to the 
same receptor. For instance, CCR1 is able to bind ten ligands with high affinity, 
while CCR3 has fifteen specific ligands (Rottman, 1999b). There is another group 
of chemokine receptors called silent chemokine receptors, which do not induce 
signal transduction due to alterations in the canonical DRYLAIV motif found in 
the second intracellular loop of the signalling chemokine receptor. The group of 
silent  receptors  are  Duffy  antigen  receptor  for  chemokines  (DARC),  D6  (or 
CCBP2),  CCX CKR  (or  CCRL1)  regulate  inflammatory  and  immune  response  by 
various  mechanisms,  including  acting  as  decoy  receptors  and  as  scavenger 
receptors (Graham, 2009); (Heinzel et al., 2007). For example, the D6 receptor 
has  a  role  in  the  resolution  of  inflammation  by  binding  chemokines  that  are 
expressed only in response to inflammatory stimuli (Mantovani et al., 2006). 
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1.2  Rheumatoid Arthritis  
Rheumatoid  Arthritis  (RA)  is  a  systemic  chronic  inflammatory  disease 
characterized  by  joint  pain,  stiffness,  and  swelling.  There  are  associated 
remodelling  changes  including  pannus  formation  and  destruction  of  cartilage, 
bone  and  associated  soft  tissue  (Klareskog  et  al.,  2009).  These  pathological 
features  eventually  lead  to  disability.  The  annual  incidence  of  RA  has  been 
reported to be around 20 to 50 cases per 100,000 of the population. Women are 
affected up to three times as often as men (Tobon et al., 2010). The immuno 
pathogenesis of RA is complex and appears to involve  primarily auto immune 
mechanisms.    IgM,  IgA  and  IgG  subclasses  1 4  anti citrullinated  protein 
antibodies (ACPA), anti keratin antibodies (AKA), anti perinuclear factor (APF) 
and anti RA33 antibodies are elevated in the serum of RA patients, and their 
titres have also been associated with severity of the disease. These rheumatoid 
factors and auto antibodies can also be used to predict the development of RA in 
early arthritis (Lin and Li, 2010); (Agrawal et al., 2007); (Nell et al., 2005). The 
major component of the RA pannus is hypertrophic synovial membrane, which 
consists of hyperproliferation of Type A synoviocytes (macrophage like synovial 
cells) and Type B synoviocytes (fibroblasts like synoviocytes) along with immune 
cells that infiltrate the synovial membrane. T cells can constitute up to 50 % of 
cells in RA synovial and most of these are CD4
+ CD45RO
+ memory T cells. Only 5% 
or fewer are B lymphocytes or plasma cells. Rheumatoid factors, ACPA and anti 
collagen antibody are also found in synovial tissue (Bartok and Firestein, 2010). 
RA is considered as a non organ specific autoimmune disease. This is because 
subcutaneous nodules, vasculitis, pulmonary fibrosis are common complication 
of RA (Williams, 2006). 
1.2.1  Aetiology of RA 
The aetiology of RA remains undefined. Both genetic factors and environmental 
factors contribute to the cause of the disease.  
A major risk factor that links genetic susceptibility and RA is the association of 
the disease with an antigenic epitope in the HLA DR ß chain that is shared with 
microbial  antigens.  This  shared  epitope  is  a  highly  conserved  amino  acid 
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with severe RA. It is located in the third hypervariable region of DR4, DR14 and 
DR1 ß chains that are expressed on macrophages, B cells and antigen presenting 
cells. The 65 kD heat shock protein from Mycobacterium tuberculosis and 40kd 
Escherichia coli dnaJ, and Epstein Barr virus (EBV) gp110 also contain the shared 
epitope (QKRAA) on DRß1*0401 (Albert and Inman, 1999); (Toussirot and Roudier, 
2008). The RA associated HLA alleles are members of HLA DRB1*0404 group (e.g. 
*0401,*0404, *0405,*0408, HLA DRB1*0101, HLA DRB1*0102, HLA DRB1*1402 and 
HLA DRB1*1001 (Holoshitz, 2010).  
Several  genetic  polymorphisms  associated  with  RA  have  been  identified  by 
genome wide  association  (GWA)  studies.  Several  population  studies  have 
demonstrated an association between a missense SNP in the PTPN22 gene, which 
encodes  a  phosphatase  involved  in  intracellular  T  cell  signalling,  with  an 
increased risk and rate of progression of RA (Lie et al., 2007, Begovich et al., 
2004).  In  addition,  other  genetic  polymorphisms  of  various  cytokine  and 
cytokine receptor genes, such as those encoding TNF, IL 1, IL 10 and IL 18, have 
been  studied  intensively  in  RA.  For  example,  a  -857C/T  SNP  at  the  TNFA 
promoter has been associated with RA and with better responses to etanercept 
(recombinant human soluble TNF receptor) therapy (Kang et al., 2005). 
A  strong  association  between  cigarette  smoking  and  the  presence  of  HLA 
DBR1*0404 or other HLA alleles comprising the shared epitope has been reported 
for  the  ACPA positive  group  of  RA  patients.  One  epidemiological  study 
demonstrated that the relative risk of developing RA was increased 20 fold in 
the  ACPA positive  group  of  RA  patients  who  had  two  alleles  for  the  shared 
epitope and had ever smoked cigarettes (Klareskog et al., 2006).  It is possible 
that smoking can induce citrullination in certain proteins in the lungs. These 
citrullinated proteins activate the immune response by binding specifically to 
HLA DR  molecules  comprising  the  shared  epitope  on  antigen presenting  cells, 
which  eventually  result  in  the  production  of  ACPA.  These  antibodies  to 
citrullinated  protein  can  contribute  to  the  development  of  RA  in  the  joint 
(Klareskog et al., 2009). 
A twin study in heritability demonstrated that the genetic contribution to RA 
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environmental  factors,  such  as  smoking,  are  also  major  contributors  to  RA 
(MacGregor  et  al.,  2000).  In  addition,  several  viral  and  bacterial  infections, 
including the Epstein Barr virus (EBV), parvovirus and lentiviruses, and bacteria 
including Mycoplasma, Mycobacteria and Yersinia species, can be risk factors for 
the development of RA. Other environmental factors including breast feeding, 
oral  contraceptives  use,  or  regular  alcohol  consumption  may  be  protective 
against the development of RA (Liao et al., 2009).  
1.2.2  Pathogenesis of RA 
The activation of T lymphocytes, particularly the CD4
+ helper Th1 subset, is part 
of the initiation of the destructive immune response in RA (McInnes and Schett, 
2007). These cells infiltrate the synovial membrane and are activated by antigen 
presenting cells (e.g. dendritic cells and B cells). Along with antigen presented 
in  the  context  of  MHC,  additional  co stimulation,  such  as  CD28–B7  receptor 
family (CD80/86), is necessary for T cell activation. Activated Th1 cells produce 
cytokines  including  IL 2,  IFNγ  and  TNF α.  These  Th1  cytokines  stimulate 
monocytes, macrophages, and synovial fibroblasts to produce IL 1, IL 6 and TNF 
α  and  to  secrete  matrix  metalloproteinases  (MMPs).  Activated  Th1  cells  also 
stimulate  B  cells,  via  CD40  ligand  mediated  co stimulation,  to  produce 
rheumatoid factor and auto antibodies.  Immune complexes, formed by auto 
antibodies,  induces  macrophage  to  produce  TNF α  by  complement  activation 
(Klareskog  et  al.,  2009).  These  activated  macrophages,  lymphocytes  and 
fibroblasts can also stimulate angiogenesis by activating synovial cells to produce 
angiogenic  factors,  such  as  macrophage  angiogenic  factor  (MAF),  vascular 
endothelial  growth  factor  (VEGF),  prostaglandins  E1  and  E2,  IL 8  and 
angiopoietin 1 (Szekanecz et al., 2009). Endothelial cells in the synovium are 
activated  and  adhesion  molecules  such  as  intercellular  adhesion  molecule 1 
(ICAM 1), vascular cell adhesion molecule 1 (VCAM 1), P selectin, and E selectin, 
are  upregulated  to  promote  the  recruitment  of  immune  cells  into  the  joint. 
Activated Th1 cells and synoviocytes also produce receptor activator of nuclear 
factor kB  ligand  (RANKL)  and  macrophage  colony stimulating  factor  (M CSF). 
These two cytokines promote the differentiation of osteoclast precursors (OCPs) 
into mature osteoclasts that have bone resorbing activity. RANKL expression is 
also regulated by TNF α, IL 1β, IL 6 and IL 17. The activity of RANKL is inhibited 
by osteoprotegerin (OPG), a soluble decoy receptor that belongs to the TNF Chapter 1    37 
receptor superfamily. TNF α and IL 1β also induce chondrocytes and fibroblasts 
to  produce  a  disintegrin  and  metalloproteinase  with  thrombospondin  motifs 
(ADAMTS) and MMPs, which degrade proteoglycan and collagen in the cartilage 
(McInnes and Schett, 2007). 
1.2.3    Roles of cytokines in RA 
1.2.3.1  Roles of pro inflammatory cytokines in RA 
Cytokines play major roles at each stage of the pathogenesis of RA by regulating 
autoimmunity,  chronic  inflammatory  synovitis  and  the  destruction  of  joint 
tissue. Several cytokines, including granulocyte macrophage colony stimulating 
factor (GM CSF), IL 1, IL 6, IL 2, IL 12, IL 15, IL 13, IL 17, IL 18, IFNγ, TNFα, and 
TGF β interact in a complex network contributing to RA pathogenesis (McInnes 
and Schett, 2007). TNF α, IL 1 and IL 6 are considered as principle cytokines 
that regulates each stage of the pathogenesis of RA. Antibodies against these 
cytokines, especially TNF α and their receptor antagonists are major therapeutic 
targets for RA drug development (Seymour et al., 2001). TNF α (Cope et al., 
1992), IL 1 (Wood et al., 1983) and IL 6 (Waage et al., 1989) and their receptors 
are highly expressed in the inflamed synovial membrane tissue in RA patients 
and  synovial  macrophages  are  the  major  source  of  these  pro inflammatory 
cytokines (Brennan and McInnes, 2008). TNF α is a pro inflammatory cytokine 
that is highly expressed on macrophages and T cells. TNF α acts by binding to 
TNF receptors, namely TNFRI (p55) and TNFRII (p75) (H. E. Seymour 2001). There 
are also soluble forms of TNFR that function to modulate inflammatory response 
by inhibiting TNF α activity. These soluble forms of TNFRs, including p75 have 
been developed to be efficient therapy for arthritis such as etanercept or anti 
TNF α; Infliximab (Seymour et al., 2001). TNF α initiates the immune response 
by inducing the production of other pro inflammatory cytokines, including IL 1β, 
IL 6,  IL 23  and  GM CSF  from  antigen  presenting  cells.  IL 1β  also  has  been 
implicated  in  pathological  mechanism  of  RA  (Abramson  and  Amin,  2002), 
although so far to date it has not been well developed as powerful treatment for 
RA (Brennan and McInnes, 2008).  There are 2 distinct IL 1 receptors, namely 
type I and type II (Sims et al., 1988). Type I IL 1R is expressed predominately on 
T cells and fibroblasts, while Type II IL 1R is expressed on activated T cells, B 
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synergistic  effects  on  the  process  of  inflammatory  joint  destruction  of  RA. 
However, TNF α seems to play the main role in synovial Inflammation, while IL 
1β seems to regulate mainly bone erosion and cartilage damage (Zwerina et al., 
2007). IL 6 is produced by fibroblasts, activated T cells, activated monocytes or 
macrophages  and  endothelial  cells  (Van  Snick,  1990).  IL 6  signals  via  IL 6 
receptor, which is a complex of receptor subunits and two signal transducing 
gp130  subunits  (Jones  et  al.,  2006).  IL 6  can  regulate  the  humoral  immune 
response by activating B cell maturation and the production of auto antibodies 
(Dayer and Choy, 2010). In addition, IL 6 also enhances the acute phase response 
during inflammation by stimulating production of the full range of acute phase 
proteins in hepatocytes (Dayer and Choy, 2010). In addition, IL 6 also contributes 
to other inflammatory pathways of RA including osteoclast activation, pannus 
formation, and mediating chronic synovitis (Dayer and Choy, 2010). IL 1β, TNF α 
and  IL 6  share  many  similar  activities  and  have  synergic  effects  on  several 
pathological  pathways  of  RA,  including  the  ability  to  enhance  cytokine 
production, proliferation of T calls and B cells, and MMP production by synovial 
cells and chondrocytes. They also enhance the leukocyte recruitment process by 
activating  the  production  of  chemokines,  including  CCL5,  CCL2,  CCL8,  and 
CCL12,  together  with  adhesion  molecules  such  as  E selectin  and  VCAM 1  on 
endothelium (Brennan and McInnes, 2008).  
1.2.3.2  Roles of T cell derived cytokines in RA 
Cytokines of T helper subsets play crucial roles in the regulation of the adaptive 
immune  responses  and  the  immuno pathology  of  rheumatoid  arthritis.  CD4
+T 
cells  are  divided  on  the  basis  of  cytokine  secretion  patterns  and  effector 
functions into 2 distinct CD4+T cells subset, namely Th1 and Th2 cells. Th1 (IL 2, 
IFN γ  and  IL 12)  cytokines  mediate  macrophage dependent  inflammation  and 
delayed type  hypersensitivity  reactions  (Schulze Koops  and  Kalden,  2001), 
whereas Th2 (IL 4, IL 5, IL 10, IL 13) cytokines play important roles in antibody 
mediated  allergic  reactions  and  macrophage  deactivation  (Kozanidou  et  al., 
2005); (Xu et al., 2008). 
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1.2.3.2.1   Role of Th1 cell cytokines in RA 
The  chronically  inflamed  RA  synovial  membrane  is  characterized  by  an 
accumulation  of  infiltrating  CD4
+T  cells,  which  are  predominately  of  the  Th1 
phenotype  (Dolhain  et  al.,  1996).  These  Th1  cells  and  effector  cytokines, 
including IL 2, IL 12 and IFN γ produced by these Th1 cells are thought to play a 
pathogenic role in the immunopathology of RA. IL 2, IL 12 and IFN γ were found 
to be highly expressed in synovial fluid, synovial tissue and peripheral blood of 
RA patients (Berner et al., 2000); (Canete et al., 2000); (Morita et al., 1998). IL 
2, IL 12 and IFN γ are considered as important regulatory cytokines for different 
stages of the pathogenesis of RA. IFN γ produced mainly by activated T cells and 
NK cells is considered to be a major effector Th1 cytokine (Farrar and Schreiber, 
1993). IFN γ and its IFN γ receptor are known to function as a pro inflammatory 
cytokine  complex  in  RA  (Tsuda  et  al.,  2009).  IFN γ  activates  macrophages 
(Nathan  et  al.,  1983),  enhancing  the  ability  of  antigen  presentation  via  up 
regulation of MHC class II expression in various cell types (Jahn et al., 1987). In 
addition,  IFN γ  also  promotes  the  production  of  IgG2a  in  mouse  and  IgG1  in 
human,  which  are  involved  in  antibody dependent  cell  cytotoxicity  (Schulze 
Koops and Kalden, 2001); (Finkelman et al., 1988).  
IL 2  acts  via  the  IL 2  receptor  (CD25,  IL 2R)  and  has  a  major  role  in  clonal 
expansion of antigen primed T cells (Schroeter and Jander, 2005). However, IL 2 
has also been reported to activate apoptosis of antigen activated T cells in IL 2 
deficient mice. This suggests that IL 2 also functions as a regulator of immune 
homeostasis following antigen clearance (Refaeli et al., 1998). The actual role of 
IL 2 in arthritis has not been well elucidated. Studies in experimental arthritis 
demonstrated  that  IL 2  could  have  both  direct  pro inflammatory  effects  and 
indirect anti inflammatory effects mediated by IFN γ on the severity of arthritis 
disease (Thornton et al., 2000).  
IL 12 is a 70 kd disulfide linked heterodimeric cytokine comprising p40 and p35 
chains  that  produced  mainly  by  macrophage lineage  cells  and  dendritic  cells 
(Malfait et al., 1998). IL 12 binds with IL 12 receptors consisting of 2 subunits 
designed IL 12β1 and IL 12β2 (Presky et al., 1996). IL 12 has a vital role in cell 
mediated immunity by inducing differentiation of T cell precursors into the Th1 
phenotype  (Malfait  et  al.,  1998).  In  addition,  IL 12  also  stimulates  the Chapter 1    40 
proliferation of activated T and NK cells and the production of IFN  γ by both T 
and  NK  cells  (O'Garra  and  Arai,  2000).    However,  the  role  of  IL 12  in  the 
pathological mechanism of RA is still unclear. The administration of IL 12 to the 
CIA mouse model of RA has been reported to dramatically attenuate the severity 
of arthritis disease (Malfait et al., 1998). In contrast, the induction of collagen 
induced arthritis (CIA) in IL 12 deficient mice has been reported to increase the 
severity  of  arthritis,  suggesting  that  IL 12  paradoxically  mediates  protection 
from autoimmune inflammation (Murphy et al., 2003).  
1.2.3.2.2   Role of Th2 cell cytokines in RA 
Th2 cell cytokines, including IL 4, IL 5, IL 10 and IL 13 play a crucial role in the 
humoral immune response; including stimulating maturation of B lymphocytes 
into plasma cells, stimulating immunoglobulin class switching from IgM to IgE and 
IgG1 (in mouse) or IgG4 (in man) isotypes, promoting allergic immune responses 
and eosinophil activation (Schulze Koops and Kalden, 2001); (Kurowska Stolarska 
et al., 2008); (Punnonen et al., 1993); (Pope et al., 2001). 
IL 4  and  IL 10  have  been  reported  to  play  protective  roles  in  autoimmune 
disease (Schulze Koops and Kalden, 2001). Increases in IL 10 concentrations in 
the peripheral blood and serum have been reported in RA patients compared 
with healthy controls. IL 4 mRNA and IL 4 producing T cells were detectable at 
low levels in the synovial fluid of RA patients. The major cellular sources of IL 10 
are  T  cells,  B  cells,  and  monocytes/macrophages,  whereas  IL 4  is  mainly 
produced by Th2 cells. In RA, IL 10 can be produced by cells in the synovial 
membrane. IL 10 functions via the IL 10 receptor which is composed of at least 
two subunits that are members of the interferon receptor (IFNR) family (Moore 
et al., 2001). IL 4 acts through the IL 4 receptor, which is a receptor complex 
consisting of IL 4R α chain and γ chain (Nelms et al., 1999). IL 4 and IL 10 have 
been shown to prevent autoimmunity by inhibiting Th1 proliferation, synovial 
inflammation and tissue destruction in RA (Schulze Koops and Kalden, 2001). IL 4 
and  IL 10  can  down regulate  the  production  of  IL 1  and  TNF α  by  peripheral 
blood monocytes and by synovial tissue from RA patients (Briolay et al., 1992); 
(de Waal Malefyt et al., 1991). Importantly, IL 4 and IL 10 also function to down 
regulate the production of Th1 cytokines IFN γ and IL 2, and to suppress their 
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IL 10  has  been  shown  to  reduce  severity  of  arthritis  and  protect  cartilage 
degradation in experimental arthritis (Joosten et al., 1997). An imbalance of 
Th1/Th2  cytokine  has  been  proposed  to  play  an  important  role  in  the 
pathogenesis of rheumatoid arthritis (Canete et al., 2000). Therefore IL 4 and IL 
10 seem to be potential therapeutic agents for RA. 
IL 5  and/or  IL 13  play  an  important  role  in  allergic  asthma  and  helminthic 
infection (Kurowska Stolarska et al., 2008); (Artis et al., 1999). IL 5 is produced 
mainly by Th2 cells and mast cells (Gregory et al., 2003), while IL 13 is produced 
by  T  cells,  mast  cells,  basophils,  dendritic  cells,  and  keratinocytes  (Schmid 
Grendelmeier et al., 2002). IL 13 acts via the IL 13Rα1 and IL 13Rα2 (Mentink 
Kane and Wynn, 2004), while IL 5 function is via the IL 5 receptor consisting of 
IL 5α  and  IL 5β  subunits  .  Both  IL 13  and  IL 5  function  mainly  to  regulate 
eosinophil trafficking and activation (Pope et al., 2001); (Ogata et al., 1998). 
Little is known about their role in the immuno pathogenesis of RA. Both clinical 
and experimental arthritis studies showed that IL 5 and IL 13 may play a crucial 
role  during  the  development  of  arthritis.  Increases  in  IL 13  and  IL 5  protein 
levels have been reported in synovial fluid of RA patients and up regulation of 
serum IL 5 has been reported in experimental arthritis during the early stages 
and onset of disease (Hitchon et al., 2004); (Schaefer et al., 1999).  Both IL 13 
and IL 5 have been reported to exacerbate the severity of arthritis by promoting 
IgE and IgG antibody isotype switching by B cells in CIA mice (Xu et al., 2008).   
1.2.3.3   Roles of chemokines in RA 
Chemokines and their receptors play crucial roles in RA pathogenesis mainly via 
the  recruitment  of  leukocytes  to  the  inflamed  joint  (Iwamoto  et  al.,  2008). 
Recent  studies  also  suggest  that  chemokines  also  play  important  roles  in the 
destruction of bone and cartilage and fibroblast proliferation.  
CXCL1 (Lisignoli et al., 1999); (Bischoff et al., 2005), CXCL8 (Kraan et al., 2001), 
CXCL5 (Koch et al., 1995), CXCL9, CXCL10 (Kuan et al., 2010), CCL2 (Szekanecz 
et  al.,  2003),  CCL5  (Yang  et  al.,  2009)and  CCL3  (Katschke  et  al.,  2001)  are 
elevated  in  the  synovial  fluid  and  in  serum  of  RA  patients.  Synovial 
macrophages,  T  cells,  synoviocytes  and  chondrocytes  produce  various 
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lipopolysaccharide  (LPS)  (Iwamoto  et al., 2008).  CXCL1  functions  as  a  potent 
neutrophil  chemo attractant  by  binding  both  CXCR1  and  CXCR2  receptors 
(Luttichau, 2010). CXCL1 has been reported in osteoblasts and in synovial fluid 
from rheumatoid arthritis patients (Lisignoli et al., 1999); (Bischoff et al., 2005). 
CXCL1 has also been reported to regulate angiogenesis during the inflammatory 
process (Barcelos et al., 2004). This group of C X C chemokines can bind to the 
same  receptor  CXCR2  (Charo  and  Ransohoff,  2006),  and  blocking  the  CXCR2 
receptor has been reported to inhibit the development of experimental arthritis 
(Barsante et al., 2008); (Lusitani et al., 2003). CCL2, CCL5 and CCL3 are potent 
chemokines that function predominantly by recruiting and activating monocytes, 
Th2 cells, B cells, NK cells, basophils, eosinophils and memory T lymphocytes. 
CCL2  and  CCL5  can  stimulate  chondrocytes  to  produce  MMP,  increase 
proteoglycan release and inhibit proteoglycan synthesis by chondrocyes (Borzi et 
al.,  2000).  CXCL9  and  CXCL10  function  as  potent  T lymphocyte  chemotactic 
factors  by  binding  into  the  receptor  CXCR3,  preferentially  on  the  Th1 
lymphocyte  subset.  In  addition,  CXCL10  induced  RANKL  expression  in  CD4+  T 
cells,  which  promote  bone  resorption  by  inducing  osteoclast  formation  and 
survival  (Lee  et  al.,  2009).  Fibroblast like  synoviocyte  proliferation  is  also 
induced  by  CXCL10  and  CXCL9  and  CCL13,  leading  to  synovial  hyperplasia 
(Garcia Vicuna et al., 2004). 
1.2.3.4  The role of growth factors in RA 
Joint  destruction  in  RA  is  mediated  mainly  by  pannus  formation  (McGonagle, 
2010).    Changes  in  the  synovium  during  the  formation  of  pannus  are 
characterized by neovascularisation, inflammatory cell infiltration and synovial 
hyperplasia (Brenchley, 2001).  The initiation of the pannus formation process, 
including  angiogenesis  and  synovial  hyperplasia  in  RA,  is  mainly  regulated  by 
angiogenic growth factor such as fibroblast growth factor 2 (FGF2) and vascular 
endothelial growth factor (VEGF) (Roccaro et al., 2005). Fibroblast growth factor 
2 is a wide spectrum mitogenic, angiogenic, and neurotrophic factor that binds 
to  FGF  receptors  (FGFR)  and  regulates  various  biological  processes,  including 
embryogenesis,  wound  healing,  angiogenesis,  and  maintenance  of  neuronal 
networks (Manfe et al., 2010). In RA, mast cells and vascular cells are the major 
sources of FGF2 (Qu et al., 1995). FGF2 functions mainly in mediating cartilage 
and bone destruction and synovial hyperplasia in RA (Qu et al., 1995). FGF2 also Chapter 1    43 
has a role in angiogenesis and recruitment of immune cells into the inflamed site 
(Malemud, 2007). Another growth factor that is also found highly expressed in 
synovial tissue of RA patients is VEGF (Nagashima et al., 1995). VEGF is a potent 
angiogeneic  factor  that  functions  via  tyrosine  kinase  receptors,  VEGFR1  (also 
known as Flt 1) and VEGFR2 (also known as KDR/flk 1) (Malemud, 2007). The 
major cellular sources of VEGF in RA are macrophages, fibroblasts surrounding 
microvessels, vascular smooth muscle cells and synovial lining cells (Nagashima 
et al., 1995).  VEGF not only has a crucial role in neovascularisation in pannus 
formation,  but  also  stimulates  endothelial  progenitor  cells  and  regulates  the 
recruitment of leukocytes (Kim et al., 2001, Lyden et al., 2001); (Asahara et al., 
1999). In addition, VEGF in the inflamed synovium may stimulate and promote 
cartilage degradation via the production of MMPs (Martel Pelletier et al., 2001). 
Both  FGF2  and  VEGF  have  been  shown  to  have  detrimental  effects  on  the 
severity of arthritis in the experimental arthritis mouse model (Yamashita et al., 
2002); (Afuwape et al., 2003).  
1.2.4    Collagen induced arthritis: murine model of RA 
Collagen induced arthritis (CIA) is an important experimental rodent model of 
RA, which is extensively used to study pathogenesis, to generate hypotheses and 
to  develop  potential  treatments  for  this  autoimmune  disease  (Kannan  et  al., 
2005).  
Immunological changes associated with RA include an increase in the numbers of 
collagen  type II  (CII)  specific  T  cells  and  increased  concentrations  of  anti CII 
antibodies in the synovial fluid and serum of RA patients during the early phase 
of disease in RA (Kim et al., 2004); (Kim et al., 1999); (Ohnishi et al., 2003); 
(Mullazehi et al., 2007). This clinical evidence suggests that collagen type II is 
one of the major autoantigens that has a crucial role in the initiation of the 
destructive immune response in RA. Since collagen type II is a component of 
articular cartilage, immunization with CII of heterologous species may induce 
joint destruction (Cho et al., 2007). This concept of CIA pathogenesis was first 
applied  in  the  rat  model  (Trentham  et  al.,  1977),  and  subsequently  in 
susceptible strains of mice (Courtenay et al., 1980). The genetically susceptible 
mouse strains are DBA/1, B10.Q and B10.RIII, which have H2q or H2r haplotypes 
on the MHC locus (Brand et al., 1996). The C57BL/6 (H 2b) mouse strain has also Chapter 1    44 
been  demonstrated  to  be  susceptible  to  CIA  induction  (Campbell  et  al., 
2000);(Inglis et al., 2008). In addition, male mice are more susceptible to CIA 
than females (Nandakumar et al., 2003). Collagen type II from various species, 
including bovine, porcine, chicken and human have demonstrated their ability to 
induce arthritis in rodent models (Myers et al., 1995).  
After  immunization  with  type  II  heterologous  collagen  in  complete  Freund’s 
adjuvant,  mice  usually  develop  asymmetrical  polyarthritis  at  around  3  weeks 
(Inglis et al., 2008). Similar to human RA, pathological features of arthritis in CIA 
mice include synovial inflammatory cell infiltration, cartilage and bone erosion 
and synovial hyperplasia (Asquith et al., 2009b). The proliferation of CII specific 
CD4
+ T cells is observed in the local lymph nodes during 3 5  weeks after the first 
immunization (Lee et al., 2006).The joint inflammation in CIA mice lasts for 2 3 
weeks after the onset of disease, followed then by a recovery phase (Inglis et 
al., 2008).  
1.2.4.1  Immunopathogenesis of Collagen induced arthritis 
Similar to human RA, the pathological mechanisms in the CIA model involve both 
cell mediated and humoral immune responses (Brand et al., 2003). Both T and B 
lymphocytes play crucial roles in the development of the disease (Holmdahl et 
al., 2002). The presence of collagen type II specific T cells in the arthritic joints 
suggests that T cells may directly regulate the immuno pathogenesis in the CIA 
model  (Holmdahl  et  al.,  1988).  The  initiation  of  a  cell  mediates  immune 
response in the CIA model is presumably driven by Th1 cells via the production 
of  IFNγ,  lymphotoxin β,  (LTβ)  and  TNF α  (McInnes  and  Schett,  2007).  The 
disease progression and the inflammation phases may be mediated by humoral 
factors including antibodies and complement (Schulze Koops and Kalden, 2001). 
Mauri et al., 1996 described the relationship between Th1 and Th2 cytokines in 
CIA models by measuring cytokine levels of cultured draining lymph node cells 
isolated  from  CIA  mice  during  the  induction  and  the  progression  phases  of 
inflammatory joint disease. IFN γ was detected in the lymph node cell culture 
during the induction phase of the disease, and stimulation with collagen type II 
caused a 10 fold increase in IFN γ production. In addition, the IFN γ levels were 
further elevated throughout the progression phase of disease.  In contrast, the 
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recovery  phase  of  the  disease.  These  data  confirm  that  Th1  lymphocyte 
cytokines may be the important regulators for the onset and the development of 
arthritis (Mauri et al., 1996). B lymphocytes and plasma cells are responsible for 
the production of anti collagen antibody. This antibody binds to cartilage and 
activates antibody and complement mediated immune destruction (Holmdahl et 
al., 2002). IgG2 is the dominant subclass of anti collagen antibody in the CIA 
model,  and  the  concentrations  of  IgG2a  and  IgG2b  antibody  were  markedly 
increased during the highest severity phase of the disease (Brand et al., 2003); 
(Brand et al., 1996).  
1.2.5   Rheumatoid arthritis as a systemic inflammatory 
disease and its association with neurological diseases 
Rheumatoid arthritis is a systemic autoimmune disease in which the peripheral 
inflammation (beyond arthritis) is reflected by the presence of extra articular 
diseases such as systemic vasculitis (blood vessel inflammation), subcutaneous 
nodules and pulmonary nodules and fibrosis in approximately 30% of RA patients 
(Young and Koduri, 2007). A recent study demonstrated that the distribution of 
pro inflammatory  CD4
+  T  cells  lacking  the  costimulatory  molecule  CD28 
(CD4
+CD28
null T cells) in the peripheral blood of RA patients has been associated 
with these extra articular manifestations (Fasth et al., 2007). For example, RA 
patients  with  persistent  expansion  of  CD4
+CD28
null  T  cells  developed 
atherosclerotic  disease  more  significantly  than  RA  patients  without  this 
expansion.  In  addition,  anti TNF α  treatment  in  RA  was  shown  to  attenuate 
these atherosclerotic changes, demonstrating a contribution of this cell subset in 
atherosclerosis development in RA (Gerli et al., 2004). Therefore, it is suggested 
that the activation of peripheral adaptive immune responses during arthritis not 
only affects joints, but also contributes to the inflammation in other organs such 
as  the  skin,  lung,  cardiovascular  system  and  peripheral  nerves  (Turesson  and 
Matteson, 2004). 
Accumulating  evidence  suggests  that  the  brain  is  also  affected  by  peripheral 
inflammation  during  arthritis.  Psychiatric  disorders  such  as  depression  and 
anxiety  are  common  in  RA,  suggesting  that  peripheral  inflammation  during 
arthritis  may  cause  alterations  in  the  brain  neurobiology.  However,  the 
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study using a single photon emission computed tomography (SPECT) scan of 6 RA 
patients showed a reduction in serotonin transporter (SERT)  density, along with 
improvements  in  physical  and  mental  functions  after  receiving  anti TNF α 
treatment, suggesting that circulating cytokines generated during autoimmune 
activation  in  RA  may  cause  changes  in  the  serotonin  system  that  induce  the 
development  of  depression  (Cavanagh  et  al.,  2010).  Neuroimaging  studies 
showed several CNS lesions in the brains of RA patients, which resolved after 
steroid  treatment,  suggesting  that  CNS  inflammatory  demyelination  is  also 
inducible by systemic inflammation during arthritis (Tsai et al., 2008); (Tajima et 
al.,  2004).  This  CNS  inflammatory  demyelination  is  also  the  major  clinical 
feature  of  multiple  sclerosis  (MS)  (Zuvich  et  al.,  2009).  MS  is  generally 
considered  to  be  a  CNS  autoimmune  disease  directed  against  CNS  myelin 
proteins,  including  myelin  basic  protein  (MBP),  myelin  oligodendrocyte 
glycoprotein (MOG) and proteolipid apoprotein (PLP) (Zozulya and Wiendl, 2008). 
However,  the  precise  pathological  mechanism  of  MS  is  unknown.  The 
immunopathogenesis  of  MS  has  been  investigated  intensively  by  using  animal 
models  of  MS,  including  experimental  autoimmune  encephalomyelitis  (EAE), 
which shares some of the clinical and neuropathological features of MS (Sriram 
and Steiner, 2005). Both clinical studies in MS patients and animal studies in the 
EAE model suggest that Th1 and Th17 CD4
+ cells, and trafficking of these cells 
from  the  periphery  into  the  brain  play  an  important  role in  the  initiation  of 
episodes  of  demyelination  in  the  relapsing remitting  phase  of  MS    (Weiner, 
2008); (Pender et al., 2000); (Greer et al., 2008); (Das et al., 1997); (Kebir et 
al.,  2007);  (Stromnes  et  al.,  2008);  (Klein,  2004).  Interestingly,  rheumatoid 
arthritis  is  a  systemic  autoimmune  disease  that  shares  similar  pathological 
mechanisms with MS. The aetiology of both autoimmune diseases is influenced 
by genes in the HLA region, particularly the class II genes. In addition, CD4
+ T 
cells  are  thought  to  play  a  crucial  role  in  both  MS  and  RA  pathogenesis. 
Therefore,  it  is  possible  that  lesions  of  CNS  inflammatory  demyelination 
reported in brains of RA patients may be the result of circulating CD4
+ T cells 
stimulated  by  the  auto immune  inflammatory  process  and  migrate  into  the 
brains during arthritis. These peripherally  activated CD4
+ T cells may include 
some that recognise and become activated by myelin proteins in the CNS or in 
secondary  lymph  nodes,  and  then  exacerbate  inflammatory  demyelination 
process  in  the  brains.  However,  to  date,  activation  of  the  adaptive  immune Chapter 1    47 
response in the brain associated with peripheral joint inflammation of RA has not 
been well elucidated.  
1.3  Immunology of the central nervous system 
The  central  nervous  system  (CNS)  is  an  important  organ  and  needs  to  be 
protected from pathogens. Physiological mechanisms of immune defence in the 
CNS are still unclear (Carson, 2002). In the past, the CNS was viewed as ‘an 
immune privileged site’, characterized by the presence of an intact blood–brain 
barrier (BBB) (Carson, 2002). The BBB serves as a physical barrier preventing the 
influx  of  immune  cells  and  inflammatory  mediators  into  the  CNS  during 
inflammation (Abbott et al., 2010). Over the last 20 years, the CNS has been 
considered an ‘immune privileged’ organ (Carson et al., 2006) however, more 
recent evidence suggests that the CNS is both immune competent and actively 
interactive  with  the  peripheral  immune  system  (Dantzer  et  al.,  2008).  In 
addition, immune cells such as macrophages and dendritic cells are present at 
the  choroid  plexus  and  meninges  of  the  brain  (Dantzer  et  al.,  2008). 
Importantly,  brain  parenchymal  cells  such  as  microglia  and  astrocytes  can 
initiate inflammatory processes by producing inflammatory mediators (cytokines 
and chemokines) (Whitney et al., 2009).  
1.3.1   Astrocytes 
The astrocyte is a non neuronal cell type in the central nervous system (CNS), 
characterized  as  being  a  star  shaped  cell  with  numerous  extended  branches 
surrounding  nearby  neurons  and  blood  vessels  (Nair  et  al.,  2008),  (Wang  and 
Bordey, 2008). Astrocytes are the most abundant subtype of glial cells in the 
CNS, comprising approximately 90% of CNS resident cells in human brain (Nair et 
al., 2008). Unlike microglia that are derived from cells of the immune system, 
astrocytes are derived from the same lineage as neurons and oligodendrocytes 
(Bolton and Eroglu, 2009) That could be the reason why astrocytes also have 
neuronal  function  as  well  as  regulation  of  immune  response.  Astrocytes  are 
multifunctional  cells  and  are  involved  in  various  essential  CNS  functions, 
including synaptic homeostasis and transmission, regulation of CNS blood flow, 
and  supply  of  energy  metabolites  (Blackburn  et  al.,  2009).  In  addition, 
astrocytes  can  also  respond  to  inflammatory  conditions  such  as  infection, Chapter 1    48 
trauma, ischemia and neurodegenerative disease by a  process called reactive 
astrogliosis (Sofroniew, 2009). 
1.3.2   Microglia 
Microglia are central nervous system (CNS) macrophage like cells, comprising 5 
20% of the total glial cell population (Graeber and Streit, 2010). Microglia in the 
normal  brain  are  characterized  by  small  cell  bodies  with  a  number  of  fine, 
branched  processes,  which  is  often  called  ramified  microglia  (Graeber  and 
Streit, 2010). In response to virus or bacterial infections or CNS injury, activated 
ramified  microglia  exhibit  morphological  changes,  including  shortening  of 
cellular processes and enlargement of their cell bodies. This phenotype is called 
amoeboid microglia (Town et al., 2005). The origin of the microglia lineage is 
still  undefined.  Microglia  share  a  large  number  of  cell  surface  markers  with 
mononuclear phagocytes, including CD11b (Mac 1, β2 integrin), CD11c (LeuM5), 
CD45 (leukocyte common antigen), CD64 (Fc γ receptor 1), CD68 (macrophage 
antigen),  complement  type  3  receptor  (CR3),  B7 2  (CD86),  and  major 
histocompatibility complex (MHC) class I and II antigens, and Toll like receptors 
(Yang  et al.,  2010).  Based  on  these  similarities  in  cell  surface  markers,  it  is 
implied  that  microglia  may  be  derived  from  the  same  lineage  as  peripheral 
macrophages (Yang et al., 2010). 
1.3.2.1   Astrocytes and microglia as immune cells in the CNS 
1.3.2.1.1   Role of astrocytes and microglia in CNS innate immunity  
Both  microglia  and  astrocytes  play  important  roles  in  innate  and  adaptive 
immune responses in the brain (Yang et al., 2010). Astrocytes and microglia also 
play a potential role in mediating innate immunity by expressing various pattern 
recognition receptors (PRRs), especially TLRs in response to viral and bacterial 
infections (Farina et al., 2007). TLR2, TLR3, TLR4, TLR5 and TLR9 have been 
reported to be expressed in human and mouse astrocytes (Farina et al., 2007). 
Primary cultured mouse microglia express TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, 
TLR7, TLR8 and TLR9 (Olson and Miller, 2004). Human microglia express TLR1, 
TLR2,  TLR3,  TLR4,  TLR5,  TLR6,  TLR7  and  TLR8  (Bsibsi  et  al.,  2002). 
Interestingly,  TLR  expression  by  microglia  is  predominantly  in  the 
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the  blood  circulation  (Chakravarty  and  Herkenham,  2005),  suggesting  that 
microglia prevent the entry of pathogens into the CNS by recognising pathogens 
that  are  present  in  the  periphery.  Astrocytes  and  microglia  seem  to  have 
different important roles in response to viral and bacterial infections. A study in 
cultured fetal human astrocytes showed that TLR3 is constitutively expressed 
under  normal  physiological  conditions.  Another  in  vitro  study  using  cultured 
adult human astrocytes showed that TLR2, TLR3, TLR4 gene expression could be 
detectable  under  normal  physiological  conditions  (McKimmie  et  al.,  2005). 
However, stimulation with various cytokines, including TNF α, IL 1β, IFN γ, IL 
12, IL 4, IL 6, also strongly induced TLR3 gene expression, but had no effect on 
TLR4 gene expression and down regulated TLR2 gene expression (Bsibsi et al., 
2006).  TLR3  is  implicated  in  host  anti viral  response  by  recognizing  double 
strand  (ds)  viral  nucleic  acid.  This,  in  turn,  activates  immune  cells  such  as 
peripheral blood monocytes to express anti viral cytokines including IFN α, TNF 
α and IL 1β (Pan et al., 2011). This evidence suggested that astrocytes may play 
a  crucial  protective  role  during  CNS  viral  infection.  In  contrast,  microglia 
predominately express TLR2 and TLR4, which are implicated in the protection 
against bacterial infections. Both TLR2 and TLR4 recognizing bacterial cell wall 
component  have  been  associated  with  the  pathology  of  neuro degeneration 
(Carpentier  et  al.,  2008);(Takeuchi  et  al.,  1999);    in  vitro  studies  have 
demonstrated that microglia respond to Group B Streptococcus (GBS) infection 
by  expressing  TLR 2,  which  then  induces  neuronal  apoptosis  in  bacterial 
meningitis (Lehnardt et al., 2006). LPS induced TLR4 expression in microglia in 
vitro can cause dramatic neuronal loss and oligodendrocyte death (Lehnardt et 
al.,  2002);  (Lehnardt  et  al.,  2003).  Other  components  of  innate  immunity, 
including  complement  receptors,  mannose  receptor  (MR)  and  scavenger 
receptors  (SRs),  have  also  been  reported  to  be  expressed  on  astrocytes  and 
microglia (Farina et al., 2007); (Barnum, 1999). 
1.3.2.1.2   Role of astrocytes and microglia in CNS adaptive 
immunity  
Astrocytes and microglia can also function as non professional antigen presenting 
cells  (APCs);  presenting  antigen  in  the  context  of  MHC  molecules,  and  can 
contribute  to  adaptive  immunity  (Yang  et  al.,  2010);  (Constantinescu  et  al., 
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express very low levels of MHC class I and class II molecules (O'Keefe et al., 
2002); (Kreutzberg, 1996); (Massa, 1993). In normal human spinal cords, only 14% 
of the microglia population express MHC class II (Stoll et al., 2006). However, in 
various CNS diseases, including infection, injury, neurodegenerative disease and 
CNS autoimmune disease, the MHC is up regulated on microglia and astrocytes 
(Yang et al., 2010); (Soos et al., 1998). IFN γ is a potent inducer of MHC of both 
microglia and astrocytes (Wong et al., 1984); (Yang et al., 2004). The ability of 
astrocytes and microglia to present myelin basic protein (MBP) to CD4
+T cells in 
the context of MHC requires an MHC class II transactivator called CIITA, which 
can be also induced by IFN γ (O'Keefe et al., 1999); (Badie et al., 2002); (Soos et 
al.,  1998).  Astrocytes  and  microglia  also  require  additional  co stimulatory 
molecules such as the CD28 B7 receptor family CD80 (B7 1)/CD86 (B7 2) in order 
to  activate  CD4
+  and  CD8
+  T  cells  (Sedgwick  et  al.,  1991);  (Nikcevich et  al., 
1997), (Tan et al., 1998); (Issazadeh et al., 1998). 
In addition to direct activation of T cells by antigen presentation, astrocytes and 
microglia  also  enhance  T cell  activation  by  the  production  of  a  variety  of 
cytokines.  Astrocytes  are  cellular  sources  of  interleukin  IL 1,  IL 6,  IL 10, 
interferon (IFN) α, IFN β, tumour necrosis factor (TNF) α,  transforming, growth 
factor  (TGF) β;  and  colony stimulating  factors,  GM CSF,  M CSF  (Dong  and 
Benveniste, 2001) in the CNS. Microglia produce a variety of cytokines, including 
IL lα, IL 1β (Giulian et al., 1986), IL 5 (Sawada et al., 1993), IL 6 (Sawada et al., 
1992), TNF α (Sawada et al., 1989), and TGFβ (Constam et al., 1992), IL 12 (Xu 
and Drew, 2007), IL 13 (Shin et al., 2004),  IL 16 (Liebrich et al., 2007), IL 17 
(Kawanokuchi et al., 2008), and IL 23 (Sonobe et al., 2008). These cytokines can 
activate the differentiation of Th1, Th2 and Th17 lymphocytes (O'Garra and Arai, 
2000);  (Miljkovic  et  al.,  2007).  Astrocytes  play  a  role  in  the  activation  and 
expansion of both Th1 and Th17 T cells via the production of IL 12 and IL 23 
(Constantinescu  et  al.,  2005).  Co cultures  of  astrocytes,  which  produced  IL 
23p19 and common IL 12/IL 23p40, and myelin basic protein stimulated T cells 
were  demonstrated  to  up regulate  the  production  of  Th1  and Th17  cytokines 
such as IL 17 and IFN γ (Miljkovic et al., 2007). Astrocytes also play a role in T 
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1.3.3   Innate immunity in the central nervous system (CNS) 
Innate  immune  responses  to  CNS  viral  and  bacterial  infection,  inadvertently 
leads to collateral neuronal damage and neurological dysfunction (Nguyen et al., 
2002). Resident microglia and astrocytes mediate host immune response against 
viral/bacterial infection by expressing innate immune receptors such as toll like 
receptors  (TLRs)  that  recognize  pathogen  related  molecular  patterns  on 
pathogens. Activation of these toll like receptors (TLRs) results in the production 
of  cytokines  to  help  protect  the  CNS  against  pathogens  (Pan  et  al.,  2011). 
However, the cytokines produced during this innate immune activation can also 
have detrimental effects on neurons. CNS bacterial infections such as Group B 
Streptococci (GBS) can activate TLR2 expressed on microglia to produce nitric 
oxide (NO) that is protective against the organism by its cytotoxicity, but also 
causes  neuronal  injury  (Lehnardt  et  al.,  2006).  Neuronal  apoptosis  in  HIV 1 
associated dementia is thought to be the induced by cytokines including TNF α, 
IL 1β, IL 6 produced by activated microglia/astrocytes (Kaul, 2009); (Sheng et 
al., 2000). In addition, activation of the immune response in the CNS has been 
implicated  in  the  neurodegeneration  of  some  neurological  diseases,  including 
Alzheimer’s  disease  (AD)  and  Parkinson’s  disease  (Whitney  et  al.,  2009). 
Accumulation  of  extracellular  fibrils  of  amyloid β  and  intracellular 
neurofibrillary tangles in the neuron causes the formation of senile plaques, and 
eventually  leads  to  neurodegeneration  in  Alzheimer’s  disease  (Weiner  and 
Frenkel, 2006). Amyloid β peptides can also initiate innate immunity in the CNS 
(Weiner and Frenkel, 2006) by directly activating astrocytes and microglia to 
produce various cytokines and chemokines, including TNF γ, IL 1β, IL 6 IFN γ, 
CCL2, CXCL10, which can damage neurons (Akama and Van Eldik, 2000); (Zaheer 
et al., 2008). These observations may suggest that CNS innate immunity can play 
crucial roles in host defence against microbial/viral pathogens and pathologic 
amyloid beta  particles.  Paradoxically,  it  also  can  cause  neurotoxicity  and 
damage neurons.  
1.3.4   Adaptive immunity in the CNS 
Medawar  1948  was  one  of  the  first  to  suggest  that  the  inability  of  initiating 
lymphocyte  responses  within  the  CNS  was  due  to  the  absence  of  major 
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professional APCs such as dendritic cells (DCs), adaptive immune cells such as T 
lymphocytes and B lymphocytes, constitutive MHC class I and II expression on 
CNS  parenchymal  cells,  and  lymphatic  vessels  in  the  brain  parenchyma 
(Engelhardt, 2006). The CNS is also protected by the BBB, which prevents the 
influx  of  immune  cells  and  inflammatory  mediators  into  the  CNS  during 
inflammation (Abbott et al., 2010). Although low numbers of T cells are found in 
the CSF of healthy individuals, they seem to be involved in immune surveillance 
of the CNS in the absence of inflammation (Engelhardt, 2006). Under this normal 
physiological  condition,  CNS resident  cells  such  as  astrocytes  and  microglia 
express low levels of MHC class II and T cell costimulation/adhesion molecules, 
which  is  restrictive  for  T cell  activation  in  the  CNS  (O'Keefe  et  al.,  2002); 
(Kreutzberg, 1996); (Massa, 1993). It is still unclear how T cells recognize target 
antigens and initiate adaptive immune response within the CNS.  
It  has  been  hypothesized  that  the  antigen  presentation  by  APCs  can  occur 
outside the CNS in the nearby lymph nodes such as in cervical lymph nodes (CLN) 
(Goverman, 2009). CNS myelin auto antigens such as proteolipid protein (PLP) 
and  myelin  basic  protein  (MBP)  that  are  synthesised  by  oligodendrocytes  can 
drain from the brain tissue into the lymphatic systems through the perivascular 
space between the brain tissue and BBB (Ichimura et al., 1991). The perivascular 
space  is  connected  to  the  brain   cerebrospinal  fluid  (CSF)  barrier  called  the 
subarachnoid space (SAS), which is eventually linked to cervical lymph nodes via 
the lymphatics of the nasal mucosa (Koh et al., 2005). Evidence for this includes 
the observation that neuronal antigens and proteins, including MBP, PLP, NF L 
(Neurofilament  triplet  L)  and  MAP 2  (Microtubule Associated  Protein)  were 
detected in CLN of MS patients and EAE mice, and these have been associated 
with  neuronal  damage  (Fabriek  et  al.,  2005);  (van  Zwam  et  al.,  2009). 
Langerhans' cells and lymph node dendritic cells in CLN can present CNS antigens 
such as MBP and PLP in the context of MHC class II (Cumberbatch et al., 1991), 
resulting in CD4
+ T cell and CD8
+ T cell activation (Goverman, 2009). It has been 
demonstrated that activated T lymphocytes migrate back from the CLN into the 
brain via the route of lymphatics of the nasal mucosa (Goldmann et al., 2006). 
The localization of type IV collagen auto antibody was observed in the CLN after 
the  injection  of  type  IV  collagen  into  the  CSF  (Walter  et  al.,  2006).  Several 
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autoimmune mediated CNS demyelinating diseases (Goverman, 2009). The onset 
of clinical symptoms of EAE correlated with increased activation of PLP specific 
CD4
+ T cells in the CLNs (Zhang et al., 2008). Surgical removal of the cervical 
lymph nodes reduced the severity and delayed the onset of EAE (Furtado et al., 
2008). 
In addition to the regional nodes, several recent studies also suggest that T cells 
can  be  activated  by  recognizing  target  antigens  directly  in  the  CNS  and  not 
necessarily in the cervical lymph nodes or other peripheral lymphoid organs. A 
study  by  Greter  et  al  showed  that  adoptive  transfer  of  pre activated  myelin 
oligodendrocyte/glycoprotein  (MOG) specific  T  cells  into  splenectomized  mice 
with a complete absence of lymph nodes and Peyer’s patches resulted in the 
same development of EAE as seen in wild type mice (Greter et al., 2005). This 
study  suggests  that  antigen  presentation  by  APCs  in  the  secondary  lymphoid 
tissues is not necessary for the activation of T cells before their migration into 
the CNS and the development of disease (Greter et al., 2005). This is supported 
by another study by McMahon et al showing that activation of dye labeled naive 
proteolipid protein (PLP)139 151 specific T cells occurred directly in the brain and 
not in the cervical lymph nodes or other peripheral lymphoid organs (McMahon et 
al., 2005).  
Dendritic  cells  (DC)  have  been  demonstrated  to  play  crucial  roles  in  the 
distribution of CNS antigens and to present antigens to T lymphocytes and B 
lymphocytes  at  the  peripheral  and  CNS  levels  (Zozulya  et  al.,  2010).  Both 
myeloid DCs and plasmacytoid DCs have been found in the CSF of healthy donors 
(Pashenkov et al., 2001). In addition, MHC class II
+ DCs are also present in the 
perivascular space, meninges and the choroid plexus of the non inflamed normal 
brain (McMenamin et al., 2003). DCs located at the CNS have been shown to play 
a role in transporting CNS antigens from the CNS to the CLN (de Vos et al., 
2002). Karman et al has demonstrated the migration of DCs from the brain to 
CLNs  after  the  injection  of  DCs  into  the  mouse  brain  parenchyma.  After 
immunization with OVA, the number of increased OVA specific CD8
+ T cells in 
the  CLNs  correlated  with  increased  injected  OVA loaded  DC  numbers.  The 
injection of increasing numbers of OVA load DCs also led to a dose dependent 
increase in the number of OVA specific CD8
+ T cells in brain, suggesting that DCs 
also play a role in the homing of antigen (Ag) specific T cells into brain (Karman Chapter 1    54 
et al., 2004). In a murine EAE model, intracerebral microinjection of activated 
DCs increased the onset and clinical course of EAE, along with T cell infiltration 
(Zozulya  et  al.,  2009).  Myeloid  DCs  originating  from  the  bone  marrow  were 
shown  to  accumulate  in  the  brain  during  the  course  of  EAE,  where  they 
preferentially  activated  Th17  lymphocytes;  producing  IL 17  which  is  the  key 
mediator for EAE immune responses (Bailey et al., 2007). Brain DCs also showed 
preference to migrate to B cell follicles rather than T cell areas in lymph nodes 
(Hatterer et al., 2006). Intra CSF injection of mouse dendritic cells to EAE mice 
also resulted in increased serum MOG specific antibody (Hatterer et al., 2008). 
These data suggest that mDCs play an important role in B lymphocyte activation 
and in the antibody response in autoimmunity. DCs have been demonstrated to 
play crucial roles in T cells activation in the non lymphoreticular environment of 
the  CNS.  A  study  in  splenectomized  mice  lacking  lymph  nodes  and  Peyer’s 
patches showed that CNS infiltrating CD11c
+ dendritic cells were essential for 
the  disease  development  of EAE  (Greter  et  al.,  2005).  An  ex  vivo  study  also 
shiwed  that  CD11c
+  dendritic  cells  were  the  most  effective  at  activating  the 
proliferation  of  (PLP)139 151 specific  T  cells  in  the  CNS  compared  to  CD11c
  
microglia and CD11c
  macrophages (McMahon et al., 2005). 
CNS  antigen  presentation  can  occur  at  the  BBB  level.  The  cerebrovascular 
endothelium of BBB constitutively expresses MHC class II and the co stimulatory 
molecule CD86 (B7 2) (McCarron et al., 1991); (Omari and Dorovini Zis, 2003). 
Upon  stimulation  by  inflammatory  cytokines  such  as  TNF α  and  IFN γ, 
cerebrovascular endothelium can also express MHC class I, CD80 (B7 1) and the 
class II trans activator (CIITA) (Tennakoon et al.,  2001); (Seino et al., 1995); 
(Girvin et al., 2002). Recognition of CNS cognate antigens presented by cerebral 
endothelial cells has been demonstrated to be essential for CD4
+ T lymphocyte 
and CD8
+ T lymphocyte migration into the brain (Galea et al., 2007); (Manes and 
Pober, 2008). 
1.3.5   The role of inflammatory mediators in the CNS 
Neuro inflammation has been long considered only to have a destructive role in 
the  CNS,  however  accumulating  evidence  recently  suggests  that  neuro 
inflammation also has a neuroprotective function (Minghetti L 1999); (Nordvall 
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balance between maintenance of homeostasis of the CNS and induction of neuro 
degeneration may be dependent on the initiation of specific types of immune 
response (Byram et al., 2004); (Polazzi and Contestabile, 2002); (Hofstetter et 
al., 2003). Inflammatory mediators such as cytokines and chemokines are now 
recognised to have both neuroprotective and neurotoxic aspects. Cytokines and 
chemokines  produced  from  neurons  have  been  reported  to  function  as 
neuromodulators, which may be essential for the maintenance of normal CNS 
function including neuro regeneration (Carson et al., 2006).  
1.3.5.1  The role of cytokines in the CNS 
Cytokines not only function to regulate the immune response in the CNS, they 
can also function as neuro modulators. Pro inflammatory cytokines, including IL 
1β,  IL 6  and  TNF α  can  enhance  excitatory  synaptic  transmission  via  alpha 
amino 3 hydroxy 5 methylisoxazole 4 propionic  acid  (AMPA)   and  N methyl D 
aspartate  (NMDA) synaptic  activation  and  suppress  inhibitory  synaptic 
transmission via GABA  and glycine synaptic inhibition (Kawasaki et al., 2008).  
IL 1β and TNF α can cause neurodegeneration via excito neurotoxicity. Excito 
neurotoxicity  is  the  mechanism  of  neuronal  cell  death  caused  by  prolonged 
exposure  to  glutamate,  leading  to  the  excitatory  signal  via  NMDA  receptor 
activation.  This  causes  excessive  influx  of  Ca2
+  into  the  neuron,  which  is 
neurotoxic  and  induces  neuronal  damage  (Fan  and  Raymond,  2007).  TNF α 
induces glutamate release from microglia and the production of glutaminase, the 
enzyme that generates glutamate from glutamine, and together these eventually 
result in increased neuronal cell death (Takeuchi et al., 2006). IL 1β induces 
excito neurotoxicity by activating tyrosine phosphorylation of NMDA receptors, 
resulting in increased intracellular Ca2
+ and loss of cultured hippocampal neurons 
(Viviani et al., 2006). In contrast, IL 6 showed a neuro protective role against 
NMDA induced death of cerebellar granule neurons (Wang et al., 2009a). This 
evidence  suggests  that  pro inflammatory  cytokines  can  be  either 
neuroprotective or neurotoxic via the modulation of neurotransmission. 
TGF β has a major role in neuroprotection (Qian et al., 2008) and is considered 
to be a therapeutic target of neurodegenerative diseases such as Alzheimer’s 
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several  neurotoxic  stimuli,  including  excitotoxicity  (Boche  et  al.,  2003),  and 
neuronal apoptosis (Zhu et al., 2002a). TGF β has been reported to be neuronal 
protective  against  Aβ neurotoxicity,  which  may  be  the  cause  of  Alzheimer’s 
disease  (Caraci  et  al.,  2008);  (Uribe San  Martin  et  al.,  2009).  These  findings 
suggest that TGF  β has a protective role in the pathogenesis of Alzheimer’s 
disease. 
1.3.5.2  The role of chemokines in the CNS 
Chemokines and their receptors are expressed within the cytoplasm of neurons 
in  several  selective  brain  regions,  including  the  cerebral  cortex,  nucleus 
accumbens,  striatum,  amygdala,  thalamus,  hypothalamus,  hippocampus, 
substantia,  nigra,  mammillary  bodies,  raphe  nuclei,  neocortex,  basal  nuclei, 
brain stem and cerebellum (Westmoreland et al., 2002); (Banisadr et al., 2002). 
Accumulating  evidence  suggests  that  chemokines  might  function  as 
neuromodulators. Similar to neurohormones, neuropeptides and neurotrophins, 
chemokines and their receptors such as CCL21, CXCR4, and CXCR5 are packaged 
to the large vesicle and transported into the dendritic processes and axons (de 
Jong et al., 2008); (Westmoreland et al., 2002). Injured neurons were shown to 
release CCL21 into the synaptic cleft and to activate microglia. This may provide 
a  communication  between  neuron microglia  that  might  be  the  pathway  to 
activate microglia that are located distant from the primary lesion (de Jong et 
al.,  2005).  Chemokines  such  as  CXCL12  might  be  involved  in  neuronal 
communication such as during cholinergic and dopaminergic neurotransmission. 
It  has  been  reported  that  CCR2  co localized  with  neurotransmitters  on 
cholinergic  neurons,  dopaminergic  neurons  and  vasopressinergic  neurons 
(Banisadr  et  al.,  2003).  In  addition,  CCL2  treated  neurons  isolated  from 
hippocampus, hypothalamus and cortex showed increased Ca2
+ influx into the 
cells,  suggesting  that  CCR2  may  regulate  the  release  of  neurotransmitters 
(Banisadr et al., 2005). Interestingly, recent findings showed that CXCL12/CXCR4 
and CX3CL1/CX3CR1 co localized with serotonergic neurons. Both CX3CL1 and 
CXCL12 enhanced the amplitude of inhibitory postsynaptic currents (sIPSC) via 
GABA synaptic activation in serotonergic neurons. In addition, CXCL12 could also 
induce  glutamate mediated  membrane  depolarization  and  increase  the 
amplitude  of  excitatory  postsynaptic  currents  (sEPSC)  via  glutamate  synaptic 
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neurotransmission  that  may  lead  to  this  being  a  therapeutic  strategy  of 
chemokines  for  depression  (Heinisch  and  Kirby,  2009);  (Heinisch  and  Kirby, 
2010).  
CXCL12/CXCR4  is  also  involved  in  neuronal  death  during  HIV 1 associated 
dementia. HIV 1 glycoprotein gp120 induces neuronal death by binding to CXCR4 
(Kaul and Lipton, 1999); (Bachis and Mocchetti, 2004); (Choi et al., 2007). Other 
chemokines are involved in neuronal survival and exhibit their neuroprotective 
effects.  CXCL1  and  CXCL8  prevent cerebellar  granule  neurons  from  apoptotic 
death  induced  by  low  K
+  (Limatola  et  al.,  2000);  (Limatola  et  al.,  2002). 
CX3CL1/CX3CR1  showed  neuroprotection  against  excitotoxity  in  hippocampal 
neurons  (Lauro  et  al.,  2008).  CXCL1  protected  hippocampal  neurons  from 
apoptosis induced by β amyloid peptide (Watson and Fan, 2005). This evidence 
suggests that chemokines not only have an inflammatory function by regulating 
the  recruitment  of  monocytes  and  leukocytes  into  the  CNS,  they  also  act  as 
neuromodulators  to  regulate  neural  transmission  and  support  survival  and 
development of neurons.  
1.4   Inflammation in the CNS 
Inflammation  not  only  has  a  crucial  role  in  host  defence  responses,  but  also 
contributes to hypersensitivity diseases and in several central nervous system 
(CNS)  disorders  such  as  Alzheimer’s  and  Parkinson  diseases  (Whitney  et  al., 
2009). However, inflammation in the brain is different from that in peripheral 
tissues  in  several  aspects,  including    mechanism  of  initiation  and  degree  of 
sensitivity  (Whitney  et  al.,  2009).  The  migration  of  peripheral  T cell  and 
antibodies  into  the  CNS  is  restricted  by  BBB  (Banks,  2010).  An  inflammatory 
process in the CNS seems to be initiated mainly by the activation of resident 
microglia  and  astrocytes  in  response  to  cellular  damage  or  exposure  to 
pathogens  (Whitney  et  al.,  2009).  Activated  microglia  and  astrocytes  release 
anti   and  pro inflammatory  cytokines  including  IFN γ,  TNF α,  IL 1β,  IL 6,  IL 4 
and IL 10 (Whitney et al., 2009) . These inflammatory mediators can disrupt the 
BBB, which may or may not be associated directly with more recruitment of 
monocytes  and  lymphocytes  to  cross  through  the  BBB  into  the  site  of 
inflammation  (Hickey,  1999);  (Lossinsky  and  Shivers,  2004).  However,  up 
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activate BBB endothelial cells to produce chemokines and adhesion molecules 
that facilitate the infiltration of monocytes and lymphocytes from the peripheral 
circulation  into  the  brain  (Engelhardt,  2006).  These  recruited  monocytes  and 
lymphocytes become activated and produce more inflammatory mediators in the 
CNS, which can contribute to neuronal damage and changes in neurobiology in 
the CNS. However, inflammatory processes in the CNS may also contribute to 
neuroprotection essential in maintaining homeostasis in the CNS (Whitney et al., 
2009) .  
1.5   Immune signals from the peripheral circulation 
induce brain inflammation 
Peripheral inflammation induced neuroinflammation has been well documented. 
Acute  brain  inflammation  induced  by  viral/bacterial  encephalitis  causes 
transient increases in cytokine production and microglia activation in the CNS. 
Several studies in models of hypoxia ischemia and LPS/virus induced acute CNS 
inflammation demonstrated that the CNS usually responds to acute inflammation 
by up regulating inflammatory mediators in transient kinetic patterns (Barichello 
et al., 2010); (Bluthe et al., 1999); (Sakata et al., 1991); (Quan et al., 1994); 
(Barichello et al., 2009). For example, experimental intra cerebroventricular LPS 
injection demonstrated that IL 1β, TNF α, IL 6, MCP 1 reached their peak levels 
(4 7  fold  increases  compare  to  the  control)  at  6  hours  after  the  challenge 
(Rankine et al., 2006), before a sharp reduction in cytokine levels back to the 
base line. Increases in cytokine production and microglia activation in the CNS 
have  also  been  reported  in  chronic  inflammatory  disease  such  as  the 
experimental models of arthritis. Microglia activation, along with increases in IL 
1β, TNF α and IL 6 were observed in spinal cord of adjuvant induced arthritis 
(Bao  et  al.,  2001).  A  similar  observation  has  been  reported  in  CIA  rats. 
Longitudinal changes in IL 1β, TNF α and IL 6 gene expression were observed in 
brains of CIA rats (del Rey et al., 2008). In addition, inducing a gut inflammation 
model of colitis using 2,4,6 trinitrobenzene sulfonic acid (TNBS) resulted in the 
activation of microglia and the production of TNF α in rat brains. Interestingly, 
increases in the TNF α protein level and the number of activated microglia in 
hippocampal dentate gyrus (DG) have been associated with brain excitability and 
seizure susceptibility (Riazi et al., 2008). A study by Terrando et al., showed 
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increases in IL 1β, which was inhibited by peripheral treatment of anti TNF α 
(Terrando et al., 2010). However, the mechanism by which the inflammatory 
signal from the periphery induces brain inflammation is not well understood. 
Multiple  mechanisms  are  implicated  in  peripheral  inflammation induced 
neuroinflammation,  including  blood  brain  barrier  (BBB)  breakdown  and 
recruitment  of  immune  cell  from  the  periphery.  However,  changes  in 
permeability of BBB and up regulation of inflammatory mediators and adhesion 
molecule facilitating the immune trafficking to the CNS are primarily induced by 
peripheral/central inflammation.  
1.6   Barriers of the central nervous system 
There  are  three  main  barriers  between  blood  and  brain:  (i)  The  blood  brain 
barrier; which is the barrier between the lumen of cerebral blood vessels and 
brain tissue. (ii) The blood – cerebro spinal fluid barrier located between choroid 
plexus blood vessels and the CSF, which provides a non restrictive barrier: (iii) 
arachnoid barriers which form the middle layer of the meninges, covering the 
whole brain (Correale and Villa, 2009). 
1.6.1   Blood Brain Barrier (BBB) 
1.6.1.1   Structure of the blood brain barrier 
The BBB consists of the endothelial cells that form the walls of brain and spinal 
cord capillaries. These endothelial cells (ECs) are connected strongly to each 
other by tight junctions (TJs) and adherent junctions (AJs) (Correale and Villa, 
2009). 
The  TJs  function  to  restrict  transport  of  macromolecules  and  hydrophilic 
molecules between blood and the brain interstitial fluid (ISF). The tight junction 
complex comprises integral membrane proteins occludin, claudins 3, 5 and 12, 
and junctional adhesion molecules (JAMs). Occludin and claudins consist of four 
transmembrane domains with two extracellular loops, which associate and bind 
to  each  other  across  the  intracellular  cleft.  The  end  terminal  cytoplasmic 
domain of occludin regulates trans epithelial migration of neutrophils and also 
function to maintain TJs aggregation and barrier function. Claudins function to 
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the immunoglobulin (Ig) superfamily, which play a role in leukocyte trafficking. 
JAMs have a single transmembrane domain and the extracellular portion consists 
of  immunoglobulin like  loops  formed  by  disulfide  bonds.  Carboxi terminal 
cytoplasmic  tails  of  occludin,  claudins  and  JAMs  are  linked  to  cytoplasmic 
adaptor  proteins  such  as  zonular  occludins 1  (ZO 1),  ZO 2,  ZO 3,  which  are 
connected to the actin/myosin cytoskeletal system within cells (Abbott et al., 
2010).  
Adherent  junctions  (AJs)  consist  of  membrane  proteins  such  as  vascular 
endothelial  (VE) cadherin  (also  known  as  adherin  5,  type  2  or  CD144)  and 
platelet endothelial cell adhesion molecule (PECAM 1), which are linked to actin 
skeleton proteins via adaptor molecules called catenins. AJs are essential for the 
formation of tight junctions, since they provide support for BBB structure and 
attachment between cells (Abbott et al., 2010).  
CNS  capillaries  are  surrounded  by,  and  associated  with,  several  cell  types; 
including pericytes, astrocytes, microglia and neuronal processes, which form a 
functional  unit  called  the  neuronal  vascular  unit.  The  interaction  between 
neuronal vascular unit and CNS capillaries results in the bi directional regulation 
of  blood  flow,  microvascular  permeability,  cell  matrix  interactions, 
neurotransmitter  turnover,  angiogenesis  and  neurogenesis  (Zlokovic,  2008). 
Pericytes  are  vascular  cells  that  extend  their  long  cytoplasmic  processes 
encircling  the  endothelial  capillaries.  Pericytes  highly  express  the  contractile 
protein α smooth muscle actin, which regulates blood flow via endothelial cell 
contraction and relaxation (Zlokovic, 2008). Both endothelial cells and pericytes 
are enclosed and contribute to the local basement membrane, which consists of 
different  extracellular  matrix  (ECM)  structural  proteins  such  as  collagen  and 
laminin (Correale and Villa, 2009). The local basement membrane is surrounded 
by the endfoot processes from astrocytes, which function mainly in the induction 
and maintenance of BBB properties (Abbott et al., 2006).  The structure of the 
BBB and a tight junction is shown in Figure 1.1. Chapter 1    61 
 
Figure 1.1 Structure of the BBB and tight junction.  
(A) The structure of BBB mainly consists of capillary endothelial cells surrounded by the 
neuronal vascular unit (pericytes, astrocytes and neuronal processes). (B) The tight 
junction complex comprises integral membrane proteins (claudins, occludin, and junction 
adhesion molecule) on adjacent endothelial cells. The image were taken from (Chou and 
Messing, 2008) by kind permission of The Journal of Clinical Investigation. 
1.6.1.2  1.6.1.2. Transport across the blood brain barrier 
Under normal physiological conditions, tight junctions between endothelial cells 
only allow the entry of water, ethanol and small gas molecule such as O2 and CO2 
via  the  paracellular  route.  Most  of  the  molecules  are  transported  across  the 
endothelial wall transcellularly into the brain. Small lipid soluble and non polar 
molecules  including  drugs  such  as  barbiturates,  diazepam,  phenobarbital  and 
phenytoin  can  diffuse  passively  through  the  lipid  membrane  to  reach  their Chapter 1    62 
neuronal  targets  in  the  brain.  However,  the  transcellular  bidirectional 
transportation  of  water  soluble  compounds  and  macromolecules  requires  a 
variety  of  BBB  transport  systems  (Abbott  et  al.,  2006).  Many  essential  polar 
nutrients such as glucose and amino acids are transported by carrier mediated 
transport, which depends on concentration gradients in the direction from blood 
to brain (Abbott et al., 2010). Active efflux transport requires the energy from 
ATP to lipid soluble compounds out of the brain. This active transport system 
also has neuroprotective and detoxifying functions by reducing influx of many 
drugs, including azidothymidine (AZT), and enhancing their efflux from the brain 
(Abbott et al., 2006). Large proteins including neuroactive peptides, cytokines, 
chemokines, transferrin, low density lipoprotein (LDL), IgG, insulin and insulin 
growth factor enter the brain by specific receptor–mediated transcytosis. This 
involves binding of circulating proteins to their specific receptors expressed on 
the  endothelial  cells.    The  protein receptor  complex  is  internalised  into  an 
endocytic  vesicle,  which  travels  across  the  cytoplasm  to  be  released  at  the 
opposite  side  of the cell  (Jones  and  Shusta,  2007).  Cationic  proteins  such as 
albumin and other plasma proteins are transported into the brain by absorptive 
mediated  transport  (AMT).  This  involves  the  interaction  between  an  excess 
positive charge on the molecule and negative charge on the BBB surface, which 
induces endocytosis and subsequent transcytosis (Herve et al., 2008).  
1.6.1.3   Blood brain barrier disruption in neuro inflammation 
 
Studies of models of CNS autoimmunity and virus induced neuro inflammation 
have  shown  evidence  of  enhanced  BBB  dysfunction,  associated  with  the 
development of a CNS inflammation. Increased BBB permeability can involve the 
entry and clearance of various viruses including West Nile virus (Wang et al., 
2004), rabies virus (Phares et al., 2006), and adenovirus type 1 (Gralinski et al., 
2009). In addition, retroviral infected lymphocytes  have been associated with 
BBB dysfunction and changes in BBB structure (Afonso et al., 2007). The blood 
brain barrier permeability in EAE mice showed a positive correlation with the 
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1.6.1.4  Peripheral inflammation induced blood brain barrier disruption 
BBB disruption can also be induced from the periphery, and one good example is 
the case of systemic infection associated with sepsis (Sharshar et al., 2005). In 
experimental models of this, peripheral inflammatory stimulation by LPS causes 
microglia activation and increased concentrations of serum cytokines (Stolp et 
al.,  2009),  leading  to  a  transient  increase  in  BBB  permeability  in  the  white 
matter tissue of neonatal rats (Stolp et al., 2005a, Stolp et al., 2005b); (Stolp et 
al.,  2007).  Subcutaneous  administration  of  complete  Freund’s  adjuvant  (CFA) 
enhanced BBB permeability to [
14C] sucrose and down regulated tight junctional 
protein expression (Huber et al., 2001). Increased  permeability of the blood 
brain barrier was also observed in murine experiments of induced surgical pain 
stress (Oztas et al., 2004) and systemic thermal injury (Berger et al., 2007). 
Interestingly, BBB breakdown in several non CNS chronic inflammatory diseases, 
such as intestinal inflammation (colitis) (Natah et al., 2005), obesity (Hafezi 
Moghadam et al., 2007) and diabetes (Hawkins et al., 2007) are thought to be 
due to the effect of circulating inflammatory mediators.  
1.6.1.5  Mechanisms of inflammation induced blood–brain barrier 
dysfunction 
Circulating cytokines for example TNF α (Tsao et al., 2001) and IL 1β (Blamire et 
al., 2000) can induce BBB disruption and interfere with BBB function by several 
mechanisms. The effect of TNF α on BBB permeability was demonstrated to be 
associated with microglial activation (Nishioku et al., 2010a). TNF α and IL 1β  
have been reported to modulate the active transport system across BBB via the 
regulation of P glycoprotein expression (Yu et al., 2007); (Bauer et al., 2007); 
(von  Wedel Parlow  et  al.,  2009).  IL 1β  has  been  shown  to  regulate  BBB 
permeability  via  the  hypoxia angiogenesis  pathway  (Argaw  et  al.,  2006). 
Systemic  administration  of  IL 1β  results  in  the  damage  of  BBB  structure, 
including loss of the tight junctional protein, claudin 5 and basal lamina protein, 
collagen IV (McColl et al., 2008). Adhesion molecules induced by cytokines also 
have a crucial role in BBB disruption. Blocking P selectin and integrin alpha v 
beta 3 resulted in the reduction of BBB leakage (Jin et al., 2010); (Shimamura et 
al.,  2006).  Chemokines  such  as  CCL2  are  also  involved  in  changes  in  BBB 
permeability.  Blocking  CCL2/CCR2  in  a  mouse  model  of  stroke  caused  a Chapter 1    64 
reduction  in  BBB  permeability,  along  with  re synthesises  of  tight  junctional 
proteins such as occludin, zonula occludin 1 and 2, and claudin 5 (Dimitrijevic et 
al., 2006). Cytokines produced from neutrophils and T lymphocytes were also 
demonstrated to enhance BBB disruption (Joice et al., 2009).  IL 17 and IL 22 
released from Th17 cells were also shown to damage BBB via disruption of tight 
junctions (Kebir et al., 2007). 
1.6.1.6   Possible transport mechanisms for peripheral cytokines into 
the brain 
Circulating cytokines may enter the brain across a damaged BBB. However, there 
is  no  promising  evidence  demonstrating  a  direct  association  between 
concentrations of brain cytokines and BBB breakdown. This also suggests that 
the transportation of cytokine across BBB may be a complex mechanism that is 
still  unresolved.  It  is  likely  that  because  of  their  biological  importance  that 
circulating cytokines can enter the brain by various well controlled mechanisms. 
However,  this  has  still  to  be  established  but  some  experimental  results  are 
shown below. 
1.6.1.6.1   Entry of cytokines into the brain at circumventricular 
sites  
Circumventricular organs (CVOs) are exceptional areas in the brain that are not 
covered by the BBB. They function to monitor changes in peripheral biochemical 
substances  such  as  hormones  and  facilitate  the  secretion  of  neuroendocrine 
hormones  into  the  blood  (Johnson  and  Gross,  1993).  Although  CVOs  are 
permeable to macromolecules, a study using 
125I IL 1β showed that CVOs were 
only responsible for less than 5% of total brain uptake of IL 1β (Plotkin et al., 
1996). A recent study in an EAE model demonstrated intensive staining of MHC 
class II
+/CD45
+ leukocytes, ICAM 1 and VCAM 1 at the CVOs, suggesting that CVOs 
are also the route for leukocyte infiltration into the CNS (Schulz and Engelhardt, 
2005). Since CVOs are areas without a BBB, it is possible that these are the first 
areas of brains that perceive inflammatory cytokine signals from the peripheral 
circulation. Several studies using in situ hybridization showed that TNF α and IL 
1  β  gene  expression  was  induced  rapidly  during  the  first  2  hours  after  LPS 
administration in brain regions such as the circumventricular organs (CVOs) and 
the choriod plexus (Quan et al., 1998); (Breder et al., 1994). These data suggest Chapter 1    65 
that peripheral immune signals can be passed transiently into the brain at the 
level of the choriod plexus and circumventricular organs (CVOs) (Price et al., 
2008). 
1.6.1.6.2   Direct entry of cytokines to the CNS across the BBB 
 
Cytokines are transported into the CNS by various transport mechanisms. TNF α, 
IL 1α, IL 1β , IL 2 and IL 6 have been reported to be transported into the CNS by 
a saturatable transport system (Gutierrez et al., 1993); (Banks et al., 1994a, 
Banks et al., 1991); (Banks et al., 2004, Banks et al., 1994b). Recent findings 
show that chronic morphine exposure and withdrawal can enhance a saturatable 
transport  of  IL 2  into  the  CNS  (Lynch  and  Banks,  2008).  A  saturatable  efflux 
system  has  also  been  proposed  as  a  mechanism  to  limit  the  accumulation  of 
cytokines in the brain in order to limit neurotoxicity (Banks et al., 2004). In 
addition, the saturatable efflux system could mediate transportation of cytokine 
such as IL 2 used as cytokine therapy for patients  with cancer (Banks et al., 
2004). It has been reported that patients with leptomeningeal metastases who 
were given intraventricular IL 2 injection showed transient up regulation of IL 2 
and other cytokines such as IL 1β, TNF α and IL 6 in the CSF (List et al., 1992) 
High concentrations of IL 2 in the periphery of these patients after the cytokine 
therapy may cause a saturatable efflux of IL 2 into the brain. It is still unclear 
how saturatable efflux systems could explain the transportation mechanism of 
cytokines during peripheral inflammation. This is because the up regulation of 
peripheral cytokines between the example of peripheral inflammatory diseases 
and the example of cytokine therapy is different in terms of concentrations of 
cytokines in the periphery. Concentration of cytokines in the periphery could be 
increased during systemic inflammatory diseases, but whether it is higher than 
the  concentration  of  the  same  cytokines  in  the  brain  that  would  cause  a 
saturatable efflux of cytokines from the periphery into the brain is still unclear. 
A few studies suggest that the transport of TNF α across the BBB requires p55 
and p75 TNF receptors. TNFR p55/p75( / ) double knockout mice were unable to 
uptake 
125I TNF α into the brain and the spinal cord (Pan and Kastin, 2002). This 
concept  was  supported  by  the  observation  in  wild  type  mice  that  the  up 
regulation of p55 and p75 TNF receptor gene expression in injured spinal cord 
corresponded to increased 
125I TNF α uptake (Pan et al., 2003). A recent finding Chapter 1    66 
demonstrated that p55 and p75 receptor mediated TNF α transport across BBB 
may involve endocytosis. Microvessel endothelial cells of rat brains showed the 
ability  to  endocytose 
125I TNF α  in  a  time dependent  manner.  In  addition, 
confocal imaging also exhibited the co localization of p55 and p75 TNF receptors 
and caveolin 1; the endocytic membrane vesicle, in TNF α treated RBE4 cells 
(Pan et al., 2007). An in vitro study using a blood–brain barrier model generated 
by co culture of porcine brain microvascular endothelial cells  with astrocytes 
demonstrated  that  the  penetration  of  IL 1β  occurred  in  a  temperature 
dependent manner that appeared to depend on the IL 1 receptor (Skinner et al., 
2009). 
1.6.1.6.3  Activation of cytokine production in the CNS by 
stimulating peripheral afferent nerves 
The up regulation of cytokines in the CNS can be regulated by the afferent vagus 
nerve  (Thayer  and  Sternberg,  2009).  Removing  the  abdominal  site  of  the 
afferent vagus nerve (vagotomy) results in reduced expression of IL 1β mRNA in 
rodent brains after peripheral administration of either LPS (Laye et al., 1995) or 
IL 1β (Hansen et al., 1998). Interestingly, activating the afferent vagus nerve by 
electrical stimulation resulted in increased IL 1β gene expression in the rat brain 
(Hosoi et al., 2000). 
1.6.1.6.4  Peripheral inflammation induces local production of 
cytokines by microglia 
Peripheral inflammation can activate CNS immune cell such as resident microglia 
to produce local cytokines by unknown mechanisms. Activated microglia isolated 
from aged mice after intraperitoneal injection of LPS showed up regulation of IL 
1β, IL 10, TLR2 and MHC class II mRNA (Henry et al., 2009). In addition, the 
activation  of  microglia  and  the  production  of  TNF α  in  rat  brains  have  been 
reported  in  a  model  of  gut  inflammation  (Riazi  et  al.,  2008).  Chemokines 
released from CNS activated microglia can also attract leukocyte recruitment 
into the CNS, leading to the production of cytokines by peripheral leukocytes. 
Elevated  CXCL2  levels,  increased  numbers  CCR2
+  monocytes,  and  microglial 
activation were observed in the brains of mice with liver inflammation (D'Mello 
et al., 2009). It is still unclear how circulating cytokines enter the brain and Chapter 1    67 
activate microglia in the brain parenchyma. One possibility is that circulating 
cytokines may activate microglia and astrocytes located at the CVOs such as in 
the subfornical organ (SFO), the organum vasculosum of the lamina terminalis 
(OVLT)  and  the  area  prostrema  (AP)  (McKinley  et  al.,  2003).  The  important 
evidence  suggesting  that  microglia  at  the  CVOs  are  more  sensitive  to 
inflammatory cytokine signals from the periphery and may be activated quicker 
than  microglia  in  other  part  of  brain  parenchyma  is  that  the  increased  TLR 
expression by microglia is predominantly in the CVOs and meninges (Chakravarty 
and Herkenham, 2005). Transient increases in TLR4 and TLR2 gene expression 
were  observed  in  choroid  plexus  subgroups  of  CVOs  such  as  the  organum 
vasculosum of the lamina terminalis (OVLT), and subfornical organ (SFO) in rat 
brains  after  systemic  injection  of  LPS  or  gram negative  bacterial  cell  wall 
components  (Laflamme  and  Rivest,  2001);  (Laflamme  et  al.,  2001).  This  was 
followed by rapid transcription of inflammatory mediators such as TNF α and 
CCL2  within  these areas  (Laflamme  et  al.,  2003).This  suggests  that  microglia 
located at CVOs may play an important role as the first line of defence against 
the entry of pathogens into the CNS by recognising pathogens that are present in 
the periphery.  
1.6.1.7  Immune cell trafficking into the CNS 
 
Under CNS inflammatory conditions, the expression of adhesion molecules and 
chemokines is induced on BBB endothelium, and these promote adhesion and 
help attract circulating leukocytes to enter into the inflamed CNS (Banks, 2010). 
BBB disruption induced by CNS inflammatory conditions may facilitate greater 
immune cells recruitment from the periphery. However, it is still controversial 
whether BBB breakdown is directly associated with an increase in immune cells 
recruitment from the periphery. Several studies reported that BBB disruption is a 
neutrophil mediated process, which is associated with leukocyte recruitment. A 
study by Bolton et al. reported the loss of BBB integrity including the proteins 
occludin  and  zonula  occludens 1  from  cerebral  vascular  endothelium  during 
neutrophil induced  BBB  disruption  (Bolton  et  al.,  1998).  This  suggests  that 
neutrophils may activate a signalling cascade leading to the loss of BBB integrity 
and BBB disruption. In contrast, several studies also suggest that the loss of BBB 
integrity  is  not  simply  to  facilitate  more  leukocyte  recruitment  from  the Chapter 1    68 
periphery  into  the  brain  (Carson  et  al.,  2006).  It  has  been  reported  that 
perivascular cells are continuously replaced by peripheral macrophages in the 
healthy  CNS.  This  suggests  that  there  may  be  homeostatic  trafficking  of 
monocytes from the periphery into the basement membrane at the surface of 
the BBB (Bechmann et al., 2001). This also means BBB integrity is designed to 
permit selective leukocyte trafficking into the CNS. In addition, to date there is 
no  evidence  demonstrating  a  direct  correlation  between  the  severity  of  BBB 
breakdown and the amount of leukocyte recruitment during CNS inflammation. 
One possibility is that the BBB is still able to restrict T lymphocyte migration 
into the CNS during BBB disruption by selectively expressing adhesion molecules 
on the brain microvascular endothelial cells. For example, vascular cell adhesion 
molecule  (VCAM),  but  not  the  mucosal  addressin  cell  adhesion  molecule 
(MAdCAM), has been shown to be highly expressed on the endothelial cells of the 
lesions from MS patients (Allavena et al., 2010). Therefore, only T lymphocytes 
that express specific receptors for these adhesion molecules can enter into the 
inflamed  CNS  (Engelhardt  et  al.,  1998).  T cells  from  inflamed  mouse  brains 
expressed a high level of α4β1integrin, the receptor for VCAM 1, but a low level 
of α4β7 integrin; the receptor for MAdCAM (Engelhardt et al., 1994).   
Immune cell trafficking into the CNS is a multiple step process. The initial step 
involves  a  weak  interaction  between  leukocytes  and  endothelium  and  the 
leukocyte  rolling  along  the  microvascular  wall  (Banks,  2010).  This  step  is 
mediated  mainly  by  E   or  P   selectins,  which  bind  to  P selectin  glycoprotein 
ligand 1  (PSGL 1)  (Alon and  Ley,  2008).  Peripheral  CD4
+  T  cells  in  CSF  of  MS 
patients expressed higher PSGL 1 and transmigrated through BBB endothelium at 
a faster pace compared with those of healthy controls, suggesting an essential 
role of PSGL 1 in the CD4
+ T cell entry into the inflamed CNS, and also suggesting 
an essential role of P selectin PSGL 1 binding in the early phase of leukocyte 
entry into the CNS (Bahbouhi et al., 2009).  Rolling leukocytes are exposed to 
chemokines, leading to further reduced rolling speed, and eventual tethering to 
endothelial  cells  by  α4β1integrin VCAM 1  binding  (Engelhardt,  2006). 
Additionally  or  alternatively,  T  cells  may  be  captured  by  the  endothelium 
without  rolling,  via  α4β1integrin VCAM 1  binding  (Banks,  2010).  The 
α4β1integrin  has  an essential  role  in  EAE  development;  T  cells  isolated  from 
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(Bauer et al., 2009). Natalizumab, the anti α4 integrin antibody, inhibited α4 
integrin mediated firm adhesion, but not the initial contact, of human T cells 
with  the  endothelium  during  EAE  (Coisne  et  al.,  2009).  These  findings 
demonstrated  that  the  α4β1integrin  functions  mainly  in  firm  adhesion  rather 
than the initial contact of T cell to the BBB. Integrin activation is mediated by 
the signalling from G protein coupled chemokine receptors (Constantin, 2008). 
The binding of chemokines expressed by endothelium and chemokine receptors 
on the surface of leukocytes causes integrin conformational changes, resulting in 
the firm adhesion of leukocytes with the  endothelium (Alon and Dustin, 2007).  
The production of several chemokines is up regulated by endothelial cells upon 
the  activation  of  cytokines  during  CNS  inflammation.  CXCL12  gradients 
stimulated  VCAM/ICAM mediated  T lymphocyte endothelium  adhesion,  and 
promoted the migration of CD4
+ T cells and CD8+T cells through human brain 
microvessel  endothelial  cells  (HBMECs)  (Liu  and  Dorovini Zis,  2009).  In  situ 
hybridization  and immuno histochemistry showed  that  CCL19  and  CCL21  were 
predominately expressed in the brain and spinal cord tissue of EAE mice (Alt et 
al., 2002). These chemokines also activated the firm adhesion of CCR7
+ T cells to 
the endothelium of inflamed CNS in binding assays on frozen sections of EAE 
brains (Columba Cabezas et al., 2003). Long term genetic over expression of IL 
1β in the hippocampus of the mouse brain resulted in BBB leakage, up regulation 
of  CCL2,  CXCL1,  CXCL2  and  a  dramatic  infiltration  of  neutrophils  into  the 
hippocampus. Interestingly, knocking out the CXCR2 gene in these mice with CNS 
over expression  of  IL 1β  exhibited  a  significant  reduction  in  neutrophil 
infiltration,  but  failed  to  prevent  BBB  leakage  (Shaftel  et  al.,  2007).  The 
infiltration of CD45
+ T cells into the sub ventricular zone (SvZ); a preferential 
site of inflammatory lesions in EAE, has been associated with the constitutive 
expression  and  the  up regulation  of  CXCL10  in  SvZ  during  EAE  development 
(Muzio et al., 2010).  
The firm adhesion of leukocytes with endothelial cells leads to the diapedesis of 
leukocytes  across  the  BBB.  The  mechanism  underlying  the  penetration  of 
leukocytes through the tight junction is still undefined. Some in vitro studies 
suggested that it may involve the transient down regulation of tight junctional 
elements such as claudin 1/3 and occludin 1 (Xu et al., 2005). The occludin loss Chapter 1    70 
in  monocyte  diapedesis  has  been  associated  with  the  activity  of  matrix 
metalloproteinase enzymes (Reijerkerk et al., 2006). 
1.7  Communication between the immune system and 
the central nervous system (CNS) 
The  communication  between  peripheral  and  the  CNS  immune  systems  is  bi 
directional.  The  brain  perceives  the  peripheral  inflammatory  signal  and  can 
coordinate responses via the autonomic nervous system (ANS) and hypothalamo–
pituitary–adrenal  (HPA)  systems  (Maier,  2003).  The  activation  of  both  the 
autonomic  nervous  system  (ANS)  and  HPA  system  is  considered  to  be  the 
negative feedback from the brain to regulate the levels of immune response in 
the periphery (Kin and Sanders, 2006) (Figure 1.2).  
CNS  modulates  stress  and  the  immune  response  via  the  sympathetic  nervous 
system  (SNS)  and  the  parasympathetic  nervous  system  (PNS).  Nerves  of  the 
autonomic nervous system originate from the spinal cord, and both sympathetic 
catecholamine  fibres  and  parasympathetic  cholinergic  fibres  distribute  and 
innervate various effecter organs and immune organs, including thymus, bone 
marrow, lymph nodes and spleen (Nance and Sanders, 2007). Activation of the 
SNS  during  stress  and  peripheral  inflammation  results  in  the  release  of 
catecholamines, including norepinephrine (NE; noradrenalin) and epinephrine (E; 
adrenalin), from nerve terminals and from the adrenals (Tjurmina et al., 1999). 
NE and E bind to two types of receptors: alpha (α) and beta (β) adrenoceptors 
(AR). Most adaptive and innate immune cells such as CD8
+ and CD4
+ T cells, and 
NK  cells  express  predominately  β2AR  (Nance  and  Sanders,  2007),  whereas 
monocytes and macrophages express α1AR (Kavelaars, 2002).  The sympathetic 
system  has  a  crucial  role  in  regulation  of  the  immune  response;  particularly 
immuno suppression.  Deletion  of  the  mouse  peripheral  sympathetic  nervous 
system has been shown to increase the proliferation of CD8
+ T cells in response 
to  viral  infection  (Grebe  et  al.,  2009).  Enhancing  NE  level  using  the 
noradrenaline reuptake inhibitors (NRIs) desipramine and atomoxetine, has been 
shown  to  inhibit  the  expression  of  the  chemokines,  CXCL10  and  CCL5,  and 
adhesion molecules VCAM 1 and ICAM 1 in the cortex and hippocampus in mice 
with LPS induced systemic inflammation, suggesting a role for NE in preventing 
leukocyte  recruitment  into  the  brain  (O'Sullivan  et  al.,  2010).  The Chapter 1    71 
parasympathetic  nervous  system  (PNS)  has  recently  been  renamed  the 
cholinergic anti inflammatory pathway. Activation of the parasympathetic vagus 
nerve  results  in  release  of  acetylcholine  (ACH),  which  binds  with  nicotinic 
acetylcholine  receptors  and  inhibits  cytokine  production  in  immune  cells 
(Tracey, 2002).  Stimulation of the nicotinic acetylcholine receptor α7 subunit 
has been shown to inhibit TNF a production in macrophages, suggesting that the 
PNS is an essential regulator of inflammation (Parrish et al., 2008); (Wang et al., 
2003).  
The  CNS  also  responds  to  stressors  by  activating  the  hypothalamo–pituitary–
adrenal (HPA) axis in order to maintain homeostasis (Kern et al., 2008). Stress 
initiates the HPA processes by activating the paraventricular nucleus (PVN) of 
the  hypothalamus  to  release  corticotrophin releasing  hormone  (CRH)  and 
arginine–vasopressin (AVP). CRH and APV then stimulate the anterior pituitary 
gland  to  release  adrenocorticotropic  hormone  (ACTH)  into  the  circulation. 
Circulating ACTH stimulates glucocorticoid producing cortex cells in the adrenal 
glands  to  release  corticosteroid  hormones  including  cortisol  (in  human)  or 
corticosterone  (in  rodents)  (Lanfumey  et  al.,  2008).  These  corticosteroids 
function  as  anti inflammatory  hormones  and  their  levels  are  normally  up 
regulated during inflammation and infection (Hadid et al., 1999).  It has also 
been reported that increased HPA activity, which is characterized by increased 
serum cortisol and ACTH levels, has been associated with degrees of anxiety and 
social  stress  (Takahashi  et  al.,  2005).  Corticosteroids  bind  with  two  types  of 
intracellular steroid receptors, the mineralocorticoid (MR) or type I receptor, 
and the glucocorticoid receptor (GCR) or type II receptor. These receptors are 
constitutively expressed in the limbic brain areas, thus they are believed to be 
involved in development of various mood and anxiety disorders (e.g. depression 
and social phobia) (Lanfumey et al., 2008). Both receptor types are expressed in 
various immune cells (monocytes and lymphocytes), and play a role in immune 
regulation (Miller et al., 1994).  GCRs have been shown to be inducible during 
adaptive and innate immune responses (Spies et al., 2007); (Bartholome et al., 
2004). GCR is a cytoplasmic nuclear factor receptor that forms a complex with 
cortisol and then translocates to the nucleus. This complex is a transcription 
factor and binds to sites on DNA leading to regulation of gene transcription of 
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inflammatory  cytokines)  (Lekander  et  al.,  2009).  Activation  of  the  HPA  by 
cytokines  has  been  reported  to  induce  somatic  signs  and  symptoms  such  as 
fever.  It has been hypothesized that cortisol released after HPA axis activation 
creates energy by supporting the breakdown of glycogen and the conversion of 
amino acids, leading to an increase in the core body temperature (Maier, 2003). 
An increase in core temperature is involved in host defence against infection and 
in inflammation by inhibiting the rapid proliferation of bacteria and assembly of 
outer coat proteins of viruses.  In addition, host immune functions including T 
cell  activation  and  complement  activation  are  much  more  efficient  at  fever 
temperatures (Watkins and Maier, 1999). Fever is one of the major symptoms of 
sickness  behaviour,  which  is  characterized  by  fever,  fatigue,  loss  of  appetite 
(anorexia), loss of interest in social and sexual interaction, reduced reactivity to 
reward (anhedonia), decline in mood and cognitive function. Sickness behaviour 
is  common  in  peripheral  inflammation/infection  such  as  during  sepsis  and 
autoimmune disease (Dantzer et al., 2008). However, whether activation of HPA 
by cytokines underlies sickness behaviour in peripheral inflammatory conditions 
is  still  controversial.  IL 1β  antagonism  has  been  reported  to  inhibit  sickness 
responses  such  as  fever,  increased  HPA  activity  and  reduced  food  and  water 
intake (Milligan et al., 1998). In contrast, IL 6 has been reported to induce HPA 
activation and fever, but not sickness behaviour (Lenczowski et al., 1997).   
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Figure 1.2 The communication between the brain and the peripheral immune system. 
The brain can regulate peripheral inflammation via the automatic nervous and 
neuroendocrine systems. The autonomic pathway of the nervous system is further divided 
into the sympathetic and parasympathetic nervous systems. The sympathetic system 
activates the immune response via the neurotransmitter norepinephrine, while the 
parasympathetic nervous system inhibits the immune response via the neurotransmitter 
acetylcholine. Peripheral inflammation and cytokines activate the hypothalamus to release 
corticortropin releasing hormone, which in turn activate the pituitary gland to release 
adrenocorticotropic hormone. This hormone, in turn, activates the adrenal gland to produce 
glucocortocoids which suppress inflammation. The image were taken from (Sternberg, 
2006) by kind permission of Nature Reviews Immunology.  
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1.8   Depression 
Depression  is  characterized  by  a  combination  of  behavioural,  emotional, 
psychomotor and cognitive symptoms, including significant weight loss, insomnia 
or  hypersomnia,  reduced  appetite,  fatigue,  extreme  feelings  of  guilt  or 
worthlessness,  concentration  difficulties  and  suicidal  thoughts  (Gotlib  and 
Joormann, 2010).  Depression is a common psychiatric disorder that affects up to 
25%  of  women  and  12%  of  men  (Gelenberg,  2010).    Depression  is  often  a 
comorbid condition with other mental and physical illnesses; most frequently 
with anxiety disorders (Castaneda et al., 2008).  
Major depressive disorder (MDD) affects some 6% of the population during 
their  lifetime.  Major  depressive  disorder  is  a  heteregenous  disorder  with 
complex  aetiology.  Many  mechanisms  have  been  investigated  including, 
sociological,  psychological  and  biological.  There  are  no  clear,  unequivocal 
mechanisms  specific  to  depression  and  the  majority  of  cases  may  be  a 
combination of aetiologies. Abnormalities of the monoamine neurotransmitter 
system  have  been  proposed  to  be  the  main  pathological  mechanism  of 
depression. Based on this monoamine hypothesis, low levels of one or more of 
the  monoamine  neurotransmitters,  which  are  serotonin,  noradrenalin  and 
dopamine,  can  induce  depression  (Singh,  1970).  Among  these,  serotonin  is 
considered to play a major role in the pathological mechanism of depression. It 
has  been  demonstrated  that  depression  is  caused  by  abnormalities  of  the 
serotonin transporter (SERT) at several levels, including the expression of the 
SERT  gene  in  different  functional  polymorphisms  (5 HTTLPR),  the  re uptake 
activity of SERT and the level of SERT expressed in the brain. Therefore SERT is 
considered  to  be  an  important  therapeutic  target  site  for  anti depressants 
(Belmaker and Agam, 2008). Several effective anti depressants that are designed 
to  modulate  the  serotonergic  system,  including  selective  serotonin  re uptake 
inhibitors  (SSRI)  and  5 HT2  receptor  antagonists  and  5 HT1A  receptor  partial 
agonists, are reported to be efficient treatments for depression (Williams et al., 
2000a).  Recently, there are a number of new psychological theories about the 
aetiology of depression. The ‘neurotrophin hypothesis of depression’ is based on 
accumulating  evidence  suggesting  an  association  between  the  cytokine  brain 
derived neurotrophic factor (BDNF) and the psychological and cognitive aspects 
of depression (Martinowich et al., 2007). Serum BDNF concentrations are lower Chapter 1    75 
in  depressed  patients,  and  increase  in  response  to  anti depressant  treatment 
(Matrisciano et al., 2009). Although clinical evidence for this theory exists, the 
direct  in  vivo  evidence  showing  that  reduced  endogenous  gene  expression  of 
BDNF  can  lead  to  depression/  depression like  behaviour  is  still  controversial 
(Sakata et al., 2010); (Chourbaji et al., 2004). It has been suggested that the 
absence  of  BDNF  in  the  brain  does  not  cause  depression   or  anxiety like 
behaviour, but rather inhibition of an improved behavioural response to anti 
depressants (Saarelainen et al., 2003); (Chen et al., 2006). 
Clinical evidence suggests that the neuroendocrine system has a crucial 
role  in  regulating  psychological  conditions  (Heiser  et  al.,  2008).  HPA  axis 
activation  and  dysregulation  are  common  in  depression  and  stress related 
psychological  disorders.  Approximately  43%  of  depression  patients  exhibit 
increased concentrations of cortisol and corticotropin releasing hormone (CRH), 
and  a  poor  ability  to  reduce  cortisol  release  as  measured  by  an  impaired 
feedback response to exogenous dexamethasone. Activation of the HPA axis in 
depression  patients  can  also  be  attenuated  by  long term  anti depressants 
(Varghese  and  Brown,  2001).  Adult  brain  neurogenesis  is  a  novel  theory  of 
depression that has generated enormous interest over the past decade and will 
be discussed in the next section.  
1.9  Hippocampal neurogenesis 
The hippocampus is the major brain region that has a crucial role in encoding 
episodic memories, especially spatial memory and working memory, which are 
often  considered  as  parts  of  cognition  (Burgess  et  al.,  2002).  Within  the 
hippocampus, the dentate gyrus (DG) generates new neurons throughout life; 
this  is  known  as  neurogenesis  (Deng  et  al.,  2010).  Neuronal  progenitor  cells 
(NPCs)  in  the  subgranular  zone  (SGZ)  of  the  dentate  gyrus  differentiate  into 
granular neurons. These cells develop electrical properties and integrate into 
functional  circuits  by  extending  their  axonal  projections  along  mossy  fibre 
pathways  to  the  CA3  area  of  the  hippocampus.  Neuronal  circuits  in  the 
hippocampus have been implicated in cognitive memory and learning, involving 
the processing of new information (Bruel Jungerman et al., 2007). The memory 
formation depends on changes in synaptic long term potentiation (LTP) and long 
term  depression  (LTD)  (Howland  and  Wang,  2008).  Bliss  et  al.,  in  1973  first Chapter 1    76 
demonstrated that LTP was inducible by stimulating dentate gyrus granule cells, 
which transmit the nerve signals to the CA3 region via the mossy fibre pathway 
(Bliss  and  Gardner Medwin,  1973).  CA3  pyramidal  neurons  then  transmit 
excitatory  synaptic  signals  to  the  CA  1  region;  which  has  been  implicated  in 
memory  storage  and  consolidation,  via  glutamate  release  and  NMDA/AMPA 
receptor activation (Kullmann and Lamsa, 2007). Hippocampal neurogenesis and 
neuronal circuit s shown in Figure 1.3. 
 
Figure 1.3. Hippocampal neurogenesis and neuronal circuit.  
Neuronal progenitor cells (NPCs) differentiate into granular neurons and integrate into the 
circuit by extending their axonal projections along mossy fibre pathways to the CA3 area of 
the hippocampus (red). These mossy fibre pathways function to transmit neuronal signals 
in the form of synaptic long term potentiation (LTP). Neurons at CA3 then transmit 
excitatory synaptic signals to the CA 1 region (green). The image were taken from (Amrein 
and Lipp, 2009) by kind permission of Biology Letters.  
1.9.1  The role of neurogenesis in hippocampal function 
How  neurogenesis  contributes  to  hippocampal  function  is  largely  unknown. 
Accumulating  evidence  suggests  that  hippocampal  neurogenesis  has  a  crucial 
role  in  hippocampal dependent  learning  and  memory  (Deng  et  al.,  2010). 
Therefore,  deficits  in  adult  hippocampal  neurogenesis  may  underlie  the 
cognitive deficits developed in depression (Sahay and Hen, 2007). Biogenic rtTA 
Bax  mice  with  genetic  deletion  of  neurogenesis  show  an  impairment  in 
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water  maze  and  contextual  fear  conditioning  (Dupret  et  al.,  2008).    Farioli 
Vecchioli and colleague demonstrated that changes in differentiation timing of 
neurons in the adult dentate gyrus also resulted in spatial learning and memory 
deficiency,  along  with  a  reduction  in  long term  potentiation  of  synaptic 
plasticity (Farioli Vecchioli et al., 2008); (Farioli Vecchioli et al., 2009). These 
findings suggested that these immature DG neurons are highly active and able to 
transmit synaptic plasticity and encode the memory at a specific stage of their 
differentiation.  
Computational  models  of  DG  newly  born  neuron  function  also  suggested  that 
neurogenesis also has a crucial role not only in encoding memory, but also in the 
consolidation of memory. Without neurogenesis, a spare subset of mature DG 
neurons encode the initial memory via a synaptic transmission to a limited set of 
pyramidal  cells  in  CA3,  leading  to  a  unique  pattern  of  activated  CA3  cell 
networks for the initial memory. The later memory is encoded by another subset 
of mature DG neurons, resulting in another unique pattern of activated CA3 cell 
networks  for  the  later  memory.  The  patterns  of  both  activated  CA3  cell 
networks  for  the initial  and  the  later  memories  thus  do not overlap.  On the 
other  hand,  with  neurogenesis,  both  initial  and  later  memories  are  encoded 
equally  by  immature  DG  neurons.  This  leads  to  two  overlapping  patterns  of 
activated CA3 cell networks, suggesting that the initial memory is consolidated 
and protected from encoding the later memory. However, these immature DG 
neurons will mature and die in a short period of time (~ 3 weeks to ~ 2 months) 
(Zhao et al., 2006). Therefore, the memory of a new event that occurs at a 
much later time is encoded by a different set of immature DG neurons, which 
are no longer able to encode the initial memory. This leads to two independent 
patterns of activated CA3 cell networks. This finding suggested that hippocampal 
neurogenesis  may  be  responsible  for  encoding  and  consolidating  memories  of 
events that occur closer in time. However, the retrieval of long term memory in 
human  may  be  hippocampal independent  or  regulated  by  other  brain  regions 
(Aimone et al., 2006).  
1.9.2  Hippocampal neurogenesis and depression 
The  ‘hippocampal  neurogenesis  hypothesis  of  depression’  is  based  on 
accumulating evidence showing a reduction of hippocampal neurogenesis in the Chapter 1    78 
model of stress related mood disorders. Animal experiments showed that stress 
or  chronic  treatment  with  corticosterone  caused  reduced  hippocampal 
neurogenesis,  along  with  a  decreased  hippocampal  volume  (Brummelte  and 
Galea,  2010);  (Czeh  et  al.,  2001).  Other  important  evidence  supporting  this 
hypothesis is that anti depressants increase hippocampal neurogenesis in both 
animals  and  humans.  Anti depressants  such  as  fluoxetine,  agomelatine, 
imipramine and electroconvulsive therapy (ECT) have been reported to increase 
neurogenesis  in  various  species,  including  rodents,  nonhuman  primates  and 
humans, and reverse reduced neurogenesis that is induced by stress and cerebral 
ischemia  (Perera  et al.,  2007);  (Malberg  et  al.,  2000);  (Banasr  et  al.,  2006); 
(Schiavon et al., 2010).  A neurogenesis study of frozen hippocampus isolated 
from  depression  patients  showed  a  reduction  in  neurons  expressing  neural 
progenitor  (NPCs)  markers  compared  to  those  of  healthy  control  subjects. 
Interestingly, the number of neural progenitor (NPCs) cells in the hippocampus 
of  depression  patients  who  received  long term  SSRIs   and  tricyclic 
antidepressants (TCAs) treatment was higher than those of untreated depression 
patients  (Boldrini  et  al.,  2009).  Importantly,  hippocampal  neurogenesis  is 
considered  to  be  a  potential  therapeutic  target  site  of  the  action  of  anti 
depressant drugs because hippocampal neurogenesis was shown to be essential 
for  behavioural  effects  of  anti depressants  in  mice.  Serotonin  1A  receptor 
deficient mice treated with fluoxetine or imipramine treatment showed higher 
level  of  appetite,  measured  by  a  depressive like  behaviour  test  called  the 
suppressed feeding test, compared to untreated serotonin 1A receptor deficient 
mice.  However,  after  ablation  of  neurogenesis  by  x irradiation,  serotonin  1A 
receptor deficient mice that received antidepressants showed no difference in 
the level of appetite compared to those without the treatment (Santarelli et al., 
2003).  However,  it  is  still  unclear  whether  impairment  in  hippocampal 
neurogenesis is an aetiological factor for depression. Reductions in hippocampal 
volume have been reported in depressed patients (von Gunten and Ron, 2004); 
(Frodl et al., 2006). It has been hypothesized that the decrease in neurogenesis 
in the SGZ of the dentate gyrus may also be the main contributor to decreased 
hippocampal volume. However, there is no direct evidence showing that changes 
in  adult  hippocampal  neurogenesis  account  for  the  reduction  in  hippocampal 
volume in patients with depression. Decreased numbers of progenitor cells were 
observed  in  the  hippocampus  of  depression  patients.  Immuno histochemical Chapter 1    79 
staining showed a reduction in the number of neurons expressing the progenitor 
cell marker, MCM2, in frozen hippocampus tissues isolated from 10 depression 
patients,  compared  to  those  from  10  sex   and  age matched  healthy  control 
subjects (Lucassen et al., 2010). However, methods and devices for imaging of 
neurogenesis in live human brains are still not fully developed. Therefore, the 
indirect approach is to use proton magnetic resonance spectroscopy (
1H MRSI) to 
identify  changes  in  neuro metabolites  that  reflect  neuronal  dysfunction,  glial 
reaction and energy metabolism. N acetylaspartate (NAA) is one of the neuronal 
markers that is commonly used in proton MR spectroscopic (MRS) imaging. This is 
because  NAA  is  a  metabolite  of  aspartate,  which  is  the  main  amino  acid 
consumed  by  CNS  neurons  (Maletic Savatic  et  al.,  2008).  Patients  with  mild 
cognitive deficiency also showed a reduced NAA in the hippocampus (Wang et 
al.,  2009b).  However,  it  has  been  reported  that  inhibition  of  hippocampal 
neurogenesis  using  X irradiation  does  not  cause  a  reduction  of  hippocampal 
volume (Santarelli et al., 2003). Pathohistological studies of post mortem tissue 
suggested that increased apoptosis of mature neurons or glial cells are the cause 
of the reduction in hippocampal volume (Czeh and Lucassen, 2007); (Sahay et 
al.,  2007).  Preclinical  studies  showed  that  changes  in  the  hippocampal 
neurogenesis volume resulted from changes in morphology of neurons such as 
reduced  dendritic  complexity,  but  not  from  ablation  of  hippocampal 
neurogenesis  (Santarelli  et  al.,  2003);  (McEwen,  2005).  In  addition,  it  is  still 
controversial whether the impairment in hippocampal neurogenesis is directly 
associated with depression like or anxiety like behaviour. Transgenic mice with a 
neurogenesis  deficiency  exhibited  an  increase  in  anxiety related  behaviour 
(Revest  et  al.,  2009).  In  contrast,  a  study  by  Saxe  et  al  reported  that  the 
inhibition  of  hippocampal  neurogenesis  does  not  influence  anxiety related 
behaviour tested by open field, light dark choice test, and elevated plus maze 
tests (Saxe et al., 2006). Moreover, an increase in hippocampal neurogenesis by 
anti depressants does not always correlate with an improvement in depression 
like or anxiety like behaviour in animals. A study in BALB/cj mice showed that 
chronic  fluoxetine  treatment  improved  depressive  behaviour  without  inducing 
changes  in  hippocampal  neurogenesis  (Huang  et  al.,  2008).  This  finding  is 
supported  by  another  study  by  Bessa  2009  showing  that  the  effect  of  anti 
depressants on depression like behaviour depended on neuronal remodelling, but 
not  hippocampal  neurogenesis  (Bessa  et  al.,  2009).  In  contrast,  hippocampal Chapter 1    80 
neurogenesis has been reported to be the essential target site for the effects of 
anti depressants  on  depression like  or  anxiety like  behaviour  in  animals 
(Santarelli et al., 2003). This evidence suggests that anti depressants may have 
both  neurogenesis dependent  and  –independent  effects  on  depression like  or 
anxiety like behaviour (David et al., 2009). The evidence in support of and in 
conflict with the ‘hippocampal neurogenesis hypothesis of depression’ suggests 
that the role of hippocampal neurogenesis in the aetiology of depression need to 
be further investigated. 
1.10   Cytokines, peripheral inflammation and 
depression 
Recent attempts have been made to classify this disorder and one approach has 
been to explore the co morbid depression seen in many medical illnesses. There 
is  increasing  evidence  of  association  between  inflammation  and  major 
depressive disorder (MMD) and this comes primarily from 3 clinical observations.  
i)  Inflammatory  medical  illnesses  –  both  CNS  and  peripheral  –  are 
associated with greater rates of major depression. 
ii)   MDD even in the absence of medical illness is associated with raised 
inflammatory markers.  
iii)  Patients  treated  with  cytokines  for  various  illnesses  are  at  risk  of 
developing major depressive illness.  
Sub typing depression may help uncover the role of biological mechanisms 
that  may  be  specific  to  these  subtypes.  Depression  with  a  prominent 
inflammatory  component  may  be  one  such  subtype.  The  uncovering  of 
different biological mechanisms relating to depressive subtypes may also aid 
the development and targeting of new treatment strategies.  
1.10.1   Depression and rheumatoid arthritis 
Depression is associated with several chronic inflammatory diseases such as RA, 
MS, psoriasis as well as diabetes (Engum et al., 2005), obesity (Atlantis et al., 
2009), and cardiovascular disease (Pitt and Deldin, 2010). In RA, the prevalence Chapter 1    81 
of depression is 14% 46% (Katz and Yelin, 1993); (Dickens et al., 2002). A recent 
clinical study of 82 RA patients showed that the prevalence of depression was 
41.5% and the degree of depression was positively associated with the duration 
of RA disease (Isik et al., 2007). Depression was shown to increase the risk of 
mortality in RA; a study of 1290 RA patients showed that those who had suffered 
from persistent or recurrent depression over the first 4 year period of disease 
had higher mortality rates compared to those without depression during an 18 
year observation period (Ang et al., 2005). Higher rates and specific pasterns of 
suicide have also been reported in RA patients with depression. 11% of hospital 
outpatients with rheumatoid arthritis (13 of 123) experienced suicidal thoughts 
(ideation)  (Treharne  et  al.,  2000).  In  a  study  of  19  suicide  victims  who  had 
hospital treated RA, 52.6% were female. In addition, 90% of these female RA 
patients  had  suffered  from  co morbid  depression  and  had  chosen  a  violent 
suicide method, compared to male RA patients who committed suicide (Timonen 
et al., 2003). The cause of depression in RA is unclear. Similar to other painful 
conditions,  depression  associated  with  RA  is  often  considered  to  be  a  simple 
consequence of the experience of chronic pain. This concept was supported in a 
large–scale study of 22131 RA patients, using a questionnaire of the Symptom 
Intensity Scale, showing that pain and fatigue were the strongest predictors of 
self reported  depression  (Wolfe  and  Michaud,  2009).  However,  a  relation 
between pain and depression in RA is still unclear because a study by Mindham 
et al indicated that pain and disability in RA are not potent factors that can 
contribute to depression (Mindham et al., 1981), and a clinical study of 218 RA 
patients showed that depression in RA patients is not only associated with pain, 
but correlated with the concentration of the acute phase response inflammation 
marker C reactive protein (CRP) level in the blood (Kojima et al., 2009). This 
suggests  the  hypothesis  that  ‘peripheral  inflammation  may  participate  in 
depression in RA’.  
Several  reports  also  suggest  that  sleep  disorders  are  associated  with  chronic 
inflammatory diseases such as rheumatoid arthritis (RA), asthma and systemic 
lupus erythematosus (SLE) (Janson et al., 1996, Gudbjornsson and Hetta, 2001, 
Bourguignon  et  al.,  2003,  Keefer  et  al.,  2006).  However,  it  is  still  unclear 
whether  sleep  abnormalities  in  patients  with  these  chronic  inflammatory 
diseases are the result of pain, stress or depression that is associated with these Chapter 1    82 
chronic inflammatory diseases. It is also possible that sleep disturbance itself 
could be a result of disease related immune changes, which increased risk of 
depression  in  patients  with  these  chronic  inflammatory  diseases.  Vice  versa, 
sleep  deprivation  has  been  reported  to  alter  immune  system  functions  by 
increasing the activity of natural killer (NK) cells and monocytes (Dinges et al., 
1994). Prolong periods of wakefulness can also result in an increase in serum IL 6 
and TNF soluble receptor concentrations (Shearer et al., 2001). The activation of 
immune responses caused by sleep deprivation may have a negative impact on 
the  availability  of  tryptophan  to  the  brain  and  hence  reducing  synthesis  of 
serotonin (5 HT), which could be a possible underlying pathological mechanism 
of depression (Fernstrom et al., 1990). A study by Song et al., demonstrated an 
inverse relationship between the low availability of plasma tryptophan and high 
serum  IL 1RA,  IL 6  and  IL 8  concentrations  in  patients  with  primary  sleep 
disorders  associated  with  major  depression  (Song  et  al.,  1998).  This  study 
suggests that sleep disruption plays a detrimental role in immune inflammation 
that possibly causes or contributes to depression. Therefore, it seems logical to 
consider  sleep  disturbances  as  one  of  the  factors  that  negatively  influences 
chronic inflammatory diseases and that it possibly plays a role in depression in 
the context of chronic inflammatory diseases.  
1.10.2    Immune activation in depression patients  
 Important  evidence  supporting  the  ‘inflammation induced  depression  in  RA’ 
hypothesis includes the increased concentrations of cytokines, immune cells and 
inflammatory marker such as CRP in the blood of depression patients.  
Alterations in the serum concentrations of various cytokines, including TNF α, IL 
1β, IL 6, IL 4, IL 10, IL 8, IL 4, IFN γ, GM CSF and IL 12, in depression patients 
have been reported. However, some of these cytokine changes have not been 
consistent  in  different  studies,  depending  on  the  particular  cytokine  and  the 
measurement  technique  used.  For  example,  a  study  of  serum  cytokine 
concentrations in 49 depression patients using a human 22 plex multi cytokine 
detection  (Luminex)  system  showed  increased  concentrations  of  15 
cytokines/chemokines  including  IL 10  and  GM CSF  (Simon  et  al.,  2008).  In 
contrast,  a  study  in  12  depressive  patients  using  an  Enzyme linked 
immunosorbent  assay  (ELISA)  method  showed  lower  than  normal  serum  IL 10 Chapter 1    83 
concentrations (Dhabhar et al., 2009). Serum levels  of GM CSF within normal 
levels, measured by using a Bio Plex human cytokine kit, was observed in 122 
depression patients (Lehto et al., 2010a). A recent meta analysis of 24 studies 
looking at serum cytokine concentrations in major depression demonstrated that 
IL 6 and TNF α were 2 cytokines that were consistently found to be higher than 
normal (Dowlati et al., 2010). An increased serum TNF α concentration has been 
associated with suicidal tendency in depression patients (Eller et al., 2009) and 
the concentrations of both soluble TNF α receptors, sTNFR 1 and sTNFR2 were 
also increased in the serum of depression patients (Grassi Oliveira et al., 2009). 
IL 6  and  TNF α  were  also  up regulated  in  the  CSF  of  depression  patients 
(Palhagen et al., 2010).  A positive correlation between CSF TNF α and IL 6 with 
the  depression  score;  measured  by  Postpartum  Blues  Scale  and  Edinburgh 
Postnatal  Depression  Scale  (EPDS),  was  observed  in  depressive  women  during 
delivery  and  during  the  postpartum  period  (Boufidou  et  al.,  2009).  Suicide 
attempters showed higher than normal IL 6 concentration in the CSF, and this 
correlated with Montgomery Åsberg Depression Rating Scale (MADRS) (Lindqvist 
et al., 2009). These data suggest that TNF α and IL 6 may have a major role in 
the  immuno pathology  of  depression.  Interestingly,  chemokines  have  recently 
been shown to have a role in depression. Serum concentrations of MCP 1, MIP 1β 
and  IL 8  were  reduced  in  patients  with  major  depression,  suggesting  that 
chemokines may play a protective role in the pathology of depression (Lehto et 
al., 2010b).  
Several studies have demonstrated that cell mediated immune activation may be 
a  key  component  in  the  pathogenesis  of  depression  (Maes,  2010).    Several 
studies  demonstrated  an  imbalance  of  Th1  and  Th2  cytokines  in  depression 
patients. The Th1/Th2 ratio, as indicated by the serum IFN γ/IL 4 concentration 
ratio was increased in depressive patients, but this ratio returned to the normal 
baseline after anti depressant treatment (Myint et al., 2005); (Kim et al., 2008). 
The  serum  IL 1β/IL 10  ratio  was  also  increased  in  patients  with  acute 
melancholic depression (Huang and Lee, 2007).  A recent study of 27 patients 
with  major  depression  showed  a  3 fold  increase  in  the  Th1/Th2  cell  ratio  as 
shown by the concentration ratio of serum IL 2/IL 10. In addition, in depression 
patients a reduction in CD4
+CD25
+ regulatory T cells in peripheral blood, along 
with  a  reduced  5 HT1a  receptor  expression  on  these  regulatory  T  cells  were Chapter 1    84 
observed. A shift in the Th1/Th2 ratio in depression suggests that activation of 
the inflammatory response may play a role in immuno pathological mechanism 
of depression. The association between reduced CD4
+CD25
+ regulatory T cells 
and a  decrease  in  5HT  receptor also  suggests  that  the  immune dysregulation 
during  depression  may  affect  the  serotonergic  system,  which  eventually 
contributes to the development of depression (Li et al., 2010).  
1.10.3  The cytokine hypothesis of depression  
The ‘cytokine hypothesis of depression’ states that peripheral inflammation can 
cause changes in cytokine expression profiles in the brain, leading to various 
neurological  outcomes  such  as  alterations  in  the  neurotransmitter  and 
neuroendocrine  systems.  These  eventually  may  result  in  somatic  and 
psychological  symptoms  such  as  sickness  behaviour,  depression  and  cognitive 
dysfunction (Schiepers et al., 2005). This hypothesis is based on the evidence 
showing  that  cytokine  therapy  can  induce  neuro psychiatric  symptoms  in 
patients with cancer or chronic hepatitis C. Cytokines such as IFN α and IL 2 can 
be used as immunotherapy for the treatment of chronic hepatitis C and cancer 
(Bonaccorso  et  al.,  2001);  (El Zayadi,  2009);  (Pasquini  et  al.,  2008). 
Approximately 30% of patients who received IFN α therapy develop sickness like 
symptoms, anxiety and major depression, which are the major side effects of 
immunotherapy (Quarantini et al., 2007). The sickness like symptoms, including 
lack of sleep, loss of appetite, weight loss and fatigue usually occurred during 
the first 2 4 weeks of the therapy and can be early indicators for depression 
which usually developed 1 3 months after the treatment (Robaeys et al., 2007); 
(Franzen  et  al.,  2010).  IFN α  therapy  also  has  an  effect  on  other  neuro 
psychological functions such as locomotor activities. Chronic hepatitis C patients 
who  receive  IFN α  exhibited  slower  response  times  in  the  rapid  visual 
information processing task. This locomotor impairment has also been associated 
with  increased  depressive  symptoms  and  fatigue  (Majer  et  al.,  2008).  IFN α 
induced impairment of locomotor activity and depressive behaviour have also 
been observed in a non human primate model, using rhesus monkeys and in a 
mouse model (Felger et al., 2007). In addition, changes in behavioural symptoms 
have also been associated with alterations in neurotransmitter levels such as 5 Chapter 1    85 
HT and dopamine in the CNS of these models (Felger et al., 2007); (Litteljohn et 
al., 2010). 
1.10.4   Possible mechanism underlying cytokine induced 
depression 
Possible  mechanisms  underlying  cytokine induced  depression are  still  unclear. 
The  central  effects  of  pro inflammatory  cytokines  on  the  neurotransmitter 
system, neuroendocrine, neurotropic factor and hippocampal neurogenesis may 
contribute to the development of depression.  
Peripheral inflammation and cytokines can modulate neurotransmitter systems 
such  as  serotonin  (5 HT),  dopamine  (DA),  and  noradrenaline  (NA)  via  the 
regulation  of  neurotransmitter  biosynthesis  and  their  transporter  activities. 
(MohanKumar et al., 1999). A study by Zhu et al demonstrated that interleukin 
1β and tumor necrosis factor α stimulated the transport activity of the serotonin 
transporter in serotonergic neurons of mouse midbrain and striatum, in a dose  
and time dependent manner (Zhu et al., 2006). The effect of pro inflammatory 
cytokines  on  tryptophan  metabolism,  particularly  the  indoleamine  2,3 
dioxygenase (IDO) pathway, has recently been considered to be one potential 
mechanism underlying inflammation induced depression. The IDO pathway seems 
to be the most important link between inflammation and serotonin metabolism. 
IDO degrades L tryptophan (L TRP), an amino acid precursor of serotonin (5HT), 
via  the  kynurenine  pathway  during  immune  activation  (Kwidzinski  and 
Bechmann, 2007). L tryptophan is catabolized into L kynurenine (L KYN), which 
is  metabolised  further  to  quinolinic  acid  (QUIN)  and  kynurenic  acid  (KA) 
(Kwidzinski and Bechmann, 2007). The expression of IDO is induced mainly by 
IFN γ and TNF α in several immune cells, including macrophages (Thomas et al., 
2001), dendritic cells (Jurgens et al., 2009, Dai and Gupta, 1990), and fibroblast 
(Dai and Gupta, 1990). IFN γ induction of IDO was also found in astrocytes (Suh 
et al., 2007) and microglia (Yadav et al., 2007). IDO also has a crucial role in 
immuno suppression by inhibiting the proliferation of CD4
+ T cells and CD8
+ T 
cells  (Forouzandeh  et  al.,  2008)  and  of  regulatory  T  cells  (Munn  and  Mellor, 
2007).  Both  clinical  and  experimental  studies  have  demonstrated  that 
depressive like behaviour induced by systemic inflammation or cytokines could 
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along with increased IL 6 and TNF α production by microglia in the cortex and 
hippocampus  of  the  mouse  brain,  caused  depressive like  behaviour  in  mice 
(O'Connor  et  al.,  2009);  (Connor  et  al.,  2008).  A  decrease  in  peripheral 
tryptophan, and the positive correlation between CSF QUIN, CSF cytokine and 
depressive  symptoms  were  observed  in  depressive  patients  during  hepatitis  C 
treatment  with  IFN α  (Raison  et  al.,  2010).  This  evidence  suggests  that 
peripheral inflammation may induce the expression of IDO enzyme as a negative 
feedback to suppress inflammation. However, IDO enzyme causes the reduction 
of  precursor  of  5HT,  leading  to  depression  during  inflammation.  In  addition, 
peripheral inflammation and chronic inflammatory diseases induce the HPA axis 
to  release  CRH  and  glucocorticoids  that  in  turn  affect  the  neurobiology  of 
cognition and mood (Pace et al., 2007). The central action of cytokines may also 
account  for  the  reduction  of  the  neurotropic  factors  such  as  BDNF.  Several 
experimental  studies  showed  that  a  reduction  of  BDNF  in  the  hippocampus 
caused by cytokines, has been reported to cause an impairment in cognition. 
Peripheral inflammation in mice caused a reduction of hippocampal BDNF and 
also  showed  an  impairmentin  hippocampal dependent  memory  (Bilbo  et  al., 
2008).  A  potential  mechanism  underlying  cytokine induced  depression  can  be 
suggested; this is that cytokines can mediate decreased neurogenesis, thereby 
causing depression. 
1.10.5   Cytokine mediated inflammation and decreased 
hippocampal neurogenesis in depression 
Hippocampal  dysfunction  due  to  a  reduction  in  neurogenesis  has  been 
demonstrated to be a major contributor to the cognitive impairment aspect of 
depression.  Adaptive  and  innate  immune  responses,  immune  cells  and 
inflammatory mediators resulting from peripheral inflammation have their roles 
in the regulation of neurogenesis. It has been hypothesised that ‘impairment of 
hippocampal  neurogenesis  by  immune  activation  may  be  an  underlying 
mechanism of the depression that develops during systemic inflammation’. This 
hypothesis  is  based  on  several  recent  studies  showing  that  alterations  in 
hippocampal  neurogenesis  by  cytokines,  immune  cells  and  immune  activation 
can contribute to behavioural changes in animal models. Socially isolated mice 
over expressing interleukin 1 receptor antagonist in the hippocampus showed an 
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neurogenesis (Ben Menachem Zidon et al., 2008). Learning experience induced 
neurogenesis has been associated with the recruitment of CNS specific T cells 
and the activation of microglia (Ziv et al., 2006). In contrast, autoimmune prone 
cytokine  B cell activating  factor (BAFF)  transgenic  mice;  a  model  of  systemic 
lupus  erythematosus,  rheumatoid  arthritis  and  Sjögren’s  syndrome,  showed 
decreased  hippocampal  neurogenesis  and  LTP,  along  with  increased  anxiety 
behaviour (Crupi et al., 2010). These findings suggest different roles for T cells 
and B cells in the regulation of neurogenesis, which can contribute to different 
aspects  (cognition  and  mood)  of  depression.  Based  on  this  evidence, 
hippocampal  neurogenesis  can  be  considered  as  an  important  link  between 
inflammation and depression.  
1.10.6   Role of peripheral inflammation in hippocampal 
neurogenesis 
Accumulating  evidence  suggests  that  inflammatory  processes,  both  local  and 
systemic, can reduce the proliferation and survival of new neurons. Ekdahl et al 
found that administering LPS locally into brains gave rise to microgial activation 
in the hippocampus which resulted in strongly impaired neurogenesis (Ekdahl et 
al.,  2003).  Monje  ML  et  al  also  demonstrated  the  effect  of  systemic 
inflammation  on  adult  hippocampal  neurogenesis.  Inducing  peripheral 
inflammation using i.p. injection of LPS in female rats, leads to the inhibition of 
neurogenesis in the adult dentate gyrus. Interestingly, the reduced neurogenesis 
can be reversed by indomethacin, a cyclooxygenase COX1/COX2 inhibitor. This 
result  also  indicated  that  the  decrease  of  neurogenesis  caused  by  chronic 
inflammation was associated with a progressive decline in learning and memory 
(Monje ML et al., 2003). 
1.10.6.1  Role of cytokines in hippocampal neurogenesis 
There  are  various  possible  mechanisms  underlying  peripheral  inflammation 
suppression of hippocampal neurogenesis. This may be due to the direct effect 
of  pro inflammatory  cytokines  produced  during  the  inflammatory  process  on 
morphological development in the hippocampus. IL 1β is an important regulator 
of  brain  cytokine  networks  that  contribute  to  the  inflammatory  process  of 
various  neurodegenerative  diseases  (Allan  et  al.,  2005).  Peripheral  LPS 
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hippocampus (Csolle and Sperlagh, 2010). In addition, the hippocampus itself is 
the brain area with the most intense expression of IL 1β and its receptor (Allan 
et  al.,  2005).  In  vivo  cell  cycle  and  proliferation  analysis  using 
bromodeoxyuridine  (BrdU)  demonstrated  that  after  1  week  of  IFN α 
administration in rats, a reduced number of BrdU labelled proliferating cells was 
observed in the dentate gyrus. Interestingly, following the injection of IFN α, an 
increased  concentration  of  IL 1β  was  also  observed  in  the  hippocampus. 
Moreover,  with  co administration  of  IL 1β  receptor  antagonist,  the  IFN α 
induced  suppression  of  the  neurogenesis  in  the  adult  dentate  gyrus  was 
completely blocked. This suggests that the IFN α inhibits neuronal proliferation 
in the dentate gyrus via IL 1β signalling (Kaneko N et al., 2006). 
1.10.6.2   Role of chemokines in hippocampal neurogenesis 
Chemokines, particularly the CXCL12/CXCR4 ligand and receptor, have crucial 
roles in hippocampal neurogenesis; particularly in the regulation of the survival 
and  maturation  of  neuronal  progenitor  cells.  CXCR4  has  a  direct  role  in  the 
regulation of the migration of granule cells. CXCR4 gene deficient mice showed 
a  dramatic  decrease  in  the  distribution  of  dividing  precursor  cells  from  the 
ventricular zone to the dentate gyrus (Bagri et al., 2002). CXCL12 also enhanced 
human  neuronal  progenitor  cell  proliferation  (Wu  et  al.,  2009).  Smaller  and 
morphologically immature cells of the hippocampal dentate gyrus were observed 
in CXCR4 gene deficient mice (Lu et al., 2002). CXCL12, which functions as a 
chemo attractant  for  leukocytes,  also  shows  a  chemo attractive  activity  for 
embryonic cerebellar neurons in the meninges (Zhu et al., 2002b). CXCL12 also 
has an effect on the maturation and differentiation of hippocampal neurons by 
regulating  axonal  patterning  at  an  early  stage  of  neuronal  development. 
Hippocampal  neurons  treated  with  CXCL12  showed  specific  morphology  with 
shorter  axons  and  more  axonal  branches  compared  to  normal  hippocampal 
neurons (Pujol et al., 2005). CXCL12 also showed an effect on axon outgrowth 
into other types of neurons and acts as a chemotactic molecule that influences 
axonal  guidance  in  cultured  retinal  ganglion  cells  (Chalasani  et  al.,  2003). 
Increased axonal elongation was observed in cerebellar granule neurons treated 
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1.10.6.3   Role of innate immunity in hippocampal neurogenesis 
Recent findings showed that innate immunity is also involved in hippocampal 
neurogenesis; mainly via TLRs. TLR2 gene deficient mice showed a reduction in 
hippocampal neurogenesis. In contrast, TLR4 deficient mice exhibited increased 
proliferation  and  neuronal  differentiation  (Rolls  et  al.,  2007);  (Keene  et  al., 
2009). Activating TLR3 suppressed neural progenitor cell proliferation in vivo, 
while hippocampal neural progenitor cells in TLR2 deficient mice showed greater 
maturation compared to controls (Lathia et al., 2008).  
1.10.6.4  Role of adaptive immunity in hippocampal neurogenesis 
The role of the adaptive immune response in hippocampal neurogenesis is still 
controversial.  A  study  by  Ziv  et  al.,  suggested  that  T  cells  supported 
hippocampal neurogenesis (Ziv et al., 2006). This observation is confirmed by a 
study showing an increase in hippocampal neurogenesis in arthritis model mice 
(AIA  model).  The  author  of  that  study  suggested  that  the  increase  in 
hippocampal  neurogenesis  was  regulated  by  T  cells  (Wolf  et  al.,  2009a).  In 
contrast,  a  study  by  Wang  et  al  showed  that  activated  T  cells  inhibited 
neurogenesis (Wang et al., 2010).  In addition, B cells also showed to reduced 
hippocampal  neurogenesis  (Crupi  et  al.,  2010).  It  seems  therefore  that 
lymphocytes can contribute to neurogenesis but that little is known about the 
mechanisms.  
1.10.6.5  Potential indirect regulation of hippocampal neurogenesis 
associated with inflammation 
As well as the direct effect of cytokines, immune cells and immune activation, 
hippocampal neurogenesis could be regulated by indirect pathways associated 
with  inflammation  such  as  from  the  neuroendocrine  system  or  neurotrophic 
factors. Peripheral inflammation and chronic inflammatory diseases induce the 
HPA axis to release CRH and glucocorticoids that in turn affect the neurobiology 
of cognition and mood (Rohleder et al., 2010). Animal experiments showed that 
stress and chronic treatment with corticosterone caused reduced hippocampal 
neurogenesis,  along  with  a  decreased  hippocampal  volume  (Brummelte  and 
Galea, 2010); (Czeh et al., 2001). Chronic administration of corticosterone was 
shown  to  inhibit  hippocampal  neurogenesis  and  reduce  hippocampal  volume, Chapter 1    90 
along with increased anxiety (light dark box test) and depression (forced swim 
test)  like behaviour, suggesting that corticosterone not only induces depression 
via  the  serotonergic  system,  but  also  via  neurogenesis  (Murray  et  al.,  2008). 
Chronic  stress  and  glucocorticoid  treatment  may  suppress  hippocampal 
neurogenesis by inhibiting BDNF production in the hippocampus (Smith et al., 
1995). A swim stress test was shown to inhibit BDNF mRNA expression and TrkB 
signalling in the mouse hippocampus (Shi et al., 2010). However, there is no 
direct  evidence  showing  that  peripheral  inflammation induced 
CRH/glucocorticoids  suppress  hippocampal  neurogenesis.  However,  a  recent 
study of human hippocampal progenitor cells showed that the anti depressant 
sertraline increased hippocampal neurogenesis via the glucocorticoid receptor 
(Anacker et al., 2011). This finding revealed a new concept of glucocorticoids 
action  on  hippocampal  neurogenesis,  suggesting  that  glucocorticoids  may  not 
only suppress neurogenesis, but can also support hippocampal neurogenesis. This 
finding could be significant in the case of glucocorticoid resistance in patients 
with  chronic  inflammatory  disease.  Glucocorticoid  resistance  is  common  in 
patients with RA and asthma (Barnes and Adcock, 2009), and it is characterized 
mainly by glucocorticoid receptor dysfunction of lymphocytes (Rohleder et al., 
2010). Glucocorticoid resistance exaggerates inflammation and hyperactivity of 
corticotropin  releasing  hormone  and  sympathetic  nervous  system  pathways, 
which may have detrimental effect on hippocampal neurogenesis (Pace et al., 
2007). It is possible that the anti depressant may also have an effect to activate 
the glucocorticoid receptor at the peripheral level and reduce HPA activation. 
This may result in enhanced hippocampal neurogenesis. However, it would be 
interesting to test this hypothesis.  
BDNF has also been shown to modulate proliferation, survival, differentiation 
and  dendritic  development  of  hippocampal  progenitors.  Ablation  of  BDNF 
expression  in the  hippocampus  with  gene deleted  mice resulted  in decreased 
hippocampal neurogenesis (Choi et al., 2009). Interestingly, ablation of BDNF in 
the hippocampus resulted in a reduction in neurogenesis, along with increased 
behaviour  associated  with  depression,  suggesting  a  role  for  BDNF induced 
neurogenesis  in  the  psychological  aspect  of  depression  (Taliaz  et  al.,  2010). 
Although  the  association  of  BDNF  and  depression  has  been  demonstrated  by 
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induced depression  via  neurogenesis  has  not  been  well  documented.  Several 
animal studies suggested that induction of peripheral inflammation, using LPS or 
IL 1β can induce a reduction of BDNF protein and mRNA in various regions in the 
brain (Guan and Fang, 2006), particularly in the synaptosome of pyramidal cells 
in  CA1,  CA3  and  dentate  gyrus  in  the  hippocampus  (Lapchak  et  al.,  1993); 
(Schnydrig  et  al.,  2007).  Paradoxically,  preventing  learning  experience  by 
isolating mice socially caused reduced hippocampal BDNF, which was reversed 
by IL 1β antagonist (Barrientos et al., 2003). IL 1β induced memory deficits may 
be mediated via BDNF mRNA reduction in the hippocampus. The role of BDNF in 
hippocampal  neurogenesis  associated  with  depressive like  behaviour  requires 
further investigation.  
Based on experimental evidence, the peripheral inflammation induced changes 
in  hippocampal  neurogenesis  seems  to  be  one  of  the  putative  mechanisms 
underlying  inflammation induced  depression.  However,  there  is  no  clinical 
evidence  in  humans  emerging  to  support  this  hypothesis.  The  ‘hippocampal 
neurogenesis  hypothesis  of  depression’  was  originally  based  on  observations 
showing  that  anti depressants  could  increase  hippocampal  neurogenesis. 
However,  so  far  there  is  no  direct  evidence  of  anti depressants  modulating 
immune response and inducing changes in hippocampal neurogenesis. Although 
several clinical studies have shown that anti depressant therapy might help to 
reduce  interferon induced  psychiatric  or  depressive  symptoms  (Raison  et  al., 
2007).  One  mechanism  underlying  the  protective  effect  against  cytokine 
therapy induced  depression  is  that  many  anti depressants  have  anti 
inflammatory  effects  that  can  modulate  cell mediated  immune  responses 
(Capuron  et  al.,  2002).  Anti depressants  can  also  have  direct  effects  on 
microglia.  Anti depressants  such  as  fluvoxamine,  reboxetine,  imipramine  and 
risperidone were shown to reduce IL 6 production by IFN γ activated microglia in 
vitro (Hashioka et al., 2007). However, there is no direct evidence showing that 
anti depressants can reverse impairment of hippocampal neurogenesis via the 
suppression  of  inflammation.  Therefore,  further  investigation  for  peripheral 
inflammation induced  changes  in  hippocampal  neurogenesis  in  depression  is 
required.  Chapter 1    92 
1.11   Aims and hypothesis 
To  summarise  the  main  points  of  the  Introduction  linking  depression  with 
immunity:  Clinical depression has been associated with chronic inflammatory 
diseases.  This  appears  to  be  an  important  clinical  co morbidity  and  the 
mechanisms  are  poorly  understood.  The  active  involvement  of  the  immune 
response  was  implicated  when  cytokine  therapy  itself  was  shown  to  induce 
depression in cancer and hepatitis C patients. In experimental models, systemic 
LPS challenge can induce an innate systemic inflammatory response as well as an 
immune response in the CNS. The involvement of cytokines in this process was 
shown by systemic administration of cytokines (TNF α, IFN γ) which caused a 
reduction  in  hippocampal  neurogenesis  in  the  brain.  An  impairment  in 
hippocampal neurogenesis has been implicated in depression, cognitive decline 
and depressive like behaviour in humans and in animal models. However, there 
are  very  few  studies  that  have  investigated  the  effects  of  peripheral 
inflammation  on  hippocampal  neurogenesis  in  chronic  inflammatory  disease 
models. An investigation of this may lead to better understanding of depression 
in  chronic  inflammatory  diseases,  leading  to  an  evidence  based  approach  to 
treatment.  
Therefore, the hypothesis of this project is that: 
‘Peripheral inflammation and cytokines associated with Rheumatoid Arthritis 
affect central production of inflammatory mediators in the brain which in 
turn impair hippocampal neurogenesis. This may lead to cognitive decline 
and mood disorders often seen in arthritis patients.’ 
In order to test this hypothesis, the aims of this project are:  
Preamble: Rheumatoid Arthritis is one of the most studied chronic inflammatory 
diseases associated with psychiatric disorders. The major aim of this project is 
to  investigate  evidence  of  brain  inflammation  and  changes  in  hippocampal 
neurogenesis in collagen induced arthritis (CIA), a well established murine model 
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Several experimental approaches have been conducted using this CIA model in 
order to address this general question, with the following specific aims: 
1.  To investigate changes in central production of inflammatory mediators in 
the brain, which may be associated with peripheral joint inflammation in 
arthritis. We determined changes in protein concentrations and mRNA 
expression levels of inflammatory mediators in brains of CII immunized mice 
compared with control mice.  
2.  To investigate the association between peripheral inflammation and central 
production of inflammatory mediators. We determined longitudinal changes 
in serum of inflammatory mediators along with longitudinal changes in 
protein and mRNA concentrations of inflammatory mediators in brains CII 
immunized mice. An extended aim of this experiment included providing 
additional information of brain immune activation and the interplay between 
inflammatory mediators in the brain of CII immunized mice throughout the 
development of disease and clinical signs of arthritis.  
3.  To investigate the effect of systemic (peripheral) treatment using the 
recombinant humanised soluble TNF receptor drug etanercept to mediate 
TNF blockade on central production of inflammatory mediators in brains of 
CII immunized mice during the period of clinical signs of arthritis. We aim to 
determine changes in inflammatory mediators in the brains of etanercept 
treated compared with PBS treated CII immunized mice and each of these 
with antigen naive healthy control mice. An extended aim is to confirm that 
changes in inflammatory mediator profiles in brains of CII immunized mice 
were due to peripheral inflammation during arthritis.  
4.  To investigate a possible mechanism of associated depression by studying the 
effect of peripheral inflammation on hippocampal neurogenesis. We aim to 
analyze changes in hippocampal neurogenesis in CII immunized mice by 
determining changes in the number of DCX positive neurons as a marker of 
neurogenesis. To confirm that any changes in hippocampal neurogenesis were 
a result of peripheral inflammation, we aim to investigate the effects of 
etanercept on changes in hippocampal neurogenesis in CII immunized mice.   Chapter 2                                                                                                                              94 
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2.1   General reagents & buffers 
2.1.1   Materials and reagents 
General Chemicals:  All chemicals were purchased from Sigma-Aldrich (Poole, 
Dorset,  UK)  or  Fisher  Scientific  (Loughborough,  Leicestershire,  UK),  unless 
otherwise indicated.  
Plastics:  Plastics used for quantitative PCR assays and nuclease free centrifuge 
tubes  were  purchased  from  Applied  Biosystems  (Warrington,  UK),  Fisher 
Scientific  (Leicestershire,  UK).  ELISA  plates  were  purchased  from  Thermo 
Labsystems (Cheshire, UK) 
Gelatin coated slides: Gelatin coated slides were prepare by dipping glass slides 
(VWR International, Ltd, Leighton Buzzard, UK) in a solution consisting of 5 g 
Type I Gelatin (Sigma, Poole, Dorset, UK) and 0.5 g chrome alum (Sigma, Poole, 
Dorset, UK) in 1 litre of water. After leaving to air dry, slides were stored at 4°C 
until required.   
2.2  Buffers and culture media 
0.2 M Phosphate buffer, pH 7.4: 0.2 M phosphate buffer (PB) was prepared by 
mixing 1120 ml Solution A (37.44g NaH2PO in 1200 ml dH2O) and 2880 ml Solution 
B (37.44g Na2HPO in 1200 ml dH2O), and then adjusting the pH to 7.4. PB buffer 
was diluted to 0.1 M with dH2O before use. 
0.3 M Phosphate buffered saline [PBS]: double strength PBS was prepared by 
mixing 200 ml 0.2 M PB buffer with 72g NaCl and 1800 ml dH2O.  
Phosphate buffered saline: PBS was purchased from Invitrogen (Paisley, UK).  
Tris acetate EDTA  (TAE)  buffer:  50x  stock  solution  of  TAE  was  prepared  by 
dissolving 242g of Tris base in 750 ml dH2O. The solution was then mixed further 
with 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA (pH8). The final volume 
was then made up to 1000 ml with dH2O. This stock buffer was then diluted 1:50 
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ELISA wash buffer: wash buffer consisted of PBS and 0.05% Tween 20.  
4%  paraformaldehyde  in  50  mM  phosphate  buffer:  100  ml  of  37 40% 
formaldehyde, 6.5g Na2HPO4     and 4g NaH  2PO4 were mixed in 900ml distilled 
water.  
2.3  In vitro procedures  
2.3.1  Animal welfare  
All animals were maintained in the pathogen free facilities of the Joint Research 
Facility (JRF), and the Clinical Research Facility (CRF) at the Biological Services 
of  the  University  of  Glasgow.  All  procedures  were  conducted  under  project 
licences approved by the United Kingdom Home Office and in accordance with 
the Animal (Scientific procedures) Act 1986.  
2.3.2  Mice  
Male  DBA/1  mice:  Male  mice  weighing  20g  were  purchased  from  Harlan 
Laboratories Inc. (Bicester, Oxon, UK) at approximately 8 weeks of age and were 
kept in quarantine for one week before experimental procedures.  
All mice were culled according to a licenced schedule 1 method.  
2.3.3  Induction of collagen induced arthritis in DBA1 mice 
Preparation of collagen in Freund’s complete adjuvant: 
CIA (collagen induced arthritis) is a commonly used experimental animal model 
of arthritis since it shares several similarities in pathology and/or pathogenesis 
to  that  of  RA  disease  in  humans.  This  concept  of  CIA  pathogenesis  was  first 
applied  in  the  rat  model  (Trentham  et  al.,  1977),  and  subsequently  in 
susceptible strains of mice (Courtenay et al., 1980). In our study, we chose to 
induce arthritis using collagen in DBA/1 mice (H 2q) since it is considered to be 
the most susceptible and most widely used strain (Inglis et al., 2008). To induce 
arthritis, male 8 week old DBA/1 mice (Harlan, Bicester, Oxon, UK) weighing 20 
g were immunized with Type II bovine collagen (MD Biosciences, St.Paul, MN, Chapter 2    97 
USA).  Briefly,  this  involved  preparation  of  2  mg/ml  type  II  bovine  collagen 
dissolved  in  0.05  M  glacial  acetic  acid  overnight  at  4°C.  To  make  a  final 
concentration of 1 mg/ml, the collagen was emulsified with an equal volume of 
4 mg/ml Complete Freund’s Adjuvant (CFA) (MD Biosciences, St.Paul, MN, USA). 
The collagen /CFA emulsion was prepared on ice using a hand held homogenizer 
freshly on the day of immunization (day 0).  
The stability of the emulsion was tested by adding one drop of the emulsion into 
a beaker of water. If the emulsion is stable, the drop will remain intact. If the 
emulsion spreads onto the water surface, then the emulsion is not stable, and 
the preparation should be re emulsified. 
Experimental arthritis model: 
Mice were sensitised on day 0 and challenged on day 21. From day 17 onward, 
mice were examined every 2 days for signs of arthritis. In detail, on day 0, the 
area at the base of the tail of each mouse was shaved with clippers and the skin 
was sterilized with 70% ethanol. The emulsion of collagen/CFA was transferred 
to a 1ml plastic syringe fitted with a gauge 26 needle. Each mouse was injected 
intradermally  with  a  sensitisation  dose  of  50   l  of  collagen/CFA  emulsion  at 
approximately 1 2 cm from the tail base. A whitish bolus beneath the dermis 
should be visible. 50ul ul of the collagen/CFA emulsion was administered at both 
side of the tail base so that each mouse received a total of 100  g of collagen. 
Mice were monitored daily for any signs of local ulceration. The second collagen 
challenge immunization was conducted on day 21. This consisted of 200  g of 
bovine collagen in 200   l of PBS injected intra peritroneally into each mouse 
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Figure 2.1 Summary of the CIA experimental procedure  
The total experimental duration was 6 weeks. The animals were immunized (sensitised) with 
type II collagen (CII) + CFA at the beginning of the experiment and boosted (challenged) with 
type II collagen (CII) + PBS 3 weeks later. The signs of arthritis were monitored from day 17 
after immunization onwards. Details in the text above. 
Evaluation of arthritis 
CII  immunized  mice  usually  developed  signs  of  arthritis  around  day  19  after 
immunization,  but  these  were  monitored  from  day  16  after  immunization 
onwards. Two clinical evaluations were used to measure the severity of joint 
inflammation  in  arthritic  mice;  clinical  arthritic  score  and  paw  thickness 
measurement.  The  arthritis  severity  in  all  CIA  experiments  was  verified 
independently by expertises including Dr. Darren Asquith, Mr. Maurice Dixon and 
Dr. Bernard Leng. 
A. Clinical arthritic score; Paw inflammation of arthritic mice was monitored 
using a subjective scoring method. Individual paws were assigned a score based 
on the criteria shown inTable 2.1. The scores of each paw were summed, giving 
a maximum severity score of 16. The mean arthritis index is the sum of the score 
of all mice divided by the number of mice in each group.  Chapter 2    99 
 
Severity score  Appearances  Description 
 
Score 0; Normal 
 
 
Score  1; 
inflamed digits 
 
Score  2; 
Erythema 
 
Score  3; 
Erythema  plus 
swelling 
 
Score  4; 
ankylosis  plus 
loss of function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No inflammation 
 
 
 
Definite  redness  and  swelling 
limited  to  individual  digits 
("sausage digits"). 
 
 
Moderate redness and swelling of 
ankle and wrist with swelling of 
one or more digits. 
 
Severe  swelling  and  erythema 
extending  over  whole  paw/joint 
including digits. 
Maximally  inflamed  paw  or 
ankylosed  paw.  If  the  paw  is 
ankylosed, the mouse cannot grip 
the  wire  top  of  the  cage  using 
front paws or walk up a cage lid 
held at a 45 degree angle. 
Table 2.1 Clinical scores of C57BL/6 mice with CIA  
Images were taken from (Inglis et al., 2008) and (Rosloniec et al., 2010) by kind permission 
of the Editor of Nature Protocols and Current Protocols. The scores of each mouse were 
summed, giving a maximum severity score of 16. Chapter 2    100 
B. Paw thickness measurements; Paw thickness measurements were used as an 
objective  measure  of  arthritic  swelling  to  confirm  the  subjective  clinical 
arthritic score. Mice were held by the scruff of the neck and paw thickness was 
measured with a dial calliper (Kroeplin, Munich, Germany). Mean paw thickness 
index is the sum of the paw thickness of all mice divided by the number of mice.  
2.3.3.1   Preparation of paws for H&E histological analysis 
2.3.3.1.1   Paw tissue processing  
Mouse paws were dissected just above the ankles and the skin and the toes were 
removed  for  better  penetration  of  fixation  buffer  into  the  tissue.  The  joints 
were transfer to a universal container with 7 ml of 4% paraformaldehyde in 50 
mM phosphate buffer. After fixation for 72hr, joints were then decalcified using 
a 5 – 10% solution of nitric acid in distilled water for 2 3 weeks with a daily 
change of solution. After decalcification, mouse decalcified joint tissues were 
transferred to 70% ethanol and embedded in paraffin. Paraffin embedded tissues 
were cut to 6  m using a microtome (Bright lnstrument Co Ltd, Huntingdon, UK) 
which  produced  a  continuous  paraffin  wax  ribbon  of  sections.  To  separate 
individual sections, the ribbon of sections was floated onto a flotation water 
bath  set  at  40ºC  and  each  section  were  separated  using a  scalpel  blade  and 
transferred  onto  a  charge  slide  (Superfrost  plus,  VWR  International,  Ltd, 
Leighton Buzzard, UK).  Slides were air dried on a hotplate (Raymond A Lamb 
Hotplate, Thermo Labsystems, Cheshire, UK) at 55ºC for 30 minutes. The slides 
were then stored at 4ºC until required. 
2.3.3.1.2   Haematoxylin and Eosin immunohistochemistry 
Haematoxylin and Eosin (H&E) immunohistochemistry is a standard histological 
method. Haematoxylin is a blue basic dye binding to negatively charged DNA or 
RNA, which is commonly used for nuclear staining. Eosin is a pink acid dye that 
binds  to  positively  charged  cell  elements  such  as  mitochondria  or  other 
cytoplasmic elements.  
The slides were put into an oven (GenLab, Cheshire, UK ) at 60°C for 2 3 min to 
melt the wax and were re hydrated following these re hydration steps; Chapter 2    101 
          Dewax in Xylene       3 minutes x 2 
  100% Alcohol (Ethanol)     3 minutes x 2 
  90% Alcohol         3 minutes x 2 
  70% Alcohol         3 minutes x 2 
  Running Water        3 minutes 
Sections were dipped in Harris Haematoxylin (Sigma, Poole, Dorset, UK) for 2 
minutes and in running water for 3 minutes to remove excess stain. Slides were 
then counter stained with 1% Eosin (Sigma, Poole, Dorset, UK) for 2 minutes and 
excess stain was washed off in running water. Finally, sections were dehydrated 
following these dehydration steps; 
          70% Alcohol         30 seconds 
  90% Alcohol         1 minute 
  100% Alcohol        3 minute x 2 
  Xylene           3 minutes x 2 
Sections were mounted in DPX (VWR, UK) and a cover slip (VWR, UK) using a 
Pasteur  pipette.  After  drying  overnight,  all  the  sections  were  examined  by 
microscopy.  
2.4  Collection of serum from mice and processing of 
brain tissue for gene and protein analysis  
Mice  were  terminally  anesthetized  with  a  halothane:oxygen  mixture.  Once 
anaesthetised,  the  thoracic  cavity  was  opened  and  the  blood  collected  by 
cardiac  puncture.    The  blood  was  allowed  to  coagulate  for  1hour  at  room 
temperature, and the serum was separated from blood by centrifugation (3,000 
rpm for 30 minutes). The serum was collected and stored at  80° C for later 
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The brain was removed and dissected bilaterally across the midline. The right 
hemispheres were snap frozen immediately in liquid nitrogen and stored at  80 
°C.  The  left  hemisphere  of  each  brain  was  homogenised  and  the  soluble 
component  was  separated  by  centrifugation  (3,000  rpm  for  30  minutes)  and 
stored at  80°C for subsequent protein analysis. The right hemisphere of each 
brain was processed for RNA extraction and gene expression analysis as detailed 
below.  
2.5   cDNA synthesis by reverse transcription (RT) 
PCR  
Reverse  transcription  and  polymerase  chain  reaction  (RT PCR)  is  a  two step 
protocol. Firstly converting extracted RNA to stable cloned (c)DNA using reverse 
transcriptase enzymes. Secondly the PCR creates an equivalent number of the 
more stable cDNA molecules which are then analysed by Real time PCR (Gallo, 
1972).  
In detail, cDNA was sythesized from typically 1.5  g of total extracted RNA using 
a commercial Superscript II
® reverse transcriptase kit (Invitrogen, Paisley, UK) as 
per manufacturer’s instruction. The following components were set up in a 1.5 
nuclease free microcentrifuge tube: 
Component  Volume per reaction 
 
500  g/ml Oligo(dT)12 18 
1.5  g of total RNA 
10 mM dNTP mix 
DEPC* water 
 
1  l 
X  l 
1  l 
Up to 10  l 
 
* This is water treated with 0.1% v/v diethylpyrocarbonate (DEPC) for at least 1 
hour  at  37°C  to  inactivate  ribonucleases,  and  then  autoclaved  to  inactivate 
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To  denature  the  RNA,  the  mixture  was  heated  at  65°C  for  5  minutes  in  the 
heating  block  of  a  polymerase  chain  reaction  (PCR)  machine  (Eppendorf® 
Mastercycler Gradient PCR, Hamburg, Germany) and quick chilled on ice for 1 
minute. A reverse transcriptase (RT) master mix was prepared to contain the 
following components (supplied in the kit) per reaction; 
Component  Volume per reaction 
 
5X First Stand Buffer 
0.1 M DTT 
50 mM MgCl2 
40 units/ l RNase OUTTM ( RNase inhibitor) 
 
4  l 
2  l 
2  l 
1  l 
 
9  l of master mix was added to each denatured RNA sample and incubated for 2 
minutes at 42 °C. 1  l of 200 units of Superscript II was added and incubated for 
50 minutes at 42 °C followed by a 15 minute inactivation step at 70 °C. cDNA 
was then diluted 1: 5 with DEPC water and stored at  20°C until use in real time 
PCR analysis of required target gene. 
2.6  Real time PCR using SYBR Green I dye 
Real time RT PCR is widely used to determine biologically relevant changes in 
mRNA  transcription  levels  in  cells  and  tissue  (Nolan  et al.,  2006).  Instead  of 
mRNA levels being directly measured, real time PCR measures complementary 
DNA  (cDNA)  because  this  is  more  stable  molecule  than  mRNA  (Nolan  et  al., 
2006). Real time PCR employs fluorescent reporter dyes to bind with the cDNA 
amplification products of the PCR reaction (Nolan et al., 2006). Therefore, the 
fluorescence signal increases as the dye binds to the increasing amount of cDNA 
in the reaction tube. In real time PCR, we determine the number of PCR cycles 
at which the increased fluorescent signal (and therefore cDNA) first crosses a 
pre determined  threshold  background  fluorescence.  The  point  at  which  the 
fluorescent  signal  first  rises  above the  baseline  signal  is  called the threshold 
cycle (Ct). Therefore, the greater the copy number of initial target genes at the 
beginning  of  the  assay,  the  fewer  threshold  cycles  are  required  for  the Chapter 2    104 
fluorescence  to  reach  the  threshold  level  of  detection  (Nolan  et  al.,  2006). 
There are several approaches to monitor PCR products, including dyes that bind 
to the double stranded DNA (i.e. SYBR
® Green) or sequence specific probes (i.e. 
Molecular  Beacons  or  TaqMan
®  Probes).  Both  detection  approaches  are 
potentially rapid and sensitive (Nolan et al., 2006). However, their principles of 
detection and optimisation are different, resulting in different advantages and 
disadvantages. In our study, we used the simple, inexpensive SYBR Green system 
to detect the PCR product as it accumulates during Real time PCR cycles.  
2.6.1  Primer design and optimization 
Real time PCR reaction consists of multiple cycles of denaturation, anneling and 
extension steps. This requires a pair of the specific oligonucleotide primers that 
bind to the cDNA template as a start point of real time PCR reaction. Optimal 
design of the PCR primers is an important initial step for accuracy and specific 
quantification of the real time PCR assay. There are several considerations when 
designing  real time  PCR  primers  for  the  SYBR Green  I  system.  The  annealing 
temperature is restricted to 58–60°C, which corresponds to the optimal working 
conditions  for  the  Taq  DNA  polymerase  enzyme  and  the  length  of  the  PCR 
product is set between 80 and150 bp. In addition, Forward & reverse primers 
should have similar Tms (ideally within 0.5
oC of each other but no more than 1
 oC 
apart) for the greater PCR product yield. Finally, to avoid primer dimmers, the 
primers should have low or no self complementarity (Ponchel et al., 2003). All 
primers  used in  this project  were  designed  using  Primer3  software  (available 
online @: http://www.broad.mit.edu/cgi bin/primer/primer3_www.cgi/).   
Primer specification: 
-  between 18 and 20 base pairs (bp) in length 
-  between 45 and 55% GC content (50% optimal) 
-  melting temperatures (Tms) between 59.5°C and 61°C 
-  Max self complementarity:   3 
-  Max 3’self complementarity:   1 
-  product size between 100 140 base pairs (bp) in length 
-  BLAST analysis (http://www.ncbi.nlm.nih.gov/BLAST/) was used to 
ensure that primer sets amplify the genes of interest with high specificity. 
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The primers used are listed in Table 2.2. 
Genes  Forward  Reverse 
mouse IL 1β  5’ GTGTAATGAAAGACGGCACA 3’  5’ AGAAACAGTCCAGCCCATAC 3’ 
mouse IL 1α  5’ GATGTCCAACTTCACCTTCA  3’  5’ ACAAACTTCTGCCTGACGA  3’ 
mouse IL 2  5’ CTGAGCAGGATGGAGAATTACAG 3’  5’ CGCAGAGGTCCAAGTTCATC 3’ 
mouse IL 4  5’  CGGCATTTTGAACGAGGT 3’  5’  TTGGAAGCCCTACAGACGAG 3’ 
mouse IL 5  5’  GCTTCCTGCTCCTATCTAACTTCA 3’  5’  TCAACCTTCTCTCTCCCCAAG 3’ 
mouse IL 6  5’ TTCCATCCAGTTGCCTTCTT 3’  5’ ATTTCCACGATTTCCCAGAG 3’ 
mouse IL 10  5’  CAACATACTGCTAACCGACTCCT 3’  5’  TGGGGCATCACTTCTACCA 3’ 
mouse IL 12  5’  ATGTGGAATGGCGTCTCTGT 3’  5’  AGTTCAATGGGCAGGGTCT 3’ 
mouse IL 13  5’ AGGGAGGAGGGTTGAGGA 3’  5’ TTTCTGTAGGGATGGGATGG 3’ 
mouse CCL1  5’ ATGGGCTCCTCCTGTCCT 3’   5’ TCTCTGGTGCTGGGATGG 3’ 
mouse CXCL1  5’ AACCGAAGTCATAGCCACACTC 3’   5’ TGGGGACACCTTTTAGCATC 3’ 
mouse CCL2  5’ CTCACCTGCTGCTACTCATTCA 3’   5’ CCATTCCTTCTTGGGGTCA 3’ 
mouse CXCL2  5’ AAGTTTGCCTTGACCCTGAA 3’   5’ TCTCTTTGGTTCTTCCGTTG 3’ 
mouse CCL3  5’ CAGCCAGGTGTCATTTTCCT 3’   5’ CAGGCATTCAGTTCCAGGTC 3’ 
mouse CXCL10  5’ GCTCAAGTGGCTGGGATG 3’  5’ GAGGACAAGGAGGGTGTGG 3’ Chapter 2    106 
mouse IFN g  5’ ATTGCGGGGTTGTATCTGG 3’  5’ TCCTCCCATCAGGAGCAC 3’ 
Genes  Forward  Reverse 
mouse TNF α  5’ CCCTTTACTCTGACCCCTTT 3’  5’ AACCTGACCACTCTCCCTTT 3’ 
mouse FGF2  5’  CGTCAAACTACAACTCCAAGCA 3’  5’  CAGCAGCCGTCCATCTTC 3’ 
mouse VEGF  5’ CCTCGTCTCCTCTCCTTACCC 3’  5’ CACTCACACACACAGCCAAGT 3’ 
mouse GAPDH  5’ AACCTGACCACTCTCCCTTT 3’  5’ TATTATGGGGGTCTGGGATG 3’ 
Table 2.2 Primer sequences used for the amplification of brain tissue cDNA  
All primers were purchased at Vhbio (www.vhbio.com) and diluted at the appropriate 
dilution (Vhbio, Gateshead, UK). 
2.6.2  Optimizing primers for SYBR Green real time PCR 
The  optimization  of  the  primer  concentration  is  essential  for  sensitivity, 
specificity, reproducibility of the real time PCR assay. Each set of primers work 
efficiently  under  different  concentration  conditions.  Inappropriate  primer 
concentrations in the real time PCR assay results in non specific primer binding 
and  the  creation  of  primer dimers.  For  optimization,  a  primer  titration  was 
performed from 50 to 12.5  M final concentration using conventional PCR. cDNA 
synthesized from a tissue or cell line known to express the gene(s) of interest 
was used as the template for testing the specificity of the primer. The mRNA 
from  various  cell  types  and  tissue  expressing  genes  of  interest  was  used  to 
generate cDNA control templates for optimizing primers as listed on Table 2.3.   
 
 
 Chapter 2    107 
Mouse cDNA template sources  Mouse Primers 
macrophages   IL 1β,  IL 1α,  IL 10,  IL 12,  TNF α,  GAPDH                                                 
LPS–stimulated macrophages   IL 6,  CCL1,  CXCL1,  CCL2,  CXCL2,  CCL3, 
CXCL10                                                                                                           
Th1 cells    IL 2,  IFN g, IL 12                                                              
Th2 cells   IL 4,  IL 5,  IL 13, IL 10                                                                               
NIH3T3 fibroblast   FGF2,  VEGF                                                         
Table 2.3 Control tissue used to test specificity of primers 
 
Conventional PCRs for the validation of the specificity of the designed primers 
against target genes were performed in 50  l reactions with the addition of 1.5 
mM  MgCl2  and  employing  ReddyMix
TM  PCR  Master  Mix  (Abgene,  Epsom,  UK).  
Reactions  were  performed  using  the  PCR  machine  (Eppendorf®  Mastercycler 
Gradient, Hamburg, Germany) under the following conditions: One cycle at 94°C 
for 10 min, and 35 cycles of 94°C for 20s, 59°C or 60°C or 61°C for 20s, and 72°C 
for 20s, one cycle of 72°C for 10 min. The PCR product were analysed by running 
in 2% agarose gels containing ethidium bromide (Sigma, Poole, Dorset, UK) and 
visualizing for a single specific band and the absence of primer dimer products.  
2.6.3  Agarose gel electrophoresis 
PCR products were visualised in 2% w/v agarose gels. Agarose gels were prepared 
by heating 3 g agarose (Invitrogen, Paisley, UK) in 150 ml Tris acetate EDTA (TAE 
buffer)  in  a  microwave  at  full  power  for  approximately  5  minutes  until  the 
agarose  was  completely  dissolved.  Approximately  5  µl  ethidium  brominde 
(Sigma,  Poole,  Dorset,  UK)  were  added and  mixed by  swirling  the  flask.  The 
melted agarose was then poured into a gel tray, the ends of which were sealed 
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form wells large enough to accommodate at least 25 µl. When the gel solidified, 
the  comb  and  the  tapes  were  removed  and  the  gel  was  placed  into  an 
electrophoresis chamber containing TAE buffer. 25  l of the PCR products were 
load into each well of the agarose gel next to a well containing a size marker 1 
Kbp  DNA  ladder (Invitrogen,  Paisley,  UK). The  gel electrophoresis  was  run  at 
100V for 40 minutes. DNA bands were visualized under UV light in a lightbox (Gel 
logic 200 imaging system, NY, US) and images recorded using Kodak camera and 
software. 
2.6.4   Generation of a DNA standard for real time polymerase 
chain reaction 
A known real time PCR standard is required as a positive control as well as a 
reference for measuring the absolute copy number of a transcript in an unknown 
test  sample.  DNA  plasmids  containing  cloned  target  sequences  are  used  as 
standards  in  quantitative  PCR.  These  constructions  of  DNA  plasmids  were 
generated  by  cloning  DNA  fragments  that  contain  genes  of  interest  into  a 
commercial  TOPO  vector  (Invitrogen,  Paisley,  UK)  using  the  manufacturer’s 
instructions.  Briefly,  PCR  products  generated  using  the  QPCR  primers  were 
isolated and purified from the agarose gel by the QIAquick PCR Purification Kit 
according to manufacturer’s instructions (Qiagen, West Sussex, UK). 4  l PCR 
product, 1  l salt solution (Invitrogen, Paisley, UK), and 1  l PCR4 TOPO vector 
were  mixed  together.  3   l  of  the  mixture  was  added  to  a  preparation  of 
competent bacteria containing TOPO vector. Following incubation on ice for 30 
minutes, the bacterial preparation was subjected to heat shock at 42°C for 30 
seconds, and then 2 minutes on ice. 300  l of supermedium (Invitrogen, Paisley, 
UK) was added into the mixture of bacteria with TOPO vector before 15 minutes 
incubation in a shaking incubator (Innova 4400, New Brunswick, Cambridge, UK) 
for 40 min. 200  l of the mixture of bacteria with TOPO vector was plated by 
spreading onto a selective growth medium in a petri dish; i.e. LB agar containing 
50   g  Ampicillin  (Sigma,  Poole,  Dorset,  UK)  under  aseptic  conditions,  and 
incubated overnight at 37°C. Next day, a single typical colony containing TOPO 
vector was picked and inoculated into 5 mL of LB broth and incubated for 16 
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1200 rpm for 4 minutes. Plasmids was isolated and purified by Qiaprep Spin Mini 
Prep Kit according to manufacturer’s instructions (Qiagen, West Sussex, UK).  
2.6.5   Plasmid verification and quantification  
The existence of the genes of interest in the resulting DNA fragments can be 
verified by checking the length of the DNA fragments obtained after digestion 
with specific restriction enzymes. The digestion scheme was as follows:  
10  l aqueous solution containing DNA plasmid, 7.5  l DEPC water, 0.5  l ECoRI 
enzyme (Invitrogen, Paisley, UK) and 2  l 10 X buffer H (Invitrogen, Paisley, UK) 
were mixed together and incubated in a 37°C water bath for 1 hour. Agarose gel 
electrophoresis was used to confirm the length of the DNA fragments separated 
from cut vectors.  
The  concentration  of  plasmids  was  measured  by  UV  spectrophotometry 
(Eppendorf®  BioPhotometer,  Hamburg,  Germany)  at  260  nm  wavelength  in 
 g/ml.  Plasmid  copy  numbers  were  then  calculated  using  the  following 
formulae, with IL 1β used as an example: 
The PCR® 4 TOPO® vector containing a DNA fragment of the IL 1β gene was 
4,500 bp in size and had a concentration of 2.059 x 10
 8 g per  l.  
Copies of molecule per mole = 6.023 x 10
23 (Avogadro’s constant) 
Average molecular weight for double stranded nucleotide = 660 Daltons 
Molecular weight of double stranded DNA  =  660  Daltons  *  PCR  product 
length  
                      = 660 * 4500 bp 
                                                                      = 2,970,000 Daltons 
Copies DNA per  l   = (6.023 x 10
23 * mass per  l) / Molecular weight DNA 
      = (6.023 x 10
23 * 2.059x10
 8) / 2,970,000 Daltons Chapter 2    110 
      = 4,175,541,077 copies per  l 
2.6.6   Real time PCR assay 
Absolute quantification was used to measure the amount of transcription of the 
gene  of  interest  by  real time  PCR  assay.  The  absolute  quantification  uses  a 
standard  curve  to  calculate  the  absolute  number  of  transcripts  in  unknown 
samples. The standard curve for the required target gene was generated from a 
10 fold serial dilution of DNA plasmids containing cloned target sequences as the 
template  described  in  2.5.5.    The  template  was  diluted  in  DEPC  water  to 
generate the dynamic range between 10
8 and 10
2 copies in a volume of 500  l. 
The amount of cDNA (and thereby the amount of tissue mRNA) is measured by in 
index called the cycle threshold (CT). This is the number of denaturing and re 
annealing cycles required for the fluorescent signal to exceed the background or 
‘threshold’ level; ie more mRNA will require fewer cycles for the fluorescent 
signal to exceed background levels. The values in each dilution were measured 
in  triplicate  using  a  real time  QPCR  with  the  primer  sets  to  generate  the 
standard  curves  for  the  gene  of  interest.  This  range  of  the  template 
concentration resulted in a Ct of between 20 and 32 since a 10 fold difference in 
concentration corresponds to 3.3 cycles. Standard curves were run at least once 
for every primer pair in order to check the efficiency of the real time PCR assay.  
A graph is made of the standard curve by plotting the Ct values on the y axis and 
the log of the number of copies on the x axis.  The slope of the line of this plot 
will give the efficiency of the reaction according to the equation E=10
 (1/slope) 1.  
A reaction of 100% efficiency represents a slope of –3.33 (Nolan et al., 2006). 
 
All amplification reactions of samples or standards were performed in triplicate. 
Each reaction consists of components listed in Table 2.4; 
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Component  Stock concentration  Volume to add 
for single 20        l 
reaction 
DEPC water    8  l 
Power SYBR Green 
PCR Master Mix  
X2  10 l 
Primers; 
Forward primer 
Reverse primer 
 
50 M, 25 M, 12.5 M 
 
0.5  l 
0.5  l 
Sample/standard  1:5 diluted sample cDNA synthesis or 
the template concentration 
containing 10
8 and 10
2 copies 
 
2  l 
Table 2.4 List of components in the mastermix used for real time PCR assay  
A working batch of mixture consisted of water, Power SYBR Green PCR Master Mix (Applied 
Biosystems, Warrington, UK) and primers (VHBio, Gatehead, UK) was made sufficient for all 
real time PCR reactions. To prepare a master mix in triplicate for each sample, 6       l of cDNA 
or standard was added in a “mixing” well of a nuclease free 24 well plate (Thermo 
Labsystems, Cheshire, UK), along with 54.5        l mixture. Approximately, 19.8        l of this 
master mix was added to each well of a 96 well optical reaction plate (MicroAmp, Applied 
Biosystems, Warrington, UK). The plate was sealed by an adhesive sealing film and gently 
centrifuged to ensure that the components settle to the bottom of the wells. The plate assay 
was run on a real time PCR instrument (ABI PRISM 7900HT Sequence Detection System, 
Applied Biosystems, Warrington, UK] using the protocol in Table 2.5.  
  Denaturation  10 seconds at 95°C 
40 cycles  Annealing  15 seconds at 95°C 
  Extension  1 min at 60°C. 
Table 2.5 Conditions for real time PCR protocol 
 Chapter 2    112 
A melting curve analysis was performed with a temperature gradient of 0.1°C/s 
from  70  to  95°C  following  each  PCR  run  to  identify  the  specific  amplified 
product and distinguish them from primer dimers and other small amplification 
artifacts.  The  principle  of  melting  curve  analysis  is  that  the  two  strands  of 
double standed  DNA  separate  or  “melt”  apart  at  the  specific  temperature, 
depending  on  both  its  size  and  the  energy  required  to  disrupt  the  different 
hydrogen bonds of its nucleotide composition. This  temperature is called the 
melting  temperature  (Tm).  During  the  melt  curve  analysis,  each  sample  was 
heated  gradually  from  the  user  defined  temperature  below  the  Tm  of  the 
products to a temperature above their melting point. Within this temperature 
gradient, fluorescent dye released by the double stranded DNA product at the 
Tm is detected by the real time machine and the accurate Tm data reported for 
every single amplified product. The melting peak of a single amplified product 
appears as a single sharp peak at the Tm, whereas peaks of small primer dimers 
appear at lower temperatures (Nolan et al., 2006).  
 
2.6.7  Normalization of cDNA samples 
Although  real time  RT PCR  is  considered  to  be  an  efficient  and  sensitive 
approach to determine biologically relevant changes in gene expression levels, 
technical as well as biological variation can cause variability of the data. Various 
errors resulting from inter sample variability in RNA degradation during storage, 
variation introduced during RNA isolation and variation during cDNA synthesis, 
can  cause  unavoidable  variation  in  the  amount  of  the  final  cDNA  product 
(Huggett et al., 2005). One common approach to minimize these errors is to 
normalize the cDNA sample using housekeeping genes as internal comparative 
standards.  Housekeeping  genes  are  typically  constitutive  genes  that  are 
expressed  at  a  relatively  stable  level.  Since  these  housekeeping  genes  are 
essential  for  cell  metabolism,  but  not  cell  differentiation,  it  is  therefore 
commonly  assumed  that  the  transcription  of  the  housekeeping  gene  is 
unaffected by experimental conditions (Suzuki et al., 2000). There are several 
housekeeping genes that have been used as reference genes for real time PCR 
assays. In our study, a housekeeping gene GAPDH (glyceraldehyde 3 phosphate 
dehydrogenase) was used as the reference gene for normalization. GAPDH is one 
of the most commonly used housekeeping genes that has been reported to be Chapter 2    113 
appropriate  for  certain  experimental  situations  (Andersen  et  al.,  2004).  The 
gene  expression  level  of  each  sample  was  normalized  against  a  ratio  of  its 
GAPDH content in relation to the 75th percentile of GAPDH levels of all samples 
assayed (an example of the normalisation process is shown in Table 2.6). The 
75th percentile of GAPDH gene copy number is calculated from GAPDH levels of 
all samples assayed and used as a reference to avoid a false calculation resulting 
from the percentage of gene level expression below the standard curve. This is 
because real time PCR also reports an intensity value although the gene is below 
the standard range. These intensity values are considered as background assay 
‘noise’ and are less reliable, and therefore more likely to fall into the lower 
percentile ranking on the array. The difference of each sample calculated from 
the 75th percentile is reliable and the change of gene X levels in the sample is 
on the assumption that the ratio of GAPDH is consistent. Any sample having a 
GAPDH content/75th percentile varying by more than a factor of 2 from the 75th 
percentile was discarded from the analysis due to an assumption of compound 
errors during sample processing.  
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A  B  C  D  E 
Sample Name 
Level of GAPDH 
   copies 
 
Level of gene x 
   copies 
   
Ratio to 75th 
Percentile 
(column C/71.25) 
Normalised level of 
gene X 
(column B/D) 
Sample 1  200  800  0.889  225 
Sample 2  1000  4000  4.444  225 
Sample 3  240  900  1.000  240 
Sample 4  200  200  0.222  900 
Sample 5  160  800  0.889  180 
              
   75th percentile  900       
Table 2.6 An example of normalisation using a housekeeping gene to determine levels of 
gene “X”  
Before normalization, sample 2 in column B has a higher value of gene X (1000 copies) than 
sample 4 (200 copies). After normalization, the results show that the level of gene X in 
sample 2 was similar to the other samples. This was due to the high level of cDNA in this 
sample. The opposite situation is seen in the pre normalised levels of gene X in sample 4 
which appears low, although the actual level is much higher, indicating that there was 
actually only a small amount of cDNA in this sample.  
2.7  Cytokine and chemokine protein expression 
analysis 
2.7.1   Protein extraction from brain tissue  
The snap frozen brain tissues were thawed, weighed, transferred to tubes on ice 
containing  approximately  3.4  ml  of  T PER  (Fisher  Scientific  UK  Ltd., 
Loughborough, UK), and Halt
TM Protease inhibitor cocktail (Fisher Scientific Ltd., 
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tissues were homogenized, incubated at room temperature for 10 minutes and 
centrifuged at 10,000 × g for 10 minutes at 4°C. Supernatants were transferred 
to  clean  microcentrifuge  tubes,  frozen  at  –80˚C  and  thawed  on  ice.  These 
protein preparations were further analysed for cytokine and chemokine protein 
levels by Luminex and ELISA.  
2.7.2  Normalization of a relative total protein concentration 
using BCA protein assay 
2.7.2.1  Protein assay 
Total protein concentrations in the brain tissue homogenates were determined 
using a BCA protein assay kit (Pierce Biotechnology, Cheshire, UK) according to 
the  manufacturer’s  instruction.  Briefly,  the  homogenate  supernatant  samples 
were diluted 1:10 with PBS and quantified in triplicate. BSA was diluted in PBS 
to give concentrations suitable for a standard curve (20 2,000 µg/ml). 25 µl of 
each standard and unknown sample replicate was added into a microplate well 
(Thermo  Labsystems,  Cheshire,  UK).  Working  Reagent  (WR)  was  prepared  by 
mixing 50 parts of BCA reagent A and 1 part of BCA reagent B supplied in the kit, 
followed by adding 200 µl of the WR to each well and mixing thoroughly on a 
plate shaker for 30 seconds. The plate was covered with an adhesive plastic 
plate cover and incubated at 37°C for 30 minutes. After cooling the plate at 
room  temperature,  the  optical  density  was  measured  at  560  nm  on  a  plate 
reader  (Dynex  Technologies  Ltd.,  Worthing,  UK).  The  test  sample  protein 
concentrations were generated by interpolation of their optical density to the 
optical density curve of the known protein standards. 
2.7.2.2   Normalization of protein samples 
An  example  of  the  calculation  used  to  quantify  the  concentration  of  one 
cytokine normalised for the total protein in one brain extract is given below: 
The  mean  OD  value of  triplicate  measurements  of  a  protein  extract  of  brain 
tissue from a wild type mouse (WT 1) is 0.464, which corresponded to a protein 
concentration of 708.7 µg/ml.  Chapter 2    116 
However, this is the concentration of a sample at 1:10 dilution, therefore the 
concentration of the neat sample is 10 x 708.7 µg/ml = 7087µg/ml. 
50 µl of each sample is used for one multiple cytokine Luminex assay.  
1,000 µl (1 ml)    contains     7087.03                           µg total proteins 
     50 µl              contains     50 x 7087.03  =  354.35   µg total protein 
                                               1,000 
According to the Luminex result, for example, the mean protein concentration 
of triplicate measurements of, for example, IL 13 is 55.03 pg/ml  
1,000 µl   contains          55.03                      pg  IL 13 protein 
     50 µl   contains         50 X 55.03   =  2.75  pg  IL 13 protein                            
                                       1,000  
Based  on  these  calculations,  a  50  µl  solution  of  WT  1  mice  brain  proteins 
contains 354.35 µg total proteins and 2.75 pg for IL 13.                 
354.35 ug total protein   contains    2.75  pg  IL 13 
1,000 ug total protein  contains  1,000 X 2.75  = 7.765 pg IL 13/mg total brain 
protein                                         354.35 
In summary, 1 mg total brain proteins of the WT1 sample contains 7.765 pg IL 
13.  
2.7.3  Measurement of multiple cytokines using a suspension 
bead array assay and a Luminex platform 
 
Quantifying  the  concentrations  of  many  cytokines  and  chemokines  in  a  small 
volume  of  biological  fluid  is  now  possible  using  a  muliplex  system.    Multiple 
cytokines (TNFα, IFNγ, IL 1α, IL 1β, IL 2, IL 4, IL 5, IL 6, IL 10, IL 12 [p40], IL 12 Chapter 2    117 
[p40/ p70], IL 13, IL 17), chemokines (IL 8, IP 10, KC, MCP 1, MIG, MIP 1α, MIP 
1β, MIP 3β, RANTES), and growth factors (FGF basic, GM CSF, PDGF BB, VEGF) 
were quantified in the soluble extracts from brain tissue and in mouse serum 
using a mouse 20 plex Luminex kit (Invitrogen, Paisley, UK) on a Bio Plex system 
(Bio Rad  Laboratories  Ltd.  Hemel  Hempstead,  UK),  according  to  the  user 
manual. The steps are detailed as follows: 
2.7.3.1   Plate preparation for Luminex assay 
A  96 well  filter  bottom  microplate  was  used  for  the  luminex  assay.  15  ml 
working  solution  concentrate  x  20  was  diluted  with  285ml  of  deionized  or 
distilled  water.  This  diluted  working  solution  was  used  to  pre wet  the  filter 
bottom of the plate (100 µl/well) and the content in the wells was removed by a 
vacuum pump.  
2.7.3.2  Preparation of beads 
The principal of the Luminex assay is based on a bead based suspension array 
using  capture  antibodies  against  an  analyte  immobilized  onto  a  microsphere 
(bead). Captured analytes (including standards of known analyte concentration, 
control specimens and unknown test samples) are detected mostly using the flow 
cytometry principle. 2.5  l of capture bead stock solution was resuspended by 
sonication for 2 3 minutes and then diluted in 2ml of working solution. 200  l of 
diluted capture beads were pipetted into each well. The fluid containing these 
capture beads was removed through the filter base of the plate using a vacuum 
pump, and the plate was similarly washed twice with working solution. The plate 
was dried by blotting the filter onto paper towel. 50  l incubation buffer was 
added  to  each  well.  This  was  immediately  followed  by  pipetting  50   l  assay 
diluent to sample wells, but not in the standard wells. 
2.7.3.3  Preparation of standard curve 
The standard curve was generated by using serial dilutions of the kit lyophilized 
standards reconstituted in assay diluent: T PER reagent (1:1). This was chosen 
because T PER reagent was used as the diluent for brain tissue homogenates. For 
serum analysis, the standards were diluted in assay diluent buffer provide in the 
kit. A mixture of 50% assay diluent plus 50% T PER reagent was also used as the Chapter 2    118 
blank in this assay. 1 ml of mixture of 50% assay diluent plus 50% T PER reagent 
was added into the bottle containing the lyophilised kit cytokine standard and 
left  for  10  minutes  to  reconstitute.  A  series  of  1:3  serial  dilution  standard 
samples was generated by diluting 150  l top standard from the standard stock 
solution into the first of a series of eppendorf tubes containing 300 mixture of 
50% assay diluent plus 50% T PER reagent and serially diluted 1 in 3. 100  l of 
standard and blank was added into standard wells containing diluted antibody 
coated bead complexes and incubation buffer.  
2.7.3.4  Assay procedure and analysis 
50  l of sample was added into sample wells containing diluted antibody coated 
bead  complexes,  assay  diluent  and  incubation  buffer.  The  assay  plate  was 
covered  with  tinfoil  (to  minimise  light  quenching  of  the  fluorochrome)  and 
incubated  at  room  temperature  for  2  hours  on  a  plate shaker  to  agitate  the 
beads.  At  this  first  incubation,  the  test  analytes  will  bind  to  the  capture 
antibodies on the beads. The fluid content in the wells are removed by a vacuum 
pump, followed by 2 washes with working buffer (100  l/well) and the filter 
bottom of the plate was dried using paper towel. Analyte specific biotinylated 
detector antibodies were diluted in biotin diluent (1:10), 100  l of detection 
antibody was added to each well and incubated for 1 hour at room temperature 
on  the  plate shaker.  During  this  second  incubation,  the  analyte specific 
biotinylated detector antibodies recognize their target cytokines that are bound 
to the appropriate beads. The excess fluid contents in the wells were removed 
by  a  vacuum  pump,  followed  by  3  wash  with  working  buffer  (100   l/well). 
Streptavidin  conjugated  to  the  fluorescent  protein,  R Phycoerythrin 
(Streptavidin RPE) was diluted (1:10) in Streptavidin RPE diluent and add into 
each well (100  l/well). The plate was then incubated for 30 minutes at room 
temperature on the plate shaker. During this final incubation, the Streptavidin 
RPE binds to the bionylated detector antibodies linked with immune complex on 
the  beads,  forming  a  four member  solid  phase  sandwich.  The  excess  fluid 
content in the wells was removed by a vacuum pump, followed by 3 wash with 
working buffer (100  l/well) to remove unbound Streptavidine RPE. The plate 
was  dried  by  blotting  on  paper  towel  and  incubated  overnight  with  working 
solution  (100   l/well)  at  4˚C.  Next  day,  the  beads  were  analysed  with  the 
Luminex  100  analyzer  instrument  (Luminex  Corp.,  Austin,  TX).  The Chapter 2    119 
concentrations  of  one  or  more  analytes  were  determined  by  monitoring  the 
spectral properties of the beads and the amount of associated R Phycoerythrin 
(RPE) fluorescence. The fluorescence was proportional to the concentration of 
the  analyte  and  quantified  with  reference  to  the  fluorescence  of  the  known 
concentration of the standard curve. 
2.7.4  Enzyme immuno assay (ELISA) protocol 
Individual concentrations of IL 1α, IL 1β, IL 2, IL 4, IL 5, IL 6, IL 10, IL 12 [p40/ 
p70],  IL 13,  IL 17,  IP 10,  KC,  MCP 1,  VEGF  and  TNFα  were  measured  using 
enzyme linked immuno assay (ELISA) in protein preparations from brain tissue. 
The  concentrations  of  antibodies  and  buffers  used  for  the  analysis  of  each 
cytokine are shown in Table 2.7 and Table 2.8.  Chapter 2                                                                                                                              120 
Cytokines  Coating buffer  Blocking buffer 
& Antibody 
diluents 
Concentration 
of capture 
antibody 
Concentration 
of detection 
antibody 
Streptavidin 
HRP dilution 
Substrate 
Solution 
Standard 
curve 
range 
mouse TNF α 
Cat # 559603 
BD Bioscience 
0.1 M Sodium 
Carbonate, pH 
9.5 
PBS with 10% 
FBS, pH 7 
1:250 
(50  l/well) 
1:250 
(50  l/well) 
1:250 
(50  l/well) 
TMB  2 ng/ml 4 
pg/ml 
mouse IL 1β 
eBioscience 
ELISA/ELISPOT 
coating buffer  
 
5x Assay Diluent 
 
1:250 
(50  l/well) 
1:250 
(50  l/well) 
1:250 
(50  l/well) 
TMB  4 ng/ml 4 
pg/ml 
mouse IL 2 
Peprotech 
PBS  0.05% Tween  
20, 0.1% BSA in 
PBS 
1  g/ml  
(100  l/well) 
0.25  g/ml  
(100  l/well) 
1:2000 
(100  l/well) 
ABTS  8 ng/ml 4 
pg/ml 
mouse IL 4 
Peprotech 
PBS  0.05% Tween  
20, 0.1% BSA in 
PBS 
1  g/ml  
(100  l/well) 
1  g/ml  
(100  l/well) 
1:2000 
(100  l/well) 
ABTS  4 ng/ml 4 
pg/ml 
mouse IL 5 
eBioscience 
ELISA/ELISPOT 
coating buffer  
 
5x Assay Diluent 
 
1:250 
(50  l/well) 
1:250 
(50  l/well) 
1:250 
(50  l/well) 
TMB  2 ng/ml 2 
pg/ml 
mouse IL 6 
Peprotech 
PBS  0.05% Tween  
20, 0.1% BSA in 
PBS 
2  g/ml  
(100  l/well) 
0.5  g/ml  
(100  l/well) 
1:2000 
(100  l/well) 
ABTS  6 ng/ml 4 
pg/ml 
 mouse IL 12 
Peprotech 
 
         PBS 
0.05% Tween  
20, 0.1% BSA in 
PBS 
1  g/ml  
(100  l/well) 
0.25  g/ml  
(100  l/well) 
1:2000 
(100  l/well) 
ABTS  5 ng/ml 
300 pg/ml 
Table 2.7 Cytokine analysis by ELISA.  
Mouse cytokines, chemokines and growth factors were analysed using capture and detection antibody listed above. The capture antibody was diluted in 
appropriate coating buffer and the detection antibody was diluted in the diluent supplied by the manufacturer. The final concentration of each antibody, the 
volume added to each well, and standard ranges are shown.   Chapter 2                                                                                                                              121 
Cytokines  Coating buffer  Blocking buffer 
& Antibody 
diluents 
Concentration 
of capture 
antibody 
Concentration 
of detection 
antibody 
Streptavidin 
HRP dilution 
Substrate 
Solution 
Standard 
curve 
range 
 
mouse IL 13 
eBioscience 
 
ELISA/ELISPOT 
coating buffer  
 
 
 
5x Assay Diluent 
 
 
1:250 
(50  l/well) 
 
1:250 
(50  l/well) 
 
1:250 
(50  l/well) 
 
 
TMB 
 
2 ng/ml 4 
pg/ml 
mouse CCL2 
eBioscience 
 
ELISA/ELISPOT 
coating buffer  
 
5x Assay Diluent 
 
1:250 
(50  l/well) 
1:250 
(50  l/well) 
1:250 
(50  l/well) 
TMB  4 ng/ml 4 
pg/ml 
 
mouse VEGF 
Peprotech 
PBS  0.05% Tween  
20, 0.1% BSA in 
PBS 
1  g/ml  
(100  l/well) 
0.5  g/ml  
(100  l/well) 
1:2000 
(100  l/well) 
ABTS  4 ng/ml 4 
pg/ml 
Table 2.8 Cytokine, chemokines and growth factor analysis by ELISA.  
A mouse cytokine (IL 13), a chemokine (CCL2) and a growth factor (VEGF) were analysed using capture and detection antibody listed above. The capture 
antibody was diluted in appropriate coating buffer and the detection antibody was diluted in the diluent supplied by the manufacturer. The final 
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The  ELISA  procedure  involved  briefly,  96 well  microtitre  plates  (Thermo 
Labsystems, Cheshire, UK) were coated with capture antibody diluted in coating 
buffer  at  appropriate  concentrations  according  to  the  manufacture’s 
instructions.  The  plates  were  covered  with  an  adhesive  plastic  cover  and 
incubated overnight at 4°C. The coating buffer containing capture antibody was 
removed the next day and the plates were washed 3 times by repeatedly filling 
and emptying the wells with 200  l wash buffer, and soaking the wells for 5 
minutes in between each wash. Washing was by flicking empty the plate over a 
sink. The remaining drops were removed by patting the plate upside down on a 
paper towel. To block the remaining protein binding sites in the coated wells, 
200  l blocking buffer was added into each well and the plates were incubated 
at 37°C for 1 hour. Following 3 further washes as above, 50  l of protein sample 
were added to each well in duplicate or triplicate in different experiments. For 
quantitative  data,  the  optical  density  of  the  unknown  test  samples  was 
compared against  the  optical  density  of  a  standard  curve  consisting  of  serial 
dilutions  of  a  known  quantity  of  the  cytokine  to  be  assayed.  Standards  in 
duplicate, and blank wells with no cytokine were run with each plate to ensure 
accuracy.  The  plates  were  covered  with  adhesive  plastic  covers  and  then 
incubated on the shaking machine for 2 hours at room temperature. The samples 
were removed and the plates were washed 5 times, followed by adding 50  l of 
diluted  detection  antibody  in  blocking  buffer  and  incubation  at  room 
temperature for 1 hour. The detecting antibody was an antibody that specifically 
recognised the cytokine to be measured and that was conjugated to an enzyme 
that would allow subsequent detection. In this case, the plates were washed and 
streptavidin horse  radish  peroxidase  (HRP),  diluted  1:1000  with  diluent,  was 
added to each well, followed by incubation on a plate shaker for 1 hour at room 
temperature.  After  this,  and  following  3  washes,  the  activity  of  the  bound 
enzyme was detected by a colour change by adding 100  l of colourless substrate 
solutions including TMB (3,3’,5,5’ tetramethylbenzidine) or ABTS (2,2’ azino di 
[3 ethyl benzothiazoline 6  sulfonic  acid]  di ammonium  salt),  which  changed 
colour after enzyme activity.. The optimum optical density was read at 630 nm 
for  TMB  and  410  nm  for  ABTS  on  a  microplate  spectrophotometer  (Dynex 
Technologies  Ltd.,  Worthing,  UK).  A  standard  curve  was  prepared  from  the 
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concentration on the x axis (log scale) vs absorbance on the Y axis (linear). The 
concentration of the sample was interpolated from this standard curve. 
2.8   Free floating section staining for doublecortin 
(DCX) 
The immature neuronal marker doublecortin (DCX) is commonly used to quantify 
change in hippocampal neurogenesis. DCX is a highly hydrophilic microtubule 
associated protein that is specifically expressed in migrating neuronal precursors 
in the dentate gyrus in the hippocampus (Couillard Despres et al., 2005). The 
doublecortin (DCX) antibody is hydrophilic which restricts penetration into the 
hydrophobic  brain  tissue,  therefore,  immunohistochemistry  of  DCX  is  best 
achieved  by  free floating  Immunohistochemistry,  in  which  thick  frozen cut 
sections  were  incubated  floating  free  in  plastic  wells  containing  diluted  DCX 
antibody  solution.  Increasing  the  penetration  of  antibody  into  the  tissue  is  a 
major advantage of the free floating Immunohistochemistry since free floating 
tissue in antibody solution allows tissue to be exposed to the antibody from both 
(back and front) sides. High salt solution (0.3 M PBS) was used as diluent and 
washing solutions, and these reduced non specific staining by decreasing charge 
induced non specific binding (Pastor Soler et al., 2010).  
2.8.1   Tissue processing 
Mice  were  terminally  anesthetized  with  halothane:oxygen.  The  brains  were 
removed,  and  immersion fixed  in  4%  paraformaldehyde  in  50  mM  phosphate 
buffer for 48 h. Brains were then cryoprotected by immersion in a 30% (W/V) 
sucrose; PBS solution at 4°C until the brains sink (usually 24 hours). Brains were 
stored in liquid nitrogen until required.  
2.8.2   Cryostat cutting and free floating section process 
The middle segment of a mouse brain, which contains the hippocampus, was 
dissected, mounted in OCT embedding compound (Tissue Tek O.C.T
TM Sakura 
Finetek, Zoeterwoude, Natherlands) and frozen in the cryostat (Thermo Electron 
Corporation, Thermo Labsystems, Cheshire, UK) set at  20°C. The brain was cut 
into sequential 60  m coronal sections. Each 60  m brain section, containing 
hippocampus  as  illustrated  between  plates  24  and  48  of  the  histology  mouse Chapter 2    124 
brain atlas of Paxinos and Watson et al.,1998 (Paxinos and Watson, 1998) (Figure 
2.2,  Figure  2.3),  was  lifted  out  from  the  blade  serially  with  a  paintbrush  to 
minimize folding or wrinkling. Each section was transferred serially into wells 
containing  0.1  M  PB  buffer,  and  immuno histochemistry  of  doublecortin  was 
performed in that 24 well plate on an orbital shaker. 200  l of all washing buffer 
and antibody solutions was transferred to each well and removed from the well 
in each step using a Pasteur pipette. 
 
Figure 2.2 A coronal rat brain atlas diagram (Paxinos and Watson, 1998).  
A black box shows the hippocampal region characterized by butterfly shaped area. Dentate 
Gyrus (DG) is a part of hippocampus (a smaller red box), which is the specific area of DCX 
immunohistochemistry.  
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Figure 2.3  Coronal brain sections at the level of hippocampus. 
Diagrammatic illustrations displaying levels of coronal brain sections that were taken, 
which are based on a standard mouse brain stereotaxic atlas (Paxinos and Watson, 1998). 
Images were taken from (O'Neill and Clemens, 2001) by a kind permission of the Editor of 
Current Protocols in Neuroscience. 
2.8.3   Immunohistochemistry 
Free floating  sections  were  immersed  in  50%  ethanol  for  30  min  before 
immunostaining  to  enhance  antibody  penetration.  The  sections  then  were 
washed 3 times with 0.1 M PB buffer for 5 minutes each. To block endogenous 
peroxidase, sections were incubated with 0.3% H2O2 (Sigma, Poole, Dorset, UK) in 
0.1 PB for 30 min.  
2.8.3.1   Chromogenic immunostaining of doublecortin (DCX) 
For chromogenic immuno staining, sections were washed in 0.3 M PBS for 3 times 
5 minutes each, and then incubated overnight at 4°C with rabbit α doublecortin 
polyclonal  antibody,  1:500  (ab18723,  Abcam,  Cambridge,  UK)  in  a  solution 
containing 0.3 M PBS, 0.3% Triton X 100. Sections were then washed extensively 
3 times for 5 minutes each, with 0.3 M PBS and further incubated with goat anti 
rabbit  IgG  conjugated  with  biotin  (Vector  Laboratories,  Peterborough,  UK)  at 
1:200 dilution in 0.3 M PBS, 0.3% Triton X 100 for 1 hour at room temperature. 
To form the avidin biotin peroxidase complex, the sections were subsequently 
incubated  in  200  µl  0.2  M  PB  buffer  containing  Avidin  DH  and  biotinylated 
horseradish  peroxidase  H  from  VECTASTAIN®  ABC  kits  (Vector  Laboratories, 
Burlingame, CA, USA) for 30 minutes at room temperature. This was followed by 
2  washes  with  0.3  M  PBS  and  1  wash  with  0.1  M  PB  buffer.  The  peroxidase 
activity was quantified by using a diaminobenzidine substrate (DAB kit, Vector Chapter 2    126 
laboratories,  Peterborough,  UK),  prepared  in  H2O  according  to  the 
manufacturer's instructions, before briefly rinsing 3 times with 0.1 M PB buffer. 
Sections were placed on gelatin coated slides using a wet paintbrush in a 4 serial 
section  sequences  per  slides  according  to  the  columns  in  a  24  well  plate. 
Sections  were  dried  overnight  in  a  glass  chamber  soaked  with  4% 
paraformaldehyde  in  50  mM  phosphate  buffer.  The  sections  were  alcohol 
dehydrated and cleared with xylene following these steps:  
H2O                   5 minutes 
70%   Ethanol                         5 minutes 
90%   Ethanol                         5 minutes 
100% Ethanol                         5 minutes 
100% Ethanol                         5 minutes 
100% Ethanol                         5 minutes 
70%   Ethanol                         5 minutes 
Xylene                  5 minutes 
Xylene                  5 minutes 
One drop of DPX mounting media (VWR International Ltd., Lutterworth, UK) was 
transferred  over  the  tissue  sections  using  a  Pasteur  pipette  and  a  cover  slip 
(VWR International Ltd., Lutterworth, UK) gently placed over tissue section. The 
DCX was allowed to dry before visualising with a Zeiss Axiostar plus microscope 
(Carl Zeiss, Germany) with a x40 objective.  
2.8.3.2   Fluorescence immunostaining of doublecortin (DCX) 
For  fluorescence  immunodetection,  sections  were  washed  extensively  and 
incubated with the mixture of species specific primary antibodies consisting of 
goat  polyclonal  α doublecortin  antibody  1:500  (DCX  C 18,  Santa  Cruz Chapter 2    127 
Laboratories,  Santa  Cruz,  CA,  USA),  mouse  α NeuN,  1:500  (Chemocon, 
Temecula, CA, USA) and Cy 5 dk mouse, 1:100 (Stratech Scientific, Luton, UK).  
Sections  were  then  incubated  with  a  cocktail  of  fluorochrome conjugated 
species specific  secondary  antibodies  comprising  of  donkey  antigoat  IgG 
conjugated  with  Alexa  488,  1:500  (Molecular  Probes,  Eugene,  OR,  USA)  and 
antimouse IgG conjugated with Rhodamine Red X, 1: 1000 (Stratech Scientific, 
Luton, UK) for 2 hours at room temperature. Sections were then stained with 
propidium iodide (Sigma, Poole, UK; 1% in PBS) in the presence of RNase (Sigma; 
10  mg/ml)  to  reveal  cell  nuclei.  Sections  were  placed  on  glass  slides  and 
mounted in glycerol based anti fade medium (Vectashield; Vector Laboratories, 
Peterborough,  UK)  and  examined  with  a  Bio Red  MRC  1024  Confocal  laser 
scanning  microscope  (Hemel  Hempstead,  UK)  equipped  with  a  krypton  argon 
laser, through a x60 oil immersion objective lens. 
The process of DCX immunohistochemistry is shown in Figure 2.4.   
  
Figure 2.4 Steps involved in tissue processing, cryostat cutting and DCX staining.  
(1) Fixation and Cryoprotection of brain tissue. (Kim et al.) & (3) Remove the middle 
segment (which contains the hippocampus). (4) Embed this segment in OCT embedding 
matrix and freeze it in  20°C in the cryostat machine, cryostat cut sections into 60  m. (5) 
Collect and transfer sections serially in 0.2 M PB buffer in a 24 well tissue culture plate. (6) 
Perform DCX immuno histochemistry in the 24 well tissue culture plate. (7) Pick sections Chapter 2    128 
one by one with a wet paintbrush and transfer to gelatine coated slides serially 
corresponding to each of the 24 well plate columns. Mount slides with DPX mounting 
media. Images were taken from (O'Neill and Clemens, 2001) by a kind permission of the 
Editor of Current Protocols in Neuroscience. 
2.8.4   Quantifying doublecortin [DCX] positive cells 
Simple  cell  counting  is  a  rapid  method  to  quantify  neuron  numbers  in  the 
hippocampus  in  several  publications  (Couillard Despres  et  al.,  2005).  The 
numbers of DCX positive cells in our study were counted by a similar counting 
method in a double blind fashion. The slide labels were masked and DCX positive 
cells in the dentate gyrus were counted by a blind observer. Each brain, DCX 
stained  brain  sections  were  placed  in  a  horizontal  serial  fashion  on  gelatine 
coated slides. DCX positive cells were counted on every sixth (60  m) coronal 
section  through  the  dentate  gyrus  by  using  a  Zeiss  Axiostar  plus  (Carl  Zeiss, 
Germany) with a x40 objective lens. This means the 6th, 12th, 18th and 24th 
sections were selected. The numbers of DCX positive cells in the dentate gyrus 
were counted in both hemispheres (Figure 2.5). The sum of these counts was 
multiplied by six to generate estimates of absolute numbers.  
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Figure 2.5 The order of DCX stained brain sections of one mouse brain onto slides.  
Twenty four DCX stained brain sections were placed in a horizontal serial fashion on 6 
gelatin coated slides (from left to right). This order corresponded to the serial order in the 
24 well tissue culture plate. 6th, 12th, 18th and 24th sections located at the 6th slide (red 
box) were used to quantify the number of DCX positive neuron in the dentate gyrus.  
2.9 Statistical analysis 
Inflammatory mediator levels below the detection limits of Luminex, ELISA or 
real time  PCR  assays  were  allocated  the  value  of  the  detection  limit  for 
statistical analysis rather than zero, in order to use the information that the 
level was low. 
Continuous  variables  were  summarised  as  mean  and  standard  deviation  if 
normally distributed, or median and inter quartile range if they had a skewed 
distribution. The distribution of the continuous variable data was inspected by 
Bartlett's test to confirm the normal distribution. The appropriate parametric 
test used to compares three or more unmatched groups is the one way ANOVA. 
Therefore,  this  was  used  as  the  multiple  comparison  test  for  comparing 
inflammatory  mediator  concentrations  and  protein/gene  expression  levels 
between  3  groups  of  mice  (arthritic,  non arthritic  and  naïve  control  groups). 
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The Student’s t test was occasionally used to compare inflammatory mediator 
concentrations  and  protein/gene  expression  levels  between  2  experimental 
groups (arthritic and non arthritic groups).  
In our longitudinal studies, we compared inflammatory mediator concentrations 
in  brains  of  CII  immunized  and  naïve  control  mice  across  time  points  and 
between these 2 groups of mice at each time point. Two way ANOVA is the most 
suitable test for these longitudinal studies because it determines how a response 
is affected by two different factors (different groups of mice and different time 
points).  Therefore,  two way  Analysis  of  Variance  (ANOVA)  with  Bonferroni 
multiple  comparison  tests  were  used  to  evaluate  longitudinal  inflammatory 
mediator  production,  with  overall  significance  for  factors  of  CII 
immunized/naïve  control  mice  and  time.  In  addition,  Two way  Analysis  of 
Variance (ANOVA) with Bonferroni multiple comparison tests were also used to 
confirm any significant difference in arthritis score, paw thickness and arthritis 
incidence  between  CII  immunized/naïve  control  mice.  Pearson’s  correlation 
coefficient was used for correlation analysis. Calculations for statistical analysis 
were performed with Prism software version 4 (Graphpad Software, San Diego, 
CA,  US).  P  <  0.05(*),  P  <  0.01(**)  and  P  <  0.001(***)  were  considered  as 
statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 3                                                                                                                              131 
 
 
 
 
 
 
 
Chapter 3 
Increased concentration of inflammatory mediators 
in the brain associated with collagen induced 
experimental arthritis. 
 
 
 
 
 
 
 
 
 Chapter 3    132 
3.1   Introduction and aims 
Rheumatoid arthritis is a systemic autoimmune disease in which, in addition to 
joint disease, the peripheral inflammation is reflected by the presence of extra 
articular  organ  manifestations  such  as  systemic  vasculitis  (blood  vessel 
inflammation),  subcutaneous  nodules  and pulmonary  fibrosis  in  approximately 
30% of RA patients (Young and Koduri, 2007). Accumulating evidence suggests 
that the brain may also be affected by peripheral inflammation during arthritis. 
For example, neuroimaging studies showed several CNS lesions in the brains of 
RA  patients,  which  resolved  after  steroid  treatment,  suggesting  that  CNS 
inflammatory  demyelination  may  also  be  inducible  by  systemic  inflammation 
during arthritis (Tsai et al., 2008); (Tajima et al., 2004). Psychiatric disorders 
such as depression and anxiety are also common in RA, and this observation may 
be a potential novel area of clinical research based on the hypothesis that these 
may be due to peripheral inflammation during arthritis causing alterations in 
brain neurobiology. To date, there are few studies investigating the potential 
mechanisms  underlying  psychological  disorders  in  RA.  One  preliminary  study 
using  a  single  photon  emission  computed  tomography  (SPECT)  scan  of  6  RA 
patients showed a reduction in serotonin transporter (SERT)  density, along with 
improvement  in  physical  and  mental  functions  after  receiving  anti TNF α 
treatment, suggesting that circulating cytokines generated during autoimmune 
activation in RA may cause changes in the serotonin system that induced the 
development of depression (Cavanagh et al., 2010). A hypothesis based on this 
clinical observation is supported by studies in animal model of RA; a study using 
a  transient  model  of  RA  by  Bao  et  al.,  showed  that  both  mRNA  and  protein 
concentration of IL 1β, IL 6 and TNF α were elevated in the spinal cord of AIA 
rats (Bao et al., 2001). Similar observations were reported in a chronic model of 
RA; brains of CIA rats showed up regulation of the expression of various cytokine 
genes, including TNF α, IL 1β and IL 6 (del Rey et al., 2008).  In addition, a 
transient increase in hippocampal neurogenesis has been reported in the brains 
of  AIA  rats,  suggesting  that  neuroinflammation  induced  by  peripheral 
inflammation  may contribute  to  neurobiological  changes  during  the course  of 
arthritis (Wolf et al., 2009b).  
Based on  this  evidence,  we hypothesised that  the  systemic immune  response 
activated  during  arthritis  can  induce  brain  inflammation  and  neurobiological Chapter 3    133 
changes,  which  may  help  explain  the  mechanism  underlying  psychological 
disorders associated with RA. Therefore, the aim of this chapter is to investigate 
changes in a wide range of inflammatory mediator proteins in the brain of CIA 
mouse model of arthritis using Luminex bead based screening assays. We also 
determine  changes  in  concentration  of  mRNA  encoding  these  inflammatory 
mediators using real time PCR and quantified as absolute copy numbers.  
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3.2   Results 
3.2.1   Induction of arthritis in DBA1 mice 
The  aim  of  this  experiment  is  to  investigate  whether  peripheral 
immune/inflammatory  responses  occurring  during  arthritis  can  change  the 
protein  and  gene  expression  profiles  of  inflammatory  mediators  (cytokines, 
chemokines, growth factors) in the brains.  
Experimental  procedure:  19  DBA1  mice  were  immunized  by  intradermal 
injection of type II collagen in complete Freund’s adjuvant on day 0. On day 21, 
mice were given an i.p. booster injection of type II collagen dissolved in PBS. 7 
sex  and age matched DBA1 mice were used as the naïve control and were not 
immunized  or  boosted  with  type  II  collagen.  The  signs  of  arthritis  in  CII 
immunized mice were monitored from day 16 after immunization onwards and 
arthritis severity in this experiment were verified independently by Dr. Darren 
Asquith. Groups of both CII immunized and control mice were sacrificed on day 
42 and serum was collected for the determination of peripheral inflammatory 
mediator proteins by a luminex multi parameter assay. The brain of each mouse 
was isolated and snapped frozen in liquid nitrogen and stored at –80˚C.  Half of 
each  brain  was  processed  for  protein  extraction  and  inflammatory  mediator 
protein analysis by luminex; the other half was processed for RNA extraction and 
inflammatory  mediator  gene  expression  determined  by  real time  PCR.  The 
experimental procedure of collagen II induced experimental arthritis (CIA) model 
is summarized in Figure 3.1. 
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Figure 3.1 The experimental procedure of collagen II induced experimental arthritis (CIA) 
model  
DBA1 mice at 6 8 weeks of age were separated into two groups: i) 7 control mice; ii) 19 
immunized mice.  Mice were immunized with 100       g type II bovine collagen + complete 
Freund’s adjuvant (CFA) at day 0 and then challenged on day 21 with 200       g type II collagen. 
A group of 7 naïve DBA1 mice which were not immunized and not treated with type II 
collagen was use as a control group.  Serum and brains from control and CII immunized 
mice were harvested at Day 42. Each mouse brain was dissected into left and right 
hemispheres. One half was processed for mRNA extraction and measurements of 
inflammatory mediator transcripts by real time PCR. Protein was extracted from the other 
half brain after homogenisation of the tissue and used to determine inflammatory mediator 
protein concentration a Luminex assay.  
Clinical response: Some of the CII immunized mice started to show clinical signs 
of arthritis from day 19 onwards and there were 12 out of the 19 CII immunized 
mice that developed arthritis (63% incidence) on day 42 (Figure 3.2A). 7 of the 
19 mice did not develop arthritis although they had an identical immunization 
and challenge, and these were therefore considered as potentially different and 
formed a separate ‘immunised but non arthritis’ study group.  
CII  immunized  mice  showed  a  significant  increase  in  paw  thickness 
compared to those in naïve control mice (P<0.0001). The mean paw thickness 
and the mean arthritis score for the whole group of CII immunized mice (n=19) 
on day 42 were 1.9 ± 0.1 mm and 4.5 ± 1.2 respectively (Figure 3.2B), (Figure 
3.2C).  Haematoxylin  and  eosin  staining  of  a  hind  paw  tissue  section  of  an Chapter 3    136 
arthritic  mouse  (this  mouse  had  a  clinical  score  of  12  on  day  42)  showed 
cartilage and bone damage/erosion and synovial hyperplasia in the joint (Figure 
3.3) 
 
Figure 3.2 development and severity of arthritis disease in CII immunized mice over 42 days 
of experimental arthritis course  
The signs of arthritis in CII immunized mice were monitored from day 16 after immunization 
onwards. (A) shows the percent incidence of arthritis in CII immunized mice, which was 
calculated from the number of CII immunized mice with arthritis divided by the total number 
of CII immunized mice used. The signs of arthritis were observed in CII immunized mice 
from day 18 onwards and there were 12 out of total 19 CII immunized mice developed 
arthritis on day 42. Mean clinical arthritic score and mean paw thickness were used as 
clinical evaluations to measure the severity of joint inflammation in arthritic mice. (B) shows 
the mean paw thickness of CII immunized mice which was calculated from the sum of the 
paw thickness of all mice divided by the number of mice. (C) shows the mean clinical score 
of CII immunized mice which was calculated from the sum of the clinical scores of all mice 
divided by the number of mice. Mean paw thickness, mean clinical score and %incidence in 
19 CII immunised mice (filled squares) were compared with those values of 7 naïve control 
mice (open circles). Data represent as mean ± SEM. (n=19 CII immunised mice). Statistical 
analysis of data was performed using two way ANOVA for multiple comparison, compared 
with a group of control naïve mice; *P<0.05, ** P<0.01, *** P<0.001.  Chapter 3    137 
 
Figure 3.3 Paw histology of an arthritic mouse  
(A) a representative histological image (10 x magnification) of a section of an arthritic 
mouse paw (this arthritic mouse had a clinical score of 12 on day 42). A smaller box section 
shows the area of joint inflammation in this arthritic mouse. Cartilage and bone 
damage/erosion, cartilage loss and synovial hyperplasia were observed in an inflamed hind 
paw of this arthritic mouse compared to a representative histological image (10 x 
magnification) of a section of a naïve mouse paw (B). Abbreviations; B = Bone, C = 
Cartilage, J = Joint space, SM = synovial membrane.  
3.2.2  Changes in inflammatory mediator protein 
concentration in serum of CII immunized mice (both arthritic 
mice and non arthritic mice) 
To investigated systemic inflammatory signals in the periphery of CII immunized 
mice,  inflammatory  mediator  proteins  in  serum  collected  from  naive  control 
mice  and  CII  immunized  mice  on  day  42  were  determined  using  a  Luminex 
cytokine 20 Plex assay. Serum concentrations of CXCL1 and FGF protein were 
within the assay detection limits (CXCL1 35 – 3023 pg/ml; and FGF2 27 – 3552 
pg/ml). Concentrations of the other serum inflammatory mediators ( TNF α, IFN 
γ, IL 1α, IL 1β, IL 4, IL 5, IL 6, IL 10, IL 12 [p40], IL 12[p40/p70], IL 13, IL 17), 
chemokines  (CXCL10,  CCL2,  CXCL9,  CCL3,  CCL4,  CCL19,  CCL5),  and  growth 
factors  (GM CSF,  PDGF BB,  VEGF)  in  brain  tissue  of  mice  of  all  experimental 
groups were lower than the detection limit of the Luminex assay.  
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One way ANOVA analysis demonstrated that there were significant differences in 
serum concentration of CXCL1 among the three groups of mice (P < 0.0001). Post 
hoc  analysis  with  Bonferroni  correction  demonstrated  significant  increases  in 
serum concentration of CXCL1 in CII immunized mice (both arthritic and non 
arthritic) compared to those in naïve control mice. The mean values of serum 
CXCL1 (arthritic versus naïve control) was 51.1 ± 2.6 pg/ml versus 33.6 ± 1.5 
pg/ml (P < 0.001). The serum concentration of CXCL1 was also elevated in CII 
immunized mice that did not develop arthritis compared to those in the naïve 
controls. The mean values of serum CXCL1 (non arthritic versus naïve control) 
was  54.8  ±  6.8  pg/ml  versus  33.6  ±  1.5  pg/ml  (P  <  0.001).  There  was  no 
significant difference in serum CXCL1 concentration between arthritic and non 
arthritic mice (Figure 3.4A). These results are consistent with a study in CIA 
model by Kurowska et al., showing an elevation of serum CXCL1 detected using a 
Luminex  assay  in  CII  immunized  mice  compared  to  the  controls.  FGF2  was 
another  inflammatory  mediator  detected  in  serum  of  mice  from  all  the 
experimental groups. However, one way ANOVA analysis showed that there was 
no  significant  difference  in  serum  FGF2  concentration  between  naïve  control 
mice and CII immunized mice (P = 0.4093) (Figure 3.4B) 
 
Figure 3.4 Serum inflammatory mediator profiles in CII immunized mice  
Concentrations of inflammatory mediator protein concentration (pg/ml) determined by 
Luminex based multiplex cytokine assay in serum of naïve control mice (n=7 naïve control 
mice) and CII immunized mice (n=19 CII immunized mice). The group of CII immunized mice 
consisted of 7 non arthritic mice and 12 arthritic mice. Mice from all experimental groups 
were sacrificed and serum samples were collected on day 42.  Only CXCL1 and FGF2 
protein concentration were detectable at the detection limit Data are presented as the mean 
values. (*P < 05 ; **P < 01; ***P < 001 by one way ANOVA analysis) 
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3.2.3   Changes in inflammatory mediator protein 
concentrations in brains of CII immunized mice (both 
arthritic mice and non arthritic mice) 
To  investigate  changes  in  inflammatory  mediator  profiles  in  brains  of  CII 
immunized mice that did (arthritic mice) or did not (non arthritic mice) develop 
arthritis compared to naïve control mice, Luminex cytokine 20 Plex assay was 
used to measure the protein concentration of various inflammatory mediators 
including  proinflammatory  cytokines  (IL 6,  IL 1  β,  TNF α  and  IL 1  α  ),  Th1 
cytokines  (IL 2,  IL 12  and  IFN γ),  Th2  cytokines  (IL 4,  IL 5,  IL 10,  IL 13), 
chemokines (CXCL1, CXCL10, CCL2, CCL3) and growth factors (FGF2, VEGF) in 
half  brain  tissue  homogenate  samples  from  mice  of  all  experimental  groups. 
Each sample was measured in triplicate. Values were reported as pg/ml. These 
values were extrapolated from the standard curves of known concentrations of a 
single mixed inflammatory mediator standard. Examples of the standard curves 
for each inflammatory mediators generated in the Luminex assay used in the 
experiment are shown in Appendix 1A and Appendix 1B. The standard curves of 
this Luminex assay demonstrated the dynamic range and sensitivity desired for 
the assay. In addition, these standard curves were to show that the Luminex 
assay was run in an acceptable performance manner.  
Values of inflammatory mediator concentrations in each brain tissue homogenate 
sample (pg/ml) were then normalized with the total protein concentration of 
brain tissue ( g/ml) of that sample, and presented as pg/mg total brain protein. 
To calculate the amount of inflammatory mediator protein level as pg/mg total 
brain  protein,  amounts  of  inflammatory  mediator  proteins  and  of  total  brain 
protein in 50  l of each sample were firstly calculated. For example, the protein 
concentration  of  IL 13  in  sample  A  measured  by  Luminex  was  55.03  pg/ml, 
therefore 50  l of sample A contains 2.8 pg IL 13. The protein concentration of 
sample A measured by BCA protein assay was 7087.03  g/ml, therefore 50  l of 
sample A was 354.35  g total brain tissue. Finally, amount of IL 13 protein in 1 
mg  total  brain  protein  (pg/mg  total  brain  tissue)  was  calculated  using  the 
following equation 
                                  1000 X Amount of IL 13 protein in 50  l (pg) 
                                   Amount of total brain protein in 50  l (mg)    
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Therefore, 1 mg total brain proteins of sample A contained 7.765 pg of IL 13.  
Values  of  protein  concentrations  of  IL 1α,  IL 2,  IL 4,  IL 5,  IL 6,  IL 10,  IL 13, 
CXCL1,  CXCL10  and  FGF2  obtained  from  the  Luminex  assay  in  brain  tissue 
homogenate samples of mice from all experimental groups were all within the 
detection  limits  of  the  assay.  Table  2.1  shows  the  dynamic  range  for  each 
inflammatory mediator generated in the Luminex assay, and the mean values of 
protein concentrations (pg/ml) of these inflammatory mediators in brain tissue 
homogenate samples of both naïve control mice and CII immunized mice before 
normalization.  This  is  to  show  that  the  actual  values  of  these  inflammatory 
mediator protein concentration in brain tissue homogenate samples of mice from 
all experimental groups were within the detection limit of the assay, although 
the amount of some brain inflammatory mediators protein in these mice seemed 
lower than the detection limit of the Luminex assay after the normalization by 
total brain protein (pg/mg total brain protein).  
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mean concentrations of brain 
inflammatory mediator proteins in  
50  l brain tissue homogeneous 
(pg/ml) 
 
 
Inflammatory 
mediators 
 
Dynamic range of 
detection limits 
(pg/ml) 
Naïve control 
mice 
CII immunized mice 
          
IL 1α 
 
20.9   14733.5 
 
 
13.8 ±  4.0 
 
 
36.4 ±  14.1 
          
IL 2 
 
17.6   13999.8 
 
 
47.2 ± 23.1 
 
107.3 ±  44.3 
          
IL 4 
 
12.7   13452 
 
 
10.1 ±  1.6 
 
 
23.5 ±  11.7 
 
IL 5 
 
6.4    10204.5 
 
 
18.9 ± 2.4 
 
31.4 ± 9.6 
 
IL 6 
 
8.3    9161.9 
 
 
7.8 ± 2.1 
 
15.1  ± 6.9 
 
IL 10 
 
46.2   40630.0 
 
 
200.9 ± 60.0 
 
454.4 ± 294.1 
 
 
IL 13 
 
25.3 – 20070.0 
 
 
22.2 ± 6.9 
 
46.5 ± 25.3 
 
CXCL1 
 
33.4  14796.0 
 
 
85.4 ± 9.7 
 
168.5 ± 58.0 
 
CXCL10 
 
33.5   38592.1 
 
 
76.1 ± 8.2 
 
154.1 ± 55.6 
 
FGF2 
 
34.8   11084.3 
 
 
522.8 ± 47.0 
 
927.7 ± 296.4 
Table 3.1 Values of protein concentrations of inflammatory mediators detected by a 
Luminex assay in brain tissue homogenate samples of naïve control mice and CII 
immunized mice  
Dynamic range of detection limits of the Luminex assay were generated by standard curve 
of known quantities of mouse recombinant inflammatory mediators. Protein concentrations 
of IL 1α, IL 2, IL 4, IL 5, IL 6, IL 10, IL 13, CXCL1, CXCL10 and FGF2 obtained from the 
Luminex assay in 50  l brain tissue homogenate samples of mice from all experimental 
groups were obtained from the Luminex assay as pg/ml. Values of protein concentrations of 
these inflammatory mediators were eventually normalized by total brain protein as 
presented as pg/mg total brain protein. The mean value of total protein concentration of 
brain tissue in 50 l of brain tissue homogenate samples of naïve control and CII immunized 
mice were 4694 ±473 g/ml and 4795 ±683  g/ml. Protein concentrations of mean 
concentrations of brain inflammatory mediator proteins were presented by (pg/ml) ± SD.  
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3.2.3.1   Pro inflammatory cytokine profiles in the brains of CII 
immunized mice (both arthritic mice and non arthritic mice) 
Pro inflammatory cytokines, including IL 1β, IL 1α, IL 6 and TNF α, are produced 
by mononuclear cells such as macrophages and are involved in the initiation of 
the immune response. The amounts of these proinflammatory cytokines were 
determined in the brains of naïve control mice, arthritic mice and CII immunized 
mice with no arthritis, but only IL 1α and IL 6 were detectable. One way ANOVA 
analysis showed that there was no significant difference in brain IL 1α and IL 6 
protein concentration between naïve control non arthritic mice and arthritice 
mice (P = 0.0543 and P = 0.8445 repectively) (Figure 3.5A, Figure 3.5B). 
 
Figure 3.5 Changes in pro inflammatory cytokine concentration in brains of CII immunized 
mice  
The dots represent protein concentration of IL 1α and IL 6 (pg/mg total brain protein) 
determined by Luminex based multiplex cytokine assay in brain tissue homogenate of naïve 
control mice (n=7 naïve control mice), non arthritic mice (n=7 non arthritic mice), and, 
arthritic mice (n=12 arthritic mice). All mice were sacrificed and brains were collected on 
day 42.  Data are presented as the mean values. (*P < 05 ; **P < 01; ***P < 001 by one way 
ANOVA analysis). Bars represent the mean values. 
3.2.3.2  Th 1 cytokines profile in the brains of CII immunized mice (both 
arthritic mice and non arthritic mice) 
Th 1 cytokines, including IL 12, IL 2 and IFN γ, were determined in the brain of 
naïve control mice and CII immunized mice with and without arthritis. IL 2 was 
the only cytokine in this category that was up regulated in arthritic mouse brains 
compared  to  those  in  the  naïve  control  group.  One way  ANOVA  analysis 
demonstrated that there was a significant difference in protein concentration of 
IL 2  among  the  three  groups  of  mice  (P  =  0.0343).  Post  hoc  analysis  with 
Bonferroni  correction  demonstrated  the  significant  difference  in  protein 
concentration of IL 2 between arthritic mice and naïve control mice. The mean 
value of IL 2 (arthritic versus naïve control) was 24.4 ± 10.2 pg/mg total brain Chapter 3    143 
protein versus 11.6 ± 2.2 pg/mg total protein (P < 0.05). There was no significant 
difference in brain IL 2 protein concentration between naïve control mice and 
non arthritic mice (Figure 3.6). There were no significant differences in brain IL 
2 concentrations between arthritic and non arthritic mice. 
 
Figure 3.6 Changes in a Th1 cytokine level in brains of CII immunized mice  
The dots represent protein concentration of IL 2 (pg/mg total brain protein) determined by 
Luminex based multiplex cytokine assay in brain tissue homogenate of naïve control mice 
(n=7 naïve control mice), non arthritic mice (n=7 non arthritic mice), and, arthritic mice 
(n=12 arthritic mice). All mice were sacrificed and brains were collected on day 42.  Data are 
presented as the mean values. (*P < 05 ; **P < 01; ***P < 001 by one way ANOVA analysis). 
Bars represent the mean values. Bars represent the mean values. 
3.2.3.3   Th 2 cytokine profiles in the brains of CII immunized mice (both 
arthritic mice and non arthritic mice) 
Th 2  cytokines,  including  IL 4,  IL 5,  IL 10  and  IL 13  were  determined  in  the 
brains of naïve control mice and CII immunized mice with and without arthritis. 
One way ANOVA analysis showed that there was no significant difference in brain 
IL 4 protein concentration between naïve control mice and CII immunized mice 
(P = 0.6696) (Figure 3.7A). One way ANOVA analysis demonstrated that there 
were significant differences in protein concentration of IL 5 and IL 13 among the 
three groups of mice (P = 0.0199 and P = 0.0355 respectively) (Figure 3.7B and 
Figure  3.7D).  Post  hoc  analysis  with  Bonferroni  correction  demonstrated 
significant increases in concentration of IL 5 and IL 13 in brains of arthritic mice 
compared  to  those  in  naïve  control  mice.  The  mean  values  of  IL 5  (arthritic 
versus  naïve  control)  were  6.8  ±  2.0  pg/mg  total  protein  versus  4.10  ±  0.69 
pg/mg total protein (P < 0.05). The mean value of IL 13 (arthritic versus naïve 
control) was 10.0 ± 3.6 pg/mg total protein versus 5.4 ± 0.6 pg/mg total protein 
(P < 0.05). There was no significant difference in brain IL 5, IL 10, and IL 13 Chapter 3    144 
protein concentration between naïve control mice and non arthritic mice (Figure 
3.7B and Figure 3.7D). There were no significant differences in brain IL 5 and IL 
13  concentrations  between  arthritic  and  non arthritic  mice.  One way  ANOVA 
analysis suggested that there was no significant difference in brain IL 10 protein 
concentration between naïve control mice and CII immunized mice (P = 0.1196) 
(Figure 3.7C).  
 
Figure 3.7 Changes in Th2 cytokine concentration in brains of CII immunized mice  
The dots represent protein concentration of IL 4, IlL 5, IL 10, IL 13 (pg/mg total brain 
protein) determined by Luminex based multiplex cytokine assay in brain tissue homogenate 
of naïve control mice (n=7 naïve control mice), non arthritic mice (n=7 non arthritic mice), 
and, arthritic mice (n=12 arthritic mice). All mice were sacrificed and brains were collected 
on day 42.  Data are presented as the mean. (*P < 05 ; **P < 01; ***P < 001 by one way 
ANOVA analysis) Bars represent the mean values. 
3.2.3.4  Chemokine profiles in the brains of CII immunized mice (both 
arthritic mice and non arthritic mice) 
Chemokines produced by activated immune cells, including CXCL1, CXCL10, CCL 
2  and  CCL3,  were  determined  in  the  brains  of  naïve  control  mice  and  CII 
immunized mice with and without arthritis. One way ANOVA demonstrated that 
there were significant differences in protein concentration of CXCL1 and CXCL10 
among the three groups of mice (P = 0.0012 and P = 0.0037 respectively) (Figure Chapter 3    145 
3.8A  and  Figure  3.8B).  Post  hoc  analysis  with  Bonferroni  correction 
demonstrated  that  brain  protein  concentrations  of  CXCL1  and  CXCL10  in  CII 
immunized mice were significant higher than those in naïve control mice. The 
mean values of CXCL1 and CXCL10 (arthritic versus naïve control) were 37.4 ± 
12.7 pg/mg total protein versus 14.1 ± 1.5 pg/mg total protein (P < 0.01), and 
35.6 ± 11.1 pg/mg total protein versus 16.5 ± 2.4 pg/mg total protein (P < 0.01) 
respectively.  There was no significant difference in the brain CXCL 10 protein 
level between naïve control mice and non arthritic mice. However, there was a 
significant  increase  in  CXCL1  protein  level  in  CII  immunized  mice  without 
arthritis compared to those in the naïve control group. The mean value of CXCL1 
(non arthritic versus naïve control) was 33.6 ± 14.8 pg/mg total protein versus 
14.1 ± 1.5 pg/mg total protein (P < 0.05) (Figure 3.8A and Figure 3.8B). There 
were  no  significant  differences  in  brain  CXCL1  and  CXCL10  concentrations 
between arthritic and non arthritic mice.  
 
Figure 3.8 Changes in chemokine concentration in brain of CII immunized mice  
The dots represent protein concentration of CXCL1 (A) and CXCL10 (B) (pg/mg total brain 
protein) determined by Luminex based multiplex cytokine assay in brain tissue homogenate 
of naïve control mice (n=7 naïve control mice), non arthritic mice (n=7 non arthritic mice), 
and, arthritic mice (n=12 arthritic mice). All mice were sacrificed and brains were collected 
on day 42.  Data are presented as the mean values. (*P < 05 ; **P < 01; ***P < 001 by one way 
ANOVA analysis). Bars represent the mean values.  
3.2.3.5   Growth factor profiles in the brain of CII immunized mice (both 
arthritic mice and non arthritic mice) 
Growth factors such as FGF2 and VEGF were quantified in the brains of naïve 
control mice and CII immunized mice with and without arthritis. FGF2 which is 
produced abundantly by CNS resident cells was detected in high concentration in 
brains from all groups of mice. One way ANOVA demonstrated that there were 
significant differences in serum concentration of FGF2 among the three groups 
of mice (P = 0.0136). Post hoc analysis with Bonferroni correction demonstrated Chapter 3    146 
that the protein level of FGF2 in arthritic mouse brains was significantly higher 
than those in the naïve control group. The mean value of FGF2 (arthritic versus 
naïve control) was 204.0 ± 58.5 pg/mg total protein versus 109.9 ± 19.1 pg/mg 
total  protein  (P  <  0.05).  There  was  no  significant  difference  in  brain  FGF2 
protein level between naïve control mice and non arthritic mice (Figure 3.9). 
There  were  no  significant  differences  in  brain  FGF  concentrations  between 
arthritic and non arthritic mice. 
 
Figure 3.9 Changes in a growth factor level in brain of CII immunized mice  
The dots represent protein concentration of FGF2 (pg/mg total brain protein) determined by 
Luminex based multiplex cytokine assay in brain tissue homogenate of naïve control mice 
(n=7 naïve control mice), non arthritic mice (n=7 non arthritic mice), and, arthritic mice 
(n=12 arthritic mice). All mice were sacrificed and brains were collected on day 42.  Data are 
presented as the mean values. (*P < 05 ; **P < 01; ***P < 001 by one way ANOVA analysis) 
Bars represent the mean values. 
In summary: numerous inflammatory mediator protein, including IL 1α, IL 2, IL 
4,  IL 5,  IL 6,  IL 10,  IL 13,  CXCL1,  CXCL10  and  FGF2  were  detected  by  the 
Luminex  assay  in  brain  tissue  homogeneous  of  mice  from  all  experimental 
groups. Significant increases in protein concentration of IL 2, IL 5, IL 13, CXCL1, 
CXCL10  and  FGF2  were  observed  in  brain  tissue  of  CII  immunized  mice  that 
develop arthritis compared to those in the naïve control mice. The inflammatory 
mediator  protein  concentration  seemed  to  increase  in  non arthritic  mouse 
brains, although one way ANOVA analysis showed that the concentrations were 
not significantly different compared to those in naïve control mice. Only CXCL1 
protein concentration was significantly elevated in non arthritic mouse brains.  
Table 3.2 shows a summary of these data as mean ± SD of fold changes of 
inflammatory mediator protein profiles in brains of CII immunized mice (both 
arthritic  and  non arthritic)  in  comparison  to  those  in  brains  of  naïve  control Chapter 3    147 
mice.  Data  were  categorized  into  5  groups  (pro inflammatory  cytokines,  Th1 
cytokines, Th2 cytokines, chemokines and growth factors). Our data showed that 
inflammatory mediator protein concentration in brains of CII immunized mice 
significantly increased from 1.7 – to 2.6 – fold compared with those in naïve 
control. Among these inflammatory mediators, the greatest mean fold change 
was observed in the group of chemokines (CXCL1 and CXCL10). The highest mean 
fold change of 2.6 was observed for CXCL1 protein concentration in brains of 
arthritic mice. Interestingly, the second highest fold change was still CXCL1 (2.4 
folds), however, observed in brains of non arthritic mice. The lowest mean fold 
change of 1.7 folds was observed in IL 5 in arthritic mouse brains.  
 
                  Arthritic                             Non arthritic 
 
Inflammatory 
mediator 
protein 
concentration 
    Fold changes        P value         Fold changes         P value 
             of                                             of 
    Protein concentration             Protein concentration 
 
Pro inflammatory cytokines 
 
         IL 1α                            1.8 ± 0.8                  NS                          1.7 ± 1.3               NS 
 
Th1 cytokines 
 
         IL 2                              2.1 ± 4.6               < 0.05*                       1.7 ± 4.8               NS   
 
Th2 cytokines 
 
         IL 5                              1.7 ± 2.6              < 0.05*                        1.5 ± 4.1               NS 
 
         IL 10                            2.0 ± 4.5                NS                            1.9 ± 5.7               NS 
 
         IL 13                           1.9 ± 6.5                < 0.05*                       1.8 ± 9.1               NS 
 
Chemokines 
 
          CXCL1                      2.6 ± 8.7               < 0.01**                         2.4 ± 10           < 0.05* 
 
         CXCL10                     2.2 ± 4.7               < 0.01**                         1.7 ± 6.1             NS 
 
Growth factors 
 
         FGF2                         1.9 ± 3.5              < 0.05*                       1.7 ± 4.4              NS 
 
Table 3.2 summary of inflammatory mediator protein profiles in brains of CII immunized 
mice  
Data summary was presented as mean ± SD of fold changes of inflammatory mediator 
protein profiles in brains of CII immunized mice (both arthritic and non arthritic) in 
comparison to those in brains of naïve control mice. One way ANOVA analysis (*P < 005; **P 
< 002; ***P < 001) was used to demonstrate significant increase in inflammatory mediator 
protein concentration in arthritic and non arthritic mouse brain compared to those in 
control mouse brains. NS = not statistically significant. Chapter 3    148 
3.2.4  Cytokine gene expression profiles in the brains of CII 
immunized mice (both arthritic mice and non arthritic mice) 
Significant  increases  in  various  inflammatory  mediator  protein  concentration 
including IL 1α, IL 2, IL 5, IL 10, IL 13, CXCL1, and CXCL10 were detected by the 
Luminex assay in brains of CII immunized mice, especially in brains of arthritic 
mice, compared to those in naïve control mice. However, we could not define 
the  cellular  source  of  these  inflammatory  mediator  proteins  in  the  brains  of 
arthritic  mice.  It  is  possible  that  they  were  either  produced  from  peripheral 
immune cells and transported into the brains, or produced from local immune 
cells  such  as  astrocytes  and  microglia.  To  investigate  this,  we  therefore 
investigated the mRNA expression levels of these brain inflammatory mediators 
at the transcription level, which can be another indicator of neuro inflammation 
during the process of peripheral joint inflammation. Changes in mRNA expression 
level  of  these  inflammatory  mediators  in  brains  of  CII  immunized  mice  may 
suggest local production by astrocytes, microglia or by peripheral immune cells 
trafficking into  the  brain.  Real time PCR was  employed  to  determined  mRNA 
expression  levels  of  the  same  20  inflammatory  mediators  as  measured  by 
Luminex (above); including proinflammatory cytokines (IL 6, IL 1 β, TNF α and 
IL 1 α), Th1 cytokines (IL 2, IL 12 and IFN γ), Th2 cytokines (IL 4, IL 5, IL 10, IL 
13),  chemokines  (CXCL1,  CXCL10,  CCL2,  CCL3),  growth  factors  (FGF2,  VEGF) 
using RNA extracted from the other half of the brain tissue.  
The expression level of mRNA of these inflammatory mediators in brains tissue of 
mice from all experimental groups were quantified as cycle threshold (Ct) values 
by real time PCR assays. These Ct values were then calculated as absolute copy 
number of target genes using standard curves generated from amplification of 
10 fold serial dilutions of known quantities of a plasmid containing the target 
sequences. The absolute mRNA copy numbers of inflammatory mediators were 
normalized  to  GAPDH  expression  as  described  in  the  Materials  and  Methods 
chapter and reported as arbitrary units. mRNA expression levels of IFN γ, CXCL1, 
CXCL10,  VEGF  and  FGF  in  brains  of  mice  from  all  experimental  groups  were 
detectable within detection limits of the assay. This was demonstrated by the 
transcription  values  of  these  brain  samples  being  within  the  linear  dynamic 
range of the standard curve (Appendix 2). Specificity of the real time PCR assay 
was  determined  by  melting  curve  analysis  as  described  in  the  Materials  and Chapter 3    149 
Methods  section.  Examples  of  melting  curve  analysis  of  each  inflammatory 
mediator are shown in Appendix 3. 
3.2.4.1    Pro inflammatory cytokine mRNA profiles in the brains of CII 
immunized mice (both arthritic mice and non arthritic mice) 
The gene expressions of pro inflammatory cytokines including IL 6, IL 1 β, TNF α 
and  IL 1α  were  determined  in  brains  of  mice  from  all  experimental  groups. 
However, the expression levels of these pro inflammatory cytokines in all brain 
samples  were  lower  than  the  detection  limit.  Despite  an  increase  in  IL 1α 
protein  concentration  in  arthritic  mouse  brains,  there  was  no  equivalent 
increase in IL 1α mRNA expression levels detected in brains of these arthritic 
mouse brains. These may suggest that the timing of induction and half life of 
mRNA  had  finished  while  the  protein  was  maintained,  and/or  there  may  be 
active  transportation  of  IL 1α  protein  from  the  periphery  into  the  brains  of 
arthritic mice.  
3.2.4.2  Th 1 cytokines mRNA profiles in the brains of CII immunized 
mice (both arthritic mice and non arthritic mice) 
Gene  expression  of  Th 1  cytokines,  including  IL 12,  IL 2  and  IFN γ,  were 
determined in the brain of control mice and mice with and without arthritis. 
One way ANOVA followed by Bonferroni's post hoc comparison tests showed that 
the expression of IFN γ was up regulated significantly in CII immunized mouse 
(both arthritic and non arthritic mice) brains compared to those of control mice 
(P = 0.0131). The mean value of IFN γ (arthritic versus naïve control) was 305 ± 
132 versus 138 ± 43 (P < 0.05). There were no significant differences in brain 
IFN γ gene expression concentration between arthritic and non arthritic mice. 
There  were  also  no  significant  differences  in  brain  IFN γ  gene  expression 
concentration  between  arthritic  and  non arthritic  mice  (Figure 3.10).  Despite 
up regulation in IFN γ mRNA expression levels in both arthritic and non arthritic 
mouse brains, there was no significant IFN γ protein level detected in brains of 
these CII immunized mouse brains. This may be difficult to interpret. It may 
suggest that the local mRNA translation of IFN γ in brains of CII immunized mice 
was  still  ongoing,  or  that  any  newly  synthesised    IFN γ  was  metabolised,  or 
indeed  that  there  was  epigenetic  or  post transcriptional  modifications  that 
prevented synthesis of IFN γ .  Chapter 3    150 
 
Figure 3.10 Changes in Th1 cytokine mRNA levels in brains of CII immunized mice  
The dots represent mRNA expression levels of IFN γ determined by real time PCR in half 
brain tissue homogenate of naïve control mice (n=7 naïve control mice), non arthritic mice 
(n=7 non arthritic mice), and, arthritic mice (n=12 arthritic mice). The levels of mRNA were 
normalized to GAPDH expression and shown as arbitrary units. All mice were sacrificed and 
brains were collected on day 42. Data are presented as the mean values. (*P < 05 ; **P < 01; 
***P < 001 by one way ANOVA analysis) Bars represent the mean values. 
3.2.4.3  Th 2 cytokines mRNA profiles in the brains of CII immunized 
mice (both arthritic mice and non arthritic mice) 
The mRNA of Th 2 cytokines, including IL 4, IL 5, IL 10 and IL 13 gene expression 
were determined in the brains of naïve control mice and CII immunized mice 
with and without arthritis. However, there was no transcription of these Th2 
cytokines  detected  in  the  brain  of  mice  from  all  experimental  groups. 
Interestingly, Th2 cytokines including IL 5, IL 10 and IL 13 protein concentration 
were increased significantly in arthritic mouse brains compared to those in naïve 
control mice, while there was no significant mRNA expression levels detected in 
the same brains of theses arthritic mice. These observations may suggest that 
the timing of induction and half life of mRNA had finished while the protein was 
maintained,  and/or  transportation  of  these  Th2  cytokine  proteins  from  the 
periphery into the brains of arthritic mice.  
3.2.4.4   Chemokine mRNA profiles in the brains of CII immunized mice 
(both arthritic mice and non arthritic mice) 
Expression levels of mRNA for CXCL1, CXCL10, CCL2 and CCL3 were determined 
in  the  brains  of  mice  from  all  experimental  groups.  One way  ANOVA 
demonstrated that there were significant differences in protein concentration of 
CXCL1 and CXCL10 among the three groups of mice (P = 0.0009 and P = 0.0002 
respectively) (Figure 3.11A and Figure 3.11B). Post hoc analysis with Bonferroni Chapter 3    151 
correction demonstrated that CXCL1 and CXCL10 were increased significantly in 
brains  of  both  arthritic  and  non arthritic  mice  compared  to  those  in  naïve 
control mice. The mean values of CXCL1 (arthritic versus naïve control) was 3160 
± 828 versus 1212 ± 162 (P < 0.001). Similar to the protein profile, mRNA level of 
CXCL1  was  also  increased  in  non arthritic  mouse  brains.  The  mean  values  of 
CXCL1 (non arthritic versus naïve control) was 2818 ± 991 versus 1212 ± 162 (P < 
0.05).  There  were  no  significant  differences  in  brain  CXCL1  gene  expression 
levels between CIA and non CIA mice (Figure 3.11A). The data suggest that there 
was  local  production  of  CXCL1  in  the  brains  of  CII  immunized  mice  by  CNS 
immune  cells  and  peripheral  immune  cells  trafficking  into  the  brains.  The 
possibility that there was also a transportation of CXCL1 protein into the brain of 
CII immunized mice was supported by the data showing the same CXCL1 protein 
profiles in serum of these CII immunized mice. Increases in serum CXCL1 protein 
concentration were observed in CII immunized mice as well as an increase in 
mRNA and protein concentration in their brains.  
CXCL10  was  another  chemokine  that  was  increased  in  the  brains  of  CII 
immunized mice. The mean values of CXCL10 (arthritic versus naïve control) was 
442  ±  150  versus  163  ±  35  (P  <  0.001).  The  up regulations  of  CXCL10  gene 
expression was also observed in brains of non arthritic mice compared to those 
in  naïve  control  mice.  There  were  no  significant  differences  in  brain  CXCL10 
gene  expression  concentration  between  naïve  control  mice  and  non arthritic 
mice. CXCL10 gene expression in arthritic mouse brains was significant higher 
than those in non arthritic mouse brains. The mean values of CXCL10 (arthritic 
versus non arthritic) was 442 ± 150 versus 283 ± 120 (P < 0.05) (Figure 3.11B). 
The significant higher level of CXCL10 in arthritic mice compared to those in 
non arthritic mice suggests that the production of CXCL10 in the brain may be 
associated with peripheral joint inflammation in arthritic mice.  
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Figure 3.11 Changes in chemokine mRNA expression levels in brains of CII immunized mice  
The dots represent mRNA levels of CXCL1 (A) and CXCL10 (B) determined by real time PCR 
in half brain tissue homogenate of naïve control mice (n=7 naïve control mice), non arthritic 
mice (n=7 non arthritic mice), and, arthritic mice (n=12 arthritic mice). The levels of mRNA 
were normalized to GAPDH expression and shown as arbitrary units. All mice were 
sacrificed and brains were collected on day 42. Data are presented as the mean values. (*P < 
05 ; **P < 01; ***P < 001 by one way ANOVA analysis) Bars represent the mean values. 
3.2.4.5   Growth factor mRNA profiles in the brains of CIA mice 
Growth factors such as FGF2 and VEGF were detectable in the brains of control 
mice and mice with and without arthritis. One way ANOVA analysis showed that 
there  was  no  significant  difference  in  the  gene  expression  level  of  FGF2, 
although  the  FGF2  protein  concentration  in  arthritic  mice  was  increased 
compared  to  the  naïve  control  mice  (P  =  0.4803)  (Figure  3.12A).  The  data 
suggest  that  there  may  be  the  transportation  of  FGF2  into  the  CNS  in  the 
arthritic mice during the course of the disease. One way ANOVA analysis showed 
that there was no significant difference in brain VEGF between naïve control 
mice and CII immunized mice (P = 0.0674) (Figure 3.12B).   
 
Figure 3.12 Changes in growth factor mRNA levels in brains of CII immunized mice  
The dots represent mRNA levels of FGF2 (A) and VEGF (B) determined by real time PCR in 
half brain tissue homogenate of naïve control mice (n=7 naïve control mice), non arthritic 
mice (n=7 non arthritic mice), and, arthritic mice (n=12 arthritic mice). The levels of mRNA 
were normalized to GAPDH expression and shown as arbitrary units. All mice were Chapter 3    153 
sacrificed and brains were collected on day 42. Data are presented as the mean values. (*P < 
05 ; **P < 01; ***P < 001 by one way ANOVA analysis) Bars represent the mean values. 
In  summary:  Real time  PCR  detected  increases  in  the  Th1  cytokine  (IFN γ), 
chemokines (CXCL1 and CXCl10) and growth factors (FGF2 and VEGF) in brain 
tissue of mice from all experimental groups. Expression levels of IFN γ, CXCL1, 
CXCL10 and VEGF were significantly increased in the brains of CII immunized 
mice (both arthritic and non arthritic) compared to those in naïve control mice. 
Table  3.3  shows  a  summary  of  these  data  as  mean  ±  SD  of  fold  changes  of 
inflammatory mediator gene expression in brains of CII immunized mice (both 
arthritic  and  non arthritic)  in  comparison  to  those  in  brains  of  naïve  control 
mice. Data were categorized into 3 groups (a Th1 cytokine, chemokines and a 
growth factor). Our data showed that inflammatory mediator mRNA expression 
levels in brains of CII immunized mice were significantly increased from 1.7 – to 
3.0  –  fold  compared  with  those  in  naïve  control.  Among  these  inflammatory 
mediators,  the  greatest  mean  fold  increase  was  for  the  growth  factor  VEGF 
mRNA expression levels in brains of non arthritic (3 fold) and arthritic (2.9 fold) 
mice. This also suggest that there was a similar degree of elevation of VEGF 
mRNA expression levels in brains of immunised and challenged mice irrespective 
of whether they developed frank arthritis. This observation was also seen for 
CXCL1 mRNA and protein concentration which were similar in both arthritic and 
non  arthritic  mouse  brains,  and  both  were  higher  than  control  mice.  This 
suggests that there may be a biological association between gene expression and 
protein level in brains of CII immunized mice.  
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                   Arthritic                                 Non arthritic 
 
Inflammatory 
mediators 
genes 
  Fold changes        P value         Fold changes          P value 
           of                                             of 
  mRNA concentration             mRNA concentration 
 
Th1 cytokines 
 
         IFN γ                     2.2 ± 3.0                     < 0.05*                1.9 ± 2.8                      NS 
 
Chemokines 
 
          CXCL1                 2.6 ± 5.1                     < 0.001***              2.3 ± 6.1                 < 0.05* 
 
          CXCL10               2.7 ± 4.3                     < 0.001***              1.7 ± 3.4                    NS 
 
Growth factors 
 
         VEGF                    2.9 ± 7.3                         NS                   3.0 ± 9.0                      NS 
 
          FGF2                    1.8 ± 0.9                        NS                   1.2 ± 2.2                       NS 
Table 3.3 Summary of inflammatory mediator gene expression profiles in brains of CII 
immunized mice  
Data was presented as mean ± SD of fold changes of inflammatory mediator mRNA profiles 
in brains of CII immunized mice (both arthritic and non arthritic) in comparison to those in 
brains of naïve control mice. One way ANOVA analysis (*P < 05 ; **P < 01; ***P < 001) was 
used to demonstrate significant increase in inflammatory mediator mRNA expression levels 
in arthritic and non arthritic mouse brain compared to those in control mouse brains. NS = 
not statistically significant. 
 
3.2.5   Comparisons of gene and protein expression of 
inflammatory mediators in arthritic and non arthritic mouse 
brains 
In summary, our data demonstrated different profiles of inflammatory mediator 
gene and protein expression in arthritic mouse (arthritic mouse) brains and non 
arthritic mouse brain (Table 3.4). Most of the inflammatory mediator proteins 
detectable by Luminex including IL 1α, IL 2, IL 5, IL 10, IL 13, CXCL10, and FGF2 
were increased significantly in arthritic mouse brains, while CXCL1 was the only 
inflammatory mediator that up regulated significantly in both CIA and non CIA 
mouse brains. By contrast, increases in inflammatory mediator mRNA, including 
IFN γ,  CXCL1,  CXCL10,  VEGF,  were  observed  in  both  arthritic  and  non non 
arthritic mouse brains.  
IL 2 protein was the only Th1 cytokine up regulated in brains of arthritic mice 
compared to those in naïve control mice, while IFN γ mRNA concentration were 
increased in brains of both arthritic and non arthritic mice compared to those in Chapter 3    155 
naïve  control  mice.  There  was  no  Th2  cytokine  (IL 5,  IL 10,  IL 13)  mRNA 
detectable  in  either  arthritic  and  non arthritic  mouse  brains,  while  protein 
concentration of these Th2 cytokines were significantly increased in brains of 
arthritic mice compared to those in naïve control mice. Interestingly, similar 
protein concentration and gene expression profiles of CXCL1 were observed in 
both arthritic and non arthritic mouse brains. Similarly, CXCL10 gene and protein 
expressions were increased in both arthritic mouse brains. Differences between 
CXCL10  mRNA  concentration  of  arthritic  and  non arthritic  mouse  brains  were 
also observed. In the category of growth factor, FGF2 protein was increased only 
in arthritic mouse brains, while elevations of VEGF mRNA were observed in both 
arthritic and non arthritic mice. 
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Protein and mRNA expression levels in brains of CII 
immunized compared with naïve control mice.  
Protein  mRNA 
 
Inflammatory  
Mediators 
Arthritic  Non arthritic  Arthritic  Non arthritic 
 
Pro inflammatory  
cytokines 
 
 
IL 1α 
 
NS 
 
NS 
 
undetectable 
 
undetectable 
 
Th1 cytokines 
       
 
IL 2 
 
< 0.05* 
 
NS 
 
undetectable 
 
undetectable 
 
IFN γ 
 
undetectable 
 
undetectable 
 
< 0.01** 
 
NS 
 
Th2 cytokines 
       
 
IL 5 
 
< 0.05* 
 
NS 
 
undetectable 
 
undetectable 
 
IL 10 
 
NS 
 
NS 
 
undetectable 
 
undetectable 
 
IL 13 
 
< 0.05* 
 
NS 
 
undetectable 
 
undetectable 
 
Chemokines 
   
 
CXCL1 
 
< 0.01** 
 
0.05* 
 
< 0.001*** 
 
< 0.05* 
 
CXCL10 
 
< 0.01** 
 
NS 
 
< 0.001*** 
 
NS 
 
Growth factor 
       
 
FGF2 
 
< 0.05* 
 
NS 
 
NS 
 
NS 
 
VEGF 
 
NS 
 
NS 
 
NS 
 
NS 
Table 3.4 A summary of inflammatory mediator gene mRNA expression and protein profiles 
in arthritic mouse brains and non arthritic mouse brains  
Differences between inflammatory mediator concentration in immunized mouse brains 
(Arthritic/Non arthritic mouse brains) and control groups were analyzed by Student's t test 
(*P < 05 ; **P < 01; ***P < 001). NS = not statistically significant. 
 
 
 
 Chapter 3    157 
3.2.6   Correlations between chemokine mRNA and protein 
concentration in arthritic and non arthritic mouse brains 
Inflammatory  mediator  gene  expression  concentration  measured  by  real time 
PCR  have  been  shown  to  correspond  with  protein  concentration  in  several 
studies (Young et al., 2008); (Stemme et al., 2001). A study by Mehra et al., 
suggest that the positive relationship between protein and mRNA concentration 
may reflect the post transcription, post translation and protein synthesis process 
within the tissue. Our data showed similar patterns of gene and protein profiles 
of CXCL1 and CXCL10 (Mehra et al., 2003). Particularly, both CXCL1 mRNA and 
protein concentration were increased in brains of both arthritic and non arthritic 
mice. The relationship between protein and mRNA expression concentration of 
CXCL1 and CXCL10 within the same samples was examined using the Pearson’s 
correlation coefficient analysis. However, there was no statistically significant 
correlation between their protein and mRNA expression within the same samples 
across all experimental groups (Figure 3.13A, Figure 3.13B, Figure 3.13C).  The 
data suggest that CXCL1 and CXCL10 in brains of these CII immunized mice may 
not be produced locally in the brain. However, it is also possible that there were 
productions of CXCL1 and CXCL10 in the brain as well as transportation of these 
chemokines from the periphery.  Chapter 3    158 
 
Figure 3.13 Correlations of mRNA and protein concentration for CXCL1 and CXCL10 in 12 
arthritic and 7 non arthritic mouse brains  
Dot plots show relationships between CXCL1 and CXCL10 mRNA (arbitrary units) and 
protein level (pg/ug total brain protein) within the samples from 12 arthritic and 7 non 
arthritic group analysed by Pearson’s correlation coefficient analysis. (A) shows the 
correlation between CXCL1 mRNA value and CXCL1 protein value for arthritic mouse brains 
(r
2 = 0.010, P = 0.752). (B) shows the correlation between CXCL1 mRNA value and CXCL1 
protein value for non arthritic mouse brains (r
2 = 0.254, P = 0.249). (C) shows the correlation 
between CXCL1 mRNA value and CXCL10 protein value for arthritic mouse brains (r
2 = 
0.01795, P = 0.678).  
3.2.7   Correlations between inflammatory mediator protein 
concentration and mRNA expression levels and arthritis 
scores 
To  determine  whether  the  disease  severity  of  the  experimental  arthritis  was 
associated with up regulation of brain inflammatory mediators in arthritic mice, 
brain inflammatory mediator protein and /mRNA and the arthritis score of each 
arthritic  mouse  was  compared  using  the  Pearson’s  correlation  coefficient 
analysis.  None  of  the  brain  inflammatory  mediator  protein  or  mRNA  levels  
correlated  with  arthritis  scores  in  arthritic  mice  (Figure  3.14A Figure  3.14D, 
Figure 3.15A Figure 3.15H). It appeared that the mediator measurement at a 
single time point was not a good measure of clinical expression of this chronic 
disease. Chapter 3    159 
 
 
 
Figure 3.14 Correlations of inflammatory mediator protein concentration and arthritis score 
in 12 arthritic mice  
Dot plots show relationships between brain inflammatory protein concentration (pg/ g total 
brain protein) and arthritis score within the samples from arthritic group (n = 12 arthritic 
mice) analysed by Pearson’s correlation coefficient analysis. (A) shows the correlation 
between brain IL 2 protein value and arthritis scores in CIA mice (r
2 = 0.033, P = 0.575). (B) 
shows the correlation between brain IL 5 protein value and arthritis scores in arthritic mice 
(r
2 = 0.05, P = 0.834). (C) shows the correlation between brain IL 13 protein value and 
arthritis scores in arthritic mice (r
2 = 0.000, P = 0.984). (D) shows the correlation between 
brain CXCL1 protein value and arthritis scores in arthritic mice (r
2 = 0.020, P = 0.665). (E) 
shows the correlation between brain CXCL10 protein value and arthritis scores in arthritic 
mice (r
2 = 0.015, P = 0.706). (F) shows the correlation between brain FGF protein value and 
arthritis scores in arthritic mice (r
2 = 0.122, P = 0.267). 
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Figure 3.15 Correlations of inflammatory mediator gene expression levels and arthritis 
score in arthritic mice  
Dot plots show relationships between brain inflammatory mediator mRNA (number of 
copies/GAPDH copies) and arthritis score within the samples from arthritic group (n = 12 
arthritic mice) analysed by Pearson’s correlation coefficient analysis. (A) shows the 
correlation between brain IFN γ mRNA value and arthritis scores in arthritic mice (r
2 = 0.257, 
P = 0.092). (B) shows the correlation between brain CXCL1 mRNA value and arthritis scores 
in arthritic mice (r
2 = 0.313, P = 0.059). (C) shows the correlation between brain CXCL10 
mRNA value and arthritis scores in arthritic mice (r
2 = 0.214, P = 0.130).  
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3.3   Result chapter 3; Summary of findings.  
The aim of this chapter was to investigate the evidence for and the potential 
process  of  peripheral  inflammation induced brain  inflammation  in  an 
autoimmune disease model of RA. A Luminex bead based assay and real time 
PCR  assays  were  used  to  explore  changes  in  inflammatory  mediator  protein 
concentration and expression levels respectively in brains of CII immunized mice 
that  may  be  involved  in  the  process  of  immune  or  inflammatory  response 
activation in the brain during arthritis. We found; 
1. Increased concentrations of IL 2, IL 5, IL 13, CXCL1, CXCL10 and FGF2 protein 
in brains of CII immunized mice with arthritis compared to naïve control mice. 
2. Increased concentration of serum CXCL1 protein in both arthritic and non 
arthritic mice compared to naïve control mice. 
3. CXCL1 was the only inflammatory mediator that was increased in brains of 
non arthritic mice compared to naïve control mice. 
4. Increased IFN γ, CXCL1 and CXCL10 mRNA expression levels were observed in 
brains of both arthritic and non arthritic mice compared to naïve control mice. 
5.  The  patterns  of  serum  CXCL1  protein  concentration,  brain  CXCL1  mRNA 
expression  levels  and  brain  CXCL1  protein  concentration  of  mice  of  all 
experimental groups were related. 
6. There was a significant increase in CXCL10 mRNA expression level in arthritic 
compared with non arthritic mouse brains. 
7. The degrees of fold increase compared to control mice of CXCL1 mRNA and 
protein  concentration  were  similar  in  both  arthritic  and  non arthritic  mouse 
brains. 
8. There was no significant correlation between CXCL1 and CXCL10 gene and 
protein expression levels of both arthritic and non arthritic brains. Chapter 3    162 
9. There was no significant correlation between the brain inflammatory mediator 
mRNA and protein levels and the arthritis scores.  
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3.4   Discussion 
For clarity, I will set out the discussion in logical sections interpreting the results 
in sequence. I will summarise and draw conclusions from these at the end. 
3.4.1   Elevations of inflammatory mediator mRNA and protein 
concentration in CII immunized mouse brains.  
 
In this chapter we have shown elevations of IL 1α, IL 2, IL 5, IL 10, IL 13, CXCL1, 
CXCL10 and FGF2 protein and mRNA expression levels in brains of CII immunized 
mice, particularly in those CII immunized mice that developed arthritis. We also 
found increases in serum CXCL1 protein in these CII immunized mice. Compared 
with control healthy mice, our data suggest that peripheral inflammatory signal 
may be associated with the activation of an immune or inflammatory response in 
the brain during arthritis.  
3.4.1.1   Increased pro inflammatory cytokine protein concentration in 
arthritic mouse brains  
Among  the  pro inflammatory  cytokines  (IL 1β,  IL 1α,  IL 6  and  TNF α) 
investigated in brain tissue of both CII immunized and naïve control mice. The 
brain IL 1α protein levels in arthritic mice seemed to be higher than those of 
naïve control mice on day 42. However, one way ANOVA suggested that there 
was no significant difference in brain IL 1α protein among all 3 groups (naïve 
control,  non arthritic  and  arthritic  groups).  This  may  reflect  small  sample 
numbers.  Therefore,  it  is  worthwhile  to  repeat  these  experiments  using  the 
larger numbers of animals.  
IL 1α is a potent pro inflammatory cytokine produced by glial cells, macrophages 
and  synovial  fibroblasts.  IL 1α  was  found  highly  expressed  in  the  inflamed 
synovia of RA patients (Brennan et al., 1989). The activities of IL 1α also play a 
pathogenic role in rheumatoid arthritis, particularly in cartilage destruction (RA) 
(Dayer and Fenner, 1992). Transgenic mice over expressing IL 1α showed chronic 
synovitis and cartilage destruction, as a result of stimulation of matrix protein 
degrading enzymes; matrix metalloproteinase (MMP) 3 and MMP 13 produced by 
chondrocytes  (Niki  et  al.,  2004);  (Rowan  et  al.,  2003).  Under  physiological 
conditions,  IL 1  (both  IL 1α  and  IL 1β)  is  almost  undetectable  in  the  CNS. Chapter 3    164 
However, after injury (e.g. stroke, haemorrhage, trauma), IL 1 family cytokines 
are  produced  by  microglia,  the  resident  brain  immune  cells  (Luheshi  et  al., 
2009). In experimental models, peripheral immune challenge results in increased 
production  of  IL 1  both  peripherally  and  centrally  (Higgins  and  Olschowka, 
1991); (Quan et al., 1994); (Maness et al., 1998). Our data showed an increase of 
IL 1α protein concentration in the brain of CII immunized mice that developed 
arthritis, but not non arthritic mice and suggests that the local increase may be 
associated with the peripheral joint inflammation. The increase of IL 1α protein 
concentration  in  brains  of  arthritic  mice  may  also  indicate  an  inflammatory 
process in brains of these mice during the course of arthritis disease. Our data 
also showed that there was no gene expression of IL 1α detectable in brains of 
these arthritic mice despite significant amount of IL 1α detectable in the same 
brains. This suggests that there may be the transportation of IL 1α protein from 
the periphery to the brain. However, we found no serum IL 1α in these arthritic 
mice  therefore  other  possibilities  are  that  IL 1α  may  enter  the  brain  via 
migration of peripheral immune cells into the brain during the course of the 
arthritis, or that IL 1α is involved at another time point. The question of how 
and when IL 1α is localized and/or transported from the periphery into the brain 
is unresolved, especially since there was no significant serum IL 1α detectable at 
that time point in these arthritic mice. This is an important and complex topic 
that needs further investigation. Useful experiments might include time point 
experiments as outlined in results chapter 4.  
3.4.1.2   Elevations of a Th1 cytokine protein and gene expression 
concentration in CII immunized mouse brains  
RA is thought to be a Th1 cell driven disease, and Th1 (IL 2, IFN γ and IL 12) 
cytokines may be part of the initiation of the destructive immune response in RA 
(McInnes  and  Schett,  2007).  We  found  significant  elevation  of  Th1  cytokine 
concentration in brains of arthritic mice. IL 2 protein concentration and IFN γ 
were increased in CII immunized mice compared to those in the naïve control 
mice. It is possible that there is an association between the increases of these 
Th1 cytokines in the brains and the inflamed joints of these arthritic mice.  
In systemic immune responses, IL 2 is produced by activated CD4
+ T cells 
and this augments the secretion of IFN γ. IL 2 acts via the IL 2 receptor (CD25, Chapter 3    165 
IL 2R) and functions in clonal expansion of antigen primed T cells (Schroeter and 
Jander,  2005).  Increases  in  IL 2  protein concentration  were  detected  in  both 
synovial  fluid  and  peripheral  blood  of  RA  patients  (Berner  et  al.,  2000). 
Importantly, it has been reported that IL 2 was also highly expressed in paws of 
arthritic  mice  (Thornton  et  al.,  1999).  We  found  increases  in  IL 2  protein 
concentration and it is possible that circulating IL 2 produced by inflamed joints 
and associated lymphoid organs migrate into the brains of these CII immunized 
mice.  IL 2  can  also  be  producible  by  microglia  locally  in  the  CNS  (Sredni 
Kenigsbuch, 2002). However, IL 2 gene expression was undetectable in brains of 
these arthritic mice, suggesting that IL 2 protein in arthritic mouse brains may 
be transported mainly from the periphery. However, we found no IL 2 protein 
level in serum these arthritic mice, suggesting that IL 2 protein may possibly 
enter the brain via trafficking of peripheral Th1 cells into the brain. The issue of 
when and how IL 2 enters the brain during the course of arthritis still remains 
unclear and needs further investigation.  
IFN γ is an important regulator that has been implicated in the pathology of RA 
and also found highly expressed in both synovial fluid and peripheral blood of RA 
patients (Canete et al., 2000). IFN γ is produced by activated T cells and NK 
cells  (Farrar  and  Schreiber,  1993).  IFN γ  is  usually  undetectable  in  the  CNS 
except in the context of inflammation, when immune cells cross the blood brain 
barrier and enter the CNS (Millward et al., 2007). During the CNS inflammatory 
process, IFN γ is produced by microglia and functions to amplifies the adaptive 
immune response in the CNS by activating astrocytes and microglia to express 
MHC class I and class II (Yang et al., 2004); (Wong et al., 1984). IFN γ also plays 
an  important  role  in  leukocyte  migration  into  the  CNS  via  activation  of 
chemokine  production  by  astrocytes  and  microglia  (Sredni Kenigsbuch,  2002). 
Our data showed elevations of IFN γ gene expression concentration in brain of 
CII immunized mice, suggesting that there may be the production of IFN γ locally 
in the brain. The increased level of IFN γ mRNA concentration in brains of these 
CII immunized mice may also indicate the CNS inflammatory process and immune 
cell  migration  into  the  brains  of  these  CII  immunized  mice.  However,  the 
mechanism of how IFN γ gene expression was induced and the cellular source of 
IFN γ in the brain of these CII immunized mice are still unclear. This may be 
associated with the elevations of IL 2 protein that also function to enhance the Chapter 3    166 
expression of IFN γ in Th1 cells (Schroeter and Jander, 2005). This question can 
be addressed by using immunohistochemistry of both IL 2 protein and markers 
for Th1 or/and microglia to investigate the co localization of IL 2 with these 
immune cells in brain sections of CII immunized mice.  
3.4.1.3   Elevations of a Th2 cytokine protein and gene expression 
concentration in arthritic mouse brains  
Th2 cytokines such as IL 4, IL 5 and IL 13 play crucial roles in humoral immunity 
such as regulating B lymphocytes to mature to plasma cells and to stimulating 
immunoglobulin class switching from IgM to IgE and IgG1 (in mouse) or IgG4 (in 
man)  isotypes  (Schulze Koops  and  Kalden,  2001).  Anti inflammatory  cytokines 
produced by Th2 such as IL 4 and IL 10 also function to inhibit Th1 proliferation, 
prevent  autoimmunity,  synovial  inflammation  and  tissue  destruction  in  RA 
(Schulze Koops and Kalden, 2001). Both clinical and animal studies demonstrated 
that Th2 cytokines were expressed in a low level in synovial fluid of RA patients 
and in draining lymph node cells during the onset, and the highest severity phase 
of the disease (Kusaba et al., 1998); (Mauri et al., 1996). Our data showed the 
up regulation  of  IL 5,  IL 13  and  IL 10  protein  concentration,  but  not  gene 
expression, in arthritic mouse brains compared to those in the control mouse 
brains.  
IL 5  and/or  IL 13  play  an  important  role  in  allergic  asthma  and  helminthic 
infection (Kurowska Stolarska et al., 2008). IL 5 is produced mainly by Th2 cells 
and mast cells (Gregory et al., 2003), while IL 13 is produced by T cells, mast 
cells, basophils, dendritic cells, and keratinocytes (Schmid Grendelmeier et al., 
2002). However, little is known about the role of IL 5 and IL 13 in pathogenesis 
and immune responses of RA. IL 5 and IL 13 expression has been reported in 
synovial tissues of RA patients. A study by Xu et al., in CIA model suggest that IL 
5  and  IL 13  exacerbate  the  severity  of  arthritis  disease  by    promoting  the 
production  of  specific  IgG  and  IgE  synthesis  by  B  cells  and  antibody  isotype 
switching in CIA. These antibodies then could bind to Fc receptors on mast cells 
and subsequently activate mast cell degranulation or/and form immune complex 
with antigen (Xu et al., 2008). Although IL 5 and IL 13 could also be produced by 
microglia and astrocytes in the brain (Sawada et al., 1993); (Shin et al., 2004), 
we found no gene expression of either IL 5 or IL 13 in brains of arthritic mice. Chapter 3    167 
This suggests that there was no local production of these Th2 cytokine in the 
brain. In addition, elevations of both IL 5 and IL 13 were observed only in CII 
immunized mice with arthritis, suggesting that IL 5 and IL 13 may be transported 
from the periphery to the brain during the course of RA. However, the issue of 
whether IL 13 and IL  5 are transported to the brain by themselves or via the 
peripheral Th2 trafficking into the brain need further investigations. 
The brain IL 10 protein levels in arthritic mice seemed to be higher than those of 
naïve control mice on day 42. However, one way ANOVA suggested that there 
was no significant difference in brain IL 10 protein among all 3 groups (naïve 
control,  non arthritic  and  arthritic  groups).  This  may  reflect  a  small  sample 
number. Therefore, it is worthwhile to repeat these experiments using the larger 
numbers of animals.  
IL 10  predominantly  an  anti inflammatory  cytokine  that  is  produced  by 
monocytes, T cells, B cells, DCs, epithelial cells (McInnes and Schett, 2007). IL 
10  could  inhibit  the  production  of  Th1  cytokine  such  as  IFN γ  (Rizzo  et  al., 
1998).  CIA  mice  receiving  neutralizing  anti IL 10  antibodies  demonstrated  a 
delay of the onset and an increase in the severity of arthritis (Kasama et al., 
1995). In the CNS, IL 10 is produced by microglia and astrocytes and also plays a 
potent  anti inflammatory  and  neuroprotective  role  in  several  CNS  diseases 
(Schroeter  and  Jander,  2005).  Increases  in  IL 10  protein  concentration  were 
observed in brains of arthritic mice, but no gene expression detectable. This 
suggests that there may be a transportation of IL 10 from the periphery into the 
brain of these arthritic mice. It has been reported that the protein concentration 
of IL 10 were elevated in the lymph nodes of CII immunized mice transiently 3 
day  after  immunization  and  the  low  concentration  of  IL 10  protein  were 
detectable throughout the time of clinical manifestation (Mauri et al., 1996). We 
could not detect serum IL 10 in the arthritic mice and we determined the brain 
IL 10  protein  level  in  these  mice  at  only  one  time  point  (day  42  after 
immunization). It is also possible that the transportation and the accumulation 
of  IL 10  protein  may  occur  at  the  earlier  time  point  throughout  42  day  of 
experimental  period.  Therefore,  conducting  time  point  experiment  to 
investigate overtime changes of brain inflammatory mediators in brains of CII 
immunized mice would be useful to test this hypothesis.  Chapter 3    168 
3.4.1.4   Elevations of a chemokine protein and gene expression 
concentration in CII immunized mouse brains  
Chemokines  are  a  group  of  inflammatory  mediator  that  function  to  regulate 
recruitment of leukocytes and angiogenesis in the inflammatory process (Koch, 
2005). In RA, synovial fibroblasts produce chemokine, which function to attack 
leukocytes  into  the  synovial  tissue  (Koch,  2005).  In  our  study,  we  found 
elevations of CXCL1 and CXCL10 protein and gene concentration in brains of CII 
immunized mice (both arthritic and non arthritic mice). Our data may indicate 
the recruitment of immune cells into the brain of CII immunized mice. 
CXCL1 functions as a potent neutrophil chemo attractant by binding both CXCR1 
and CXCR2 receptors (Luttichau, 2010). CXCL1 have been reported in osteoblasts 
and  synovial  fluid  from  rheumatoid  arthritis  patients  (Lisignoli  et  al.,  1999), 
(Bischoff et al., 2005). An administration of CXCL1 antibody has shown to delay 
the onset and reduce in the disease severity of CIA mice (Kasama et al., 1995). 
We found the up regulation of CXCL1 protein in serum of CII immunized mice. 
Our data are consistent with a study by Kurowska Stolarska et al showing the 
increase concentration of serum CXCL1 in CIA mice (data are in press PNAS). 
Interestingly,  the  serum  CXCL1  protein  profiles  of  these  CII  immunized  mice 
were similar to brain CXCL1 protein profiles for both arthritic and non arthritic 
mice. These data suggest that there may be transportation of CXCL1 from the 
periphery  into  the  brain  of  these  CII  immunized  mice.  We  also  found  up 
regulation CXCL1 gene expression in these CII immunized mice, suggesting that 
there was also the local production of CXCL1 in the brain of these CII immunized 
mice. Interestingly, degrees of fold elevations of brain CXCL1 mRNA and protein 
concentration were quite similar for both arthritic and non arthritic mice. This 
seems  pretty  convincing  evidence  suggest  that  both  brain  CXCL1  protein  and 
gene could be generated locally within the CNS and by the same cellular source. 
However,  we  found  no  significant  correlation  between  mRNA  and  protein 
concentration  of  brain  CXCL1  in  CII  immunized  mice.  Therefore  we  cannot 
conclude from our data set about the location and the cellular source of the 
CXCL1  production  in  brains  of  these  CII  immunized  mice.  Microglia  and 
astrocytes  are  the  major  source  of  CXCL1  in  the  brain  and  it  has  been 
demonstrated that the induction of peripheral inflammation by LPS could induce 
microglia activation and  the  production  of  CXCL1  in  the  brain (Brown  et  al., Chapter 3    169 
2010).  CXCL1  was  transiently  expressed  at  circumventricular  organs  (CVOs), 
which are exceptional areas in the brain that are not covered by BBB, after the 
peripheral LPS induction (Reyes et al., 2003). On the other hand CXCL1 can be 
produced  inside  the  brain  during  the  neuroinflammatory  process  such  as 
encephalomyelitis  (Rubio  and  Sanz Rodriguez,  2007)  or  injury  via  IL 1β 
signalling, leading to the infiltration of neutrophils into the brain (McColl et al., 
2007).The elevations of CXCL1 may indicate leukocyte infiltration into the brains 
of CII immunized mice. However, the location, cellular source of brain CXCL1 
and  the  relationship  between  peripheral  CXCL  and  brain  CXCL1  need  further 
investigation. 
CXCL10  functions  as  a  potent  T lymphocyte  recruiter  by  binding  into  the 
receptor  CXCR3,  preferentially  on  the  Th1 lymphocyte  subset.  In  RA,  CXCL10 
induced  CCL5  expression  in  CD4
+  T  cells,  which  promote  bone  resorption  by 
inducing osteoclast formation and survival (Lee et al., 2009). The up regulation 
of CXCL10 has been reported in serum and inflamed joints of CIA mice sacrificed 
on day 42 (Kwak et al., 2008). CXCL10 has also been implicated in pathogenesis 
of  neuroinflammatory  diseases.  CXCL10  and  its  receptor,  CXCR3,  are  highly 
expressed by the CNS and by CNS infiltrating lymphocytes, respectively, only in 
patients with ongoing CNS inflammation such as viral encephalitis and multiple 
sclerosis (Klein, 2004). The pathological mechanism of these neuroinflammatory 
diseases involves the infiltration of leukocytes into the CNS and CXCL10 has been 
reported  to  regulate  peripheral  Th1  infiltration  into  the  CNS  during  these 
neuroinflammatory  diseases  (Klein,  2004).  Therefore,  the  elevations  of  both 
CXCL10 gene and protein concentration in brains of CII immunized mice could be 
an important indicator of the presence of neuro inflammation that may/may not 
associated with the peripheral joint inflammation. Interestingly, elevations of 
CXCL10 protein were only observed in brains of CII mice with arthritis and there 
were  differences  in  CXCL10  mRNA  concentration  between  arthritic  and  non 
arthritic mice. These observations in our study may suggest that the elevations 
of brain CXCL10 in arthritic mice may be associated with Th1 infiltration from 
the peripheral inflammatory joints into the brains. This hypothesis is supported 
by a study in CIA model showing that non arthritic mice showed a significant 
deficiency in T cell responses and significantly lower concentration of anti CII 
Abs after the secondary challenge compared to mice that developed arthritis Chapter 3    170 
(Pan et al., 2004). Another interesting observation is that there were increases 
in CXCL10 mRNA concentration in non arthritic mouse, but no CXCL10 detectable 
in the same mouse brains. This suggests that there was a local production of 
CXCL10  in  the  brain  of  non arthritic  mice.  It  has  been  reported  that  the 
induction of CXCL10 gene expression in the brain depends on IFN γ (Carter et 
al.,  2007).  Therefore,  it  is  possible  that  elevations  of  CXCL10  mRNA 
concentration may be associated with elevations of IFN γ mRNA concentration 
observed in non arthritic mouse brain.  It is also possible that the pathway of 
brain CXCL10 production in non arthritic mice is different from those in arthritic 
mice.  This  is  because  the  peripheral  administration  of  CFA  can  also  cause 
microglia  activation  and  cytokine  production  in  the  CNS  (Raghavendra  et al., 
2004).  Therefore,  CII  immunized  mice  received  CFA  that  did  not  develop 
arthritis could also induce the production of brain cytokines/chemokines without 
migration of immune cells and cytokines/chemokines from inflamed joint to the 
brain. 
3.4.1.5   Elevations of a growth factor protein and gene expression 
concentration in CII immunized mouse brains  
 
We also found elevations of FGF2 protein concentration in brains of arthritic 
mice  and  elevations  of  VEGF  mRNA  concentration  in  both  arthritic  and  non 
arthritic mice. The elevations of these angiogenic factors may indicate changes 
in BBB properties that occurred during the systemic joint inflammatory process. 
Fibroblast  growth  factor  2  is  a  wide spectrum  mitogenic,  angiogenic,  and 
neurotrophic  factor  that  bind  to  FGFR  (FGF  receptors  and  regulates  various 
biological processes, including embryogenesis, wound healing, angiogenesis, and 
maintenance of neuronal networks (Manfe et al., 2010). In RA, FGF2 is produced 
mainly by endothelial cells and fibroblast; predominantly at the sites of chronic 
inflammation (Malemud, 2007). Elevation of FGF2 was observed in the synovial 
tissue of patients with RA (Thomas et al., 2000), and this worsened the joint 
inflammation in CIA rats (Yamashita et al., 2002).  FGF2 play a crucial role in the 
final  step  of  osteoclastic  bone  resorption  in  rheumatoid  arthritis  joint 
destruction that is preceded by recruitment and differentiation of osteoclasts by 
other factors (Chikazu et al., 2000). FGF2 also play a role in angiogenesis and 
recruitment of the immune cell into the inflamed site (Malemud, 2007). An in Chapter 3    171 
vivo  study  showed  that  FGF2  synergistically  enhanced  the  recruitment  of 
monocytes, T cells and PMNs in response to a variety of inflammatory mediators, 
including IFN γ, TNF α and CCL 2. FGF2 also enhanced leukocyte recruitment to 
sites of inflammation by inducing endothelial adhesion molecule expression such 
as ICAM 1 and integrins (Zittermann and Issekutz, 2006). We found elevations of 
FGF2 protein in brains of arthritic mice, but no FGF2 gene expression detectable 
in the same brain, suggesting that there may be the contribution of FGF2 from 
the peripheral inflamed joint into the brain. However, we could detect FGF2 
protein concentration in these arthritic mice but the concentrations were not 
different from those in naïve control mice. Therefore, we cannot conclude from 
our experiment about the location and cellular source of FGF2 in the brains of 
these arthritic mice. One reason is that we only investigated the expression of 
the  protein  concentration  at  one  time  point  on  day  42,  it  is  possible  the 
contribution of FGF2 from the periphery into the brains of arthritic mice may 
occur at the earlier time point. Therefore, it is important to investigate changes 
of  these  brain  inflammatory  mediators  in  other  time  point  throughout 
experimental time period. 
The brain VEGF protein levels in arthritic mice seemed to be higher than those 
of naïve control mice on day 42. However, one way ANOVA suggested that there 
was no significant difference in brain VEGF protein among all 3 groups (naïve 
control,  non arthritic  and  arthritic  groups).  This  may  reflect  a  small  sample 
number. Therefore, it is worthwhile to repeat these experiments using the larger 
numbers of animals.  
VEGF and its receptor VEGFr play a crucial role in angiogenesis process in RA 
because the pannus formation in RA requires neovascularisation that regulate 
mainly by VEGF. VEGF was highly expressed by RA synovium (Nagashima et al., 
1995)  and  also  thought  to  play  an  important  role  in  the  chronic  edema  and 
swelling in arthritis joint (Malemud, 2007). We found elevations of VEGF mRNA 
in  both  arthritic  and  non arthritic  mice,  but  there  was  no  VEGF  protein 
detectable in brains of these CII immunized mice. This suggests that they may be 
the local production in the brains. However, the mechanism of how VEGF mRNA 
expression was induced in the brains of these CII immunized mice is still unclear. 
One  possibility  is  that  FGF2  also  has  an  autocrine  effect  on  angiogenesis  by 
inducing vascular endothelial growth factor (VEGF) in endothelial cells (Seghezzi Chapter 3    172 
et al., 1998). Therefore, the increased VEGF gene expression in arthritic mouse 
brains could be associated with the up regulation of FGF protein level. We could 
not address the question of why VEGF mRNA concentrations were increased in 
non arthritic  mouse  brain.  One  possible  explanation  is  that  VEGF  is  also  an 
angiogenic factor that enhance BBB permeability, and BBB disruption is observed 
in several models of neuroinflammation such as EAE and viral encephalomyelitis 
models (Kirk and Karlik, 2003); (Sasaki et al., 2010). The up regulations of VEGF 
mRNA concentration in CII immunized mouse brains could be an indicator of BBB 
breakdown in this model. The BBB breakdown in the brain is often followed by 
the  infiltration  of  leukocyte  into  the  brain.  The  administration  of  VEGF  into 
mouse  brains  result  in  breakdown  of  the  blood–brain  barrier,  leukocyte 
recruitment into the brain (Croll et al., 2004b). Therefore, the up regulation of 
VEGF mRNA concentration in brains of non immunized mice may be associated 
with the increases in CXCL1 and CXCL10 that may function to regulate peripheral 
leukocyte recruitment into the brain.  
In  this  study,  we  demonstrated  increases  of  various  inflammatory  mediators, 
including IL 1α, IL 2, IFN γ, IL 5, IL 10, IL 13, CXCL1, CXCL10 and FGF2 in brains 
of CII immunized mice. However, we could not detect some inflammatory such 
as IL 1 cytokines, including IL 1β, TNF α and IL 6, that have been reported to be 
increase in the CNS of mouse models of RA (Bao et al., 2001); (del Rey et al., 
2008).  A  study  by  Boa  et  al.,  reported elevations  of both  protein and  mRNA 
concentration  of  these  pro inflammatory  cytokines  (IL 1β,  TNF α  and  IL 6)  in 
spinal cord of AIA mice (Adjuvant induced arthritis model) (Bao et al., 2001). 
Differences in the procedure for inducing arthritis and immunopathogenesis may 
account for contradictory results from the literature. Adjuvant induced arthritis 
(AIA) is an arthritis model, induced by a single intradermal injection of complete 
Freund’s  adjuvant  (CFA)  consisting  of  heat killed  Mycobacterium  tuberculosis 
(Mt) and incomplete Freund’s adjuvant (IFA) (Hossain et al., 2001). Polyarthritis 
rapidly  develops  around  10  days  after  immunization  using  adjuvant  and  the 
whole course of the disease lasts for 21 days (Bendele, 2001). In addition, the 
AIA model is Th1 cell and neutrophil dependent, and complement independent. 
There is no evidence demonstrating that B cells play a role in the pathogenesis 
of AIA. By contrast, the immune response of CIA involves both CII specific T cells 
and B cells, which produce antibodies to type II collagen. The differences in the Chapter 3    173 
immunopathological  mechanism  of  both  arthritic  models  may  cause  different 
peripheral inflammatory mediator profiles, which may result in different brain 
inflammatory mediator expression patterns. For example, TNF α, IFN γ, IL 1, IL 
6, and IL 17A are dominant in the periphery of AIA model, while several pro  and 
anti inflammatory cytokines, including TNF α and IL 1β, IL 6, IL 12, IL 1Ra, IL 10 
and TGF β, are highly expressed in the periphery of mice with CIA (Hegen et al., 
2008). In addition, time course studies of inflammatory mediator expressions in 
periperal tissue (paws and lymph nodes) of CIA mouse model reveal increases of 
different cytokines/chemokines expressions at different time points (Thornton et 
al., 1999);(Rioja et al., 2004);(Mauri et al., 1996). A study by Mauri et al., show 
increases  of  IL 10,  IFN γ  and  TNF α  in  the  culture  lymph  node  of  CIA  mice 
between day 3 – day 6 after immunization (Mauri et al., 1996). Another study by 
Rioja  et  al  showed  transient  increases  of  IL 1β  and  IL 6  mRNA  and  protein 
concentration  in  paws  of  arthritic  mice  during  the  first  4  days  after 
immunization,  while  the  prolonged  expression  of  TNF α  mRNA  and  protein 
concentration  throughout  15  days  after  immunization  (Rioja  et  al.,  2004). 
Another study by Thornton et al., demonstrated different cytokine expression 
patterns in paws of CIA mice. Transient increases in IL 2, IL 6 and TNF α mRNA 
were  observed  during  the  early  disease  stage  (day  21 day  28  after 
immunization), while CXCL2 and IL 1β mRNA concentration were increased later 
during day 35 after immunization (Rioja et al., 2004). These evidence suggest 
the possibility that the contribution of inflammatory mediators from inflamed 
joint to the brain could be manifested at anytime throughout the experimental 
course.  In  this  chapter,  we  only  determined  brain  inflammatory  mediator 
concentration in brain of CII immunized on the final day of the experimental 
course on day 42. Therefore, we hypothesized that some cytokines, particularly 
pro inflammatory cytokines IL 1β, TNF α, IL 6 that we could not detect in CII 
immunized mouse brain at this time point, may be up regulated at earlier time 
point.  This  hypothesis  is  supported  by  a  recent  data  showing  the  transient 
elevations of IL 1β mRNA concentration during first 10 days after immunization 
and elevations of IL 6 mRNA concentration during early stage of arthritis disease 
in CIA rat brains (day 20 – day 30 after immunization) (del Rey et al., 2008). In 
addition, experimental evidence showing the elevations of cytokine/chemokine 
expression in paws of CIA mice during the early time point of CIA experimental 
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observation of disassociation between arthritic scores and brain inflammatory 
mediator  concentration  in  arthritic  mice  in  our  study.  It  is  possible  that 
peripheral  joint  inflammation  may  involve  production  of  brain  inflammatory 
mediators  at  earlier  time  point  in  the  CIA  experimental  course,  but  the 
elevations  of  these  inflammatory  mediator  concentration  observed  in  these 
arthritic mice at late time point of the CIA experimental course (day 42) may be 
generated  from  local  cellular  sources  in  the  brain.  Therefore,  time  course 
experiment  of  inflammatory  mediator  expressions  in  brains  of  CII immunized 
mice  is  essential  for  further  investigations  of  brain immune  system joint 
communication. 
In summary: this chapter we demonstrated elevations of various inflammatory 
mediators, including IL 1α, IL 2, IFN γ, IL 5, IL 10, IL 13, CXCL1, CXCL10, FGF2 
in brains of CII immunized mice, which may indicate the immune activation and 
inflammatory process in the brains of CII immunized mice. However, our data 
raised several questions; (i) how these inflammatory mediators access from the 
periphery into the brain, (ii) when these inflammatory mediators access from 
the periphery into the brain, (iii) what cellular sources of these inflammatory 
mediators  in  the  brain,  (iv)  how  peripheral  joint  inflammation  signals  CNS 
immune  cells  to  produce  these  inflammatory  mediators  in  the  brain.  In  an 
attempt to address these questions, in the next chapter, we conducted time 
course  experiment  of  inflammatory  mediator  expressions  in  brains  of  CII 
immunized  mice.  This  was  to  investigate  the  association  between  arthritis 
disease  development  and  overtime  changes  in  inflammatory  mediator 
concentration  in  brains  of  CII immunized  mice,  which  may  indicate  brain 
immune system joint communication in this model. 
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4.1  Introduction and aims 
In the previous results chapter (Chapter 3), we showed increased concentrations 
of inflammatory mediator mRNA and protein, including IL α, IL 2, IL 5, IL 10, IL 
13, CXCL1, CXCL10, FGF2 and VEGF in brains of mice immunized with collagen II 
in  Freund’s  adjuvant;  particularly  in  those  mice  that  subsequently  developed 
arthritis. However, we could not demonstrate a clear association between the 
increased concentrations of these brain inflammatory mediators and peripheral 
joint inflammation as indicated by the lack of association between the arthritis 
scores and the concentrations of the inflammatory mediators in the brains. In 
addition, we could not detect some cytokines such as IL 1β, TNF α and IL 6, that 
have  been  reported  to  be  elevated  in the  CNS  of  arthritic  mice  (Bao  et al., 
2001). One reason for that may have been because we only determined brain 
inflammatory mediator expression mice at only one time point on day 42; which 
was the final day of the experimental course of the collagen induced arthritis 
(CIA) model. Therefore, the aim of this chapter was to determine the changes in 
brain inflammatory mediators at other time points during the development of 
experimental  arthritis  to  investigate  potential  pathological  pathways  of  how 
peripheral joint inflammation might signal to the brain to increase synthesis of 
inflammatory mediators.  
Background: Collagen  induced  arthritis  (CIA)  in  mice  is  considered  to  be  a 
disease model of chronic inflammatory arthritis (Luross and Williams, 2001). In 
this  model  longitudinal  changes  in  cytokine  concentrations  are  found  in 
peripheral  tissues  including  the  joints  and  lymph  nodes  following  initial 
sensitisation with collagen (Rioja et al., 2004). Several studies investigated a 
cytokine  expression  cascade  in  the  progression  of  RA  by  measuring  cytokine 
expression in the peripheral tissues at different time points throughout the CIA 
experimental course (Thornton et al., 1999); (Rioja et al., 2004); (Mauri et al., 
1996).  These  studies  often  divided  the  CIA  experimental  course  into  several 
phases such as the acute phase (onset phase) and the chronic phase (Geng et al., 
2008);  (Mauri  et  al.,  1996),  and  investigated  longitudinal  changes  in  cytokine 
patterns at different phases of the course of experimental disease. The acute 
phase  (onset  phase)  occurs  after  immunization  and  is  characterized  by  rapid 
disease progression (Mauri et al., 1996). The chronic phase of the disease course 
is  characterized  by  erosion  of  cartilage  but  the  disease  progression  becomes Chapter 4    177 
slower than during the acute (onset) phase (Geng et al., 2008). Studies suggest 
that  different  cytokine  expression  patterns  that  occur  during  these  different 
phases are associated with differences in pathological stages of arthritis. A study 
by Thornton et al., showed that elevation of IL 2, IL 1β and CXCL2 mRNA in the 
paws may be associated with more leukocyte and neutrophil infiltration into the 
paw  during  the  onset  of  disease.  In  contrast,  TGF β  may  be  associated  with 
increased in fibrosis and the number of fibroblast/macrophage type cells in the 
paw during the chronic stage (Thornton et al., 1999). In addition, accumulating 
evidence  also  showed  the  contribution  of  different  cytokines  in  different 
peripheral  tissues  at different  phases  of  disease.  For  example, Th1  cytokines 
such as IL 12 and IFN γ are predominately expressed in lymph nodes and the 
spleen  and  in the  peritoneal  cavity  during  the acute  phase (onset  phase).  In 
contrast, IFN γ is expressed for a limited period around the time of disease onset 
in the joint, but prolonged expression of IL 1, IL 10, TNF α, TGF β and IL 6 are 
detected in the joint during the chronic phase (Okamoto et al., 2000); (Stasiuk 
et al., 1996); (Mussener et al., 1997). If there is a contribution of inflammatory 
mediators from the peripheral inflamed tissues (joints and lymph nodes) into the 
brain  in  the  CIA  model,  then  the  longitudinal  changes  in  brain  inflammatory 
mediators  should  correspond  or  be  associated  with  longitudinal  changes  in 
peripheral  inflammatory  mediators  throughout  CIA  experimental  course.  This 
hypothesis is supported by a study by del Ray et al showing that the longitudinal 
change  in  brain  IL β  mRNA  concentrations  corresponded  to  the  longitudinal 
change in IL β protein in lymph nodes in CIA rats (del Rey et al., 2008) .    
Based on this evidence, we hypothesized that there may be longitudinal changes 
in  brain  inflammatory  mediators  associated  with  peripheral  inflammatory 
mediator  changes  throughout  the  progression  of  disease  in  CII  immunized 
arthritis mice. The aims of this chapter are:   
(i)  To determine changes in inflammatory mediators in brains of CII 
immunized mice at different time points. 
(ii)  To determine changes in peripheral inflammatory mediators at 
different time points by measuring inflammatory mediator protein 
concentrations in the serum of CII immunized mice. Chapter 4    178 
The data obtained from this time course experiment may provide the additional 
evidence of how peripheral joint inflammation signals to the brain to produce 
local inflammatory mediators. In addition, the results from this experiment may 
also  provide  interesting  insights  into  up   and  down regulation  of  the  brain 
cytokine  network,  which  may  reflect  the  biological  interplay  and  the  local 
cellular  sources  of  brain  inflammatory  mediators  over  the  course  of  arthritis 
disease. 
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4.2  Results 
4.2.1   Induction of arthritis in DBA1 mice 
In the type II collagen induced arthritis model, the disease progression always 
develops from the acute phase into the chronic phase (Ohmachi et al., 2002). 
Several studies suggest that the CIA experimental course can be divided into 
several phases; (i) disease onset period, where CII immunized mice started to 
develop disease; (ii) acute phase period, where arthritis disease severity and 
disease progression increase rapidly, (iii) chronic or transition to chronic phase, 
where arthritis disease severity and disease progression increases slower than 
the last period but the paw swelling and the cartilage erosion are still manifest 
(Geng et al., 2008). A report by Ferraccioli et al., divided the CIA experimental 
period into 2 phases after the secondary immunization (or boosting). The early 
disease was defined as occurring on days 12–15 after day 21 (corresponding to 
the first clinical signs of joint swelling). The late disease phase was defined as 
days 23–25 after boosting (corresponding to the maximum clinical signs of joint 
swelling) (Ferraccioli et al., 2010). Based on mean arthritis score, mean paw 
thickness  and  %incidence  of  arthritis  in  CII  immunized  mice  of  the  previous 
chapter (Chapter 3; section 3.2.1), all of the CII immunized mice started to show 
signs of arthritis during day 22 day 28, therefore we considered this period as a 
disease onset period. Arthritis disease severity and disease progression in the CII 
immunized  mice  increased  dramatically  during  day  28 day  35,  we  therefore 
considered this period as early disease phase. We considered that last stage of 
CIA experimental course (day 35 day 42 after immunization) as a late disease 
phase since most of CII immunized mice developed paw swelling slower than the 
last period and paw swelling in some of the mice stopped or decreased. 
Several studies have reported the increases in inflammatory mediators, including 
IL 2, IL 6, TNF α, CXCL1 and IL 10 in peripheral tissue such as paws and lymph 
nodes of CIA animals at both early and late stages of the experimental course of 
CIA (day 22  to day 42) (Thornton et al., 1999);(Rioja et al., 2004);(Mauri et al., 
1996).  These  suggest  the  possibility  that  the  contribution  of  inflammatory 
mediators from peripheral inflamed tissues (paws and lymph node) to the brain 
could  be  manifested  at  anytime  during  the  stage  of  disease  progression.  We 
hypothesized that  some  cytokines,  particularly  pro inflammatory  cytokines  IL Chapter 4    180 
1β, TNF α, IL 6  that we could not detect in CII immunized mice on day 42, may 
be detectable in earlier time points  throughout the stage of disease progression 
( day 22 –day 42). This hypothesis is supported by a study showing up regulation 
of IL 1α, IL 6 and TNF α in CNS tissue of arthritis rats on day 21 (Bao et al., 
2001). Based on this evidence and hypothesis, we measured the expression of 
inflammatory mediators in brains of CII immunized mice in 4 appropiate time 
points  after  immunization;  throughout  both  early  and  late  stages  of  disease 
progression.  We  started  on  day  22  after  immunization  because  day  22  is 
considered to be the time point of the RA disease onset in this experimental 
arthritis model.  
In  this  chapter,  we  randomly  divided  CII  immunized  mice  into  4  groups  (n=6 
each), which were culled on days 22, 28, 35 and 42 respectively. 24 DBA1 mice 
were  immunized  by  intradermal  injection  of  type  II  collagen  in  Freund’s 
complete adjuvant on day 0, and rechallenged by intraperitoneal injection of 
collagen II in PBS on day 21 and then culled at different time points (days 22, 28, 
35, 42) throughout the disease course. The signs of arthritis in CII immunized 
mice  were  monitored  from  day  16  after  immunization  onwards  and  arthritis 
severity in this experiment were verified independently by Mr. Maurice Dixon. 4 
groups (6 mice per group) of sex  and age matched untreated non immunized 
DBA1 mice were used as antigen naïve control groups, which were also culled on 
days 22, 28, 35, 42. Serum and brains of all experimental groups of mice were 
harvested and snap frozen in liquid nitrogen and stored at –80˚C. Half of each 
brain was processed for protein extraction and inflammatory mediator protein 
analysis by luminex; the other half was processed for RNA extraction and the 
inflammatory  mediator  gene  expression  was  determined  by  real time  PCR 
(Figure 4.1).  Chapter 4    181 
 
Figure 4.1 CIA experimental procedure for time course experiment  
24 DBA1 mice at 6 8 weeks of age were immunized with 100       g type II bovine collagen + 
complete Freund’s adjuvant (CFA) at day 0 and then challenged on day 21 with 200       g type II 
collagen. Mice were randomly divided into 4 groups (6 mice/group), which were culled on 
different days (days 22, 28, 35, 42) as indicated. Another 4 groups of untreated normal mice 
culled on the same days indicated were used as controls. Brain and serum from mice of all 
experimental groups were collected and processed for inflammatory mediator 
measurements using Luminex, ELISA and real time PCR. 
4.2.1.1  Development and severity of arthritis disease of each group of 
CII immunized mice at each time point. 
All 6 CII immunized mice in Group 1 were culled on day 22 after immunization, 
there was no mice in that group developed arthritis.  
On day 28 after immunization, another 6 CII immunized mice in Group 2 were 
culled. There were 2 CII immunized mice in that group with arthritis (33.33% 
incidence) at the day of cull. The onset of arthritis disease of CII immunized 
mice in Group 2 occurred between days 26 and 28 after immunization. The mean Chapter 4    182 
clinical score and the mean paw thickness of CII in Group 2 calculated on the 
cull day were 1.67 ± 0.7 and 1.84 ± 0.05 mm, respectively. CII immunized mice 
in this group also showed a significant increase in paw thickness compared to 
those in naïve control mice (P=0.0022) (Figure 4.2A, Figure 4.2B, Figure 4.2C). 
CII immunized mice in Group 3 (n=6) were culled on day 35 after immunization. 
At that time point, there were 3 CII immunized in Group 3 developed arthritis 
(50% incidence). Arthritic mice in this group started to show signs of arthritis 
between day 22 and day 28 after immunization. The mean clinical score and the 
mean paw thickness of CII in Group 3 calculated on the cull day were 3.17 ± 1.87 
and 1.95 ± 0.14 mm, respectively. A significant increase in paw thickness was 
observed in CII immunized mice in this group compare to those in naïve control 
mice (p=0.0032) (Figure 4.2A, Figure 4.2B, Figure 4.2C). 
At  the  final  time  point  on  day  42,  6  CII  immunized  mice  in  Group  4  were 
harvested.  3  CII  immunized  in  this  group  developed  arthritis  and  the  clinical 
signs of arthritis were observed in these arthritic mice between day 20 and day 
28 (50% incidence) after immunization. The mean arthritis score and the mean 
paw thickness of CII in Group 4 calculated on the cull day were 3.33 ± 1.63 and 
2.04 ± 0.09 mm, respectively. Overall mean paw thickness of CII immunized mice 
of Group 4 was significantly higher than those in naïve control mice (P<0.0001) 
(Figure 4.2A, Figure 4.2B, Figure 4.2C). Chapter 4    183 
 
Figure 4.2 Development and severity of arthritis disease of each group of CII immunized 
mice at each time point  
24 CII immunized mice were divided into 4 groups (6 mice/group), which were culled on 
different days (days 22, 28, 35, 42 after immunization) throughout CIA experimental course. 
(A) shows incidence of arthritis of each group of CII immunized mice at each time point, 
which was calculated from number of CII immunized mice with arthritis/total number of CII 
immunized mice used and present as percentage. The signs of arthritis in CII immunized 
mice were monitor from day 16 after immunization onwards. The first group of CII 
immunized mice (Group 1) were culled on day 22 after immunization. There was no CII 
immunized mice in that group developed arthritis (yellow line). CII immunized mice in Group 
2 started to show signs of arthritis from day 26 after immunization onwards and all the CII 
immunized mice in Group 2 were culled on day 28 (green line). CII immunized mice in Group 
3, which were culled on day 35 after immunization, started to show signs of arthritis from 
day 22 onwards and on the day of cull there were 3 CII mice in that group developed arthritis 
(blue line). At the terminal day of CIA experimental course (day 42), another 6 CII immunized 
mice were culled and there were 3 CII immunized mice developed arthritis on the day of cull. 
These arthritic mice in Group 4 started to develop arthritis from day 20 after immunization Chapter 4    184 
onwards. (B) shows mean paw thickness of CII immunized mice which was calculated from 
the sum of the paw thickness of all mice divided by the number of mice in each time point 
group. (C) shows mean clinical of CII immunized mice which was calculated from the sum of 
the clinical scores of all mice divided by the number of mice in each time point group. Both 
mean clinical score and mean paw thickness of each time point were calculated on the day 
of cull. Mean paw thickness, mean clinical score and %incidence in CII immunised mice (n= 
6 CII immunised mice /group) were compared with those values of naïve control mice (n = 
6/group) at each time point. Data represent as mean ± SEM. (n=6 CII immunised mice 
/group). Statistical analysis of data was performed using two way ANOVA for multiple 
comparison, compared with a group of control naïve mice; *P<0.05, ** P<0.01, *** P<0.001.  
Individual clinical scores and thickness of the paws of individual CII immunized 
mice  in  each  group  calculated  on  the  cull  day  are  show  in  Figure  4.3.  The 
numbers of arthritic mice, mean arthritis scores, and mean swelling scores in 
each group are shown in Table 4.1. 
 
Figure 4.3 Individual clinical scores and thickness of the paws of individual CII immunized 
mice in each group  
(A) the dots represent mean paw thickness for each mouse calculated by sum of thickness 
of all four paws divided by 4. (B) the dots represent a cumulative arthritis score for all paws 
of each mouse, with a maximum score of 16 per mouse. Each group of CII immunized mice 
(n=6 CII immunised mice/group) were culled of different time points as indicated (Group 1; 
day 22, Group 2; day 28, Group 3; day 35 and Group 4; day 42) and both individual clinical 
scores and individual paw thickness were calculated on the day of cull. Bars represent the 
mean values. (*P < 05; **P < 01; ***P < 001 by one way ANOVA analysis) 
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Number  Mean  Maximum  Mean   
Group 
 
Day  
of 
cull  
of 
arthritic mice 
(6 mice/group) 
arthritic 
scores 
arthritic 
scores 
paw 
diameter 
(mm) 
 
1 
 
 
 Day 22 
 
0/6 
 
0 
 
0 
 
1.7 
 
2 
 
 
Day 28 
 
2/6 
 
1 
 
4 
 
1.84 
 
3 
 
 
Day 35 
 
3/6 
 
3.17 
 
 
10 
 
1.95 
 
 
4 
 
 
Day 42 
 
3/6 
 
3.33 
 
12 
 
2.04 
Table 4.1 Numbers of arthritic mice, mean arthritis scores, and mean swelling scores of CII 
immunized mice in each time point groups  
Mice immunized with type II collagen were divided into 4 groups (group 1, 2, 3 and 4) which 
were culled on days as indicated. Numbers of immunized mice developed arthritis from 
each time point group were counted on the cull day. Mean arthritis scores (total arthritis 
score/number of mice in the group), maximum arthritis score and mean swelling of 
immunized mice from each time point group were calculated on the cull day. 
4.2.2   Time course analysis of serum inflammatory mediator 
protein concentration in CII immunized mice. 
To  investigate  changes  in  peripheral  inflammatory  mediators  over  the  time 
course of arthritis, a Luminex cytokine 20 Plex assay was used to determine the 
protein concentration of several cytokines and chemokines in serum collected 
from control mice and CIA mice on days 22, 28, 35 and 42. Longitudinal changes 
in serum IL 1β, IL 5, CCL2 and FGF2 were observed in CII immunized mice. 
4.2.2.1   Changes in serum pro inflammatory cytokine protein 
concentrations in CII immunized mice 
 
The pro inflammatory cytokines TNF α, IL 1β and IL 6 were measured in serum 
of CII immunized and naïve control mice. Protein IL 1β was the only cytokine in 
this category that showed a change in CII immunized mouse serum compared to 
those  in  the  naïve  control  group.  Two way  ANOVA  analysis  followed  by 
Bonferroni posttests demonstrated that IL 1β in serum was significantly higher in 
CII immunized mice compared to those in naïve control mice on day 22 and 28 
after  the  immunization  (P  <  0.0001).  The  mean  value  of  serum  IL 1β  (CII 
immunized versus naïve control) on day 22 and day 28 was 237.3 ± 21.3 pg/ml 
versus 176.6 ±  0.9 pg/ml (P < 0.0001), and 254.9 ± 64.5 pg/ g total protein Chapter 4    186 
versus  176.5  ±  1.3  pg/ml  (P  =  0.0139)  respectively.  This  was  followed  by  a 
significant  decline  in  serum  IL 1β  protein  concentrations  to  the  base line 
concentration  from  day  28  to  day  42  (Figure  4.4A).  One way  ANOVA 
demonstrated  that  there  were  significant  differences  in  serum  IL 1β 
concentrations among the four groups of mice culled on day 22, 28, 35 and 42 (P 
=  0.0027).  Post  hoc  analysis  with  Bonferroni  correction  demonstrated  that 
concentrations of serum IL 1β in CII immunized mice on day 22 and day 28 were 
significantly higher than serum IL 1β concentrations on day 35 and day 42. The 
mean value of serum IL 1β of CII immunized mice (day 22 versus day 42) was 
237.3 ± 21.3 pg/ml versus 178.5 ± 1.3 pg/ml (P < 0.01). The mean value of serum 
IL 1β  of  CII  immunized  mice  (day  28  versus  day  35)  was  254.9  ±  64.5  pg/ml 
versus  189.9  ±  21.7  pg/ml  (P  <  0.05),  while  the  mean  value  of  IL 1β  of  CII 
immunized mice (day 28 versus day 42) was 254.9 ± 64.5 pg/ml versus 178.55 ± 
1.3 pg/ml (P < 0.05) ((Figure 4.4B). These data suggest that serum IL 1β protein 
concentration  peaked  during  22  to  28  days  after  immunization,  and  then 
decreased to the base line concentration from day 28 to day 42.  
 
Figure 4.4 Time course of a serum pro inflammatory cytokine in CII immunized mice  
 (A) Mice immunized with type II collagen (filled squares) were culled on day 22, 28, 35, 42 
and serum samples from CII immunized mice of all time points were collected for peripheral 
inflammatory mediator measurement using a Luminex assay. Serum samples collected from 
naive control mice (open circle) culled on the days indicated were used as controls. IL 1β 
protein concentrations in serum are expressed as pg/ml. Data represent means ± SEM (n = 
CII immunised mice/group). Statistical analysis of data was performed using two way 
ANOVA, compared with naïve control mice: *P<0.05, **P<0.01, ***P<0.001. (B) shows 
longitudinal changes of serum IL 1β  concentrations in a group of CII immunized mice 
culled on the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by 
one way ANOVA analysis). Chapter 4    187 
4.2.2.2  Changes in serum Th1 cytokine protein concentrations in CII 
immunized mice 
IFN γ, IL 2 and IL 12 were Th1 cytokines that were selected for analysis in the 
serum of CII immunized and control mice. However, there were no Th1 cytokines 
detectable in serum of any mice from all the experimental groups. 
4.2.2.3   Changes in serum Th2 cytokine protein concentrations in CIA 
mice 
Th 2 cytokines, including IL 4, IL 5, IL 10 and IL 13 were selected for analysis in 
the serum of naïve control mice and CII immunized mice. IL 5 was the only one 
of these Th2 cytokine that was detectable in the serum of CII immunized mice. 
Two way ANOVA analysis followed by Bonferroni posttests demonstrated that IL 
5 in serum was significantly higher in CII immunized mice compared to those in 
naïve control mice on day 22 and 28 after the immunization (P = 0.037). The 
mean values of serum IL 5 (CII immunized versus naïve control) on day 22 and 
day 28 were 209.8 ± 39.1 pg/ml versus 160.8 ± 2.0 pg/ml (P = 0.012), and 195.2 
± 29.2 pg/ml versus 161.2 ± 1.6 pg/ml (P = 0.0171) respectively (Figure 4.5A). 
The  serum  IL 5  concentration  of  CII  immunized  mice  thereafter  decreased 
continuously during day 28 to day 42. One way ANOVA followed by Bonferroni's 
post hoc comparison tests demonstrated that there were significant differences 
in serum IL 5 concentrations among the four groups of mice culled on day 22, 28, 
35 and 42 (P = 0.0067). The serum IL 5 concentrations of CII immunized mice on 
day 22 were significantly higher than those on day 35 (209.8 ± 39.1 pg/ml versus 
164.2 ± 14.4 pg/ml; P < 0.05), and on day 42 (209.8 ± 39.1 pg/ml versus 159.6 ± 
2.5 pg/ml; P < 0.05). There were no significant differences between serum IL 5 
concentrations of CII immunized mice on day 28 and those on day 35 and day 42 
(Figure 4.5B). These data suggest that serum IL 5 protein concentrations peaked 
during  22  days  after  immunization,  and  then  decreased  to  the  baseline 
concentration from day 28 to day 42.  
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Figure 4.5 Time course of a serum Th2 cytokine in CII immunized mice  
 (A) Mice immunized with type II collagen (filled squares) were culled on day 22, 28, 35, 42 
and serum samples from CII immunized mice of all time points were collected for peripheral 
inflammatory mediator measurement using a Luminex assay. Serum samples collected from 
naïve control mice (open circle) culled on the days indicated were used as controls. IL 5 
protein concentrations in serum are expressed as pg/ml. Data represent means ± SEM (n = 6 
CII immunised mice/group). Statistical analysis of data was performed using two way 
ANOVA, compared with naïve control mice: *P<0.05. (B) shows longitudinal changes of 
serum IL 5 concentrations in a group of CII immunized mice culled on the days indicated. 
Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA analysis) 
4.2.2.4  Changes in serum chemokine protein concentrations in CII 
immunized mice 
Among  the  chemokines  analysed  (CXCL1,  CXCL10,  CCL2  and  CCL3),  only  the 
serum concentration of CCL2 in CII immunized mice increased significantly at 
day 22 and day 28 compared to those of the naïve controls. Two way ANOVA 
analysis followed by Bonferroni posttests demonstrated that CCL2 in serum was 
significantly higher in CII immunized mice compared to those in naïve control 
mice on day 22 and 28 after the immunization (P = 0.001). The mean value of 
serum CCL2 (CII immunized versus naïve control) on day 22 and day 28 were 
175.5 ± 18.5 pg/ml versus 139.0 ± 1.0 pg/ml (P = 0.0007), and 174.8 ± 22.4 
pg/ml versus 137.9 ± 1.7 pg/ml (P = 0.0025) respectively (Figure 4.6A). One way 
ANOVA  followed  by  Bonferroni's  post hoc  comparison  tests  demonstrated  that 
there were significant differences in serum CCL2 concentrations among the four 
groups  of  mice  culled  on  day  22,  28,  35  and  42  (P  =  0.0007).  There  was  a 
decrease in serum CCL2 concentration of CII immunized mice after day 28. The 
serum concentration of CCL2 in CII immunized mice on day 35 and day 42 were 
significantly lower than those on day 22. The mean value of serum CCL2 of CII 
immunized mice (day 22 versus day 35) was 175.5 ± 18.5 pg/ml versus 146.3 ± 
11.4 pg/ml (P < 0.05), while the mean value of serum CCL2 of CII immunized 
mice (day 22 versus day 42) was 175.5 ± 18.5 pg/ml versus 139.7 ± 1.4 pg/ml (P 
<  0.01).  A  significant  reduction  of  serum  CCL2  was  also  observed  in  CII Chapter 4    189 
immunized mice on day 35 and day 42 compared to those on day 28. The mean 
value of serum CCL2 of CII immunized mice (day 28 versus day 35) was 174.8 ± 
22.4 pg/ml versus 146.3 ± 11.4 pg/ml (P < 0.05), while the mean value of serum 
CCL2  of  CII  immunized  mice  (day  28  versus  day  42)  was  174.8  ±  22.4  pg/ml 
versus 139.7 ± 1.4 pg/ml (P < 0.01) (Figure 4.6B). 
 
Figure 4.6 Time course of a serum chemokine in CII immunized mice   
(A) Mice immunized with type II collagen (filled squares) were culled on day 22, 28, 35, 42 
and serum samples from CII immunized mice of all time points were collected for peripheral 
inflammatory mediator measurement using a Luminex assay. Serum samples collected from 
naïve control mice (open circle) culled on the days indicated were used as controls. CCL2 
protein concentrations in serum are expressed as pg/ml. Data represent means ± SEM (n = 6 
CII immunised mice/group). Statistical analysis of data was performed using two way 
ANOVA, compared with naïve control mice: **P<0.01, ***P<0.001. (B) shows longitudinal 
changes of serum CCL2 concentrations in a group of CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA 
analysis). 
4.2.2.5   Changes in serum growth protein concentrations in CII 
immunized mice  
Growth  factor  concentrations  including  fibroblast  growth  factor  (FGF2)  and 
vascular  endothelial  growth  factor  (VEGF)  were  determined  in  the  serum  of 
naïve control mice and CII immunized mice. Two way ANOVA analysis followed 
by  Bonferroni  posttests  demonstrated  that  FGF2  in  serum  was  significantly 
higher in CII immunized mice compared to those in naïve control mice on day 22 
and 28 after the immunization (P <0.0001). Significantly higher concentrations of 
serum FGF2 protein were observed on day 22 and day 28 compared to those of 
the naïve controls. The mean value of serum FGF2 (CII immunized versus naïve 
control) on day 22 and day 28 were 3243.8 ± 644.4 pg/ml versus 719.4 ± 0.7 
pg/ml  (P<0.0001),  and  2482.0  ±  1283.2  pg/ml  versus  719.7  ±  1.0  pg/ml  (P  = 
0.0072)  respectively  (Figure  4.7A).  One way  ANOVA  demonstrated  that  there 
were significant differences in serum FGF2 concentrations among the four groups Chapter 4    190 
of mice culled on day 22,  28, 35 and 42  (P <0.0001). Post hoc analysis with 
Bonferroni correction demonstrated that concentrations of serum FGF2 protein 
of CII immunized mice dropped significantly between days 28 to 42. The mean 
value of serum FGF2 of CII immunized mice (day 22 versus day 35) was 3243.8 ± 
644.4 pg/ml versus 803.3 ± 135.7 pg/ml (P < 0.001), while the mean value of 
serum FGF2 of immunized mice (day 22 versus day 42) was 3243.8 ± 644.4 pg/ml 
versus  719.7  ±  1.2  pg/ml  (P  <  0.001).  Serum  FGF2  concentration  of  CII 
immunized mice on day 35 and day 42 were also significant lower than those of 
immunized mice on day 28. The mean value of serum FGF2 of CII immunized 
mice (day 28 versus day 35) was 2482.0 ± 1283.2 pg/ml versus 803.3 ± 135.7 
pg/ml (P < 0.01), while the mean value of serum FGF2 of immunized mice (day 
28 versus day 42) was 2482.0 ± 1283.2 pg/ml versus 719.7± 1.2 pg/ml (P < 0.01) 
(Figure 4.7B).  
 
Figure 4.7 Time course of a serum growth factor in CII immunized mice   
(A) Mice immunized with type II collagen (filled squares) were culled on day 22, 28, 35, 42 
and serum samples from CII immunized mice of all time points were collected for peripheral 
inflammatory mediator measurement using a Luminex assay. Serum samples collected from 
naïve control mice (open circle) culled on the days indicated were used as controls. FGF2 
protein concentrations in serum are expressed as pg/ml. Data represent means ± SEM (n = 6 
CII immunised mice/group). Statistical analysis of data was performed using two way 
ANOVA, compared with naïve control mice: **P<0.01, ***P<0.001. (B) shows longitudinal 
changes of serum FGF2 concentrations in a group of CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA 
analysis). 
4.2.3   Time course analysis of inflammatory mediator protein 
concentrations in the brains of CII immunized mice by 
Luminex cytokine 20 Plex 
We  performed  a  time course  study  on  the  protein  concentrations  of  various 
inflammatory mediators including the pro inflammatory cytokines (IL 6, IL 1 β, 
TNF α and IL 1α ), Th1 cytokines (IL 2, IL 12 and IFN γ), Th2 cytokines (IL 4, IL Chapter 4    191 
5, IL 10 and IL 13), chemokines (CXCL1, CXCL10, CCL2 and CCL3) and growth 
factors  (FGF  and  VEGF)  in  half  brain  tissue  homogenate  samples  of  CIA  and 
control  mice  from  all  experimental  groups  using  a  Luminex  cytokine  20 Plex 
assay. We found longitudinal changes in protein concentrations of IL 2, CXCL1, 
VEGF and FGF2 in the brains of CII immunized mice. 
4.2.3.1  Time course analysis of pro inflammatory cytokine protein 
concentrations in the brains of CII immunized mice by Luminex 
cytokine 20 Plex assay 
The protein concentrations of pro inflammatory cytokines including IL 6, IL 1 β, 
TNF α  and  IL 1α  were  assayed  in  brain  homogenates  of  mice  from  all 
experimental  groups.  However,  the  concentrations  of  these  pro inflammatory 
cytokines in all brain samples were lower than the assay detection limit.  
4.2.3.2  Time course analysis of Th 1 cytokine protein concentrations in 
the brains of CII immunized mice by Luminex cytokine 20 Plex 
The  protein  concentration  of  Th 1  cytokines,  including  IL 12,  IL 2  and  IFN γ, 
were assayed in the brain tissue of CII immunized mice and control mice culled 
on  days  22,  28,  35  and  42.  Two way  ANOVA  analysis  followed  by  Bonferroni 
posttests  demonstrated  that  IL 2  protein  concentrations  in  brain  tissue  were 
significantly higher in CII immunized versus naïve control mice on day 35 (P = 
0.0016). The mean value of brain IL 2 (CII immunized versus naïve control) on 
day 35 was 2.6 ± 0.9 pg/mg total brain protein versus 1.7 ± 0.4 pg/mg total brain 
protein  (P  =  0.0357)  (Figure  4.8A).    The  brain  IL 2  concentrations  of  CII 
immunized mice increased significantly from day 28 to day 35. One way ANOVA 
analysis showed that there was also no significant difference in brain IL 2 protein 
concentrations in different groups of CII immunized mice culled on day 22, day 
28, day 35 and day 42 (Figure 4.8B).  Chapter 4    192 
 
Figure 4.8 Time course of a Th1 cytokine protein concentrations in brains of CII immunized 
mice by a Luminex assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brains from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL 2 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a Luminex assay. IL 2 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: *P<0.05. (B) 
shows longitudinal changes of brain IL 2 in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA 
analysis). 
4.2.3.3  Time course analysis of Th 2 cytokine protein concentrations in 
the brains of CII immunized mice by Luminex cytokine 20 Plex 
The protein concentrations of Th2 cytokines including IL 4, IL 5, IL 10 and IL 13 
were  assayed  in  brains  of  mice  from  all  experimental  groups.  However,  the 
concentrations of these Th2 cytokines in all brain samples were lower than the 
assay detection limits.  
4.2.3.4   Time course analysis of chemokine protein concentrations in 
the brains of CII mice by Luminex cytokine 20 Plex 
Among the chemokines quantified in mouse brains (CXCL1, CXCL10, CCL2 and 
CCL3), CXCL1 was the only chemokine that was detectable in mouse brain tissue 
within the detection limits of the assay. Two way ANOVA analysis followed by 
Bonferroni  posttests  demonstrated  that  there  was  no  significant  difference 
between brain CXCL1 protein concentrations in CII immunized mice and naïve 
control  mice  across  all  time  points  (Figure  4.9A).  One way  ANOVA  analysis 
followed by Bonferroni posttests demonstrated that there was also no significant 
difference  in  brain  CXCL1  protein  concentrations  in  different  groups  of  CII 
immunized mice culled on day 22, day 28, day 35 and day 42 (Figure 4.9B).  Chapter 4    193 
 
Figure 4.9 Time course of a chemokine protein concentrations in brains of CII immunized 
mice by a Luminex assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. CXCL1 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a Luminex assay. CXCL1 concentrations in 
brain tissue, normalized against total brain protein, are expressed as pg/mg total brain 
protein. Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis 
of data was performed using two way ANOVA compared with naïve control mice: *P<0.05, 
**P<0.01, ***P<0.001. (B) shows longitudinal changes of brain CXCL1 in CII immunized mice 
culled on the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by 
one way ANOVA analysis). 
4.2.3.5  Time course analysis of growth factor protein concentrations in 
the brains of CII immunized mice by Luminex cytokine 20 Plex assay 
The  protein  concentration  concentrations  of  VEGF  and  FGF2  were  detectable 
within the detection limits of the assay. Two way ANOVA analysis followed by 
Bonferroni  posttests  demonstrated  that  FGF2  protein  concentrations  in  brain 
tissue were significantly higher in CII immunized versus naïve control mice on 
day 42 (P<0.001). The mean value of brain FGF2 (CII immunized versus naïve 
control) on day 42 was 242.3 ± 46.4 pg/mg total brain protein versus 183.3 ± 
40.2  pg/mg  total  brain  protein  (P  =  0.0402)  (Figure  4.10A).  There  was  a 
continuous  downward  trend  in  brain  FGF  protein  concentrations  of  CII 
immunized  mice.  One way  ANOVA  demonstrated  that  there  were  significant 
differences in FGF2 protein concentrations among the four groups of mice on day 
22,  28,  35  and  42  (P  =  0.0006).  Post  hoc  analysis  with  Bonferroni correction 
demonstrated that concentrations of brain FGF2 of CII immunized mice on day 
22 were significantly higher than those of immunized mice culled on day 28, day 
35 and day 42. The mean value of brain FGF2 of immunized mice (day 22 versus 
day 28) was 502.4 ± 133.5 pg/mg total brain protein versus 345.5 ± 72.6 pg/mg 
total brain protein (P < 0.05). The mean value of brain FGF2 of CII immunized 
mice (day 22 versus day 35) was 502.4 ± 133.5 pg/mg total brain protein versus Chapter 4    194 
324.9 ± 83.0 pg/mg total brain protein (P < 0.05), while the mean value of brain 
FGF2 of CII immunized mice (day 22 versus day 42) was 502.4 ± 133.5 pg/mg 
total  brain  protein  versus  242.3  ±  46.4  pg/mg  total  brain  protein  (P  <  0.01) 
(Figure 4.10B). 
 
Figure 4.10 Time course of a growth factor (FGF2) protein concentrations in brains of CII 
immunized mice by a Luminex assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. FGF2 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a Luminex assay. FGF2 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain FGF2 in CII immunized mice culled on 
the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way 
ANOVA analysis). 
Two way ANOVA analysis followed by Bonferroni posttests demonstrated that a 
significant  difference  in  brain  VEGF  protein  concentration  was  observed  in 
immunized mice and control mice on day 42 (P = 0.0015). The mean value of 
brain VEGF protein concentration (CII immunized versus naïve control) on day 42 
was  9.3  ±  1.7  pg/mg  total  brain  protein  versus  7.0  ±  1.2  pg/mg  total  brain 
protein (P = 0.0219) (Figure 4.11A). One way ANOVA demonstrated that there 
was  also  no  significant  difference  in  brain  VEGF  protein  concentrations  in 
different groups of CII immunized mice culled on day 22, day 28, day 35 and day 
42 (Figure 4.11B).  Chapter 4    195 
 
Figure 4.11 Time course of a growth factor (VEGF) protein concentrations in brains of CII 
immunized mice by a Luminex assay 
 (A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. VEGF protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a Luminex assay. VEGF concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: *P<0.05. (B) 
shows longitudinal changes of brain VEGF in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA 
analysis). 
4.2.4  Time course analysis of inflammatory mediator protein 
concentrations in the brain homogenates of CII immunized 
mice validated by ELISA assays 
In this chapter, we used a Luminex assay to determine longitudinal changes in 
protein  concentrations  in  brains  of  CII  immunized  mice.  We  only  found 
significant changes of IL 2, VEGF and FGF2 protein concentrations in brains of CII 
immunized mice compared to those in naïve control mice. In contrast, data from 
previous chapter showed a broader range of inflammatory mediator proteins that 
were up regulated in the brains of CII immunized mice. In this chapter, we could 
not detect various inflammatory mediators such as IL 1α, IL 4, IL 5, IL 6, IL 10, 
IL 13 and CXCL10 that were detectable by the same Luminex assay in the brains 
of CII immunized mice in the last chapter.  We therefore repeated the analysis 
using  potentially  more  sensitive  ELISA  assays  as  an  alternative  to  determine 
longitudinal changes in these inflammatory mediators in brains of CII immunized 
mice. TNF α, IL 1β, IL  4, IL 5, IL 6, IL 10, IL 12, and IL 13, CCL2, VEGF ELISA 
kits  were  used  to  measure  changes  in  inflammatory  mediators  that  were 
undetectable  by  Luminex  in  brains  of  mice  from  all  experimental  groups. 
Longitudinal  changes  in  TNF α,  IL 1β,  IL   4,  IL 10,  IL 12  and  CCL2  protein 
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4.2.4.1  Time course analysis of pro inflammatory cytokine protein 
concentrations in the brains of CII immunized mice by ELISA assays 
Pro inflammatory cytokines, including IL 1β, IL 6 and TNF α, were determined in 
brains of mice from all experimental groups using commercial ELISA kits. IL 1β 
and TNF α protein concentrations in half brain tissue homogenate samples of 
mice from all experimental groups were detectable within the assay limits of 
detection. 
Two way  ANOVA  analysis  followed  by  Bonferroni  posttests  demonstrated  that 
TNF α protein concentrations in brains were significantly higher in immunized 
versus control mice on days 35 and 42 (P = 0.001). The mean value of brain TNF 
α (CII immunized versus naïve control) on day 35 was 44.1 ± 7.6 pg/mg total 
brain protein versus 29.1 ± 3.7 pg/mg total brain protein (P = 0.0113), while the 
mean value of TNF α (CII immunized versus naïve control) on day 42 was 47.1 ± 
12.4 pg/mg total brain protein versus 29.1 ± 1.8 pg/mg total brain protein (P = 
0.0075) (Figure 4.12A). One way ANOVA analysis showed that there was also no 
significant difference in brain TNF α protein concentrations in different groups 
of CII immunized mice culled on day 22, day 28, day 35 and day 42. (Figure 
4.12B).  
 
Figure 4.12 Time course of a pro inflammatory cytokines (TNF α α α α) protein concentrations in 
brains of CII immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. TNF α α α α protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. TNF α α α α concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain TNF α α α α in CII immunized mice culled on Chapter 4    197 
the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way 
ANOVA analysis). 
Two way  ANOVA  analysis  followed  by  Bonferroni  posttests  demonstrated  that 
brain  IL 1β  protein  concentrations  in  CII  immunized  mice  were  significantly 
increased compared to those in naïve control mice on day 22 (P = 0.0011). The 
mean value of brain IL 1β (CII immunized versus naïve control) on day 22 was 
341.7 ± 68.5 pg/mg total brain protein versus 226.9 ± 60.1 pg/mg total brain 
protein (P = 0.0235) (Figure 4.13A). One way ANOVA demonstrated that there 
were  significant  differences  in  IL 1β  protein  concentrations  among  the  four 
groups of mice culled on day 22, 28, 35 and 42 (P = 0.0069). The concentration 
of IL 1β protein in brain of CII immunized mice seemed to peak on day 22. IL 1β 
protein  concentrations  in  brains  of  CII  immunized  mice  on  day  22  were  also 
significantly higher than those in brains of CII immunized mice on day 35 and day 
42. The mean value of brain IL 1β of CII immunized mice (day 22 versus day 35) 
was 341.7 ± 68.5 pg/mg total brain protein versus 225.6 ± 72.4 pg/mg total brain 
protein (P < 0.05), while the mean value of brain IL 1β of CII immunized mice 
(day 22 versus day 42) was 341.7 ± 68.5 pg/mg total brain protein total brain 
protein versus 190.8 ± 19.1 pg/mg total brain protein (P < 0.01) (Figure 4.13B).  
 
Figure 4.13 Time course of a pro inflammatory cytokines (IL 1β β β β) protein concentrations in 
brains of CII immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL 1β β β β protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. IL 1β β β β concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain IL 1β β β β in CII immunized mice culled on 
the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way 
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4.2.4.2  Time course analysis of Th 1 cytokine protein concentrations in 
the brains of CII immunized mice by ELISA assays 
IL 12 was the only Th1 cytokine detectable using an ELISA assay in brain tissue of 
mice  from  all  experimental  groups.  Two way  ANOVA  analysis  followed  by 
Bonferroni  posttests  demonstrated  that  brain  IL 12  concentrations  were 
significantly elevated in CII immunized mice versus naïve control mice on days 
22, 28, 35 and 42 (P <0.0001).  The mean value of brain IL 12 (CII immunized 
versus naïve control) on day 22 was 1514.7 ± 714.3 pg/mg total brain protein 
versus 251.7 ± 26.4 pg/mg total brain protein (P = 0.0018). The mean value of 
brain IL 12 (CII immunized versus naïve control) on day 28 was 1011.9 ± 273.0 
pg/mg total brain protein versus 257.2 ± 32.1 pg/mg total brain protein (P = 
0.0009). The mean value of brain IL 12 (CII immunized versus naïve control) on 
day 35 was 949.6 ± 398.4 pg/mg total brain protein versus 442.0 ± 86.3 pg/mg 
total brain protein (P = 0.02). The mean value of brain IL 12 (CII immunized 
versus naïve control) on day 42 were 615.6 ± 86.2 pg/mg total brain protein 
versus  241.1  ±  74.5  pg/mg  total  brain  protein  (P<0.0001)  (Figure  4.14A).  A 
downward trend in the brain IL 12 protein concentrations was observed in CII 
immunized mice over the period of 21 days after immunization. One way ANOVA 
demonstrated  that  there  was  a  significant  difference  in  IL 12  protein 
concentrations among the four groups of mice culled on day 22, 28, 35 and 42 (P 
= 0.0110). Post hoc analysis with Bonferroni correction demonstrated that the 
brain  IL 12  protein  concentrations  in  CII  immunized  mice  on  day  42  were 
significantly lower than those of CII immunized mice on day 22. The mean value 
of brain IL 12 of CII immunized mice (day 22 versus day 42) was 1514.7 ± 714.3 
pg/mg total brain protein versus 615.6 ± 86.2 pg/mg total brain protein (P < 
0.01) (Figure 4.14B). 
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Figure 4.14 Time course of a Th1 cytokines (IL 12) protein concentrations in brains of CII 
immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL 12 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. IL 12 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain IL 12 in CII immunized mice culled on 
the days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way 
ANOVA analysis). 
4.2.4.3   Time course analysis of Th 2 cytokine protein concentrations 
in the brains of CII immunized mice measured by ELISA assays 
IL 4 and IL 10 protein concentrations were detectable by ELISA in brain tissue of 
mice from all experimental groups.  
Two way  ANOVA  analysis  followed  by  Bonferroni  posttests  demonstrated  that 
brain  IL 4  protein  concentrations  were  up regulated  significantly  in  CII 
immunized mice compared to those in naïve control mice on day 22 and day 28 
(P = 0.0002). The mean value of brain IL 4 (CII immunized versus naïve control) 
on day 22 was 1011.3 ± 267.1 pg/mg total brain protein versus 473.0 ± 54.1 
pg/mg total brain protein (P = 0.0015), while the mean value of brain IL 4 (CII 
immunized versus naïve control) on day 28 was 815.2 ± 188.4 pg/mg total brain 
protein  versus  473.5  ±  38.6  pg/mg  total  brain  protein  (P  =  0.0037)  (Figure 
4.15A). The brain IL 4 protein concentrations in brain of CII immunized mice 
peaked  during  day  22  and  day  28  after  immunization.  One way  ANOVA 
demonstrated  that  there  were  significant  differences  in  IL 4  protein 
concentrations among the four groups of mice culled on day 22, 28, 35 and 42 (P 
= 0.0002). Post hoc analysis with Bonferroni correction demonstrated that brain 
IL 4 protein concentrations in CII immunized mice on day 22 were significantly Chapter 4    200 
higher than those in CII immunized mice on day 35 and day 42. The mean value 
of brain IL 4 of CII immunized mice (day 22 versus day 35) was 1011.3 ± 267.1 
pg/mg total brain protein versus 483.4 ± 246.4 pg/mg total brain protein (P < 
0.01), while the mean value of brain IL 4 of CII immunized mice (day 22 versus 
day  42)  was  1011.3  ±  267.1  pg/mg  total  brain  protein  versus  424.5  ±  145.2 
pg/mg total brain protein (P < 0.001). CII immunized mice on day 35 and day 42 
showed significant lower concentrations of brain IL 4 protein compared to those 
in CII immunized mice on day 28. The mean value of brain IL 4 of CII immunized 
mice (day 28 versus day 42) was 815.2 ± 188.4 pg/mg total brain protein versus 
424.5 ± 145.2 pg/mg total brain protein (P < 0.05) (Figure 4.15B). 
 
Figure 4.15 Time course of a Th2 cytokine (IL 4) protein concentrations in brains of CII 
immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL 4 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. IL 4 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, 
***P<0.001. (B) shows longitudinal changes of brain IL 4 in CII immunized mice culled on the 
days indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way 
ANOVA analysis). 
Two way  ANOVA  analysis  followed  by  Bonferroni  posttests  demonstrated  that 
significant increases in IL 10 protein concentrations were observed in brains of 
CII  immunized  mice  compared  to  naïve  control  mice  on  days  22,  28,  35,  42 
(P<0.0001). The mean value of brain IL 10 (CII immunized versus naïve control) 
on day 22 was 1175.6 ± 134.0 pg/mg total brain protein versus 381.1 ± 54.3 
pg/mg total brain protein (P<0.0001), while the mean value of brain IL 10 (CII 
immunized versus naïve control) on day 28 was 787.0 ± 94.6 pg/mg total brain 
protein versus 396.2 ± 38.4 pg/mg total brain protein (P <0.0001). The mean Chapter 4    201 
value of brain IL 10 (CII immunized versus naïve control) on day 35 was 1030.9 ± 
221.2 pg/mg total brain protein versus 488.1 ± 80.9 pg/mg total brain protein (P 
=  0.0003),  while  the  mean  value  of  brain  IL 10  (CII  immunized  versus  naïve 
control) on day 42 was 932.6 ± 121.7 pg/mg total brain protein versus 429.1 ± 
34.3  pg/mg  total  brain  protein  (P  =  0.0003)  (Figure  4.16A).  The  brain  IL 10 
protein concentration in CII immunized mice fluctuated throughout the 21 days 
after immunization. A significant drop in brain IL 10 protein concentration was 
observed during day 22 to day 28, followed by a significant increase brain IL 10 
protein concentration from day 28 to day 42.  One way ANOVA demonstrated 
that there was a significant difference in IL 10 protein concentrations among the 
four  groups  of  mice  culled  on  day  22,  28,  35  and  42  (P  =  0.0052).  Post  hoc 
analysis with Bonferroni correction demonstrated a significant down regulation 
in brain IL 10 protein concentration in CII immunized mice on day 28 compared 
to those in CII immunized mice on day 22. The mean value of brain IL 10 of CII 
immunized mice (day 22 versus day 28) was 1175.6 ± 140.0 pg/mg total brain 
protein  versus  787.00  ±  94.59  pg/mg  total  brain  protein  (P  <  0.01).  (Figure 
4.16B) 
 
Figure 4.16 Time course of a Th2 cytokine (IL 10) protein concentrations in brains of CII 
immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL 10 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. IL 10 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: ***P<0.001. (B) 
shows longitudinal changes of brain IL 10 in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA 
analysis). 
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4.2.4.4   Time course analysis of chemokine protein concentrations in 
the brains of CII immunized mice by ELISA assays 
CCL2 was the only chemokine that could be detected using ELISA in brain tissue 
extracts  of  mice  from  all  experimental  groups.  Two way  ANOVA  analysis 
followed  by  Bonferroni  posttests  demonstrated  that  brain  CCL2  protein 
concentrations  were  increased  significantly  in  immunized  mice  compared  to 
those in control mice on days 22, 28, and 42 (P < 0.05). The mean value of brain 
CCL2 (CII immunized versus naïve control) on day 22 was 268.5 ± 20.1 pg/mg 
total brain protein versus 102.3 ± 26.7 pg/mg total brain protein (P = 0.0118), 
The mean value of brain CCL2 (CII immunized versus control) on day 28 was 
234.8 ± 31.3 pg/mg total brain protein versus 122.1 ± 35.7 pg/mg total brain 
protein (P = 0.0238). The mean value of brain CCL2 (CII immunized versus naïve 
control) on day 42 was 193.1 ± 48.0 pg/mg total brain protein versus 93.7 ± 74.7 
pg/mg  total  brain  protein  (P  =  0.0125)  (Figure  4.17A).  One way  ANOVA 
demonstrated that there was also no significant difference in brain CCL2 protein 
concentrations in different groups of CII immunized mice culled on day 22, day 
28, day 35 and day 42 (Figure 4.17B).  
 
Figure 4.17 Time course of a chemokine (CCL2) protein concentrations in brains of CII 
immunized mice by an ELISA assay  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. CCL2 protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using an ELISA assay. CCL2 concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: *P<0.05. (B) 
shows longitudinal changes of brain CCL2 in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA 
analysis). 
 Chapter 4    203 
4.2.4.5   Differences in inflammatory mediator protein concentrations in 
brain of arthritic mice and non arthritic mice 
3 mice out of 6 mice from immunized mice group 3 and 4, which were culled on 
day  35  and  day  42  respectively,  developed  arthritis.  In  order  to  investigate 
differences in brain inflammatory mediator gene expression level and protein 
concentrations between mice with and without arthritis, cytokine, chemokine 
and growth factor mRNA and protein concentrations in arthritic mice and non 
arthritic  mice  were  compared.    There  was  no  difference  in  protein 
concentrations of IL 1β, TNF α, IL 2, IL 12, IL 4, IL 10, CCL2 and FGF2 between 
brains of arthritic mice and non arthritic mice. This was consistent with our data 
of  the  previous  chapter  showing  non significant  difference  in  protein 
concentrations of IL 1β, IL 1α, IL 2, IL 5, IL 10, IL 13, CXCL10, VEGF and FGF2 
between  brains  of  arthritic  mice  and  non arthritic  mice  (Figure  4.18A Figure 
4.18H, Figure 4.19A). However, our data in this chapter showed that there was a 
significant difference in brain CXCL1 protein concentrations between arthritic 
and  non arthritic  mice  on  day  42.  This  was  inconsistent  to  data  from  the 
previous  chapter  showing  no  significant  difference  in  brain  CXCL1  protein 
between arthritic and non arthritic mice at the same time point (day 42). The 
CXCL1 protein concentrations in brains of arthritic mice were significantly higher 
than those of non arthritic mice on day 42. The mean value of CXCL1 of CII 
immunized mice on day 42 (arthritic versus non arthritic) was 9 ± 0.5 pg/mg 
total brain protein versus 7 ± 0.6 pg/mg total brain protein (P = 0.0262) (Figure 
4.19B) 
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Figure 4.18 Differences in inflammatory mediator protein concentrations in brains of 
arthritic mice and non arthritic mice  
(A), (B), (C), (D), (E), (F), (G), and (H) show inflammatory mediator protein concentrations 
(pg/mg total brain protein) in brains of CII immunized mice with and without arthritis (n =3 
CII immunised mice/group) on day 35 and day 42. Data are presented as the mean ± S.D. (*P 
< 05; **P < 01; ***P < 001 by Student’s t test.) 
 
Figure 4.19 Differences in VEGF and CXCL1 protein concentrations in brains of arthritic 
mice and non arthritic mice  
Brain VEGF and CXCL1 protein concentrations (pg/mg total brain protein) in arthritic (n=3 
arthritic mice) and non arthritic (n=3 non arthritic mice) were compared on day 35 and day Chapter 4    205 
42. Data are presented as the mean ± S.D. (*P < 0.05; **P < 0.02; ***P < 0.01 by Student’s t 
test.) 
4.2.5  Cytokine gene expression profiles in CIA mouse brains 
by Real time PCR 
 
To further investigate local production of inflammatory mediators in brains of CII 
immunized mice, real time PCR was used to quantify the gene expression of the 
same pro inflammatory cytokines (IL 6, IL 1 β, TNF α and IL 1 α), Th1 cytokines 
(IL 2, IL 12 and IFN γ), Th2 cytokines (IL 4, IL 5, IL 10 and IL 13), chemokines 
(CXCL1, CXCL10, CCL2 and CCL3) and growth factors (FGF2 and, VEGF) in one 
half  of  the  brain  tissue  of  mice  from  all  experimental  groups.  Longitudinal 
changes in gene expression of IL 1α, IL 2, IL 4, IL 5, IL 6, CXCL1, CXCL10 and 
FGF were observed in brains of CII immunized mice. 
4.2.5.1   Time course analysis of pro inflammatory cytokine mRNA 
concentrations in the brains of CII immunized mice 
The gene expressions of pro inflammatory cytokines including IL 6, IL 1 β, TNF α 
and  IL 1α  were  determined  in  brains  of  mice  from  all  experimental  groups. 
There was no pro inflammatory cytokine gene expression detectable in brains of 
CII immunized mice by the real time PCR assay.  
4.2.5.2   Time course analysis of Th1 cytokine mRNA expression levels 
in the brains of CII immunized mice 
Changes in gene expressions of Th 1 cytokines, including IL 12, IL 2 and IFN γ, 
over time were determined in the brain of mice from all experimental groups. 
The  expression  of  IL 12  was  the  only  Th1  cytokine  that  was  up regulated 
significantly in CII immunized mouse brains compared to those in naïve control 
mice. Two way ANOVA analysis followed by Bonferroni posttests demonstrated 
that  a  significant  increase  in  IL 12  gene  expression  was  observed  in  CII 
immunized mice on day 35 compared to those in naïve control mice (P = 0.0190). 
The  mean  value  of  brain  IL 12  gene  expression  (CII  immunized  versus  naïve 
control) on day 35 were 6318 ± 4120 versus 4872 ± 2088 (P = 0.0264) (Figure 
4.20A).  One way  ANOVA  demonstrated  that  there  was  also  no  significant 
difference in brain IL 12 gene expression in different groups of CII immunized 
mice culled on day 22, day 28, day 35 and day 42 (Figure 4.20B).  Chapter 4    206 
 
Figure 4.20 Time course of a Th1 (IL 12) mRNA expression levels in brains of CII immunized 
mice by Real time PCR  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. IL 12 mRNA levels in brain tissue homogenate of mice from all experimental 
groups were determined using a real time PCR assay. The expression levels of IL 12 mRNA 
were normalized against GAPDH expression and shown as arbitrary units. Data represent 
means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data was performed 
using two way ANOVA compared with naïve control mice: *P<0.05. (B) shows longitudinal 
changes of brain IL 12 in CII immunized mice culled on the days indicated. Bars represent 
mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA analysis). 
4.2.5.3  Time course analysis of Th2 cytokine mRNA levels in the brains 
of CII immunized mice 
Th 2  cytokines,  including  IL 4,  IL 5,  IL 10  and  IL 13  gene  expression  were 
determined in the brains of mice from all experimental groups. There was no 
Th2 cytokine gene expression detectable in brains of CII immunized mice by the 
real time PCR assay.  
4.2.5.4  Time course analysis of chemokine mRNA levels in the brains 
of CII immunized mice 
CXCL1, CXCL10, CCL 2 and CCL 3 gene expression were determined in the brains 
of control mice from all experimental groups. Among these chemokines, only 
brain CXCL1 and CXCL10 mRNA were detectable within the assay detection limit.   
Two way  ANOVA  analysis  followed  by  Bonferroni  posttests  demonstrated  that 
brain CXCL1 gene expression levels were elevated in immunized mice compared 
to those in control mice on day 22 and day 42 (P < 0.0001). The mean value of 
brain  CXCL1  gene  expression  (CII  immunized  versus  naïve  control)  on  day  22 
were 13406 ± 5054 versus 6140 ± 1700 (P < 0.0001), while the mean value of 
brain CXCL1 (CII immunized versus naïve control) on day 42 was 15935 ± 8744 
versus 6591 ± 2148 (P = 0.0067) (Figure 4.21A). One way ANOVA demonstrated Chapter 4    207 
that there were significant differences in CXCL1 gene expression among the four 
groups of mice culled on day 22, 28, 35 and 42 (P = 0.0017). Post hoc analysis 
with  Bonferroni  correction  demonstrated  that  the  levels  of  CXCL1  mRNA  in 
brains of CII immunized mice on day 22 were significantly higher than those of 
day 28. The mean value of brain CXCL1 gene expression of CII immunized mice 
(day 22 versus day 28) was 14576 ± 1700 versus 4700 ± 2200 (P < 0.01). The 
levels  of  CXCL1  mRNA  in  brains  of  CII  immunized  mice  on  day  28  were 
significantly lower than those of day 42. The mean value of brain CXCL1 gene 
expression of CII immunized mice (day 35 versus day 42) was 8115 ± 1916 versus 
15935 ± 2148 (P < 0.01) (Figure 4.21B).   
 
Figure 4.21 Time course of a chemokine (CXCL1) mRNA levels in brains of CII immunized 
mice by Real time PCR 
 (A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. CXCL1 mRNA levels in brain tissue homogenate of mice from all experimental 
groups were determined using a real time PCR assay. The levels of CXCL1 mRNA were 
normalized against GAPDH expression and shown as arbitrary units. Data represent means 
± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data was performed using 
two way ANOVA compared with naïve control mice: *P<0.05, **P<0.01, ***P<0.001. (B) shows 
longitudinal changes of brain CXCL1 in CII immunized mice culled on the days indicated. 
Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA analysis). 
Two way ANOVA analysis followed by Bonferroni posttests demonstrated that CII 
immunized mice showed significant increases in CXCL10 mRNA levels compared 
to those in control mouse brains on day 28 and day 35 (P = 0.0118). The mean 
value of brain CXCL10 gene expression (CII immunized versus naïve control) on 
day 28 were 2316 ± 681 versus 1244 ± 588 (P = 0.0154), while the mean value of 
brain CXCL10 gene expression (CII immunized versus naive control) on day 35 
were 4100 ± 2351 versus 1058 ± 289 (P = 0.0105) (Figure 4.22A). A peak in mRNA 
of  CXCL10  in  brains  of  CII  immunized  mice  was  observed  on  day  35  after 
immunization. However, one way ANOVA demonstrated that there was also no Chapter 4    208 
significant difference in brain CXCL10 gene expression in different groups of CII 
immunized mice culled on day 22, day 28, day 35 and day 42 (Figure 4.22B).  
 
Figure 4.22 Time course of a chemokine (CXCL10) mRNA concentrations in brains of CII 
immunized mice by Real time PCR  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. CXCL10 mRNA concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using a real time PCR assay. The concentrations of 
CXCL10 mRNA were normalized against GAPDH expression and shown as arbitrary units. 
Data represent means ± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data 
was performed using two way ANOVA compared with naïve control mice: *P<0.05. (B) 
shows longitudinal changes of brain CXCL10 in CII immunized mice culled on the days 
indicated. Bars represent mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA 
analysis). 
4.2.5.5  Time course analysis of growth factor mRNA levels in the brains 
of CII immunized mice 
Gene expressions of growth factors including FGF2 and VEGF were detectable in 
the brains of mice from all experimental groups.  
Two way ANOVA analysis demonstrated that there was no significant different in 
FGF2  gene  expression  levels  in  brains  of  CII  immunized  mice  versus  those  of 
naïve  control  mice  (Figure  4.23A).  One way  ANOVA  demonstrated  that  FGF2 
mRNA levels in brains of CII immunized mice from different time point groups 
were not significantly different (Figure 4.23B).  
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Figure 4.23 Time course of a growth factor (FGF2) mRNA levels in brains of CII immunized 
mice by Real time PCR  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. FGF2 mRNA levels in brain tissue homogenate of mice from all experimental 
groups were determined using a real time PCR assay. The levels of FGF2 mRNA were 
normalized against GAPDH expression and shown as arbitrary units. Data represent means 
± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data was performed using 
two way ANOVA compared with naïve control mice. (B) shows longitudinal changes of brain 
FGF2 in CII immunized mice culled on the days indicated. Bars represent mean values: (*P < 
05; **P < 01; ***P < 001 by one way ANOVA analysis). 
Two way  ANOVA  analysis  followed  by  Bonferroni  posttests  demonstrated  that 
brain  VEGF  gene  expression  levels  were  elevated  in  CII  immunized  mice 
compared to those in naïve control mice on day 28 and day 35 (P = 0.0005). The 
mean value of brain VEGF gene expression (CII immunized versus naïve control) 
on day 28 were 10265 ± 3384 versus 4261 ± 2141 (P = 0.0043), while the mean 
value of brain VEGF gene expression (CII immunized versus naïve control) on day 
35 were 16860 ± 8380 versus 4829 ± 1158 (P = 0.0059) (Figure 4.24A). One way 
ANOVA  demonstrated  that  there  was  no  significant  difference  in  brain  VEGF 
mRNA level of immunized mice at different time points (Figure 4.24B).   
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Figure 4.24 Time course of a growth factor (VEGF) mRNA levels in brains of CII immunized 
mice by Real time PCR  
(A) Mice immunized with type II collagen (filled squares) were culled on days 22, 28, 35, 42 
and brain from CII immunized mice at all time points were harvested. Brain samples 
collected from naïve control mice (open circle) culled on the days indicated were used as 
controls. VEGF mRNA levels in brain tissue homogenate of mice from all experimental 
groups were determined using a real time PCR assay. The levels of VEGF mRNA were 
normalized against GAPDH expression and shown as arbitrary units. Data represent means 
± SEM. (n = 6 CII immunised mice/group). Statistical analysis of data was performed using 
two way ANOVA compared with naïve control mice: **P<0.01. (B) shows longitudinal 
changes of brain VEGF in CII immunized mice culled on the days indicated. Bars represent 
mean values: (*P < 05; **P < 01; ***P < 001 by one way ANOVA analysis). 
4.2.5.6  Differences in inflammatory mediator mRNA levels in brain of 
arthritic mice and non arthritic mice 
We  also  compared  mRNA  levels  of  inflammatory  mediators  including  IL 12, 
CXCL1, CXCL10, FGF2 and VEGF. There were no significant differences in brain 
mRNA levels of IL 12 CXCL10, FGF2 and VEGF between arthritis and non arthritis 
mice on day 35 and day 42 (Figure 4.25A Figure 4.25D).   
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Figure 4.25 Differences in inflammatory mediator mRNA levels in brains of arthritic mice and 
non arthritic mice  
(A), (B), (C) and (D) show inflammatory mediator protein levels (pg/mg total brain protein) in 
brains of CII immunized mice with and without arthritis (n =3 CII immunised mice/group) on 
day 35 and day 42. Data are presented as the mean ± S.D. (*P < 05; **P < 01; ***P < 001 by 
Student’s t test.) 
Interestingly,  a  significant  difference  in  brain  CXCL1  mRNA  levels  between 
arthritic and non arthritic mice was observed on day 35, which was similar to 
brain  CXCL1  protein  profile  of  arthritic  and  non arthritic  mice  on  day  42. 
Arthritic  mice  on  day  35  showed  a  significant  increase  in  brains  CXCL1  gene 
expression levels compared to those in brains of non arthritic mice on day 35. 
The mean value of brain CXCL1 gene expression (arthritic versus non arthritic) 
on day 35 were 6908 ± 1255 versus 4283 ± 1037 (P = 0.0493) (Figure 4.26B).  
 
Figure 4.26 Differences in CXCL1 mRNA levels in brains of arthritic mice and non arthritic 
mice  
Brain CXCL1 mRNA levels (pg/mg total brain protein) in arthritic (n=3 arthritic mice) and 
non arthritic (n=3 non  arthritic mice) were compared on day 35 and day 42. Data are 
presented as the mean ± S.D. (*P < 05; **P < 01; ***P < 001 by Student’s t test.) Chapter 4    212 
4.2.6   Comparison between time course changes in 
inflammatory mediator protein and mRNA levels in brain of 
CII immunized mice 
Both  mRNA  and  protein  expression  of  IL 12,  CXCL1,  VEGF  and  FGF2  were 
detectable  and  longitudinal  changes  of  these  inflammatory  mediators  were 
observed in brains of immunized mice. The comparison between overall trends 
in inflammatory mediator protein and mRNA levels may provide some evidence 
of how the periphery induces central inflammatory mediator production and the 
possible  cellular  sources  of  these  inflammatory  mediators  in  the  brain  of  CII 
immunized mice. 
Our data showed that the overall trends of time course profiles of inflammatory 
mediator protein concentrations were not similar to the time course profiles of 
the same inflammatory mediator gene expression in brain of immunized mice. 
However,  overlapping  or  parallel  trends  of  time  course  profiles  of  brain 
inflammatory mediator protein concentrations and brain gene expression were 
observed at some time points. 
4.2.6.1  Comparison between time course changes in Th1 cytokine 
protein and mRNA expression levels in brain of CII immunized mice 
Longitudinal changes of both mRNA expression levels and protein concentrations 
of  IL 12,  a  Th1  cytokine,  were  observed  in  brains  of  CII  immunized  mice 
compared to those of naïve control mice. Parallel trends of time course profiles 
of brain IL 12 protein concentration and gene expression in CII immunized mouse 
brains  was  observed  during  days  22  to  28  after  immunization.  Differences 
between IL 12 protein concentration and gene expression were observed from 
day 28 onwards. While brain IL 12 protein concentrations continued to decrease 
gradually, an increase in IL 12 gene expression levels was observed during the 
same period and this was followed by an unchanged IL 12 gene expression level 
(Figure 4.27). This data suggest that there may be migration of peripheral Th1 
cells into the brain or induction of local production of IL 12 during the period of 
onset  of  disease  (day  22 day  28  after  immunization).  The  migration  of  these 
peripheral Th1 cells may continued throughout the acute and chronic phases of 
CIA experimental course, indicated by the prolong expression of IL 12 protein 
during day 28 to day 42 after immunization. However, the concentrations of the Chapter 4    213 
Th1 cytokine migration may be reduced over time during day 28 day 42 and not 
as much as the period of disease onset. By contrast, mRNA expression levels of 
IL 12  increased  during  day  28  to  day  42  after  immunization,  suggesting  that 
there  may  be  induction  of  the  local  production  of  IL 12  in  brains  of  CII 
immunized mice throughout the period of acute and chronic phases of disease 
(Figure 4.27).  
 
Figure 4.27 Longitudinal changes of a Th1 (IL 12) cytokine protein concentrations and 
mRNA expression levels in brains of CII immunized mice  
Brain samples collected from CII immunized mice culled on the days indicated were 
harvested. Half brain samples were processed for protein quantification by an ELISA assay 
(red filled squares), while the other half brain was processed for mRNA quantification and 
real time PCR (blue filled squares). Data represent means ± SEM (n = 6 CII immunised 
mice/group). IL 12 protein concentrations in brain tissue, normalized against total brain 
protein, are expressed as pg/ g total brain protein. IL 12 mRNA levels in brain tissue, 
normalized against the expression of housekeeping gene GAPDH, are presented as 
arbitrary units. 
4.2.6.2   Comparison between time course changes in chemokine 
protein and mRNA levels in brain of CII immunized mice 
Trends of time course profiles of brain CXCL1 protein concentrations and gene 
expressions in immunized mouse brains fluctuated during day 22 to day 35 after 
immunization. Brain CXCL1 protein and gene expression levels decreased on day 
28 and then increased back on day 35. However, the divergence in trends of 
time course profiles of brain CXCL1 protein concentrations and gene expressions 
was  observed  during  the  final  period.  A  gradual  increase  in  CXCL1  gene 
expression  was  observed  during  day  35  to  day  42,  while  CXCL1  protein 
concentrations in immunized mouse brains decreased slightly during the same 
period (Figure 4.28). CXCL1 in the brain is produced mainly by microglia (Brown 
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of CII immunized mice may suggest the local production of CXCL1 by microglia 
over the period of onset and acute phase of CIA experimental course. It was also 
possible the there may be the transportation of CXCL1 into the brains of these 
CII immunized mice, which was reduced during the late disease phase (day 35 
day  42  after  immunization).  However,  in  that  period  the  gene  expression  of 
CXCL1  still  increased,  suggesting  the  continuous  production  of  CXCL1  by  CNS 
immune cells in the chronic phase of disease.   
 
Figure 4.28 Longitudinal changes of a chemokine (CXCL1) protein concentrations and 
mRNA expression levels in brains of CII immunized mice  
Brain samples collected from CII immunized mice (open circle) culled on the days indicated 
were harvested. Half brain samples were processed for protein quantification by a Luminex 
assay (red filled squares), while the other half brain was processed for mRNA quantification 
and real time PCR (blue filled squares). Data represent means ± SEM (n = 6 CII immunised 
mice/group). CXCL1 protein concentrations in brain tissue, normalized against total brain 
protein, are expressed as pg/ g total brain protein. CXCL1 mRNA levels in brain tissue, 
normalized against the expression of housekeeping gene GAPDH, are presented as 
arbitrary units. 
4.2.6.3   Comparison between time course changes in growth factor 
protein and mRNA levels in brain of CII immunized mice 
The overall trends of longitudinal changes of brain FGF2 protein concentrations 
was similar to those of brain FGF2 gene expression in immunized mice across all 
the  time  points.  Parallel  trends  of  time  course  profiles  of  brain  FGF  protein 
concentrations and gene expressions in immunized mouse brains was observed 
during day 22 to day 28 after immunization. The trend of time course profile of 
brain FGF protein concentrations remained unchanged during day 28 and day 35, 
followed by a slight decrease until the terminal day. In contrast, brain FGF2 
gene expression levels slightly increased during day 28 and day 35 and then the 
expression level of FGF mRNA remained unchanged until day 42 (Figure 4.29). 
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throughout the period of CIA experimental period may suggest local production 
of FGF2 in the brains (Figure 4.29).  
 
Figure 4.29 Longitudinal changes of a growth factor (FGF2) protein concentrations and 
mRNA expression levels in brains of CII immunized mice  
Brain samples collected from CII immunized mice (open circle) culled on the days indicated 
were harvested. Half brain samples were processed for protein quantification by a Luminex 
assay (red filled squares), while the other half brain was processed for mRNA quantification 
and real time PCR (blue filled squares). Data represent means ± SEM (n = 6 CII immunised 
mice/group). FGF2 protein concentrations in brain tissue, normalized against total brain 
protein, are expressed as pg/ g total brain protein. FGF2 mRNA levels in brain tissue, 
normalized against the expression of housekeeping gene GAPDH, are presented as 
arbitrary units. 
The overall trends of longitudinal changes of VEGF protein concentrations were 
quite similar to those of time course profiles of VEGF gene expressions in brain 
of CIA mice across all the time points. The overall trends of time course profiles 
of VEGF protein concentrations overlapped those of VEGF gene expression levels. 
Increases in both brain VEGF gene expressions and protein concentrations were 
observed in immunized mouse brain during day 28 and day 35. However, trends 
of both brain VEGF gene and protein expression profiles were divergent during 
the last period. While brain VEGF gene expression levels remained unchanged 
from day 35 to 42, protein concentrations of VEGF decreased during the same 
period (Figure 4.30). These data suggest that the majority of VEGF detectable in 
CII immunized mice may be produced locally in the brain.  Chapter 4    216 
 
Figure 4.30 Longitudinal changes of a growth factor (VEGF) protein concentrations and 
mRNA expression levels in brains of CII immunized mice  
Brain samples collected from CII immunized mice (open circle) culled on the days indicated 
were harvested. Half brain samples were processed for protein quantification by a Luminex 
assay (red filled squares), while the other half brain was processed for mRNA quantification 
and real time PCR (blue filled squares). Data represent means ± SEM (n = 6 CII immunised 
mice/group). VEGF protein concentrations in brain tissue, normalized against total brain 
protein, are expressed as pg/ g total brain protein. VEGF mRNA levels in brain tissue, 
normalized against the expression of housekeeping gene GAPDH, are presented as 
arbitrary units. 
4.2.7   Summary; longitudinal changes in mRNA and protein 
concentrations in brain of CII immunized mice 
In this experiment we determined changes in inflammatory mediators in brain of 
arthritic  mice  in  4  time  points,  which  represented  different  stages  of 
inflammatory joint disease. Therefore, 42 day period of CIA experimental course 
was divided into 3 phases. The period of disease onset was defined as day 22  
day 28 after immunization, early disease phase was defined as day 28 day 35 
after immunization, and the transition to the late disease phase was defined as 
day 35 to day 42 after immunization. We found elevation of mRNA and protein 
concentrations of various brain inflammatory mediators, including IL 1β, TNF α, 
IL 4, IL 12, IL 2, IL 10, CCL2, CXCL1, CXCL10, VEGF and FGF2 in different phases 
of CIA experimental course (Table 4.2). 
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Day 22 
 
 
Day 28 
 
Day 35 
 
Day 42 
 
 
 
Cytokies, 
chemokines 
Growth 
factors   
protein 
 
 
gene 
 
protein 
 
gene 
 
protein 
 
gene 
 
protein 
 
gene 
 
IL 1β 
 
 0.0235 
 
 
undt 
 
NS 
 
undt 
 
NS 
 
undt 
 
NS 
 
undt 
 
TNF α 
 
NS 
 
 
undt 
 
NS 
 
undt 
 
 0.0113 
 
 
undt 
 
 0.0075 
 
 
undt 
 
IL 4 
 
 0.0015 
 
 
undt 
 
0.0037 
 
 
undt 
 
NS 
 
undt 
 
NS 
 
undt 
 
IL 10 
 
  <0.0001 
 
 
undt 
 
 <0.0001 
 
 
undt 
 
0.0003 
 
 
undt 
 
0.0003 
 
 
undt 
 
IL 2 
 
NS 
 
 
undt 
 
NS 
 
undt 
 
0.0357 
 
 
undt 
 
NS 
 
undt 
 
IL 12 
 
0.0018 
 
 
NS 
 
0.0009 
 
 
NS 
 
0.02 
 
 
  0.0264 
 
 
    <0.0001 
 
 
NS 
 
CCL2 
 
0.0118 
 
 
undt 
 
 0.0238 
 
 
undt 
 
NS 
 
undt 
 
0.0125 
 
 
undt 
 
CXCL1 
 
NS 
 
  0.0001  
 
NS 
 
NS 
 
NS 
 
NS 
 
NS 
 
   0.007 
 
 
CXCL10 
 
undt 
 
 
NS 
 
undt 
 
  0.0154 
 
 
undt 
 
 0.0105 
 
 
undt 
 
NS 
 
VEGF 
 
NS 
 
NS 
 
NS 
 
  0.0043 
 
 
NS 
 
  0.0059 
 
 
0.0219 
 
 
NS 
 
FGF2 
 
 
NS 
 
NS 
 
NS 
 
NS 
 
NS 
 
NS 
 
0.0402 
 
NS 
Table 4.2 Longitudinal changes in concentrations brain inflammatory mediator profiles in 
brains of CII immunized mice relative to those of those in control mice  
Red arrows represent an increase of inflammatory mediator protein concentrations, while 
blue arrows represent an increase of inflammatory mediator mRNA expression levels in 
brains of CII immunized mice compared to those in naïve control mice on day 22, day 28, 
day 35 and day 42 after immunization. Differences between inflammatory mediator 
concentrations in CII immunized mouse brains and naïve control groups were analyzed by 
Student's t  test (*P < 05; **P < 01; ***P < 001). NS = not statistically significant, untd = 
undetectable.  
During  the  period  of  onset  of  arthritis  disease  (day  22  –  day  28  after 
immunization)  in  CII  immunized  mice,  we  found  transient  elevation  of  IL 1β 
protein concentrations in brains of these CII immunized mice. IL 1β has been 
reported to regulate the production of CXCL in the CNS (Shaftel et al., 2007). 
Therefore,  the  increased  in  concentrations  of  brain  IL 1β  protein  may  be 
associated  with  the  elevation  of  CXCL1  mRNA,  which  was  also  increased 
transiently  at  the  same  period  of  time.  From  day  22  after  immunization 
onwards, protein concentrations of both Th1 (IL 12 and IL 2) and Th2 (IL 4 and Chapter 4    218 
IL 10)  cytokines  started  to  increase.  The  prolonged  elevation  of  brain  IL 12 
protein concentrations in CII immunized mice were observed throughout the CIA 
experimental course (day 22 – day 42 after immunization), while elevation of IL 
12 mRNA levels were only observed on day 35. This suggests that the majority of 
IL 12  protein  may  be  transported  from  the  periphery  and  may  be  via  the 
recruitment of peripheral Th1 into the CNS. The concentrations of IL 2 in brains 
of CII immunized mice also peaked on day 35, at the end of the acute phase of 
the  CIA  experimental  course.  Interestingly,  the  IL 12  protein  concentrations 
started at the beginning of disease onset before the peak of CXCL10, a potent 
recruiter of Th1 lymphocytes, during day 28 and day 35 after immunization. This 
may suggest the influx of Th1 cells may be apparent during the early phase of 
the disease course. The prolonged elevation of Th2 cytokines, particularly IL 10 
were also observed throughout the CIA experimental course (day 22 – day 42 
after immunization), although the brain IL 4 protein concentrations were only 
increased during the period of onset of arthritis disease and the concentrations 
were reduced towards the end of the CIA experimental course. Interestingly, the 
prolonged elevation of Th2 cytokines seemed to correspond to the prolonged up 
regulations of CCL2 protein in the brains of CII immunized mice throughout the 
period of the CIA experimental course. CCL2 is known to regulate the trafficking 
of Th2 cells into the inflamed site. Therefore, the coincidence between CCL2 
and Th2 cytokines suggested that there may be recruitment of Th2 lymphocytes 
from the periphery into the brain. We found increased concentrations of the 
growth  factors  FGF2  and  VEGF,  which  are  angiogenic  factors  that  have  been 
reported to be associated with BBB breakdown during the neuro inflammatory 
process,  especially  during  the  early  phase  of  the  disease.  The  coincidental 
elevation of these growth factors (VEGF, FGF2) and chemokines such as CXCL1 
and CXCL10 during day 28   day 35 after immunization may suggested that BBB 
breakdown and the recruitment of peripheral immune cells into the brain during 
the  early  phase  of  CIA  experimental  course  may  be  regulated  by  peripheral 
inflammatory cytokine signals.  
4.3   Result chapter 4: Summary of major findings.  
The  aim  of  this  chapter  was  to  investigate  longitudinal  changes  of  brain 
inflammatory  mediators  that  may  be  associated  with  longitudinal  changes  in 
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arthritis  disease  in  CII  immunized  mice.  We  determined  changes  in  brain 
inflammatory mediators in CII immunized mice in 3 phases across the 42 day 
period of the CIA experimental course. Day 22 – day 28 after immunization was 
the period of disease onset, day 28 – day 35 after immunization was the acute 
phase of disease and day 35 – day 42 after immunization was the transition to 
chronic phase of the disease. We found:  
1. Transient elevation of serum IL 1β, IL 5, CCL2 and FGF2 protein concentration 
during the period of onset of disease (day 22 – day 28 after immunization) in CII 
immunized mice. This was followed by a reduction in these serum inflammatory 
mediator  concentrations  during  the  acute  and  chronic  phases  of  disease 
development.  
2. Transient elevation of pro inflammatory cytokine IL 1β protein concentration 
during the onset of disease in the brains of CII immunized mice. In contrast, an 
elevation  of  brain  TNF α  protein  concentration  was  observed  in  brains  of  CII 
immunized  mice  during  the  late  disease  stage  (day  35 day  42  after 
immunization).  
3. Prolonged elevation of the Th1 cytokine IL 12 concentration in brains of CII 
immunized mice throughout the CIA experimental period, while a peak of IL 2 
protein  in  the  brains  of  CII  immunized  mice  was  observed  on  day  35  after 
immunization. 
4. Prolonged elevation of the Th2 cytokine IL 10 protein concentration in brains 
of  CII  immunized  mice  throughout  the  CIA  experimental  period,  while  IL 4 
protein concentration was elevated in brains of CII immunized mice only during 
the period of onset of the disease (day 22 – day 28 after immunization). 
5.  Transient  elevation  of  brain  CXCL1  mRNA  expression  in  brains  of  CII 
immunized mice during the onset of the disease (day 22 after immunization) and 
at the end of the CIA experimental course (day 42 after immunization) 
6. Prolonged elevation of the chemokine CCL2 protein concentration in brains of 
CII immunized mice throughout the CIA experimental period.  Chapter 4    220 
7. Coincidental increase of CXCL10 and VEGF mRNA expression levels in brains of 
CII immunized mice during the acute phase of the disease (day 28 day 35 after 
immunization).  
8. The FGF2 and VEGF protein concentrations and mRNA expression levels in 
brains of CII immunized mice started to increase from day 28 after immunization 
onwards.  
9. There was no significant difference in brain mRNA expression levels of IL 12, 
CXCL10, VEGF and FGF2 and protein concentrations of IL 1β, TNF α, IL 2, IL 12, 
IL 4, IL 10, CCL2, VEGF and FGF2 between arthritic and non arthritic mice on 
day 35 and day 42. However, there were differences in CXCL1 gene expression 
levels and protein concentrations between arthritic and non arthritic mice on 
day 35 and day 42.  
10.  Overlapping  or  parallel  trends  of  time  course  profiles  of  brain  IL 12  and 
CXCL1 protein concentrations and gene expression in brains of CII immunized 
mice  were  observed  at  some  time  points  across  the  42 day  period  of  CIA 
experimental course. However, the divergence between IL 12 and CXCL1 gene 
and protein concentrations was observed during the transition to the chronic 
phase of the disease. The concentrations of brain IL 12 and CXCL1 protein were 
reduced between day 35 and day 42 after immunization, while mRNA expression 
levels of IL 12 and CXCL1 in brains of were increased during that period.  
11. Overlapping or parallel trends of time course profiles of brain FGF2 and VEGF 
protein concentrations and gene expression in brains of CII immunized mice were 
observed at some time points across the 42 day period of CIA disease course. 
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4.4  Discussion 
In  this  chapter  we  investigated  the  possible  mechanism  by  which  peripheral 
inflammation,  ie  serum  cytokines,  induced  production  of  brain  inflammatory 
mediators in CII immunized mice. We found increased concentrations of serum 
IL 1β,  IL 5,  CCL2  and  FGF2  in  CII  immunized  mice  (day  22  –  day  28  after 
immunization), suggesting they provided a possible inflammatory signal during 
the onset and the early disease period. We also found increased concentrations 
of  these  same  inflammatory  mediators  (IL 1β,  CCL2  and  FGF2)  in  the  brain 
during the onset of the disease, suggesting the possible transportation of these 
inflammatory  mediators  from  the  periphery  into  the  brain  of  CII  immunized 
mice, or alternatively local synthesis. In addition, we demonstrated coincidental 
increase of serum concentrations and mRNA expression levels of inflammatory 
mediators, for example, IL 1β and CXCL1 or FGF2 and VEGF during the same CIA 
experimental period, and these cytokines can mutually regulate each other. This 
could  be  important  evidence  suggesting  that  the  peripheral  inflammatory 
cytokine signal may induce local production of inflammatory mediators in brains 
of  CII  immunized  mice  during  the  onset  and  the  early  disease  period.  For 
example, it is possible that the production of brain CXCL1 and VEGF production 
may be induced via the peripheral inflammatory cytokine signals of IL 1β and 
FGF2 during the onset and the early disease period. We demonstrated the up  
and  down regulation  of  different  inflammatory  mediators  in  brains  of  CII 
immunized mice at different time point over the CIA disease course. In addition, 
we  also  showed  a  prolonged  increase  of  the  concentration  of  the  Th1 
inflammatory  cytokine  IL 12,  which  was  coincidental  with  down regulation  of 
Th2 anti–inflammatory cytokine IL 4 in brains of CII immunized mice. These data 
suggest  that  there  may  be  an  interplay  and  regulation  between  brain 
inflammatory  mediators,  which  indicates  the  possible  immune  activation  and 
inflammatory process in the brains of CII immunized mice. We therefore set out 
to discusse and interpreted our data in detail separately in 3 main aspects; (i) 
peripheral  inflammation  signal  in  CII  immunized  mice;  (ii)  peripheral 
inflammation induced  brain  inflammation  in  CII  immunized  mice;  (iii)  the 
possible interplay between inflammatory mediators in brains of CII immunized 
mice. Chapter 4    222 
4.4.1   Longitudinal changes in peripheral inflammatory 
mediators in CII immunized mice.  
We  analysed  changes  in  inflammatory  mediator  protein  concentrations  in  the 
peripheral  circulation  of  CIA  mice  by  using  a  Luminex  multi analyte  assay  to 
determine changes in serum cytokines, chemokines and growth factor protein 
concentrations in CIA mice across all time points of the disease course. We found 
increased concentrations of serum IL 1β, IL 5, CCL2 and FGF2 in CII immunized 
mice  during  the  onset  of  disease  (day  22  and  day  28),  suggesting  these 
inflammatory mediators may play crucial roles at different pathological stages in 
the development of disease. IL 1β is considered to be a key cytokine in the RA 
process (Koenders et al., 2008) and up regulation of IL 1β has been reported in 
the joints of CIA mice during the onset of disease. A time course study in joint 
cytokine expression in CIA mice showed transient expression of pro inflammatory 
cytokines IL 6, IL 1β and TNF α during the period of 15 days after immunization. 
mRNA and protein concentrations of IL 6 increased sharply by day 1, while TNF α 
concentration  showed  a  significant  increase  occurring  on  days  4  to  8.  IL 1β 
concentration  was  up regulated  on  day  4  and  its  concentration  remained 
significantly high until the onset of the disease. These data suggest that pro 
inflammatory  cytokines  may  induce  the  disease  development  in  this  model 
shortly  after  the  primary  sensitisation  /  immunization,  and  that  changes  in 
serum  cytokines  may  be  observed  in  this  model  in  the  early  (onset  of  the 
disease) period of time after immunization (Rioja et al., 2004). However, most 
studies in CIA models showed that the IL 1β concentrations in serum of CIA mice 
were low or undetectable. A time course study by Marije et al., showed that IL 
1β serum concentration in CIA mice did not increase over time throughout the 
CIA experimental course (Koenders et al., 2008). Another study by J M Kim et 
al.,  showed  that  the  IL 1β  serum  concentration  in  CIA  mice  on  day  40  after 
immunization was undetectable, but there was marked increase of IL 1β in the 
joints  of  CIA  mice,  suggesting  that  IL 1β  protein  may  not  necessarily  be 
increased in the blood during the joint inflammatory process, but the increase of 
IL 1β in the joint may be more important for the development of arthritis in the 
CIA model (Kim et al., 2003). We also found an increased concentration of the 
Th2 cytokine IL 5 in serum of these CII immunized mice during the period of 
onset  of  arthritis  disease  (day  22 day  28)  after  immunization.  Our  data  was Chapter 4    223 
consistent with a previous study by Schaefer et al., showing up regulation of IL 5 
protein in serum of CIA mice (Schaefer et al., 1999). Our data, combined with 
this previous report, suggests that IL 5 and Th2 cells may play an important role 
in  the  development  of  arthritis.  This  premis  is  supported  by  clinical  studies 
showing that raised concentrations of Th2 cytokines such as IL 4, IL 5, IL 10 and 
IL 13 were predominately detected in RA synovial fluid during the early stage of 
disease  (Hitchon  et  al.,  2004);  (Hitchon  and  El Gabalawy,  2002).  A  transient 
increase  of  serum  CCL2  protein  concentration  was  observed  in  these  CII 
immunized mice during the period of onset of disease (day 22 day 28), followed 
by  a  marked  decrease  over  time  throughout  the  early  and  the  late  disease 
phases. A similar longitudinal change in serum CCL2 protein profile has been 
reported previously in a study in arthritic rats by Stolina et al., (Stolina et al., 
2009). CCL2 is chemotactic for monocytes and Th2 cells, and this chemokine has 
been detected in high concentrations in synovial fibroblasts from RA patients 
(Szekanecz et al., 2003), especially in response to IL 1 and TNF α. The main 
function of CCL2 during the onset of arthritis disease may be the recruitment of 
Th2 cells into the joint. This premis is supported  by our finding showing the 
coincidental increase of serum CCL2 and IL 5 concentrations in CII immunized 
mice during the same period of onset of disease. The association between CCL2 
and IL 5 has also been demonstrated in CCL2 deficient mice. Lower production 
of  Th2  cytokines  including  IL 4,  IL 5  and  IL 10  and  an  inability  to  produce 
specific antibodies were observed in CCL2 deficient mice (Gu et al., 2000). This 
finding suggests that CCL2 might also regulate the production of Th2 cytokines. 
The presence of increased concentrations of this serum chemokine in immunized 
mice  during  the  onset  of  the  disease  suggests  that  there  could  be  increased 
immune  cell  migration  into  the  inflamed  tissue  that  may  be  associated  with 
angiogenesis.  We  also  found  significantly  increased  concentrations  of  serum 
FGF2,  an  angiogenic  factor,  in  immunized  mice  during  the  onset  and 
development of disease. This increased concentration of FGF2 may be associated 
with  the  process  of  cartilage  and  bone  erosion  including  synoviocyte 
proliferation and osteoclastogenesis, that has been shown to be highly active 
during the onset of disease (Malemud, 2007); (Stolina et al., 2009).  
However,  during  the  early  and  late  disease  phase  (day  28  –  day  35  after 
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several  inflammatory  mediators,  including  IL 1β  IL 5,  CCL2  and  FGF2  in 
immunized mice. Several studies report the same observation; showing transient 
increases  in  serum  cytokine  concentrations  during  the  onset  of  disease  that 
became undetectable during the period of clinical manifestation of disease. A 
study by Tsuji et al, in which time course changes in serum cytokine profiles in 
CIA mice were also determined by Luminex over the course of the experimental 
disease  (Tsuji  et  al.,  2009).  They  reported  transient  increases  of  various 
cytokines, including IL 12, TNF α, IFN γ, IL 9, IL 17 and CCL4 in serum of CIA 
mice  after  the  primary  immunization  and  the  concentrations  of  these  serum 
cytokines reached their peak on day 22. This was followed by a reduction of 
serum protein concentrations of these cytokines from day 22 onwards (Tsuji et 
al., 2009).  Another study by Asquith et al., 2009 also demonstrated that protein 
concentrations of several cytokines and chemokines, including IL 1α, IL 6, IL 17, 
CCL2, CCL3 and CCL6 in serum of CIA mice on day 31 were at or lower than the 
detection limits of the assays, and this suggest that there was no elevation of 
serum  inflammatory mediators  in  CIA  mice  during  the  early  phase  of  disease 
(Asquith et al., 2009a). In addition, several studies demonstrated that serum 
cytokine concentrations in CIA mouse model were inconsistent and in many cases 
undetectable as was consistent with our results (Harnett et al., 2008); (Lu et al., 
2010);  (del  Rey  et  al.,  2008).  There  are  several  explanations  underlying  the 
absence  or  the  undetectable  concentrations  of  serum  cytokines  in  CIA  mice 
during  the  late  disease  phase.  One  possibility  is  that  these  inflammatory 
mediators  are  generated  locally  at  the  inflammatory  site  and  also  function 
locally to induce bone and cartilage destructive process, but may not circulate 
in the bloodstream. This has been demonstrated by several studies in CIA mice 
showing  high  expression  of  inflammatory  mediators  in  inflamed  joints,  but 
undetectable concentrations in the serum (Lu et al., 2010); (Palmblad et al., 
2001). Another possibility is that the distribution of inflammatory mediators and 
immune  cells  from  inflamed  sites  to  adjacent  tissues  may  be  mainly  via  the 
lymphatic system rather than via the bloodstream. This is supported by a study 
of  lymphatic  vessels  draining  foot  joints  of  RA  patients  showing  several fold 
higher  concentrations  of  lymph  cytokines  and  chemokines  than  the  serum 
cytokine  concentrations.  High  flow  rates  of  lymphatic  vessels  containing  high 
cytokine  concentrations  through  the  regional  lymph  nodes  observed  in  RA 
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and  inflammatory  mediators  from  the  inflammation  site  to  the  periphery 
(Olszewski et al., 2001). 
4.4.2  Association between peripheral inflammation and 
increased concentrations of brain inflammatory mediators: 
possible evidence that peripheral inflammatory cytokine 
signals induce neuro inflammation. 
 
The model of systemic LPS challenge showing that peripheral inflammation could 
induce brain inflammation has been well documented (Datta and Opp, 2008), 
(Laye et al., 1994); (Quan et al., 1994); (Gatti and Bartfai, 1993); (Breder et al., 
1994); (Gabellec et al., 1996); (Grinevich et al., 2001). One study by de Ray et 
al is the only study that demonstrated an association between peripheral joint 
inflammation and inflammation in the brain of CIA rats, which is an equivalent 
model of a chronic autoimmune disease to the murine model used in this thesis 
(del  Rey  et  al.,  2008).  However,  the  communication  between  joint immune 
system brain in the CIA model was not well documented in that study. We first 
investigated  the  possibility  that  peripheral  inflammation  induced  brain 
inflammation in brains and serum of CII immunized mice by using a Luminex and 
PCR  assays  to  quantify  gene  expression  and  protein  concentrations  of 
inflammatory  mediators.  We  found  that  IL 1β,  CCL2,  FGF2  and  Th2  cytokine 
proteins  were  increased  in  brains  of  CII  immunized  mice  as  well  as  in  their 
serum,  compared  to  those  in  naïve  conrol  mice.  Our  data  suggest  that  the 
peripheral inflammation may signal brain inflammatory cytokine production via 
IL 1β, CCL2, FGF2 and Th2 cells during the course of arthritis.  
We found transient increases in brain IL 1β protein during the onset of disease in 
CII immunized mice, which corresponded to a transient elevation of serum IL 1β. 
A similar coincidental increase of IL 1β in the periphery and in the brain of CIA 
rats  has  been  reported  previously  by  del  Ray  et  al  (del  Rey  et  al.,  2008). 
However, we found no corresponding IL 1β mRNA expression levels in brains of 
these CII immunized mice, suggesting there may be no local IL 1β production in 
the brain. Our data, combined with the finding of the previous report suggest 
the possibility that there may be a contribution of IL 1β from the periphery into 
the brain of CII immunized mice during the course of disease. There was one 
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mechanism, suggesting a specific receptor (Banks et al., 1991). However, the 
mechanism  of  how  IL 1β  protein  could  be  transported  into  the  brain  of  CII 
immunized  mice  during  the  period  of  disease  onset  needs  to  be  further 
investigated.  The  increase  of  IL 1β  protein  concentration in  the  serum  of  CII 
immunized mice was coincidental with transient increases in brain CXCL1 mRNA 
expression levels during the onset of the disease (day 22 after immunization). It 
is possible that peripheral IL 1β may signal brain immune cells such as microglia 
to produce CXCL1 in brain CII immunized mice. This is supported by in vivo and 
in vitro studies demonstrating that increases in concentrations of brain IL 1β can 
induce CXCL1 production in the brain by microglia (Shaftel et al., 2007). 
TNF α  was  another  pro inflammatory  cytokine  that  was  up regulated  in  the 
brains of arthritic mice during the early and late stages of disease. However, we 
could  not  define  the  source  of  this  TNF α  protein  in  the  brains  of  these  CII 
immunized mice, since brain TNF α mRNA and serum TNF α were undetectable 
in CII immunized mice in this study. This is difficult to explain but is similar to a 
study by de Ray who also reported that TNF α was detectable in the brain of 
arthritic  rats,  despite  no  detectable  serum  TNF α.  It  has  been  reported  that 
TNF α protein was detected in high concentration in the peripheral tissue such 
as peritoneal cavity and spleen of CIA mice during the early and late stages of 
disease (Stasiuk et al., 1996); (Mussener et al., 1997). It is still unclear how TNF 
α from the periphery might have affected the brain during the period of clinical 
manifestation  of  disease,  despite  no  TNF α  detectable  in  the  serum.  This 
problem  needs  to  be  further  investigated,  perhaps  by  using  peripheral 
administration of TNF blockade into the CII immunized mice during the early and 
late  stage  of  disease  and  determine  changes  in  brain  cytokines.  These 
experiments will form Chapter 6 of this thesis. 
Prolonged increased concentrations of CCL2 were observed in the brains of CII 
immunized  mice  throughout  the  CIA  experimental  course,  which  may  be 
associated with transient increases of serum CCL2 during the period of disease 
onset  (day  22  and  day  28).  Our  data  seem  to  suggest  that  there  may  be  a 
contribution  of  CCL2  from  the  periphery  into  the  brain  during  the  period  of 
disease onset (day 22 and day 28). The prolonged increased concentration of 
CCL2  in the  brain  of  CII  immunized  mice  continued  until  the end of  the  CIA 
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the  brain  after  the  onset  of  disease.  However,  we  found  no  CCL2  gene 
expression in brains of CII immunized mice over the period of early and late 
phases of the disease. This seems to suggest that there may be an accumulation 
of  CCL2 in  the brains  of  CII immunized  mice after the  period  of  the  disease 
onset. Prolonged increased concentrations of CCL2, a potent chemotactic factor 
of  Th2  lymphocytes,  may  potentially  be  associated  with  increased 
concentrations  of  Th2  cytokines,  including  IL 4  and  IL 10  in  the  brains  of  CII 
immunized mice during the disease process. However, we could not demonstrate 
the presence of any Th2 cytokine in the brains of CII immunized mice in our 
study. However, we found a coincidental increase of CCL2 and Th2 cytokines in 
both serum and in the brains at the same period of time, suggesting that there 
may be trafficking of Th2 cells, regulated by CCL2, from the periphery into the 
brain  of  CII  immunized  mice.  This  premise  was  supported  by  a  study  in  the 
mouse  model  of  liver  injury  showing  that  peripheral  hepatic  inflammation 
induced brain micoglia to produce CCL2, which was followed by infiltration of 
monocytes into the brains (D'Mello et al., 2009). This evidence also suggest that 
CCL2 up regulated during the early and late disease phase may be associated 
with an increase of TNF α, which is produced mainly by monocytes, during the 
same period of time. However, the hypothesis that CCL2 recruits Th2 cells and 
monocytes  into  the  brains  of  CII  immunized  mice  needs  to  be  further 
investigated perhaps by using immuno histochemistry for Th2 cells and monocyte 
markers in CIA brain tissues.  
We also found prolonged increased concentrations of IL 12 in the brains of CII 
immunized mice across all CIA experimental periods. Increases in IL 12 mRNA 
expression levels were also observed in these CII immunized mice, particularly at 
the late phase of the disease. This is in contrast  to brain Th2 cytokines, for 
which  their  mRNA  expression  levels  were  undetectable.  This  may  suggest 
difference in the location at which these Th1 and Th2 were activated and the 
origin of these Th1 and Th2 cells before potentially migrating into the brains of 
these CII immunized mice. The pathological mechanism of the joint destruction 
in RA is thought to be driven by Th1 cells and Th1 cytokines, including IL 12, and 
IL 2 can be detected in lymph node, spleen and joints of CIA mice throughout 
the period of onset and early disease (Okamoto et al., 2000); (Mussener et al., 
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these CII immunized mice. This suggests that there is a possibility that there was 
no trafficking of Th1 from the periphery into the brains of CII immunized during 
the course of arthritis. Instead, up regulation of IL 12 mRNA in brains of these 
CII immunized mice suggests that IL 12 may be produced from CNS T cells. The 
mechanism  of  CNS  T  cells  activation  has  been  well  documented  in  model  of 
neuro inflammatory disease such as EAE, where the inflammatory demyelination 
development  is  driven  by  autoreactive  Th1  cells  (Klein,  2004).  Although  the 
pathological mechanism of EAE is thought to be due to autoreactive Th1 T cells 
that invade the CNS, several studies in EAE suggested that the major source of 
Th1 cells were activated within the CNS. A study by Greter et al, in mice that 
lacked  secondary  lymphoid  tissue  showed  that  activation  of  T  cells  in  the 
presence of a cognate antigen occurred in the brain, and that T cell trafficking 
to APCs located in secondary lymphoid tissues was not necessarily to initiate 
tissue  destruction  (Greter  et  al.,  2005).  This  has  been  confirmed  by  another 
study (Juedes and Ruddle, 2001) showing that CNS T cells produce cytokines such 
as TNF α and IFN γ only when stimulated with CNS APCs. These data suggest that 
the activation of T cells in the presence of a cognate antigen occurred in the 
secondary lymph node and that trafficking of autoreactive Th1 T cells into the 
brain  may  not  be  the  main  mechanism  of  the  pathological  condition  of 
peripheral  inflammation  associated  with  neuro inflammation.  Instead,  the 
activation of T cells in the presence of a cognate antigen is more important. 
Based on the fact that the aetiology of RA and MS are influenced by genes in the 
HLA region, particularly the class II genes, therefore, CD4
+ T cells are thought to 
play a crucial role in both MS and RA pathogenesis (Zozulya and Wiendl, 2008), 
(McInnes and Schett, 2007). This, combined with our data showing undetectable 
Th1 cytokines and highly detectable brain IL 12 mRNA expression levels in CII 
immunized mice, allowed us to hypothesis that there may be activation of CNS T 
cells occurring in the brain of CII immunized mice during the course of arthritis. 
This hypothesis is supported by our finding showing that the increased expression 
of IL 12 mRNA and protein concentrations occurred from day 22 onwards before 
the peak of mRNA expression levels of CXCL10, a potent Th1 recruiter, in brains 
of CII immunized mice on day 35. This suggested that the activation of CNS T 
cells may have occurred in the CNS before Th1 cells actually trafficking into the 
brain. Similarly, the peak of IL 12 protein also preceded the peak of VEGF, an 
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of Th1 cells in brains of CII immunized mice may have occurred before the BBB 
breakdown. Although the increase in VEGF concentration in the brains has been 
reported to be associated with BBB breakdown (Argaw et al., 2009) some studies 
reported that BBB breakdown is not necessary to be the cause of an increase in 
peripheral immune cells infiltration into the CNS (Carson et al., 2006); (D'Mello 
et al., 2009); (Shaftel et al., 2007). This raises one important question; how the 
peripheral  cytokines  signal  to  the  brain  in  order  to  activate  the  CNS  Th1 
lymphocytes to produced IL 12 in the brain? The only possibility that we could 
suggest from our data is that the production of IL 12 by CNS immune cells such 
as T cells may be induced via the peripheral inflammation signal from IL 1β that 
was found to be up regulated in the serum and brain tissues of CII immunized 
mice during the onset of the disease (day 22  day28 after immunization). We 
also  found  a  downward  trend  in  longitudinal  changes  in  brain  IL 12,  which 
corresponded to a reduction in serum IL 1β in CII immunized mice. Important 
evidence  supporting  our  finding  is  that  IL 1β  can  enhance  the  activation  of 
encephalitogenic  T  lymphocytes,  contributing  to  the  development  of  EAE 
(Matsuki  et  al.,  2006).  This  hypothesis  can  be  tested  by  using  peripheral 
administration  of  anti IL 1β  into  the  CII  immunized  mice  and  determining 
changes in Th1 cytokines in the brain.  
A  recent  study  has  shown  BBB  disruption  in  CIA  mice,  characterized  by  an 
increase in BBB permeability and changes in the tight junction structure of BBB 
during the progress of arthritis (Nishioku et al., 2010b). Our data also suggest 
the possible signs of BBB disruption in brains of CII immunized mice, indicated by 
increased concentrations of VEGF in the brains of CII immunized mice during the 
early and late stages of disease (day 28 day 42 after immunization). VEGF is an 
angiogenic  factor  that  has  been  implicated  in  BBB  breakdown  in  several 
inflammatory conditions of the CNS (Croll et al., 2004a). Our data also showed 
that  both  VEGF  mRNA  expression  levels  and  protein  concentrations  were  up 
regulated  during  the  same  period  (day  35   day  42  after  immunization), 
suggesting that there may be local production of VEGF in the brain by CNS cells 
such  as  astrocytes,  vascular  endothelium,  microglia  or  neurons  (Croll  et  al., 
2004a);  (Mani  et  al.,  2005).  However,  the  mechanism  underlying  how  the 
peripheral inflammatory signals induce VEGF production and BBB breakdown in 
the brains of CII immunized mice during the early disease stage in our study is Chapter 4    230 
still unclear. One possibility is that VEGF production in the brain may be induced 
via the peripheral inflammatory signal obtained from FGF2 protein that is up 
regulated in the serum of these CII immunize mice during the onset and the 
early disease stages. This is because FGF2 is considered to be a strong inducer of 
VEGF  in  endothelial  cells  (Seghezzi  et  al.,  1998).  FGF2  is  detectable  at  high 
concentrations in the synovial fluid of RA patients as well as in the joints of 
arthritic  mice  (Manabe  et  al.,  1999);  (Yamashita  et  al.,  2002).  These 
observations  suggest  that  FGF2  may  play  a  role  in  the  joint  destruction  by 
inducing  osteoclastogenesis  that  is  strongly  increased  during  the  onset  of 
arthritis disease (Stolina et al., 2009). It is also possible that there may be a 
contribution of FGF2 from the joint into the peripheral circulation, and then 
from the circulation the FGF2 may be transported to the brain during the onset 
of disease. This can be seen by the up regulation of serum FGF2 concentration 
during the onset of disease (day 22), followed by a reduction of serum FGF2 
concentration during the chronic phase as seen in our longitudinal data during 
disease progression in CII immunized mice. However, this hypothesis needs to be 
further investigated, perhaps by using peripheral administration of anti  FGF2 
into  the  CII  immunized  mice  during  the  early  and  late  stage  of  disease  and 
determine changes in brain cytokines, particularly VEGF. 
4.4.3  The potential interplay between inflammatory mediators 
in brains of CII immunized mice: Possible evidence for 
ongoing immune activation and inflammatory processes. 
The  data  obtained  from  this  time course  experiment  provided  interesting 
observations  suggesting  that  there  may  be  ongoing  immune  activation  and 
inflammatory process in the brains of CII immunized mice over the course of 
disease  development.  We  demonstrated  up   and  down regulation  of  different 
inflammatory mediators in brains of CII immunized mice at different time points 
across the period of clinical manifestation in the CIA experimental course. These 
changes in mediators may reflect the biological interaction of brain cytokines 
during the course of disease. There was a prolonged increase in several brain 
inflammatory cytokines such as IL 12, IL 10 and CCL2 in brains of CII immunized 
mice throughout the course of disease. These longitudinal patterns of change in 
brain  cytokine  profiles  are  not  common  in  acute  inflammation  such  as  the 
systemic  LPS challenge  model.  Several  studies  in  the  systemic  LPS challenge Chapter 4    231 
model showed transient increases in brain cytokine, seen as single concentration 
peaks at different time points in the experimental period in various brain regions 
(Laye et al., 1994); (Quan et al., 1994); (Gatti and Bartfai, 1993); (Breder et al., 
1994); (Gabellec et al., 1996); (Grinevich et al., 2001). We found some brain 
inflammatory mediators such as IL 1β, CCL2 and FGF2 that were up regulated 
corresponding  to  the  up regulation  of  the  same  cytokines  in  serum  occurring 
during  the  onset  of  disease.  However,  we  also  found  several  inflammatory 
mediators such as TNF α that were up regulated in the brain, but not in the 
serum during the period of clinical disease (day 35 – day 42 after immunization). 
This  suggests  that  there  may  be  immune  activation  and  cytokine  production 
within the brains of arthritic mice. Interestingly, our data showing that IL 12 
protein concentrations were elevated in the brains of CII immunized mice during 
the onset of the disease and then were decreased towards the latter stages of 
the disease. This profile was similar to the longitudinal changes in IL 12 mRNA 
expression levels in the CNS of EAE model of chronic CNS disease (Issazadeh et 
al.,  1995).  This  suggests  that  the  inflammatory  process  in  the  brain  may  be 
chronic rather than acute. This premise is supported by a study by de Ray et al 
showing a prolonged increase of IL 6 mRNA expression levels in brains of CIA rats 
during the period of onset and early disease period. That study also showed an 
increase of IL 1β mRNA expression levels in brains of CIA rats during the period 
of disease onset; which is similar to our finding in the brains of CII immunized 
mice. Transient increases in brain IL 1β protein concentrations during the onset 
of  disease  may  also  be  associated  with  sharp  increases  in  IL 12  protein 
concentrations observed during the same period. Although we have discussed 
earlier in this chapter that the increase in IL 12 was possibly generated by CNS 
activated  T  cells,  the  possibility  that  IL 12  could  also  be  produced  from 
astrocytes and microglia should also be considered. An in vitro study suggested 
that brain astrocytes and microglia can produce IL 12 upon stimulation with pro 
inflammatory cytokines such as IL 1β and TNF α (Stalder et al., 1997). This may 
also  explain  our  finding  showing  a  coincidental  increase  in  IL 12  mRNA 
expression levels and TNF α protein concentration in the brains of CII immunized 
mice during the late stage of disease. TNF α not only activates CNS astrocytes 
and  microglia,  but  also  T  cells  causing  them  to  produce  Th1  cytokines.  IL 2, 
another Th1 cytokine that is up regulated as a single peak on day 35 may also be 
associated with the increase in TNF α protein concentration at the same time Chapter 4    232 
period. This could be explained by an in vivo study showing that IL 1 and TNF α 
are required for IL 12 induced development of Th1 cells (Shibuya et al., 1998). 
Further indirect evidence for this was seen by adoptive transfer of antigen (PLP) 
primed T cells when pre treated with TNF α caused more severe EAE, along with 
a significant increase in TNF α production (Leonard et al., 1995). These data 
together with the data presented in this thesis suggest that pro inflammatory 
cytokines  and  Th1  cytokines  may  mutually  regulate  each  other  and  may 
contribute to the development of cell mediated immune responses within the 
central nervous system of CII immunized mice.   
  A longitudinal shift from a Th1 type to Th2 type response is one of the 
major  characteristics  of  autoimmune  disease.  The  temporal  interplay  and 
mutual  inhibition  between  Th1  and  Th2  cytokines  has  been  demonstrated  in 
several  CNS  inflammatory  demyelinating  disease  models  such  as  EAE  and 
Theiler’s murine encephalomyelitis virus (TMEV). However, the specific roles of 
the Th1 and Th2 cytokines in neuro inflammation in the CNS have not been fully 
elucidated.  This  is  mainly  because  studies  using  different  CNS  inflammatory 
demyelinating  models  reported  different  temporal  relationships  and  cytokine 
expression profiles. For example, IL 2, IL 6, IL 12 and IFN γ concentrations in 
EAE mouse brains increased during the relapse stage, while brain concentrations 
of  the  Th2  cytokines  such  as  IL 4  and  IL 10  were  up regulated  during  the 
remission  or  recovery  stages  (Issazadeh  et  al.,  1996).  In  contrast,  the 
coincidental expression of Th1 and Th2 cytokines including IL 2, IFN γ, IL 4, IL 5 
and  IL 10  were  observed  during  the  remission  phase  of  the  TMEV induced 
demyelinating  disease  model  (Sato  et  al.,  1997).  Therefore,  the  neuro 
inflammation in the CIA model, which could be considered as a model of neuro 
inflammation induced by systemic autoimmunity, may demonstrate a different 
temporal interplay between Th1 and Th2 cytokines. Our data showed increased 
concentrations of brain Th2 cytokines, including IL 4 and IL 10 which occurred at 
the  same  time  as  up regulation  of  Th1  cytokines  IL 2  and  IL 12,  and  pro 
inflammatory  cytokines  in  CII  immunized  mouse  brain  during  the  course  of 
disease. This suggests that there might be a Th1/Th2 shift that could promote an 
anti inflammatory environment, perhaps in the joint in an attempt to suppress 
or regulate ongoing pro inflammatory Th1 cell activation. The concentration of 
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as  the  temporal  expression  profile  of  brain  IL 1β  in  CII  immunized  mice, 
suggesting  that  IL 4  production  might  be  up regulated  to  suppress  the  pro 
inflammatory  functions  of  IL 1β  (te  Velde  et  al.,  1990).  Alternatively,  the 
observed reduction of brain IL 4 concentration could be the result of the up 
regulation of Th1 cytokines e.g. IL 2 and IL 12. However, IL 12 has also been 
reported  to  stimulate  IL 10  production  in  the  EAE  model,  therefore,  the  up 
regulation of IL 10 in CII immunized mouse brains might be associated with an 
increased concentration of brain IL 12 (Berghmans et al., 2006).  
Pro inflammatory  cytokines  are  known  to  stimulate  the  production  of 
chemokines in the CNS, which may then initiate migration of immune cells from 
the blood into the CNS parenchyma. Cultured astrocytes stimulated by TNF α 
and  TGF β  produced  CCL2  (Hurwitz  et  al.,  1995),  while  cultured  microglia 
stimulated by IL 1β and TNF α produced CCL2, CCL3, CCL4 and CXCL8 (McManus 
et al., 1998). Our data showed a prolonged up regulation of brain CCL2 protein 
concentration  in  CII  immunized  mice  during  the  course  of  disease.  This  was 
coincidental with the up regulation of brain IL 1β and TNF α protein production 
in  CII  immunized  mice,  suggesting  that  CCL2  in  CIA  mouse  brain  may  be 
generated  by  IL 1β  /TNF activated  microglia/astrocytes.  Temporal  relations 
between chemokine and cytokine expression in the CNS have been demonstrated 
in  a  model  of  chronic  relapsing  experimental  autoimmune  encephalomyelitis 
(ChREAE) (Glabinski et al., 2003). During the relapse stage, which involves the 
migration of new autoantigen specific T cells into the CNS, TNF α, IFN γ and IL 6 
production  was  increased  at  the  same  time  as  various  chemokines  including 
CCL1, CCL2, CCL3, CCL4, CCL5 and CXCL2–3 in the brains of mice with ChREAE. 
Another  possibility  is  that  CCL2  may  move  actively  or  passively  from  the 
periphery, or that peripheral IL 1β might induce brain production of CCL2 in CII 
immunized mice. This can be seen by up regulation of serum IL 1β and CCL2 
during the onset of disease on day 22 and this was followed by a reduction of 
their  serum  concentrations  over  time,  while  brain  protein  concentrations  of 
CCL2  remained  increased  in  CIA  mice.  Our  data  also  showed  that  the  up 
regulation of brain CXCL1 mRNA expression levels occurred at the same time as 
the  peak  of  brain  IL 1β  protein  production.  A  similar  observation  has  been 
reported  in  a  study  by  Shaftel  et  al  showing  that  chronic  IL β  expression  in 
mouse brains resulted in the up regulation of brain CXCL1 mRNA (Shaftel et al., Chapter 4    234 
2007). A study using a TNF induced demyelination (TID) model, which is another 
MS model, showed that mRNA expression levels of CXCL10 and other chemokines 
including  CCL1  and  CXCL2  were  up regulated  in  the  brains  of  mice  with 
inflammatory  demyelination  during  the  acute  phase  of  disease.  This  also 
correlated with marked immune cell infiltration into the CNS (Quinones et al., 
2008). This study suggested that the increased concentration of brain TNF α is 
associated with the up regulation of brain CXCL10 expression, which may partly 
explain  our  finding  showing  the  coincidental  expression  of  brain  TNF α  and 
CXCL10 in CIA mice at day 35. These data collectively with the data presented in 
this  thesis  suggest  that  pro inflammatory  cytokines  IL 1β  and  TNF α  may 
regulate  chemokine  production,  which  eventually  contribute  to  immune  cell 
trafficking from the periphery to the brains of CII immunized mice. We don’t 
present any supportive evidence for this in this thesis and this topic may be for 
future studies. 
Vascular  endothelial  growth  factor  is  only  not  an  angiogenic  factor,  but  also 
functions  to  induce  inflammation.  In  RA,  VEGF  can  regulate  angiogenesis 
contributing to the proliferation of the inflammatory synovial pannus, and can 
also  promote  leukocyte  recruitment  into  the  site  of  neovascularisation  by 
inducing CCL2 production by endothelial cells (Marumo et al., 1999). In addition, 
VEGF has been reported to modulate T cells response and cytokine IL 8, CCL2, 
TNF α  and  IL 1β  production  by  peripheral  blood  monocytes  (Selvaraj  et  al., 
2003). Very little is known about the role of VEGF mediated inflammation in the 
brain.  However,  it  has  been  reported  that  brain  VEGF  functions  to  regulate 
monocyte  recruitment  into  the  brain.  VEGF  has  been  shown  to  induce  CCL3 
production by endothelial and brain parenchyma cells (Croll et al., 2004b). In 
addition, during the neuro inflammation process, the production of VEGF in the 
brains is induced by pro inflammatory cytokine such as IL 1β (Li et al., 1995). 
Our data showed coincidental increases of VEGF, CXCL10, CCL2, and TNF α in 
brains of CII immunized mice during the early stage of disease (day 28 – day 35 
after immunization), suggesting there may be an association between VEGF and 
CXCL10, CCL2, and TNF α that may also involve recruitment of leukocytes and 
monocytes into the brain. Another inflammatory action of VEGF is to regulate T 
cells. Administration of anti VEGF antibody in CIA mice resulted in inhibition T 
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blockade  also  reduced  TNF α  and  IL 6  concentrations  measured  in  peripheral 
blood  mononuclear  cells  derived  from  RA  synovial  fluid  (Yoo  et  al.,  2005). 
Alternatively, T cells have been reported to produce VEGF after stimulation by 
IL 2 (Mor et al., 2004). This observation may explain our findings in which we 
demonstrated coincidental increases in VEGF, IL 2 and IL 12 in the brains of CII 
immunized  mice  during  the  early  stage  of  disease  (day  28  –  day  35  after 
immunization). This data suggest that there may be an association between Th1 
cells  and  VEGF.  However,  this  hypothesis  needs  to  be  further  investigated, 
perhaps by an in vitro study of these CNS T cells and CNS immune cells isolated 
from CII immunized mice during the early stage of disease. Interestingly, there 
was no VEGF detectable in brains of CII immunized mice during day 22 to day 28 
after  immunization,  which  is  the  period  during  which  the  anti inflammatory 
cytokines  IL 4  and  IL 10  were  up regulated.  It  is  possible  that  IL 4  and  IL 10 
suppressed the expression of VEGF during that period since it has been reported 
that  the  combination  of  IL 4  and  IL 10  inhibited  the  production  of  VEGF  in 
rheumatoid synovial fibroblasts (Hong et al., 2007). The prolonged increase of 
IL 10 across the whole period of the clinical manifestation of disease may be 
associated with longitudinal decreases in FGF2 mRNA and protein in brains of CII 
immunized mice. This may be due to IL 10 which also has an anti angiogenic 
effect inhibiting the expression of FGF2 as well as VEGF (Cervenak et al., 2000). 
However, the actual reason underlying the longitudinal reduction in FGF2 is still 
unclear. However, our data also showed that brain FGF2 concentrations in both 
normal and CII immunized mice decreased with the age, suggesting age related 
alterations in FGF2 production. This is supported by a study comparing wound 
repairs of young mice and aged mice in which wounds of aged mice heal more 
slowly and contained less FGF2 than wounds in the young, indicating that age 
may be associated with macrophage production of FGF2 during the inflammatory 
process (Swift et al., 1999).  
A summary of the possible brain immune activation induced by peripheral 
inflammatory signals in CII immunized is shown in Figure 4.31. 
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Figure 4.31 Potential mechanisms of immune activation induced by peripheral inflammatory 
cytokine signals occurring in brains of CII immunized mice 
In this chapter we investigated longitudinal changes in brain inflammatory mediators in CII 
immunized mice during 3 stages of arthritis disease (onset of disease, early stage of 
disease and late stage of disease). We have shown that longitudinal changes in brain 
inflammatory mediators in CII immunized mice have been associated with changes in 
peripheral inflammatory mediators at different stages of disease progression. Increased 
concentrations of serum IL 1β, IL 5, CCL2 and FGF2 were observed during the onset of 
disease (day 22 day 28) at the same time as increased concentrations of brain IL 1β, CCL2 
and FGF2. This suggests that there may be the transudation of IL 1β, CCL2 and FGF2 from 
the periphery into the brain by an as yet unknown mechanism. At this early time period of 
disease, we found increased expression of CXCL1 mRNA, which potentially was generated 
from astrocytes induced by pro inflammatory cytokines such as IL 1β. Up regulation of both 
IL 12 mRNA and protein were also observed, suggesting the local production of IL 12 that 
could be the result of bystander activation of T cells in the brain. The peripheral 
inflammatory signal of IL 1β may also play a role to augment the activation of CNS T cells. 
Th2 cytokines IL 4 and IL 10 were up regulated by the time of onset of disease, which may 
be due to the trafficking of Th2 cells into the brain regulated by the chemotactic activity of 
CCL2. During the early stage of the disease (day 28 – day 35), increased levels of VEGF 
mRNA expression were observed and may be generated from local CNS cells such as BBB 
endothelial cells after stimulation by peripheral inflammatory signal from FGF2. Both FGF2 
and VEGF may be down regulated by IL 4 and IL 10 during the onset of disease during 
which there was no significant increase of FGF2 and VEGF concentrations in brains of CII 
immunized mice during that period. Also during that period, mRNA and protein 
concentrations of Th1 cytokines, IL 12 and IL 2 were increased. This could be due to more 
Th1 cells trafficking from the blood into the brain by the chemotactic activity of CXCL10. 
Another possibility is that CNS immune cells such as microglia and astrocytes could also 
produced IL 12 upon stimulation by pro inflammatory cytokines TNF α and IL 1β. IL 12 may 
also suppress the production of anti inflammatory IL 4, because there was no further 
increase in IL 4 protein concentrations after the onset of disease. A prolonged increase of 
VEGF from the early stage of disease onwards may indicate a breakdown of the BBB during 
the period of clinical expression of disease.  TNF α may activate astrocytes to produce 
CXCL1. There may also be the activation of T cells upon stimulation by IL 2, resulting in the 
production of VEGF in the brain of CII immunized mice during the late stage of 
disease.Purple arrows denote transportation of peripheral immune cells and inflammatory Chapter 4    237 
mediators. Blue arrows denote activation and production of inflammatory mediators. Red 
arrows denote inhibition and suppression of productions of inflammatory mediators. Green 
arrows denote effects of chemokines on immune cells trafficking in brains of CII immunized 
mice.  Mic = microglia. 
Summary 
In summary, we have demonstrated the possibility that peripheral inflammatory 
signal derived from the cytokines IL 1β, IL 5, CCL2 and FGF2 may induce the 
production of brain inflammatory mediators associated with the onset and early 
disease stages of arthritis. There may also be trafficking of immune cells from 
the  periphery  into  brains  in  response  to  the  increased  concentrations  of 
chemokines including CCL2, CXCL10, CXCL1 and angiogenic factors such as VEGF 
and  FGF2.  These  may  be  associated  with  increased  permeability  of  the  BBB 
which  may  have  occurred  during  the  early  disease  stage  indicated  by  raised 
levels of VEGF mRNA expression in brains of CII immunized mice during the early 
and late stages of arthritis.  
One important question follows from this. How can inflammatory mediators such 
as TNF α be up regulated in the brain of CII immunized mice during the clinical 
expression of the arthritis, despite there being no serum inflammatory mediators 
detectable?  In  the  next  chapter,  we  therefore  addressed  the  issue  of  the 
apparent lack of clear association between joint immune brain communication 
by using peripheral administration of TNF blockade in the CII immunized mice 
during the early and late stages of disease and determining changes in brain 
cytokines. 
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5.1  Introduction 
Data  described  in  Chapter  4  (Section  4.2.2,  4.2.4  and  4.2.5)  demonstrated 
various  longitudinal  changes  of  inflammatory  mediator  expression  profiles, 
including IL 1β, TNF α, IL 2, IL 10, IL 4, IL 12, CCL2, CXCL1, CXCL10, VEGF and 
FGF2  in  the  brains  of  CII  immunized  mice  throughout  the  course  of  disease 
development from onset, acute and chronic changes. These data suggested that 
there may be ongoing immune activation in the CNS of these mice, which may be 
associated with, or caused by peripheral inflammation during development of 
arthritis.  Interestingly,  we  found  increased  concentrations  of  inflammatory 
mediators,  including  IL 1β,  IL 5,  CCL2  and  FGF2  in  the  serum  of  these  mice 
during the onset of disease (day 22 to day 28 after immunization). Some of these 
inflammatory  mediators,  IL 1β  and  CCL2  were  also  found  in  increased 
concentration in brains at the same time period, suggesting that the peripheral 
inflammatory signals from serum IL 1β and CCL2, associated with the onset of 
arthritis disease may induce the production of brain inflammatory mediators. 
However, during the early and the late stages of arthritis we could no longer 
detect serum inflammatory mediators (at day 28 to day 42 after immunization), 
but  we  could  still  detect  increased  concentrations  of  several  inflammatory 
mediators, including TNF α, IL 4, IL 10, IL 2, IL 12, CCL2, CXCL1, CXCL10, VEGF 
and FGF2 in the brains of these CII immunized mice. We could not address the 
question  of  how  the  cytokines  associated  with  peripheral  inflammation  could 
signal to the brain in order to produce these inflammatory mediators.  
To  confirm  that the changes  in  inflammatory  mediator  profiles  were a 
consequence  of  the  peripheral  inflammation  during  the  period  of  clinical 
expression of arthritis, we blocked the peripheral inflammation in the CIA model 
and  determined  the  effect  of  anti inflammatory  treatment  on  the  brain 
inflammatory mediator profiles. In the CIA experiment of the present Chapter, 
we  administrated  etanercept,  a  drug  that  consists  of  a  recombinant  human 
soluble TNF receptor which can cause TNF blockade. It is an extremely effective 
treatment  for  RA  (Haberhauer  et  al.,  2010),  and  it  can  be  administered 
successfully  to  the  murine  CIA  model  as  a  preventative  therapy  (Marinova 
Mutafchieva et al., 2000). A recent finding by Terrando et, al., demonstrated 
that peripheral administration of TNF blockade to a model of surgery induced 
peripheral inflammation could also reverse an increase of brain IL 1β expression Chapter 5    240 
(Terrando et al., 2010). Clinical evidence also demonstrated an improvement in 
mood in patients with chronic systemic inflammatory diseases such as psoriasis 
and  RA  when  receiving  etanercept.  Psoriasis  patients  receiving  long term 
etanercept treatment showed 50% improvement in depression score compared 
with  those  receiving  placebo  as  indicated  by  HAM D  and  Beck  Depression 
Inventory  (BDI)  (Tyring  et  al.,  2006).  In  addition,  a  reduction  in  serotonin 
transporter (SERT) density and improvement in physical and mental functions 
have been reported in RA patients receiving anti TNF α treatment (Cavanagh et 
al.,  2010).  This  clinical  evidence  suggests  that  etanercept  not  only  inhibits 
peripheral inflammation at the site of disease, but may also contribute to the 
suppression  of  central  neuro inflammation  often  associated  with  systemic 
autoimmune  diseases.  This  eventually  inhibits  changes  in  neurobiology 
contributing to the development of neuropsychiatric disorders such as depression 
occurring during the course of autoimmune disease. 
We hypothesise that ‘Using etanercept to treat peripheral inflammation in the 
CIA model by TNF blockade would affect the brain inflammatory mediator profile 
by  suppressing  disease associated  up regulation  of  brain  inflammatory 
mediators’. Therefore, the aim of this chapter is to investigate whether systemic 
etanercept  treatment  modulates  the  inflammatory  mediator  profiles,  usually 
associated  with  peripheral  inflammation,  in  the  brains  of  mice  during  the 
development of arthritis using the experimental CIA model.  
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5.2  Results 
5.2.1   Effect of etanercept on development of collagen 
induced arthritis (CIA). 
Data  from  the  previous  chapter  (Chapter  4;  sections  4.2.3,  4.2.4  and  4.2.5) 
demonstrated  up regulation  of  production  of  various  inflammatory  mediators, 
including TNF α, IL 4, IL 10, IL 2, IL 12, CCL2, CXCL10 and VEGF, in the brain of 
CII immunized mice during the period of clinical expression of arthritis (day 28 to 
day 35 after immunization). However, we found no inflammatory mediators in 
the serum of these CII immunized mice during this period. To further test the 
association  between  peripheral  inflammation  and  the  production  of 
inflammatory mediators in the brain, we used etanercept to block peripheral 
inflammation  during  the  period  of  clinical  expression  of  arthritis  in  CII 
immunized  mice  and  measured  associated  changes  in  brain  inflammatory 
mediators.  TNF  neutralizing  agents  have  been  very  effective  in  ameliorating 
joint  disease  and  300ug/mouse  of  etanercept  has  been  suggested  to  be  the 
appropriate  dose  to  reduce  the  severity  of  joint  inflammation  in  CIA  model 
(Williams  et  al.,  2000b).  In  this  chapter,  we  investigated  the  effect  of 
etanercept  on  the  severity  of  arthritis  and  production  of  brain  inflammatory 
mediators at 2 time points during the period of clinical expression of disease 
(day 32 and day 35 after immunization as time points of early and late stage of 
disease  respectively).  We  also  determine  changes  in  brain  inflammatory 
mediators  during  the  before  disease  onset  (day  14  after  immunization)  and 
before etanercept treatment on day 18, as a control time point. 
5.2.1.1  Administration of etanercept and induction of arthritis in DBA1 
mice 
Nineteen DBA1 mice were immunized by intradermal injection of type II collagen 
in  Freund’s  complete  adjuvant  on  day  0.  On  day  14,  3  CII  (collagen  type  II) 
immunized mice (Group 1) were culled and the brains and serum of these mice 
were harvested for the measurement of inflammatory mediator concentrations 
before the second immunization on day 21. There was no CII immunized mice in 
Group 1 that developed arthritis on day 14 after the primary immunization. The 
other 16 CII immunized mice were randomly divided into 2 groups of 8, namely 
the treatment and placebo groups. From day 18 onwards, CII immunized mice in Chapter 5    242 
the treatment group received etanercept (300  g/mice, i.p.) every 3 days, while 
the placebo group received PBS (i.p.) every 3 days. The signs of arthritis in CII 
immunized mice were monitored from day 16 after immunization onwards and 
arthritis severity scores in this experiment were verified independently by Dr. 
Bernard Leng. CII immunized mice from both groups were re challenged by intra 
peritoneal injection of collagen II in PBS on day 21. CII immunized mice of the 
placebo (PBS treated) group started to show sign of arthritis earlier (day 19 after 
the primary immunization) than those of the treatment group (day 21 after the 
primary immunization). 3 CII immunized mice of the treatment group (Group 2) 
and 3 CII immunized mice of the placebo group (Group 3) were culled and serum 
and brains of these CII immunized mice were harvested on day 32. CII immunized 
mice  of  both  treatment  and  placebo  groups  (Group  4  and  Group  5;  5  CII 
immunized  mice/group)  were  culled  and  serum  and  brains  of  these  CII 
immunized mice were harvested on day 35; which is the peak day of disease. 
Another 8 sex  and age matched untreated DBA1 mice were used as antigen 
naïve control mice. These naïve control mice were neither sensitized with type II 
collagen nor given etanercept treatment. 3 naïve control mice were culled on 
day 14, and a further 3 and 5 naïve control mice were culled on day 32 and day 
35 after the primary immunization respectively. Serum and brains of mice from 
all experimental groups were harvested on the day indicated and snap frozen in 
liquid nitrogen and stored at –80˚C. Half of each brain was processed for protein 
extraction and inflammatory mediator proteins analysed by Luminex; the other 
half  was  processed  for  RNA  extraction  and  the  inflammatory  mediator  gene 
expression was determined by real time PCR (Figure 5.1).  Chapter 5    243 
 
Figure 5.1 Administration of etanercept during the CIA experimental procedure 
19 DBA1 mice at 6 8 weeks of age were immunized with 100       g type II bovine collagen + 
complete Freund’s adjuvant (CFA) at day 0. On day 14, 3 CII immunized mice in Group 1 
were culled and brains and serum of these CII immunized mice from group 1 (3 mice/group) 
were harvested. At this time point, another 3 naïve control mice, which were neither 
sensitized nor challenged with type II collagen, were also culled and their brains and serum 
samples were used as controls to compared changes in brain inflammatory mediators with 
those of CII immunized mice culled on day 14. On day 18, CII immunized mice were 
randomly divided into 2 groups (8 CII immunized mice/group), which were a treatment group 
and a placebo group.  From this day onwards, 300        g/mouse etanercept was administrated 
(i.p.) to CII immunized mice of the treatment group every 3 days, while PBS was injected to 
CII immunized mice of the placebo group every 3 days. CII immunized mice of both groups 
were challenged on day 21 with 200       g type II collagen. From day 21 onwards, etanercept 
treated CII immunized mice of etenercept group were randomly divided into 2 groups, 
namely Group 2 and Group 4. Etanercept treated CII immunized mice in Group 2 (3 CII 
immunized mice/group) were culled and serum and brains of these CII immunized mice were 
harvested on day 32, while etanercept treated CII immunized mice in Group 4 (5 CII 
immunized mice/group) were culled and serum and brains of these CII immunized mice were Chapter 5    244 
harvested on day 35. Similarly, PBS treated CII immunized mice in the placebo group was 
randomly divided into 2 groups, namely Group 3 and Group 5. PBS treated CII immunized 
mice in Group 2 (3 CII immunized mice/group) were culled and serum and brains of these CII 
immunized mice were harvested on day, while PBS treated CII immunized mice in Group 4 (5 
CII immunized mice/group) were culled and serum and brains of these CII immunized mice 
were harvested on day 35. Another 8 naïve control mice were culled on the day indicated (3 
naïve mice for day 32 and 5 naïve mice for day 35) and their serum and brain were used as 
controls. Brain and serum from mice of all experimental groups were collected and 
processed for inflammatory mediator measurements using Luminex, ELISA and real time 
PCR. 
5.2.1.2   Effect of etanercept on severity of arthritis in CII immunized 
mice on day 32 and day 35. 
To determine the effect of blocking TNF α during the induction of arthritis, mice 
were given injections from days 18 onwards (before the second collagen booster 
immunization) with 300  g etanercept every 3 days. Placebo groups received 
PBS. There were 4 mice in the treatment group 2 and the placebo group 3, both 
groups of mice were culled on day 32. Mice started to develop arthritis on day 22 
days after immunization in the etanercept treated group 2, compared with 20 
days in the PBS treated group 3 (Figure 5.2). There was no significant difference 
in % incidence, mean paw thickness, and arthritis score between etanercept 
treated mice and PBS treated mice.  
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Figure 5.2 Effect of etanercept on severity of arthritis in CII immunized mice on day 32 
(groups 1 3)  
CII immunized mice in Group 2 (3 etanercept treated CII immunized mice/group; blue line) 
were given injections from days 18 onwards (before collagen booster immunization) with 
300  g etanercept every 3 days. 3 CII immunized mice in Group 3 were given PBS as 
placebo (3 PBS treated CII immunized mice /group; red line). Mice in both Group 2 and 
Group 3 were culled on day 32. The signs of arthritis in CII immunized mice were monitored 
from day 16 after immunization onwards. (A) shows the percent of incidence of arthritis in 
etanercept treated and PBS treated CII immunized mice, which was calculated from number 
of CII immunized mice with arthritis per group/total number of CII immunized mice used per 
group. Mean clinical arthritis score and mean paw thickness were used as clinical 
evaluations to measure the severity of joint inflammation in arthritic mice. (B) shows mean 
paw thickness of etanercept treated and PBS treated CII immunized mice which was 
calculated from the sum of the paw thickness of all mice in each group divided by the 
number of mice per group. (C) shows mean clinical of etanercept treated and PBS treated 
CII immunized mice which was calculated from the sum of the clinical scores of all mice in 
the each group divided by the number of mice per group. Mean paw thickness, mean clinical 
score and % incidence in CII immunised mice (3 CII immunized mice/group) were compared 
with those values of antigen naïve control mice (3 naïve mice; green line). These naïve 
control mice were neither sensitized with type II collagen nor given etanercept treatment. 
Data represent as mean ± SEM. (all 19 CII immunized mice in all groups). Statistical analysis 
of data was performed using two way ANOVA for multiple comparison, compared with a 
group of control naïve mice; *P < 05; **P < 01; ***P < 001. 
However,  the  etanercept  treatment  significantly  reduced  the  severity  of 
arthritis and delayed the start of arthritis in treatment group 4 compared to the 
placebo group 5. There were 5 mice in the treatment group 4 and the placebo 
group 5, both groups of mice were culled on day 35.  Mice in group 4 started to 
develop arthritis on day 19 days after immunization in the etanercept treated 
group, compared with 27 days in the PBS treated group 5 (Figure 5.3A). Anti Chapter 5    246 
TNF a treatment caused a significant reduction in paw swelling of etanercept 
treated mice in group 4 compared to those in PBS treated mice in group 5. The 
mean paw thickness of mice in group 4 and 5 (etanercept treated versus PBS 
treated) was 1.9 ± 0.89 mm versus 2.23 ± 0.33 mm (P=0.002) (Figure 5.3B). Mean 
clinical scores were also significantly reduced in the etanercept treated mice in 
group 4, compared to those of PBS treated mice in group 5. The mean clinical 
score of mice in group 4 and 5 (etanercept treated versus PBS treated) was 1.4 ± 
1.4 versus 3.8 ± 2.0 (P = 0.0014) (Figure 5.3C).  
 
Figure 5.3 Effect of etanercept on severity of arthritis in CII immunized mice on day 35 
(groups 4 and 5) 
CII immunized mice in Group 4 (5 etanecept treated CII immunizedc mice /group; blue line) 
were given injections from days 18 onwards before collagen immunization with 300  g 
etanercept every 3 days. 3 CII immunized mice in Group 5 were given PBS as placebo (5 
PBS treated CII immunizedc mice /group; red line). Mice in both Group 4 and Group 5 were 
culled on day 35. The signs of arthritis in CII immunized mice were monitored from day 16 
after immunization onwards. (A) shows the percent of incidence of arthritis in etanercept 
treated and PBS treated CII immunized mice, which was calculated from number of CII 
immunized mice with arthritis per group/total number of CII immunized mice used per 
group. Mean clinical arthritis score and mean paw thickness were used as clinical 
evaluations to measure the severity of joint inflammation in arthritic mice. (B) shows mean 
paw thickness of etanercept treated and PBS treated CII immunized mice which was 
calculated from the sum of the paw thickness of all mice in each group divided by the 
number of mice per group. (C) shows mean clinical of etanercept treated and PBS treated 
CII immunized mice which was calculated from the sum of the clinical scores of all mice in 
the each group divided by the number of mice per group. Mean paw thickness, mean clinical 
score and % incidence in CII immunised mice (5 CII immunized mice/group) were compared 
with those values of naïve control mice (5 naïve mice; green line). These naïve control mice Chapter 5    247 
were neither sensitized with type II collagen nor given etanercept treatment. Data represent 
as mean ± SEM. (all 19 CII immunized mice in all groups). Statistical analysis of data was 
performed using two way ANOVA for multiple comparison, compared with a group of 
control naïve mice; *P < 05; **P < 01; ***P < 001. 
Overall, there were 5 out of 8 PBS treated CII immunized mice from Group 3 and 
Group 5 (~62.5 % incidence) that showed clinical signs of arthritis from day 19. 
Etanercept  treated CII  immunized  mice  showed  a  lower  disease  incidence 
compared to those in PBS treated CII immunized mice. 3 out of 8 etanercept 
treated CII immunized mice from Group 2 and 4 developed arthritis from day 22 
(~37.5 % incidence) (Figure 5.4A). Clinical signs of arthritis were observed in 
PBS treated  CII  immunized  mice  from  Group  3  and  5  from  day  19  after 
immunization onward and there were 5 out of 8 PBS treated CII immunized mice 
developed  arthritis  (62.5%  incidence).  The  cumulative  mean  paw swelling 
diameter of all PBS treated CII immunized mice from Group 3 and Group 5 (n=8) 
was 2.2 ± 0.2 mm, which was significantly higher than those in naïve control 
mice  (1.700  ±  0.08  mm;  P=  0.0001).  Etanercept treated  CII  immunized  mice 
showed significantly less swelling than PBS treated CII immunized mice (2.0 ± 
0.08  mm;  P  <0.0001).  Two way  ANOVA  analysis  also  indicated  that  the 
cumulative mean of swelling diameter of etanercept treated CII immunized mice 
was significantly higher than those in control mice (1.70 ± 0.08 mm; P= 0.0005) 
(Figure  5.4B).  The  cumulative  mean  arthritis  score  of  etanercept treated  CII 
immunized mice was significantly lower than those of PBS treated CII immunized 
mice (2.25 ± 1.21 mm versus 3.75 ± 1.35 mm, p=0.001) (Figure 5.4C). A summary 
of  number  of  arthritic  mice,  mean  arthritis  score,  maximum  arthritis  score, 
mean paw diameter of etanercept treated and PBS treated CII immunized mice 
is presented in Table 1.  
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Figure 5.4 Effect of etanercept on severity of arthritis in all CII immunized mice in Group 2, 
3, 4 and 5  
CII immunized mice in Group 2 and Group 4 (n=8 for both groups; blue line) were given 
injections from days 18 onwards before collagen immunization with 300  g etanercept every 
3 days. 3 CII immunized mice in Group 3 and Group 5 were given PBS as placebo (n=8 CII 
immunized mice /for both groups; red line). Mice in both Group 4 and Group 5 were culled 
on day 32, while Mice in both Group 4 and Group 5 were culled on day 35. The signs of 
arthritis in CII immunized mice were monitor from day 16 after immunization onwards. (A) 
shows the cumulative percent of incidence of arthritis in all etanercept treated and all PBS 
treated CII immunized mice, which was calculated from number of CII immunized mice with 
arthritis per group/total number of CII immunized mice used per group. Cumulative mean 
clinical arthritis score and cumulative mean paw thickness were used as clinical evaluations 
to measure the severity of joint inflammation in arthritic mice. (B) shows cumulative mean 
paw thickness of all etanercept treated and all PBS treated CII immunized mice which was 
calculated from the sum of the paw thickness of all mice in each group divided by the 
number of mice per group. (C) shows cumulative mean clinical of all etanercept treated and 
all PBS treated CII immunized mice which was calculated from the sum of the clinical 
scores of all mice in the each group divided by the number of mice per group. Cumulative 
mean paw thickness, cumulative mean clinical score and cumulative % incidence in CII 
immunised mice (n= 3 CII immunised mice /group) were compared with those values of 
naïve control mice (n = 8 naïve control mice; green line). These naïve control mice were 
neither sensitized with type II collagen nor given etanercept treatment. Data represent as 
mean ± SEM. (n=16 CII immunized mice). Statistical analysis of data was performed using 
two way ANOVA for multiple comparison, compared with a group of control naïve mice; *P < 
05; **P < 01; ***P < 001. 
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Group 
 
Treatments 
 
 
Day of 
harvesting 
 
Arthritic/total 
number of 
mice 
 
Mean 
Arthritis 
scores 
 
Maximum 
Arthritis  
  scores 
 
Mean 
Paw    
Diameter 
 
 
2 
 
Etanercept 
 
32 
 
2/3 
 
3.67 ± 2.33 
 
8 
 
2.08 ± 0.23 
 
3 
 
PBS 
 
32 
 
2/3 
 
3.67 ± 1.86 
 
6 
 
2.2 ± 0.3 
 
4 
 
Etanercept 
 
35 
 
1/5 
 
1.4 ± 1.4 
 
7 
 
1.9 ± 0.9 
 
5 
 
PBS 
 
35 
 
3/5 
 
3.8 ± 2.0 
 
10 
 
2.2 ± 0.3 
Table 5.1 Numbers of arthritic mice, mean arthritis scores, and mean swelling scores of CIA 
mice in etanercept treated and PBS treated groups.  
Etanercept treated mice and PBS treated mice (Group 2 and 3) were culled on day 32, while 
etanercept treated mice and PBS treated mice (Group 4 and 5) were culled on day 35. 
Numbers of CII immunized mice developed arthritis from each time point group were 
counted on the harvesting day. Mean arthritis scores (total arthritis score/number of mice in 
the group), maximum arthritis score and mean swelling of CII immunized mice from each 
treatment time point group were calculated on the harvesting day. 
5.2.2  Effect of etanercept on serum inflammatory mediator 
protein concentrations in CII immunized mice on day 14, day 
32 and day 35 by Luminex cytokine 20 plex assay 
The aim of this experiment is to investigate whether etanercept has any effect 
on  peripheral  inflammatory  mediator  protein  profiles  of  CII  immunized  mice 
during the early and the late stages of disease in the CIA model. Serum collected 
from etanercept treated and PBS treated control mice on day 32 and day 35 
were  determined  for  changes  in  several  cytokines,  chemokines  and  growth 
factors using a Luminex cytokine 20 plex assay. However, all the inflammatory 
mediator protein concentrations in serum of mice from all experimental groups 
were lower than the detection limits of this assay.   Chapter 5    250 
5.2.3   Changes in inflammatory mediator protein 
concentrations in the brains of etanercept treated and 
untreated CII immunized mice on day 14, day 32 and day 35  
Etanercept has shown its protective effect on the joint inflammation in this CIA 
model by delaying the onset of arthritis and reducing the severity of arthritis in 
CIA model (Williams et al., 2000b). In this study, etanercept was administrated 
to CII immunized mice as a protective therapy before the disease onset (from 
day 18 onwards). Results from the previous chapter (Chapter 4; sections 4.2.3 
and  4.2.4)  demonstrated  that  longitudinal  changes  in  several  inflammatory 
mediators  in  brains  of  CII  immunized  mice  throughout  the  period  of  clinical 
expression of the disease (onset of the disease, early and late phase of disease). 
Several inflammatory mediators were up regulated in brains of CII immunized 
mice  during  the  onset  and  early  disease  stage  (day  22  –  day  35  after 
immunization), and some of these inflammatory mediators were up regulated 
during the late stage of the disease (day 35 – day 42 after immunization). In the 
previous chapter, we started to measured inflammatory mediators in brains of 
CII immunized mice from day 22 as a time point of disease onset. However, del 
Ray  et  al.,  reported  the  upregulation  of  IL 1β  and  IL 6  in  brains  of  CIA  rats 
before  the  onset  of  RA  disease  (during  the  first  20  days  after  the  primary 
immunization)  (del  Rey  et  al.,  2008).  In  our  study,  changes  in  these  brain 
inflammatory cytokine concentrations before the onset of the disease have not 
been determined. To determine changes in brain inflammatory mediator protein 
concentrations  in  CII  immunized  mice  before  the  onset  of  RA  disease,  we 
measured  protein  concentrations  of  brain  inflammatory  mediator  in  CII 
immunized mice on day 14 to represent a reasonale time point before disease 
onset and before the etanercept treatment.  
We  investigated  the  effects  of  etanercept  on  brain  inflammatory  mediator 
profiles  in  treated  and  un treated  CII  immunized  mice  during  the  period  of 
clinical expression of the disease, and studied the association with its effect on 
the  amelioration  of  joint  disease  during  those  time  points.    We  determined 
changes in brain inflammatory mediator protein concentrations on day 32 as the 
time point of early stage of disease and day 35 as the time point of late stage of 
the disease. Inflammatory mediators in brains of mice of all experimental groups 
were  determined  using  a  Luminex  and  ELISA  assay.  To  investigate  effects  of Chapter 5    251 
etanercept  on  brain  inflammatory  mediator  protein  profiles, half  brain  tissue 
homogenates of CII immunized mice treated with etanercept on day 32 and day 
35 were determined for inflammatory mediator protein concentrations compared 
to those in CII immunized mice treated with PBS or control naive mice. 
5.2.3.1   Effects of etanercept on pro inflammatory cytokine protein 
profiles in the brain of CII immunized mice on days 14, 32 and 35 
The protein concentrations of pro inflammatory cytokines including IL 6, IL 1 β 
and TNF α were determined by ELISA assays in brain homogenates of mice from 
all experimental groups. 
On day 14, the concentrations of brain TNF α protein of CII immunized mice and 
naïve  control  mice  were  not  significantly  different  (Figure  5.5A).  During  the 
period  of  clinical  expression  of  disease  on  day  32  and  day  35,  there  was  no 
significant difference in the concentrations of brain TNF α protein between PBS 
treated  CII  immunized  mice  and  naïve  control  mice.  However,  etanercept 
treated  mice  showed  a  significant  reduction  in  brain  TNF α  protein 
concentrations compared to those in naïve control mice and in PBS treated CII 
immunized mice (Figure 5.5A). One way ANOVA analysis followed by Bonferroni's 
post hoc comparison tests demonstrated that there were significant differences 
in protein concentration of TNF α among the three groups of mice culled on day 
32  (P  =  0.0006)  (Figure  5.5A).  The  mean  value  of  brain  TNF α  protein 
concentrations on day 32 (etanercept treated versus PBS treated CII immunized) 
was 54.3 ± 2.9 pg/mg total brain protein versus 92.2 ± 8.9 pg/mg total brain 
protein  (P  <  0.01),  while  the  mean  value  of  brain  TNF α  of  on  day  32 
(etanercept treated  versus  naïve  control)  was  54.3  ±  2.9  pg/mg  total  brain 
protein versus 79.2 ± 4.2 pg/mg total brain protein (P < 0.001). A similar pattern 
of TNF α protein concentrations was observed in brain of treated, PBS treated 
CII immunized mice compared to those of the naïve control mice on day 35. 
However,  one way  ANOVA  analysis  showed  that  there  was  no  significant 
difference  between  TNF α  protein  concentrations  in  brains  of  etanercept 
treated, PBS treated CII immunized mice and naïve control mice on day 35 (P = 
0.1632) (Figure 5.5A). Chapter 5    252 
During the pre onset period (day 14) there was no significant difference in brain 
IL 1β  protein  concentrations  between  naïve  control  and  CII  immunized  mice 
(Figure  5.5B).  One way  ANOVA  analysis  showed  that  there  was  no  significant 
difference between IL 1β protein concentrations in brains of etanercept treated, 
PBS treated CII immunized mice and naïve control mice on day 32 (P = 0.5619). 
However, one way ANOVA analysis followed by Bonferroni's post hoc comparison 
tests  also  demonstrated  that  there  were  significant  differences  in  protein 
concentration of IL 1β among the three groups of mice culled on day 35 (P = 
0.0030). The brain IL 1β protein concentrations of PBS treated CII immunized 
mice were significantly lower than those of naïve control mice. The mean value 
of  brain  IL 1β    protein  concentrations  on  day  35  (PBS treated  versus  naïve 
control ) was 62.6 ± 18.5 pg/mg total brain protein versus 75.9 ± 15.3 pg/mg 
total brain protein (P < 0.01). Similarly, the brain IL 1β protein concentrations of 
etanercept treated  CII  immunized  mice  were  also  lower  than  those  of  PBS 
treated mice; the mean value of brain IL 1β protein concentrations on day 35 
(etanercept treated  versus  naïve  control)  was  68.2  ±  6.6  pg/mg  total  brain 
protein versus 75.9 ± 15.3 pg/mg total brain protein (P < 0.05) (Figure 5.5B).  
Similar  to  TNF α  and  IL 1β,  there  was  no  significant  difference  in  brain  IL 6 
protein concentrations between naïve control mice and CII immunized mice on 
day  14  (Figure  5.5C).  One way  ANOVA  analysis  showed  that  there  was  no 
significant  difference  between  IL 6  protein  concentrations  in  brains  of 
etanercept treated, PBS treated CII immunized mice and naïve control mice on 
day  32  (P  =  0.7684).  One way  ANOVA  analysis  showed  that  there  was  no 
significant  difference  between  IL 6  protein  concentrations  in  brains  of 
etanercept treated, PBS treated CII immunized mice and naïve control mice on 
day 35 (P = 0.1368) (Figure 5.5C). 
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Figure 5.5 Effects of etanercept on brain pro inflammatory cytokine protein profiles in CII 
immunized mice on days 14, 32 and 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards. The protein concentrations of brain pro inflamamtory 
cytokines (TNF α α α α, IL 1β β β β and IL 6) of CII immunized mice and naïve control mice were 
determined on day 14 as a time point of pre onset of disease and before etanercept 
treatment. CII immunized mice treated with PBS as a placebo control, were described as 
PBS treated CII immunized mice. Etanercept treated and PBS treated CII immunized mice 
were culled on day 32 and day 35, and brains were harvested and processed for 
inflammatory mediator protein determination. Brain samples collected from antigen naïve 
control mice (white bars) culled on the days indicated were used as controls. TNF α α α α (A), IL 
1β β β β (B) and IL 6 (C) protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using ELISA assays. Pro inflammatory cytokine 
protein concentrations in brain tissue, normalized against total brain protein, are expressed 
as pg/mg total brain protein. Error bars represent means ± SD (n = 3 mice on day 14 and day Chapter 5    254 
32, n = 5 mice on day 35). Statistical analysis of data was performed using one way ANOVA 
(*P < 05; **P < 01; ***P < 001). 
5.2.3.2  Effects of etanercept on Th1 cytokine protein profiles in the 
brain of CII immunized mice on days 14, 32 and 35 
IL 2 and IL 12 were the only Th1 cytokines that could be detected using ELISA 
assays in the brain tissue of mice from all experimental groups. Similar to the 
profile of pro inflammatory cytokines, there were no significant changes in Th1 
cytokine (IL 2 and IL 12) protein concentrations in brains of CII immunized mice 
compared  to  naïve  control  mice  during  the  pre onset  time  point  on  day  14 
(Figure 5.6A and Figure 5.6B) 
One way  ANOVA  analysis  showed  that  there  was  no  significant  difference 
between  IL 2  protein  concentrations  in  brains  of  treated,  PBS treated  CII 
immunized mice and naïve control mice on day 32 (P = 0.2046). One way ANOVA 
demonstrated that there was a significant difference in protein concentration of 
IL 2 among the three groups of mice on day 35 (P = 0.0222). Post hoc analysis 
with  Bonferroni  correction  demonstrated  that  there  was  a  significant  up 
regulation  in  brain  IL 2  cytokine  concentrations  in  etanercept treated  CII 
immunized mice compared to those of PBS treated CII immunized mice on day 
35. The mean value of brain IL 2 protein concentrations on day 35 (etanercept 
treated versus PBS treated) was 422.9 ± 45.4 pg/mg total brain protein versus 
337.5 ± 48.3 pg/mg total brain protein (P < 0.05) (Figure 5.6A). 
One way ANOVA analysis demonstrated that there was a significant difference in 
protein concentration of IL 12 among the three groups of mice on day 32 (P = 
0.0110). Post hoc analysis with Bonferroni correction demonstrated that there 
was a significant reduction in brain IL 12 protein concentrations in etanercept 
treated mice compared with PBS treated CII immunized mice on day 32. The 
mean value of brain IL 12 on day 32 (etanercept treated versus PBS treated) was 
35.0 ± 10.3 pg/mg total brain protein versus 265.6 ± 107.2 pg/mg total brain 
protein (P < 0.05). The similar pattern of brain IL 12 protein concentrations in 
mice from all experimental groups was also observed on day 35. One way ANOVA 
followed  by  Bonferroni's  post hoc  comparison  tests  demonstrated  that  there 
were significant differences in protein concentration of IL 12 among the three 
groups of mice on day 35 (P < 0.0001). Again, brain IL 12 protein concentrations Chapter 5    255 
in etanercept treated CII immunised mice were significantly lower than those in 
naïve  control  and  PBS  treated  mice.  The  mean  value  of  brain  IL 12  protein 
concentrations on day 35 (etanercept treated versus naïve control) was 37.9 ± 
7.8 pg/mg total brain protein versus 199.8 ± 13.4 pg/mg total brain protein (P < 
0.001), while the mean value of brain IL 12 protein concentrations on day 35 
(etanercept treated  versus  PBS treated)  was  37.9  ±  7.8  pg/mg  total  brain 
protein versus 197.8 ± 21.7 pg/mg total brain protein (P < 0.001) (Figure 5.6B). 
 
Figure 5.6 Effects of etanercept on brain Th1 cytokine protein profiles in CII immunized mice 
on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen naïve control mice (white bars). The protein 
concentrations of brain Th1 cytokines (IL 2 and IL 12) of CII immunized mice and naïve 
control mice were determined on day 14 as a time point of pre onset of disease and before 
the etanercept treatment. CII immunized mice treated with PBS as a placebo were 
considered as PBS treated CII immunized mice. Etanercept treated and PBS treated CII 
immunized mice were culled on day 32 and day 35, and brains were harvested and 
processed for inflammatory mediator protein determination. Brain samples collected from 
naïve control mice (white bars) culled on the days indicated were used as controls. IL 2 (A) 
and IL 12 (B) protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using ELISA assays. Th1 cytokine protein 
concentrations in brain tissue, normalized against total brain protein, are expressed as 
pg/mg total brain protein. Error bars represent means ± SD (n = 3 mice on day 14 and day 
32, n = 5 mice on day 35). Statistical analysis of data was performed using one way ANOVA 
(*P < 05; **P < 01; ***P < 001). 
5.2.3.3  Effects of etanercept on Th2 cytokine protein profiles in the 
brain of CII immunized mice on days 14, 32 and 35 
The  Th2  cytokines  IL 4,  IL 5,  IL 10  and  IL 13  protein  concentrations  were 
detectable by ELISA assays in brain tissue of mice from all experimental groups. 
Again,  there  was  no  significant  different  in  these  Th2  cytokine  protein 
concentrations between CII immunized mice and control mice on day 14 before 
the onset and the etanercept treatment (Figure 5.7A   Figure 5.7D) Chapter 5    256 
One  way ANOVA analysis demonstrated that there was no significant difference 
between IL 4 protein concentrations in brains of etanercept treated and PBS 
treated CII  immunized  mice  and  naïve  control  mice  on  day  32  (P  =  0.7808). 
There  was  no  significant  difference  between  IL 4  protein  concentrations  in 
brains of etanercept treated, PBS treated CII immunized mice and naïve control 
mice on day 35 (P = 0.8415) (Figure 5.7A). 
One way ANOVA analysis demonstrated that there were significant differences in 
protein concentration of IL 5 among the three groups of mice on day 32 (P = 
0.0183). Post hoc analysis with Bonferroni correction demonstrated that there 
was a significant reduction in brain IL 5 protein concentrations in etanercept 
treated mice compared with PBS treated CII immunized mice on day 32. There 
was no significant difference in brain IL 5 protein concentrations between PBS 
treated  CII  immunized  mice and  naïve  control  mice.  significant  reductions  in 
brain  IL 5  protein  concentrations  of  etanercept treated  CII  immunized  mice 
compared to those in naïve control mice and PBS treated CII immunized mice 
were observed on day 32. The mean value of brain IL 5 protein concentrations 
on day 32 (etanercept treated versus naïve control) was 4.4 ± 0.9 pg/mg total 
brain protein versus 9.3 ± 1.7 pg/mg total brain protein (P < 0.05), while the 
mean value of brain IL 5 protein concentrations on day 32 (etanercept treated 
versus PBS treated) was 4.4 ± 0.9 pg/mg total brain protein versus 8.9 ± 2.1 
pg/mg total brain protein (P < 0.05). One way ANOVA analysis demonstrated that 
there were significant differences in protein concentration of IL 5 among the 
three groups of mice on day 35 (P = 0.0025). Post hoc analysis with Bonferroni 
correction  demonstrated  that  there  was  a  significant  reduction  in  brain  IL 5 
protein concentrations in etanercept treated mice compared with PBS treated 
CII immunized mice on day 35. PBS treated CII immunized mice had lower brain 
IL 5 protein concentrations compared to those of naïve control mice. The mean 
value of brain IL 5 protein concentrations on day 35 (PBS treated versus naïve 
control) was 6.5 ± 1.3 pg/mg total brain protein versus 9.7± 2.6 pg/mg total 
brain protein (P < 0.05). Interestingly, etanercept treated CII immunized mice 
also show significant reductions in brain IL 5 protein concentrations compared to 
those in naïve control mice on day 35. The mean value of brain IL 5 protein 
concentrations on day 35 (etanercept treated versus naïve control) was 4.8 ± 0.9 Chapter 5    257 
pg/mg total brain protein versus 9.7± 2.6 pg/mg total brain protein (P < 0.01) 
(Figure 5.7B).  
One way ANOVA analysis demonstrated that there was no significant difference 
between  IL 10  protein  concentrations  in  brains  of  etanercept treated,  PBS 
treated CII immunized mice and naïve control mice on day 32 (P = 0.6607). One 
way  ANOVA  analysis  also  showed  that  there  was  no  significant  difference 
between  IL 10  protein  concentrations  in  brains  of  etanercept treated,  PBS 
treated CII  immunized  mice  and  naïve  control  mice  on  day  35  (P  =  0.3533) 
(Figure 5.7C). 
One way ANOVA analysis demonstrated that there was no significant difference 
between  IL 13  protein  concentrations  in  brains  of  etanercept treated,  PBS 
treated CII  immunized  mice  and  control  naïve  mice  on  day  32  (P  =  0.3703). 
However, one way ANOVA demonstrated that there was a significant difference 
in protein concentration of IL 13 among the three groups of mice on day 35 (P = 
0.0185). Post hoc analysis with Bonferroni correction demonstrated that there 
was  a  significant  reduction  in  brain  IL 13  protein  level  in  PBS treated  CII 
immunized  mice  compared  to  those  of  naïve  control  mice  and  treated  CII 
immunized mice on day 35. The mean value of brain IL 13 protein concentrations 
on day 35 (PBS treated versus naïve control) was 28.0 ± 15.9 pg/mg total brain 
protein versus 50.5 ± 9.0 pg/mg total brain protein (P < 0.05) (Figure 5.7D).  
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 Figure 5.7 Effects of etanercept on brain Th2 cytokine protein profiles in CII immunized 
mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen naïve control mice (white bars). The protein 
concentrations of brain Th2 cytokines (IL 4, IL 5, IL 10 and IL 13) of CII immunized mice and 
naïve control mice were determined on day 14 as the time point of pre onset and before the 
etanercept treatment. CII immunized mice treated with PBS as placebo, were considered as 
PBS treated CII immunized mice. Etanercept treated and PBS treated CII immunized mice 
were culled on day 32 and day 35, and brains were harvested and processed for 
inflammatory mediator protein determination. Brain samples collected from naïve control 
mice (white bars) culled on the days indicated were used as controls. IL 4 (A), IL 5 (B), IL 10 
(C) and IL 13 (D) protein concentrations in brain tissue homogenate of mice from all 
experimental groups were determined using ELISA assays. Th2 cytokine protein 
concentrations in brain tissue, normalized against total brain protein, are expressed as 
pg/mg total brain protein. Error bars represent means ± SD (n = 3 mice on day 14 and day 
32, n = 5 mice on day 35). Statistical analysis of data was performed using one way ANOVA 
(*P < 05; **P < 01; ***P < 001). 
5.2.3.4  Effects of etanercept on chemokine protein profiles in the brain 
of CII immunized mice on days 14, 32 and 35 
Changes in CXCL1 protein concentrations in brain tissue extracts of mice from all 
experimental  groups  were  detected  using  a  Luminex  assay.  There  was  no 
significant  difference  in  brain  CXCL1  protein  concentrations  between  naïve 
control mice and CII immunized mice on day 14 before the onset of disease and 
the etanercept treatment. In addition, one way ANOVA analysis demonstrated 
that there was no significant difference between CXCL1 protein concentrations Chapter 5    259 
in  brains  of  etanercept treated,  PBS treated  CII  immunized  mice  and  naïve 
control mice on day 32 (P = 0.0798). One way ANOVA analysis also demonstrated 
that there were significant differences in protein concentration of CXCL1 among 
the  three  groups  of  mice  on  day  35  (P  =  0.0004).  Post  hoc  analysis  with 
Bonferroni correction demonstrated that there was a significant increase in brain 
CXCL1 protein concentrations in PBS treated CII immunized mice compared to 
those  in  the  naïve  control  mice  on  day  35.  The  mean  value  of  brain  CXCL1 
protein concentrations on day 35 (PBS treated versus naïve control) was 51.6 ± 
7.0 pg/mg total brain protein versus 26.9 ± 10.8 pg/mg total brain protein (P < 
0.001). Interestingly, etanercept decreased brain CXCL1 protein concentrations 
in CII immunized mice as etanercept treated CII immunized showed a significant 
reduction  in  brain  CXCL1  protein  concentrations  compared  to  those  in  PBS 
treated  CII  immunized  mice.  The  mean  value  of  brain  CXCL1  protein 
concentrations on day 35 (etanercept treated versus PBs treated) was 51.6 ± 7.0 
pg/mg total brain protein versus 29.5 ± 6.3 pg/mg total brain protein (P < 0.01) 
(Figure 5.8). 
 
Figure 5.8 Effects of etanercept on brain chemokine (CXCL1) protein profiles in CII 
immunized mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen naïve control mice (white bars). The protein 
concentrations of brain a chemokine CXCL1 of CII immunized mice and naïve control mice 
were determined on day 14 as the time point of pre onset and before the etanercept 
treatment. CII immunized mice treated with PBS as a placebo, were considered as PBS 
treated CII immunized mice. Etanercept Treated and PBS treated CII immunized mice were 
culled on day 32 and day 35, and brains were harvested and processed for inflammatory 
mediator protein determination. Brain samples collected from naïve control mice (white 
bars) culled on the days indicated were used as controls. Chemokine CXCL1 protein 
concentrations in brain tissue homogenate of mice from all experimental groups were 
determined using a Luminex assay. Chemokine CXCL1 protein concentrations in brain 
tissue, normalized against total brain protein, are expressed as pg/mg total brain protein. 
Error bars represent means ± SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). 
Statistical analysis of data was performed using one way ANOVA (*P<0.05, **P<0.01, 
***P<0.001). Chapter 5    260 
 
5.2.3.5  Effects of etanercept on growth factor protein profiles in the 
brain of CII immunized mice on days 14, 32 and 35 
VEGF  and  FGF2  growth  factors  were  detected  using  an  ELISA  assay  and  a 
Luminex assay  in  brain  tissue  extracts  of mice  from  all  experimental  groups. 
One way  ANOVA  analysis  showed  that  there  was  no  significant  difference 
between  VEGF  protein  concentrations  in  brains  of  etanercept treated,  PBS 
treated CII immunized mice and naïve control naïve mice on day 32 (P = 0.2730). 
However,  one way  ANOVA  analysis  also  demonstrated  that  there  was  a 
significant difference in protein concentration of VEGF among the three groups 
of mice on day 35 (P = 0.0115). Post hoc analysis with Bonferroni correction 
demonstrated  that  brain  VEGF  protein  level  was  significantly  increased  in 
etanercept treated  CII  immunized  mice  compared  to  those  in  PBS treated  CII 
immunized mice. The mean value of brain VEGF protein concentrations on day 
35 (PBS treated versus etanercept treated) was 431.6 ± 59.8 pg/mg total brain 
protein versus 332.6 ± 32.5 pg/mg total brain protein (P < 0.05) (Figure 5.9A). 
There  was  no  significant  difference  between  FGF2  protein  concentrations  in 
brains of etanercept treated, PBS treated CII immunized mice and naïve control 
mice on both day 32 and day 35 (Figure 5.9B).  
 
Figure 5.9 Effects of etanercept on brain growth factor protein profiles in CII immunized 
mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen naïve control mice (white bars). The protein 
concentrations of brain growth factors (VEGF and FGF2) of CII immunized mice and naïve 
control mice were determined on day 14 as the time point of pre onset and before the 
etanercept treatment. CII immunized mice treated with PBS as a placebo, were considered 
as PBS treated CII immunized mice. Etanercept treated and PBS treated CII immunized mice 
were culled on day 32 and day 35, and brains were harvested and processed for 
inflammatory mediator protein determination. Brain samples collected from naïve control 
mice (white bars) culled on the days indicated were used as controls. VEGF (A) and FGF2 
(B) protein concentrations in brain tissue homogenate of mice from all experimental groups Chapter 5    261 
were determined using ELISA assays. Growth factor protein concentrations in brain tissue, 
normalized against total brain protein, are expressed as pg/mg total brain protein. Error 
bars represent means ± SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). 
Statistical analysis of data was performed using one way ANOVA (*P<0.05, **P<0.01, 
***P<0.001). 
5.2.4   Changes in inflammatory mediator gene expression in 
the brains of etanercept treated and PBS treated CII 
immunized mice on day 14, day 32 and day 35 by real time 
PCR 
We  also  investigated  the  effects  of  etanercept  on  the  gene  expression  of 
inflammatory  mediators  in  CII  immunized  mice.  Real time  PCR  was  used  to 
quantify the gene expression of the same pro inflammatory cytokines (IL 6, IL 1 
β, TNF α and IL 1α), Th1 cytokines (IL 2, IL 12 and IFN γ), Th2 cytokines (IL 4, 
IL 5, IL 10 and IL 13), chemokines (CXCL1, CXCL10, CCL2 and CCL3) and growth 
factors (FGF2 and, VEGF) using one half of the brain tissue of mice from all 
experimental groups. Gene expression of IL 1β, CXCL1, CXCL10, FGF2 and VEGF 
were detectable within the assay detection limits.  
5.2.4.1   Effects of etanercept on pro inflammatory cytokine mRNA 
profiles in brains of CII immunized mice on days 14, 32 and 35 by 
Real time PCR assays 
The gene expression of pro inflammatory cytokines including IL 6, IL 1β and TNF 
α and IL 1α were determined in brains of mice from all experimental groups. In 
our study, IL 1β was the only pro inflammatory cytokine gene expression levels 
detectable within the detection limit of the assays.  
There was no significant difference in brain IL 1β mRNA levels between naïve 
control mice and CII immunized mice on day 14 before the etanercept treatment 
and onset of the disease. On day 32, one way ANOVA analysis showed that there 
was no significant difference between IL 1β mRNA levels in brains of etanercept 
treated, PBS treated CII immunized mice and naïve control mice (P = 0.2444). 
Brain IL 1β mRNA levels in PBS treated CII immunized mice was higher, but not 
significant,  than  those  of  naïve  control  mice.  One way  ANOVA  analysis 
demonstrated  that  there  were  significant  differences  in  IL 1β  mRNA  levels 
among the three groups of mice on day 35 (P = 0.0011). Post hoc analysis with 
Bonferroni correction demonstrated that PBS treated CII immunized mice had a 
significantly higher brain IL 1β mRNA level compared to those in naïve control Chapter 5    262 
mice on day 35. The mean value of brain IL 1β mRNA levels on day 35 (PBS 
treated versus naïve control) was 1261 ± 158 versus 702 ± 109 (P < 0.05). At this 
time  point,  IL 1β  mRNA  levels  in  brains  of  etanercept treated  CII  immunized 
mice  was  decreased  significantly  compared  to  those  of  PBS treated  CII 
immunized mice. The mean value of IL 1β mRNA levels on day 35 (etanercept 
treated versus PBS treated) was 478 ± 33 versus 1261 ± 158 (P < 0.01) (Figure 
5.10). 
 
Figure 5.10 Effects of etanercept on a brain pro inflammatory cytokine gene expression 
profiles in CII immunized mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen naïve control mice (white bars). The mRNA 
levels of a brain pro inflammatory cytokine IL 1β β β β of CII immunized mice and naïve control 
mice were determined on day 14 as the time point of pre onset and before the etanercept 
treatment. CII immunized mice treated with PBS as a placebo, were considered as PBS 
treated CII immunized mice. Etanercept treated and PBS treated CII immunized mice were 
culled on day 32 and day 35, and brains were harvested and processed for inflammatory 
mediator protein determinations. Brain samples collected from normal mice (white bars) 
culled on the days indicated were used as controls. IL 1β β β β mRNA levels in brain tissue 
homogenate of mice from all experimental groups were determined using Real time PCR. 
mRNA levels of pro inflammatory cytokines in brain tissue, normalized against the 
housekeeping gene GAPDH, are expressed as arbitrary units. Error bars represent means ± 
SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). Statistical analysis of data was 
performed using one way ANOVA (*P<0.05, **P<0.01, ***P<0.001). 
5.2.4.2  Effects of etanercept on Th1 cytokine mRNA profiles in brains 
of CII immunized mice on days 14, 32 and 35 by real time PCR assays 
Changes in gene expression of Th 1 cytokines, including IL 12, IL 2 and IFN γ, 
over time were determined in the brains of mice from all experimental groups. 
However,  there  was  no  significant  difference  between  Th 1  cytokines  mRNA 
levels in brains of treated, PBS treated CII immunized mice and control naïve 
mice on day 32 and day 35. Chapter 5    263 
5.2.4.3  Effects of etanercept on Th2 mRNA profiles in brains of CII 
immunized mice on days 14, 32 and 35 by real time PCR assays 
Th 2  cytokines,  including  IL 4,  IL 5,  IL 10  and  IL 13  gene  expression  were 
determined in the brains of mice from all experimental groups. However, there 
was no significant different between Th 2 cytokines mRNA levels in brains of 
treated, PBS treated CII immunized mice and control naïve mice on day 32 and 
day 35. 
5.2.4.4  Effects of etanercept on chemokine mRNA profiles in brains of 
CII immunized mice on days 14, 32 and 35 by real time PCR assays 
CXCL1, CXCL10, CCL2 and CCL3 gene expression levels were determined in the 
brains of control mice from all experimental groups. Among these chemokines, 
only CXCL1 and CXCL10 were detectable within the assay limits. During the pre 
onset time on day 14, there was no significant difference in CXCL1 and CXCL10 
mRNA  levels  between  naïve  control  mice  and  CII  immunized  mice  on  day  14 
before the etanercept treatment.  
One way ANOVA analysis demonstrated that there was no significant difference 
between  CXCL1  mRNA  levels  in  brains  of  etanercept treated,  PBS treated  CII 
immunized mice and naïve control mice on day 32 and day 35 (P = 0.0761 and P 
= 0.2627 respectively). Increases in brain CXCL1 mRNA levels was observed in 
PBS treated  CII  immunized  mice  compared  to  those  in  naïve  control  and 
etanercept treated  CII  immunized  mice  on  both  time  points.  However,  a 
statistical analysis using one way ANOVA analysis showed that the differences 
were not significant (Figure 5.11A).  
One way ANOVA analysis demonstrated that there was no significant difference 
between CXCL10 mRNA levels in brains of treated, untreated CII immunized mice 
and  naïve  control  mice  on  day  32  and  day  35  (P  =  0.5512  and  P  =  0.5347 
respectively) (Figure 5.11B). 
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Figure 5.11 Effects of etanercept on a brain chemokine gene expression profiles in CII 
immunized mice on day 32 and day 35  
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen naïve control mice (white bars). The mRNA 
levels of a brain chemokine CXCL1 and CXCL10 of CII immunized mice and naïve control 
mice were determined on day 14 as the time point of pre onset and before the etanercept 
treatment. CII immunized mice treated with PBS as a placebo, were considered as PBS 
treated CII immunized mice. Etanercept treated and PBS treated CII immunized mice were 
culled on day 32 and day 35, and brains were harvested and processed for inflammatory 
mediator protein determinations. Brain samples collected from normal mice (white bars) 
culled on the days indicated were used as controls. CXCL1 (A) and CXCL10 (B) mRNA levels 
in brain tissue homogenate of mice from all experimental groups were determined using 
Real time PCR. mRNA levels of chemokines in brain tissue, normalized against the 
housekeeping gene GAPDH, are expressed as arbitrary units. Error bars represent means ± 
SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). Statistical analysis of data was 
performed using one way ANOVA (*P<0.05, **P<0.01, ***P<0.001). 
 
5.2.4.5   Effects of etanercept on growth factor mRNA profiles in brains 
of CII immunized mice on days 14, 32 and 35 by real time PCR assays 
Gene expression of growth factor mRNA for FGF2 and VEGF were detectable in 
the  brains  of  mice  from  all  experimental  groups.  There  was  no  significant 
difference in FGF2 and VEGF mRNA levels observed in brains of CII immunized 
mice and naïve control mice.  
One way ANOVA analysis demonstrated that there was no significant difference 
between VEGF mRNA levels in brains of treated, PBS treated CII immunized mice 
and  naïve  control  mice  on  day  32  and  day  35  (P  =  0.6335  and  P  =  0.6188 
respectively) (Figure 5.12A). 
One way ANOVA analysis demonstrated that, on day 32, there was no significant 
difference  between  FGF2  mRNA  levels  in  brains  of  etanercept treated,  PBS 
treated CII immunized mice and naïve control mice (P = 0.1145). However, brain 
FGF2  mRNA  levels  in  both etanercept treated  and  PBS treated CII  immunized 
mice appeared lower than those in naïve control mice at that time point. On day Chapter 5    265 
35,  One way  ANOVA analysis  also  demonstrated  that  there  was  no  significant 
difference in brain FGF2 mRNA levels among the three groups of mice on day 35 
(P = 0.0544) (Figure 5.12B). 
 
Figure 5.12 Effects of etanercept on a brain growth factor gene expression profiles in CII 
immunized mice on day 32 and day 35 
CII immunized mice were treated with etanercept (gray bars), or PBS (black bars) from day 
18 after immunization onwards; and antigen naïve control mice (white bars). The mRNA 
levels of a brain chemokine VEGF and FGF2 of CII immunized mice and naïve control mice 
were determined on day 14 as the time point of pre onset and before the etanercept 
treatment. CII immunized mice treated with PBS as a placebo, were considered as PBS 
treated CII immunized mice. Etanercept treated and PBS treated CII immunized mice were 
culled on day 32 and day 35, and brains were harvested and processed for inflammatory 
mediator protein determinations. Brain samples collected from normal mice (white bars) 
culled on the days indicated were used as controls. VEGF (A) and FGF2 (B) mRNA levels in 
brain tissue homogenate of mice from all experimental groups were determined using Real 
time PCR. mRNA levels of growth factors in brain tissue, normalized against the 
housekeeping gene GAPDH, are expressed as arbitrary units. Error bars represent means ± 
SD (n = 3 mice on day 14 and day 32, n = 5 mice on day 35). Statistical analysis of data was 
performed using one way ANOVA (*P<0.05, **P<0.01, ***P<0.001). 
5.3   Summary; Effects of etanercept on inflammatory 
mediator mRNA and protein profiles in brains of CII 
immunized mice 
In  this  chapter,  we  investigated  the  effect  of  TNF blockade  therapy  using 
etanercept  on  brain  inflammatory  mediator  profiles,  comparing  etanercept 
treated  and  PBS treated  CII  immunized  mice  during  the  period  of  clinical 
expression  of  the  disease,  and  studied  the  association  with  its  effect  on  the 
amelioration  of  joint  disease  during  those  time  points.    We  found  that 
etanercept  treatment  not  only  alleviated  arthritis,  but  also  had  effects  on 
inflammatory mediator mRNA and protein profiles in the brains of CII immunized 
mice. These changes in mRNA expression and protein concentrations of IL 1β, 
TNF α, IL 6, IL 4, IL 5, IL 10, IL 13, IL 2, IL 12, CXCL1, CXCL10, VEGF and FGF2 
are summarised in Table 5.2 Chapter 5    266 
 
Day 32 
 
 
Day 35 
 
 
Inflammatory 
mediators 
 
Protein 
 
mRNA 
 
 
Protein 
 
mRNA 
IL 1β  NS  NS  NS  P < 0.01 
 
TNF α  P < 0.01  UD  NS 
 
UD 
IL 6  NS  UD  NS 
 
UD 
IL 4  NS  UD  NS  UD 
IL 5  P < 0.01 
 
UD  NS   UD 
IL 10  NS  UD  NS 
 
UD 
IL 13  NS  NS  UD 
 
UD 
IL 2  NS  UD      P < 0.05 
 
UD 
IL 12  P < 0.05 
 
UD  P < 0.001 
 
UD 
CXCL1  NS  NS      P < 0.01 
 
NS 
CXCL10  UD  NS  UD 
 
N 
VEGF  NS  NS  P < 0.05 
 
NS 
FGF2  NS  NS  NS  NS  
 
Table 5.2 Effects of etanercept on inflammatory mediator protein and mRNA profiles in 
brains of etanercept treated CII immunized mice relative to those of PBS treated CII 
immunized mice  
Red arrows represent changes in of inflammatory mediator protein concentrations, while 
blue arrows represent changes in inflammatory mediator mRNA levels in brains of 
etanercept treated CII immunized mice compared to PBS treated CII immunized mice on day 
32 and day 35. Differences between inflammatory mediator concentrations in etanercept 
treated CII immunized mouse brains and PBS treated CII immunized mouse brains were 
analyzed by Student's t  test (*P < 005; **P < 002; ***P < 001). NS = not statistically 
significant, UD= Undetectable (below assay detection limit. 
In  this  experiment,  we  investigated  effects  of  etanercept  on  inflammatory 
mediator production in brains of CII immunized mice during the early stage of 
disease  (day  32  after  imunization)  and  late  stage  of  disease  (day  35  after 
immunization).  We  found  that,  at  the  early  stage  of  RA  disease,  etanercept 
reduced  the  production  of  TNF α  and  the  Th1  cytokine  IL 12,  which  are 
considered  to  be  the  main  cytokines  that  initiate  the  RA  disease  process. 
However,  at  the  late  stage  etanercept  reduced  IL 1β  and  TNF α  production, Chapter 5    267 
while increasing IL 6 production. Surprisingly, etanercept showed contradictory 
effects on two different Th1 cytokines, IL 2 and IL 12. Etanercept reduced brain 
IL 12  protein  concentrations,  but  increased  brain  IL 2  protein concentrations, 
suggesting that etanercept may induce different signals on Th1 cells to generate 
different types of Th1 cytokines, for example IL 2 is an autocrine T cell growth 
factor that is produced early in T cell activation (Lorre et al., 1990), whereas IL 
12 is produced later as a functional cytokine after T cell polarisation (Feili Hariri 
et al., 2005). Another possibility is that etanercept not only activated Th1 cells, 
but  also  could  regulate  other  type  of  immune  cell  populations  that  can  also 
produce Th1 cytokines in the brain such as astrocytes and microglia. Etanercept 
seemed to have no effect on brain Th2 cytokine production, including IL 4, IL 13 
and  IL 10.  However,  etanercept  significantly  reduced  brain  IL 5  protein 
concentrations in the brains of etanercept CII immunized mice throughout the 
period of clinical expression of disease. The most striking data in this section 
seems to be the effect of etanercept suppressing the increased production of 
brain CXCL1 and IL 1β that was seen in control PBS treated CII immunized mice. 
These  two  cytokines  are  functionally  related;  IL 1β  is  known  to  be  a  potent 
cytokine that stimulates the expression of CXCL1. It has been shown that chronic 
expression of IL 1 β can induce the expression of CXCL1 in the mouse brain. 
Therefore,  it  is  possible  that  etanercept  acts  by  inhibiting  IL 1β  production 
resulting in a reduction of CXCL1 and potentially reduceing immune cells influx 
into  the  brain.  Interestingly,  at  this  stage,  etanercept  can  also  activate  the 
production of VEGF and FGF2. These growth factors are known as angiogenic 
factors that may suggest BBB breakdown in the CIA mouse brain. However, these 
growth factors may also have other functions in the brain and whether or not 
etanercept may worsen BBB breakdown in CIA mouse brains via enhancement of 
these brain growth factors need to be further investigated.  
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5.4   Result chapter 5: Summary of major findings.  
The  aim  of  this  chapter  was  to  investigate  the  effects  of  etanercept  on  the 
production of inflammatory mediators in the brain of CII immunized mice. We 
compared changes in brain inflammatory mediators among etanercept treated 
CII  immunized  and  control  PBS treated  CII  immunized  mice  at  3  time  points 
across the 42 day experimental course of CIA. Day 14 after immunization was 
studied as a representative time–point prior to the onset of disease and before 
the etanercept treatment. The other 2 time points were during the period of 
clinical expression on day 32 representing the time point of early disease and at 
day  35  after  immunization  representing  the  time  point  of  the  late  stage  of 
disease. We found that: 
1.  There was no significant difference in brain inflammatory mediators 
between antigen naïve control mice and CII immunized at day 14 after 
immunization which is representative of a time point prior to the onset of 
disease and pre etanercept treatment. 
2.   In the first of two experiments, etanercept treatment did not delay the 
onset of arthritis nor reduce the incidence at day 32. In addition, 
etanercept treatment did not decreasing the severity of arthritis by 
reducing the mean paw thickness and the clinical score compared to PBS 
treated CII immunized mice. However, etanercept treatment was 
associated with reductions in TNF α, IL 5 and IL 12 protein concentrations 
in brains of etanercept treated CII immunized mice.  
3.  In the second experiment, etanercept treatment did delay the onset of 
arthritis and reduced the incidence at day 35, as well as attenuating the 
severity of arthritis by reducing the mean paw thickness and the clinical 
score compared to PBS treated CII immunized mice. At this time point, 
etanercept treatment was associated with reductions in IL 12, CXCL1 
protein concentrations and with increases in IL 2 and VEGF protein 
concentrations in brains of etanercept  treated CII immunized mice. 
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5.5  Discussion 
To extend our investigation of the association between peripheral inflammation 
and changes in brain inflammatory mediator profiles in CII immunized mice, we 
attempted  to  reduce  the  peripheral  inflammatory  signal  using  the  anti 
inflammatory  drug  etanercept  as  a  preventive  therapy  for  arthritis.  We  then 
examined  the  changes  in  the  brain  inflammatory  mediator  profile  during  the 
time course of the development of arthritis in CII immunized mice.  
We  found  that  systemic  administration  of  the  TNF α  blockade  drug 
etanercept  not  only  had  an  effect  on  the  amelioration  of  joint  disease  by 
reducing mean paw thickness and incidence of arthritis in CII immunized mice, 
but also had effects on brain inflammatory mediator profiles in these mice. We 
found  increases  in  IL 6,  IL 2,  VEGF  protein  concentrations  and  FGF2  mRNA 
levels, along with decreases in TNF α, IL 5, IL 12, CXCL1 protein concentrations 
and  IL 1β  mRNA  levels  in  brains  of  etanercept treated  CII  immunized  mice 
compared to those of PBS treated CII immunized mice. Our data suggest that 
changes in inflammatory mediators in brains of CII immunized mice may be a 
consequence of changes in the peripheral inflammatory cytokine signal during 
the clinical development of arthritis.  
5.5.1   Effect of etanercept on the amelioration of joint disease 
in CII immunized mice 
Etanercept is a recombinant human soluble p75 TNFR:Fc fusion protein that has 
been  developed  for  the  therapeutic  treatment  of  RA.  The  administration  of 
etanercept has been reported to attenuate the development of clinical arthritis 
and, in CIA mouse model, the development of experimental RA. Our data showed 
that the experimental arthritis disease process could be attenuated when the 
etanercept treatment was administrated therapeutically from day 18 after the 
immunization, as indicated by significant reductions in mean arthritis scores, in 
mean paw swelling and in disease percent incidence compared to PBS treated 
CIA mice. Our finding is in agreement with several reports on the prevention of 
arthritis in CIA and AIA models of RA by the administration of 300ug/mouse/3 
days  of  recombinant  human/rodent  TNFR:Fc  fusion  protein.  In  one  of  these 
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14 onwards resulted in the delay of arthritis disease development, along with 
reduced arthritis disease severity as determined by paw swelling. However, that 
study did not address the effect on disease incidence (Williams et al., 2000b). 
The ability to prevent arthritis in the CIA model by peripheral TNF blockade in 
the days (typically <21 days) before the disease onset might be due to the fact 
that TNF α plays a critical role in initiating an immuno inflammatory cascade 
leading to the development of arthritis. TNF α is involved in regulating other 
cytokine and chemokine release, recruitment of immune cells and expression of 
endothelial  adhesion  molecules  at  the  inflamed  site.  However,  the  precise 
action of human soluble p75 TNFR:Fc fusion protein on the immune response to 
collagen challenge in the CIA model is not currently clear. The few studies in 
print  suggested  that  recombinant  human  soluble  p75  TNFR  inhibited  the 
immune mediated  arthritis  by  suppressing  IgG2a  anti collagen  antibody 
production,  this  is  the  dominant  antibody  subclass  in  the  CIA  model  and  is 
induced by Th1 type cells (Mukherjee et al., 2003). A study of RA demonstrated 
that  soluble  p75  TNFR  treated  CIA  mice  had  lower  concentrations  of 
inflammatory Th1 driven IgG2a antibodies to CII than controls (Mageed et al., 
1998). In addition, several studies also suggested that the immunosuppressive 
effects of this TNF α blockade are related to inhibition of CD4+ activation and to 
down regulation  of  the  Th1  response.  TNFR p75  has  been  shown  to  be  an 
essential co stimulator for the survival of CD4
+ T cells during clonal expansion, 
and  p75 deficient  T  cells  showed  a  defect  in  IL 2  production  (Kim  and  Teh, 
2004). CIA mice treated with TNF α blockade also showed reduced number of 
CD4
+ T cells in the joint (Marinova Mutafchieva et al., 2000).  
In this experiment, CII immunized mice after day 21 were randomly divided into 
4 groups (Group 2   5) consisting of 3   5 mice per group. Each group of mice 
were allocated a separate cage and set up as follows;  
Group 2: CII immunized mice treated with PBS and culled on day 32 
Group 3: CII immunized mice treated with etanercept and culled on day 32  
Group 4: CII immunized mice treated with PBS and culled on day 35 
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The incidences of RA appear to be around 60% for CII immunized mice in Group 
2, 3 and 5. However, the data shown for paw thickness and arthritis score in CII 
immunized mice in each group were different. This suggests that each group 
mice developed arthritis in different severity. Therefore the data shown for paw 
thickness  and  arthritis  score  in  the  mice  culled  at  day  32  and  day  35  are 
different (Figure 5.2Figure 5.3). The different patterns of the arthritis score and 
paw thickness between CII immunized mice on day 32 and 35 may have been due 
to  the  small  sample size  (n  =  3 5  CII immunized  mice)  and  the  inequality  in 
number of mice culled on day 32 and day 35. The small number of mice per 
group may help to explain the inconsistency in the data shown for paw thickness 
and  arthritis  score  in  the  mice  culled  on  day  32  and  day  35.  Therefore, 
repetition of this experiment using a greater group size to increase in statistical 
power may help to improve the consistency of the data.  
5.5.2   Effects of peripheral etanercept treatment on 
inflammatory mediators in brains of CII immunized mice; 
possible evidence of peripheral inflammatory signal 
inducing neuro inflammation 
By  blocking  peripheral  inflammatory  cytokine  signal  using  etanercept  in  CII 
immunized  mice,  we  found  interesting  evidence  of  immune  activation  and 
inflammation in the brains of CII immunized mice during the development of 
arthritis.  In  this  study,  we  also  investigated  changes  in  brain  inflammatory 
mediators in CII immunized mice compared to those in naïve control mice during 
the period before the onset of arthritis disease on day 14 after immunization. 
That time point was also used as a control time point before the etanercept 
treatment  began  on  day  18.  At  that  time  point,  no  CII  immunized  mice 
developed arthritis and we found no significant difference in brain inflammatory 
mediator concentrations between CII immunized mice and those in naïve control 
mice.  However,  changes  in  inflammatory  mediators  in  brains  of  etanercept 
treated and PBS treated CII immunized mice compared to those of naïve control 
mice were observed on day 32 and day 35 as the CII immunized mice developed 
arthritis. This finding suggested that the production in inflammatory mediators 
in brains of CII immunized mice may be stimulated by immune activation and 
inflammatory  signals  from  cytokines  in  the  peripheral  circulation.  This  also 
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the CNS level to regulate the production of brain inflammatory mediators in CII 
immunized  mice.  Another  important  piece  of  evidence  suggesting  that 
peripheral  inflammation  induced  neuro inflammation  was  that  etanercept 
treatment was administrated peripherally, but we could still observe changes in 
inflammatory  mediators  in  the  brains  of  CII immunized  mice.  In  particular,  a 
reduction of brain TNF α and IL 12, initiators of the joint destructive pathology 
of RA, were observed in etanercept treated CII immunized mice on both day 32 
and day 35. This suggested that etanercept may act mainly by inhibition of TNF 
α and subsequently Th1 cells. However, we could not detect serum inflammatory 
mediators in mice from any of the experimental groups in this study, suggesting 
that  the  Luminex  assay  may  not  have  been  sufficiently  sensitive  to  detect 
biologically  active  concentrations  of  relevant  cytokines  in  this  system.  We 
therefore could not conclude whether or not etanercept actually blocked any 
specific peripheral inflammatory cytokine signal by reducing serum TNF α and 
other  inflammatory  mediators  during  the  development  of  arthritis.  It  is  also 
possible  that  TNF α  is  present  in  the  serum  at  low  concentrations  that  is 
sufficient to initiate disease and/or it is transiently cleared after inflammatory 
challenge. A study by Goto et al has demonstrated rapid clearance (120 min) of 
recombinant TNF α from the rat circulation following intravenous injection of 
LPS  (Goto  et  al.,  2001).  We  hypothesized  that  TNF α  may  activate  the 
production of inflammatory mediators in the circulation and that these may be 
rapidly cleared. This hypothesis is supported by a study in a model of surgical 
trauma showing that anti TNF transiently reduced the protein concentrations of 
serum  IL 1β  both  at  6  and  24  h  following  surgery  (Terrando  et  al.,  2010). 
Interestingly, in the brains of etanercept treated CII immunized mice we found a 
significant reduction of IL 12, TNF α, IL 5 on day 32, and a reduction of brain IL 
12 on day 35 associated with a significant lower mean clinical score and paw 
thickness compared to PBS treated CII immunized mice on day 35.  
The transient effect of anti TNF therapy on CNS cytokine production has 
also  been demonstrated  in  recent  studies;  in  a  model  of acute  inflammatory 
brain injury in morphine tolerant rats (Shen et al., 2011) and in traumatic brain 
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5.5.3   Effects of peripheral etanercept treatment on pro 
inflammatory cytokines in brains of CII immunized mice 
We will now consider how CIA may be associated with brain inflammation. In the 
CNS,  TNF α  and  TNFR  signalling  play  crucial  roles  in  neuro inflammatory 
processes.    The  p75  TNFR  was  shown  to  be  increased  on  peripheral  blood 
monocytes and lymphocytes of MS patients (Jurewicz et al., 1999). In addition, 
TNF/TNFR signalling was shown to induce oligodendrocyte apoptosis and primary 
demyelination in an MS model (Akassoglou et al., 1998). In an EAE model, TNF α 
plays an essential role in the initiation of clinical symptoms, and the therapeutic 
administration of TNFR IgG could prevent the development of disease (Korner et 
al.,  1997).  In  experimental  cerebral  ischemia,  p75  TNFR  signalling  was 
demonstrated  to  initiate  CNS  inflammation  as  indicated  by  endothelial  cell 
activation, meningeal inflammation, and vessel fibrosis in p75 TNFR transgenic 
mice (Akassoglou et al., 2003). Recently, etanercept, TNF blockade, has been 
shown to be effective treatment for both immune and non immune mediated 
CNS injury. A study by Genovese et al showed that the inflammation associated 
with  acute  spinal  cord  injury  was  significantly  decreased  by  etanercept. 
Etanercept  has  shown  to  attenuate  central  endotoxin induced  brain  injury 
(Campbell  et  al.,  2007).  Our  data  showing  that  peripheral  administration  of 
etanercept  reduced  the  local  concentrations  of  pro inflammatory  cytokines 
including TNF α and IL 1β in the brains of CII immunized mice are in agreement 
with recent reports of models of morphine tolerant rats (Shen et al., 2011) and 
traumatic brain injury (Chio et al., 2010).  
5.5.4   Effects of peripheral etanercept treatment on TNF α in 
brains of CII immunized mice 
Our  data  showed  down regulation  of  brain  TNF α  in  etanercept  treated   CII 
immunized mice compared to those in PBS treated CII immunized mice on days 
32 and 35. We were not able to define the precise action of etanercept on this 
suppression of brain TNF α in CII immunized mice mainly because  we could not 
detect TNF α protein in serum or mRNA in the brains of etanercept treated and 
PBS treated CII immunized mice in our study. We could therefore speculate that 
one possible mechanism is that the etanercept binds systemic TNF α and thereby 
prevent the transport of TNF α through the blood brain barrier (Jiang et al., Chapter 5    274 
2008). This is the most likely mechanism because etanercept does not cross the 
blood brain barrier due to its hydrophilic property and high molecular weight 
(Francis et al., 2004), suggesting that it is unlikely that etanercept could inhibit 
production of TNF α in the brains of CII immunized mice. However, in another 
study, TNF α transport across the blood–brain barrier is shown to be mediated by 
p75 TNFR (Pan and Kastin, 2002), which was strongly up regulated during CNS 
inflammation and injury (Pan et al., 2003). This suggests that an increase in p75 
TNFR may paradoxically enhance the transportation of peripheral TNF α into the 
brain. The soluble form of p75 TNFR that is released from monocytes during 
inflammation is thought to function by modulating the availability and biological 
activity of TNF α via neutralization or stabilization (Joyce and Steer, 1996). A 
study  in  an  LPS challenge  mouse  inflammation  model  suggested  that  dimeric 
sTNFR are effective inhibitors of TNF and, under some circumstances, could also 
function as TNF carriers. Administration of a mortality reducing dose of sTNFR 
reduced the rise in serum TNF bioactivity that normally occured in response to 
LPS.  However,  a  lower  dose  of  sTNFR  resulted  in  increased  serum  TNF 
concentrations compared to mice given LPS but no soluble receptor. The actual 
role  of  TNFR  signalling  and  sTNFR  as  a  TNF  carrier  during  peripheral 
inflammation that could then induce neuro inflammation has not been resolved. 
In  addition,  key  sites  of  anti inflammatory  effects  of  etanercept  on  TNF α 
transport from the periphery to the brain and the brain TNF α production in this 
model needs to be investigated further (Mohler et al., 1993) perhaps by using 
immuno histo chemistry  of  brain  tissue  to  identify  cell  producing  local  TNF α 
during the disease process of arthritis. 
5.5.5   Effects of peripheral etanercept treatment on IL 1β in 
brains of CII immunized mice 
TNF α stimulates the production of other pro inflammatory cytokines such as IL 
1β. It was shown that blockade of TNF α in CIA mice reduced IL 1β expression in 
the joint, suggesting that the production of IL 1β in the CIA model is driven by 
TNF α  (Williams  et  al.,  2000b).  In  the  CNS,  brain  IL 1β  production  has  been 
shown to be inducible by peripheral inflammation. In addition, brain IL 1β has 
been  reported  to  play  a  crucial  role  in  cognitive  decline  and  symptoms  of 
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were up regulated significantly on day 35 in CII immunized mice compared to 
control mice. The increased brain IL 1β mRNA levels in these CII immunized mice 
were  likely  to  be  suppressed  by  etanercept,  as  indicated  by  a  significant 
reduction in brain IL 1β mRNA levels in etanercept treated CII immunized mice. 
Our finding suggested that TNF α blockade may inhibit peripheral inflammation 
mediated brain IL 1β production. However, whether TNF α blockade inhibits IL 
1β initially at the peripheral level or at the CNS level was not addressed in our 
study.  A  recent  study  in  a  model  of  surgical  trauma  suggested  that  TNF α 
blockade  may  inhibit  the  production  of  IL 1β  at  the  peripheral  level.  The 
administration of TNF α blockade was demonstrated to reduce serum IL 1β after 
surgical  trauma.  The  inhibition  of  brain  IL 1β  by  TNF α  blockade  during 
peripheral inflammation observed in our study was also seen in this study. The 
administration of TNF α blockade resulted in a reduction in brain IL 1β protein 
caused by surgery induced inflammation (Terrando et al., 2010). In addition, the 
effect  of  etanercept  reversing  IL 1β induced  depressive like  and  sickness 
behaviour has been previously reported by (Jiang et al., 2008). In that study, 
etanercept inhibited peripheral TNF α production following IL 1β challenge. In 
addition,  the  andedonic  effects  of  IL 1β  in  the  brain  were  blocked  by  pre 
treatment with etanercept. However, that study did not address the effect of 
etanercept  on  brain  IL 1β  production  (Jiang  et  al.,  2008).  The  combined 
evidence of our results and these reports demonstrated that TNF α may be the 
main  regulator  for  brain  IL 1β  production  and  action.  However,  the  precise 
action of etanercept on the brain IL 1β production by local brain immune cells 
such as microglia in this CIA model needs to be further investigated perhaps by 
using  immuno histochemistry  of  brain  tissue  to  identify  cells  producing  local 
TNF α as well as IL 1β to examine the dynamics of this response of these two 
cytokines during the development of arthritis.  
5.5.6  Effects of peripheral etanercept treatment on Th1 
cytokines in brains of CII immunized mice 
TNF/TNFR signalling plays a role in CD4+ activation and regulation of the Th1 
response  via  the  production  of  IFN γ  and  IL 12  (Marinova Mutafchieva  et  al., 
2000). Our data showed a significant reduction in brain IL 12 concentration in 
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immunized mice on days 32 and 35. To date, the precise role of p75 TNFR on Th1 
immune responses in the CNS has not been well addressed. A study by Becher 
and  Dodelet  1996  showed  that  p75  TNFR  could  inhibit  IL 12  production  by 
activated human adult microglial cells (Becher et al., 1996). In addition, p75 
TNFR was shown to act on antigen presenting cell derived IL 12 to inhibit Th1 
polarization in the EAE model (Becher et al., 1999). In contrast, TNFR p75 has 
been reported to function as an essential co stimulator for CD4
+ T cell responses 
to cognate antigen (Kim et al., 2006). The effect of etanercept on Th1 immune 
responses in the CNS may also be associated with the role of TNF/TNFR signalling 
in recruiting T cells from the periphery into the CNS during neuro inflammation, 
the mechanism of which has not been elucidated. Animals treated with TNFR:Fc 
after immunization with myelin basic protein or proteolipid protein in adjuvant, 
but  before  onset  of  clinical  symptoms,  did  not  develop  disease  but  have 
continued inflammation as indicated by the number of CNS infiltrating T cells 
(Korner et al., 1997). Another study reported that p75 TNFR gene knockout mice 
exhibited exacerbated EAE, enhanced Th1 cytokine production, and enhanced 
CD4+T  cell  infiltration  to  the  CNS  (Suvannavejh  et  al.,  2000).  This  evidence 
could help explain our finding that on the early time point of disease (day 32), 
TNF blockade  may  inhibit  the  biologic  activities  of  TNF  on  Th1  response, 
whereas at the later time point (day 35), p75 TNFR may function to activate CD4 
T cells and enhance CD4 T cell recruitment into the CNS by an as yet unknown 
mechanism. Therefore, the role of TNF/TNFR signalling in Th1 immune responses 
in  the  CNS  during  peripheral  inflammation  in  CIA  model  needs  to  be  further 
investigated perhaps by using separate p75 and p55 TNFR gene deleted mice to 
study the effects of etanercept on development arthritis in CIA mice. 
5.5.7  Effects of peripheral etanercept treatment on Th2 
cytokines in brains of CII immunized mice 
In considering the effects of etanercept on Th2 cytokine profiles in brains of CII 
immunized mice, we found that etanercept treatment had no effect on brain IL 
4 and IL 10 concentrations. However, etanercept reduced IL 5 concentrations in 
brains of CII immunized mice on days 35. To date, the details of any precise 
mutual regulation between TNF α and Th2 cytokines is still not well understood 
in the CNS. 1L 10 and IL 4 are known to inhibit TNF α production by monocytes 
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increase  in  the  production  of  Th2  cytokine  such  as  IL 10  by  monocytes 
(Schuerwegh  et  al.,  2003).  However,  the  regulation  between  TNF α  and  Th2 
cytokines could be divergent in the different cell types and tissue. In the CNS, 
TNF α  has  been  reported  to  stimulate  the  production  of  IL 10  by  human 
microglia (Sheng et al., 1995). In a model of airway hyper responsiveness, TNF α 
has  been  shown  to  enhance  Th2  responses,  to  up regulate  IL 5  and  increase 
eosinophil  recruitment  in  pulmonary  fibrosis,  a  non allergic  model  of  lung 
inflammation  (Zhang  et  al.,  1997).  In  contrast,  a  recent  study  in  model  of 
allergic hyper reactivity showed that etanercept treatment reduced eosinophil 
recruitment into the lungs (Nie et al., 2009), which may be associated with a 
reduced  production  of  Th2  cytokine  IL 5  essential  for  the  bone  marrow 
production, recruitment and activation of eosinophils (Holgate, 2004). Our data 
also showed a similar inhibitory effect of etanercept on IL 5 in the brains of CII 
immunized  mice.  However,  the  question  of  how  etanercept  regulated  the 
production of IL 5 in the brain of CII immunized mice is still unclear and needs 
further investigation. We could not identify the cellular source of brain IL 5 in 
our experiments because this was beyond the scope of our work, but this might 
be important and could be done by immuno histochemistry.  
In  RA,  IL 5  plays  a  role  in  the  pathological  mechanism  of  arthritis  by 
promoting the production of specific IgG and IgE that can bind and activate mast 
cell  degranulation  and  form  immune  complex  with  antigen,  leading  to  the 
exacerbation of joint destruction (Xu et al., 2008). Since we could not detect IL 
5 mRNA in brains of mice from all experimental groups, but we could measure 
IL 5 protein in some, we concluded that there may be a contribution of IL 5 from 
the periphery into the brains of these CII immunized mice during the course of 
disease. It is also possible that etanercept may inhibit the peripheral production 
of IL 5. Although we could not detect IL 5 mRNA in the brain of CII immunized 
mice, the possibility that etanercept may inhibit the local production of IL 5 in 
the brain by CNS immune cells such as astrocyte should not be ignored. A study 
in CIA model also showed that anti TNF α therapy reduced astrocyte activity in 
the spinal cord of CIA mice (Inglis et al., 2007). To test these hypotheses, in 
vitro experiments of both peripheral and CNS immune cell cultures derived from 
CII  immunized  mice  are  required  to  investigate  the  regulatory  effect  of 
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5.5.8  Effects of peripheral etanercept treatment on 
chemokines in brains of CII immunized mice 
TNF α  plays  a  critical  role  in  inducing  chemokine  production  and  leukocyte 
trafficking.  TNF  blockade  therapy  in  RA  was  shown  to  reduce  the  leukocyte 
migration to the joints and the expression of chemokines such as MCP 1 (Taylor 
et  al.,  2000).  The  inhibitory  effect  of  TNF  blockade  therapy  on  chemokine 
expression  has  also  been  reported  in  neuro inflammation.  In  the  EAE  murine 
model,  p75  TNFR  treatment  decreased  the  expression  of  various  chemokines 
including CCL3, CCL4, CXCL1 and CXCL2 in the CNS (Glabinski et al., 2003). Our 
data also showed that increased concentrations of brain CXCL1 protein in CIA 
mice  was  suppressed  by  etanercept  treatment.  TNF α  could  induce  the 
production of CXCL1 by brain microglia (Hayashi et al., 1995), astrocytes (Guo et 
al., 1998) and peripheral blood monocytes (Shea Donohue et al., 2008) during 
peripheral  inflammation.  However,  we  could  not  determine  the  origin  of  the 
CXCL1 detected in the brain of CII immunized mice in our study. This could be 
done by appropriate immuno histochemistry. In addition, an in vitro study of the 
effect  of  etanercept  on  the  production  of  the  immune  cells  isolate  from  CII 
immunized mice may help to address the underlying mechanism of the reduction 
in CXCL1 concentrations in the brains of CII immunized mice.  
5.5.9   Effects of peripheral etanercept treatment on growth 
factors in brains of CII immunized mice 
Angiogenesis and neovascularisation in inflammation, characterized by increases 
in  several  angiogenic  factors  such  as  VEGF  and  FGF,  have  been  recently 
considered  as  a  potential  therapeutic  target  mechanisms  of  TNF  blockade 
(Paleolog, 2002).  In RA patients, a decline in vascular permeability, along with a 
rapid  reduction  of  VEGF  concentration  in  serum  were  observed  during  early 
attenuation  of  joint  swelling  after  anti TNF  therapy  (Paleolog  et  al.,  1998). 
Etanercept has also been reported to reduce VEGF concentrations in psoriatic 
lesions of psoriasis. However, the angiogenesis associated with changes in BBB 
permeability during neuroinflammatory processes has not been well elucidated. 
A recent report by (Wilson et al., 2009), showed TNF blockade resulted in a 
reduction in BBB permeability, suggesting a protective role of TNF blockade on 
BBB damage. However, that study did not address the effect of TNF blockade on 
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increases  in  brain  VEGF  protein  concentrations  in  etanercept  treated CII 
immunized mice compared to those in control PBS treated CII immunized mice. 
In addition, although the ANOVA did not detect a significant difference in FGF2 
gene  expression  levels  between  etanercept  treated CII  immunized  mice  and 
those  in  control  PBS  treated CII  immunized  mice,  the  FGF2  gene  expression 
levels in etanercept treated CII immunized mice were lower than to those in 
control PBS treated CII immunized mice. This may be explained by the divergent 
effect of TNF α that can be both a pro angiogenic and an anti angiogenic factor, 
depending on the TNF α concentration and the duration of the exposure in the 
pathological conditions. These divergent roles for p55 and p75 TNFR contribute 
to different angiogenic signalling as described in a recent study. This report by 
Goukassian et al showed that p75 TNFR gene deficient mice failed to develop 
neovascularisation during post ischemic recovery, along with reductions in VEGF 
and FGF2 concentrations (Goukassian et al., 2007). This finding suggested that 
p75  TNFR  may  be  essential  for  the  production  of  angiogenic  factors  during 
angiogenesis and neovascularisation. The data from that study implies that an 
increase in p75 TNFR level (etanercept) could possibly enhance the production 
of VEGF and FGF2 in the brain, rather than suppressing the production of these 
angiogenic growth factors. 
Summary 
In  this  section  we  demonstrated  the  effect  of  peripheral  administration  of 
etanercept  on  changes  in  inflammatory  mediator  profile  associated  with 
peripheral and local brain inflammation in the CIA arthritis model.  
This may provide preliminary evidence to support the clinical observation that 
etanercept  could  improve  cognitive  decline  and  depression  in  patients  with 
chronic  inflammatory  diseases.  However,  a  limitation  of  this  study  is  that, 
because of its complexity, the experiment was conducted using small sample 
sizes (3 5 mice/group). Smaller samples yield larger standard errors and wider 
confidence intervals, which may impact the interpretion of the data by making it 
more  difficult  to  determine  significant  differences  between  groups.  In  future 
studies, this experiment could be repeated using a greater group size to increase 
in statistical power, resulting in better biological interpretation. In addition, the Chapter 5    280 
effect of etanercept on specific immune cell types involved in the production of 
these  brain  mediators  associated  with  the  inflammation  in  the  CIA  model  is 
worthy of further study.   
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6.1   Introduction 
In  Chapter  3  we  reported  increased  concentrations  of  several  inflammatory 
mediators that were observed in brains of CII immunized mice, particularly those 
with  arthritis.  In  Chapter  4,  we  demonstrated  that  up regulation  of  these 
inflammatory  mediators  in  brains  of  arthritic  mice  may  be  associated  with 
peripheral inflammation during the CIA experimental course. In Chapter 5, we 
reported  that  peripheral  administration  of  etenercept  treatment  profoundly 
reduced the concentration of inflammatory cytokines in brains of CII immunized 
mice  during  the  period  of  clinical  manifestation  of  arthritis.  One  important 
question remains; do these inflammatory mediators up regulated in the brain 
have biological functions and contribute to neurobiological changes in brains of 
CII  immunized  mice?  To  test  this  hypothesis,  we  investigated  changes  in 
hippocampal neurogenesis in CII immunized mice during the period of clinical 
manifestation.  We  also  investigated  whether  TNF blockade  using  the  anti 
inflammatory drug etanercept (recombinant human soluble TNFR), could reverse 
the effects of peripheral inflammation on hippocampal neurogenesis. 
Accumulating evidence suggests that peripheral inflammation can contribute to 
neurobiological  changes  the  brain.  One  neurobiological  change  that  has  been 
reported to be affected by peripheral inflammation is neurogenesis. Although 
the role of neurogenesis as part of hippocampal function is still unclear, some 
experimental evidence suggests it is involved in memory formation and in mood 
regulation. Impairment of hippocampal neurogenesis has been associated with 
cognitive decline in Alzheimer’s disease (AD), and in major depression (Ekdahl et 
al., 2003). Several studies have shown that peripheral inflammation generated 
by systemic administration of the innate immune response activator LPS, or by 
pro inflammatory  cytokines  such  as  IL 1β,  could  cause  impairment  of 
hippocampal neurogenesis, leading to progressive cognitive deterioration (Monje 
et  al.,  2003);  (Ekdahl  et  al.,  2003);  (Kaneko  et  al.,  2006).  However,  less  is 
known about the effect of peripheral inflammation on hippocampal neurogenesis 
in chronic inflammatory disease models.  
In this study, our hypothesis is that the activation of an immune response and 
systemic  inflammation  generated  during  the  course  of  experimental  arthritis 
may  cause  impairment  in  hippocampus  neurogenesis.  Data  from  the  previous Chapter 6    283 
result chapters (Chapter 4; Section 4.2.3, Section 4.2.4 and Section 4.2.5) has 
highlighted up regulation of several inflammatory mediators, including TNF α, 
IL 1β  and  IL 12  in  the  brains  of  CII  immunized  mice  throughout  the  CIA 
experimental  course.  These  brain  inflammatory  mediators,  presumably 
generated by activated microglia, have been reported to promote the death of 
hippocampal  progenitor  cells  in  vitro  (Monje  et  al.,  2003).  To  investigate 
whether the impairment of neurogenesis observed during the development of 
arthritis is induced by a mechanism involving activation of the cytokine cascade, 
we applied TNF blockade using therapeutic recombinant soluble TNF receptor 
(Etanercept)  peripherally  into  CIA  mice.  TNF α  is  a  potent  pro inflammatory 
cytokine that is thought to be an inducer of other inflammatory mediators in the 
inflammatory response. Data from our previous Chapter 5 (Chapter 5; Section 
5.2.3,  Section  5.2.4)  demonstrated  that  TNF  blockade  suppressed  the  up 
regulation of brain inflammatory mediators such as IL 1β and CXCL1. In addition, 
recent experimental evidence suggests that TNF α may influence the survival of 
new  neurons  generated  from  the  neural  stem  cells  of  the  adult  brain  in  the 
dentate gyrus subgranular zone (SGZ) and in the subventricular zone, lining the 
lateral ventricles (Iosif et al., 2006). TNF α can  trigger apoptosis and excito 
toxicity  of  dentate  granule  neurons  through  its  receptor  and  intracellular 
signalling  (Harry  et  al.,  2008).  Interestingly,  Etanercept  treatment  has  been 
shown to improve cognitive decline and depression symptoms in patients with 
chronic  inflammatory  diseases  such  as  psoriasis,  suggesting  that  Etanercept 
possibly reverses the impairment of hippocampal neurogenesis associated with 
chronic systemic inflammation (Tyring et al., 2006). Based on this experimental 
and clinical evidence, we propose a further hypothesis that TNF blockade may 
have a protective effect on dentate granule neurons by inhibiting the neurotoxic 
action of TNF α and/or suppressing the neuro inflammatory cascade initiated by 
TNF α. Therefore, one aim of this chapter is to investigate whether systemic 
Etanercept treatment can reverse the impairment of hippocampal neurogenesis 
induced by peripheral inflammation in the brain of CIA mice during the course of 
experimental arthritis.  
The study in this Results chapter will be in 3 main stages.  
In the first stage we will evaluate the immunohistochemical expression of 
doublecortin (DCX), the neuronal marker for hippocampal neurogenesis in brain Chapter 6    284 
tissue of a normal DBA1 mouse. The optimal DCX antibody concentrations for 
both  immunofluorescent  staining  and  avidin biotin peroxidase  immuno 
histochemistry  were  successfully  evaluated.  The  biotin peroxidase  immuno 
histochemistry was used for quantitative analysis of hippocamapal neurogenesis.  
In the second stage, we conducted a CIA experiment using 10 DBA1 mice 
and performed DCX immuno histochemistry of brain of these CII immunized mice 
culled on day 42, using a biotin peroxidase immuno histochemistry technique. To 
investigate  the  changes  in  hippocampal  neurogenesis  that  may  be  effect  of 
peripheral inflammation, we then compared the number of DCX positive cells 
the  dentate  gurus  of  CII  immunized  mice  and  those  of  naïve  control  mice 
sacrificed on the same day.  
In the third stage, we will investigate the effect of etanercept treatment 
on changes in hippocampal neurogenesis in CII immunized mice to test whether 
any changes may be associated with the peripheral inflammation.  
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6.2  Immunohistochemistry of Doublecortin (DCX) in 
mouse hippocampus 
Neurogenesis is the ongoing process of neuronal turnover in the dentate gyrus 
that  regulates  hippocampus dependent  learning  and  memory  formation.  The 
change in the number of proliferative and immature neurons during neuronal 
proliferation and maturation stages in the dentate gyrus reflects the level of 
hippocampal  neurogenesis.  In  this  study,  we  quantitatively  evaluated 
neurogenesis by doublecortin (DCX) immuno histochemistry. The first step was 
to  optimize  the  concentration  of  DCX  antibody  for  immuno histochemistry  to 
visualise  the  specific  staining  of  DCX positive  neurons  in  the  mouse  dentate 
gyrus.  
6.2.1   Optimization of Doublecortin Immuno histochemistry 
The  concentration  of  DCX  antibody  for  both  immunofluorescent  and  avidin 
biotin peroxidase  immuno histochemistry  was  optimized  for  the  specificity  of 
DCX immunostaining in mouse brains.  
Histologically, approximately 60% of the brain is fat, due to the myelin insulating 
the axons of neurons and glia. This high fat content may block the penetration of 
antibodies and thus lower the chance to identify target proteins. Therefore, in 
order  to  obtain  successful  staining,  it  is  essential  to  optimize  the  ability  of 
antibody  to  penetrate  through  the  brain  tissue.  In  the  normal  immuno 
histochemistry approach, the section mounted on the slide has only one side 
exposed,  which  limits  the  opportunity  for  reagents  to  penetrate  the  tissue 
completely. In contrast, the free floating method enhances the permeability of 
antibody by exposing both sides of the section. Briefly, brain tissues from DBA1 
mice were cut using a cryostat machine set at 60 um. All the sections containing 
the  hippocampus  region  were  kept  freely  floating  in  an  appropriate  glass 
container during the staining process.  
6.2.1.1   Immunofluorescent staining in mouse brain tissue 
A study suggested that 1:500 is the appropriate dilution of DCX antibody used to 
develop an immunofluorescent staining in mouse brain tissue (Couillard Despres 
et al., 2005). Thus, to optimize the concentration for staining, the DCX antibody Chapter 6    286 
was diluted around this concentration; from 1:100, 1:200, 1:500 to 1:1000. The 
secondary  antibody  (1:500)  containing  Green  Alexa  fluor  dye  was  added. 
Consistent with a previous report by Couillard Despres et al., our results from 
confocal microscopy showed that 1:500 was the optimal dilution of DCX antibody 
because the best image of granule cell dendritic morphology was exhibited. As 
DCX  is  a  cytoskeleton  protein,  the  attached  green  fluorescent  dye  could  be 
visualized in the cytoplasm of the soma and dendrite (Figure 6.1A). These DCX 
labelled  cells,  depicted  by  a  neuronal  cell  body  with  extensive  dendrites, 
gathered along the dentate gyrus (Figure 6.1B) 
 
 
Figure 6.1 Immunofluorescent staining of DCX   
(A) Confocal images (10 x magnification) of immature (doublecortin positive) neurons in the 
dentate gyrus of a DBA1 mouse labeled by Green AlexaFluor 488. (B) illustrates the 
anatomic location of dentate gyrus and the location of DCX staining. The red dashed lines 
showed the hippocampal region. 
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6.2.1.1.1  Triple immunofluorescent staining to define immature 
neuronal cells 
 
DCX  is  exclusively  expressed  on  immature  neurons,  particularly  during  the 
maturation and differentiation stages, and has been widely used as an immature 
neuronal marker (Brown et al., 2003); (Rao and Shetty, 2004); (Couillard Despres 
et  al.,  2005).  Toward  the  final  stage  of  neuronal  maturation, precursor  cells 
begin to express proteins typically present in mature neurons such as the nuclear 
neuronal  marker  NeuN  (Brown  et  al.,  2003).  Neuronal  precursor  cells  in  the 
dentate gyrus of hippocampus begin to express DCX while actively dividing, and 
the expression of DCX lasts for up to 3 weeks as these neuronal precursor cells 
develop to be mature neurons. A reduction of DCX expression in these precursor 
cells begins after 2 weeks, and occurs at the same time that these cells begins 
to  express  NeuN,  a  marker  for  mature  neurons  (Brown  et  al.,  2003).  This 
suggests  that  neuronal  precursor  cells  express  different  neuronal  markers  at 
different  stages throughout the  process  of  neurogenesis.  For that  reason,  we 
used co immunofluorescence of DCX and NeuN to distinguish the population of 
immature neurons in the dentate gyrus. Neurons in the immature differentiation 
stage should express only DCX, but not NeuN.    
Anti DCX Alexa green was used to define the morphology of immature neuron 
progenitor  cells  as  mentioned.  Anti NeuN Cy5,  a  nuclear  antigen  present  in 
mature cells, was employed to identify the morphology of mature neuron cells. 
Thirdly,  propidium  iodide  (PI)  a  fluorescent  molecule  that  can  bind  DNA  was 
used to stain the DNA inside the nucleus independent of the type and developing 
stage of cells. Therefore, overlapping PI staining with either DCX Alexa green or 
NeuN Cy5  demonstrates  immature  neuron  cells  and  mature  neuron  cells, 
respectively. By this triple immunofluorescent staining, immature neuron cells 
can  be  clearly  identified.    DCX Alexa  green  staining  shows  a  few  immature 
neuron  cells,  characterized  by  a  neuronal  cell  body  with  extensive  dendrites 
(Figure 6.2A). The NeuN Cy5 positive staining also shows a number of mature 
neuron cells (in blue) locating along the dentate gyrus and in the hippocampus 
(Figure 6.2B). The same population of these neurons was also stained positive for 
the nuclear DNA dye (propidium iodide) (Figure 6.2C).  
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Figure 6.2 Immunofluorescent staining of DCX, NeuN and PI 
(A) Confocal images (40 x magnification) show expression patterns of three neuronal 
markers in the dentate gyrus of a DBA1 mouse. Sections show the expression of 
doublecortin visualized with green fluorescence (A), the presence of NeuN was seen in blue 
(B), and the DNA staining by propidium iodide was detected as red (C).  
When  these  images  are  overlapped  (Figure  6.3),  it  is  clear  that  i)  immature 
neuron cells doubly stained by DCX Alexa green (green) and PI (red) exclusively 
distribute along the dentate gyrus; ii) mature neuron cells with dual staining of 
NeuN Cy5 (blue) and PI (red) locate in the same area; iii) the absence of co 
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localization of DCX Alexa (green) and NeuN Cy5 (blue) demonstrates that DCX is 
not on mature neuron cells, and may identify immature neurons.  
 
Figure 6.3 An overlay image of triple immunofluorescent staining of DCX, NeuN and PI in the 
dentate gyrus of a DBA1 mouse 
A confocal image (40 x magnification) shows co expression of DCX together with PI 
observed in cells with no expression of NeuN, a mature neuronal marker. The circle 
surrounds a neuron that expresses both DCX and PI. However, this cell is negative for 
NeuN. 
6.2.1.2  Optimization of avidin biotin peroxidase immuno 
histochemistry 
Although  these  specific  fluorescence  labels  successfully  defined  immature 
neuron  cells  and  their  distribution,  it  is  necessary  to  conduct  a  further 
peroxidase staining to confirm that they locate in the dentate gyrus of the brain. 
Preliminary  experiments  demonstrated  that  the  dilution  (1:500)  used  in  the 
fluorescence IHC protocol successfully detected DCX positive cells. A further 10 
times  dilution  (1:5000)  was  suggested  to  identify  DCX  in  the  Avidin biotin 
peroxidase  immuno histochemistry  protocol  to  avoid  non specific  binding  and 
minimise background staining.  
The test dilutions of anti DCX antibody have been varied from 1:1000, 1:5000, 
1:10,000. Normal goat IgG of the same concentrations as the primary antibody 
was  used  to  generate  negative  controls  for  the  immuno histochemistry.  The 
results from the light electron microscopy demonstrated that the DCX antibody Chapter 6    290 
dilution  at  1:1000  was  the  optimal  for  the  Avidin biotin peroxidase  immuno 
histochemistry  protocol.  However,  at  dilution  1:1000,  there  was  some  non 
specific staining of red blood cells and blood vessels observed on the slides (data 
not shown). This was the result of endogenous peroxidase in the blood vessels 
which reacts with the substrate DAB (3,3 diaminobenzidine). Therefore, to block 
the endogenous peroxidase in the brain sections, the treatment of 0.3% H2O2 in 
phosphate  buffer  for  30  min  was  used  before  primary  antibody  incubation. 
Consequently,  most  of  the  non specific  staining  was  eliminated  and  a  higher 
intensity of DCX staining in the dentate gyrus was observed (Figure 6.4). DCX 
positive cells were distributed throughout the extent of the DG in normal DBA 1 
mice  (Figure  6.5A).  By  contrast,  the  negative  control  antibody  for  immuno 
histochemistry did not show any non specific binding (Figure 6.5B). DCX positive 
neurons  in  the  DG  exhibited  the  phenotype  of  immature  neurons  in  their 
maturation stage (Jones et al., 2003). The cell bodies of DCX positive neurons 
were located in either the subgranular zone (SGZ) or granular cell layer (GCL) of 
the DG.  Apical dendrites of these DCX positive neurons extend their delicate 
dendritic tree branching into the molecular layer (ML) (Figure 6.6).  
 
Figure 6.4 Avidin biotin peroxidase immuno histochemistry of DCX 
(A) An image (10 x magnification) from a light electron microscope shows 
immunoperoxidase staining of DCX of immature (DCX positive) neurons in the dentate 
gyrus of a DBA1. (B) Illustrates the anatomic location of dentate gyrus and the location of 
DCX staining.  
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Figure 6.5 Avidin biotin peroxidase immuno histochemistry of DCX in the dentate gyrus of a 
DBA 1 mouse 
An image (10 x magnification) represents the immunoperoxidase staining for DCX and the 
distribution of DCX positive neurons in the adult dentate gyrus of a DBA1 mouse (A). (B) 
shows a negative control of immuno histochemistry generated by replacing DCX primary 
antibody with the same amount of normal goat IgG.  
 
Figure 6.6 High magnification of a representative image of DCX immuno histochemistry in 
the dentate gyrus of a DBA1 mouse 
An image (20 x magnification) presents the morphology of DCX positive neurons which 
have their cell bodies located either in the subgranular zone (SGZ) or the granular cell layer 
(GLC) of the dentate gyrus. These DCX positive neurons extend their delicate dendritic tree 
branching into the molecular layer (ML) 
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6.3   Induction of arthritis in DBA1 mice 
6.3.1   CIA experimental procedure 
The  aim  of  this  experiment  is  to  investigate  whether  the  peripheral 
immune/inflammatory response occurring during arthritis in DBA1 mice induced 
by type II collagen can change hippocampal neurogenesis in the brain. In the 
second stage of this chapter, we conducted another CIA experiment and brains 
of these CII immunized mice were processed for doublecortin (DCX) immuno 
histochemistry  in  order  to  determine  changes  in  the  number  of  DCX positive 
neurons.  Since DCX expression in neuronal precursor cells in the dentate gyrus is 
transient and persists for up to 3 4 weeks (Brown et al., 2003), it is difficult to 
estimate the optimal time point during the experimental course to determine 
changes in hippocampal neurogenesis in a chronic inflammatory model like the 
CIA model. However, a study by Wolf et al., in an AIA model showed that an 
increase  in  hippocampal  neurogenesis  was  observed  during  the  massive 
infiltration of inflammatory cells into the knee joint of arthritic mice. That study 
also showed a significant positive correlation between paw swelling and neuronal 
cell proliferation in these arthritic mice (Wolf et al., 2009b). These data suggest 
that  change  in  hippocampal  neurogenesis  may  occur  during  the  clinical 
manifestation of arthritis in AIA mice. For that reason, we chose to determine 
changes in hippocampal neurogenesis on day 42 of the CIA experimental course. 
This  time  point  is  during  the  maximum  clinical  manifestation  of  disease.  In 
addition, we determined changes in brain inflammatory mediator concentrations 
in CII immunized mice on day 42 in Chapter 3 (Section 3.2.3 and Section 3.2.4), 
and  we  found  increases  in  several  inflammatory  mediator  concentrations  in 
brains  of  CII  immunized  mice  at  that  time  point.  Therefore,  we  conducted 
another CIA experimental identical to the one in Chapter 3 (Section 3.2.1), but 
brains  of  mice  in  this  CIA  experiment  were  processed  for  DCX immuno 
histochemistry.  In  doing  so,  we  may  be  able  to  use  the  data  of  Chapter  3 
(Section  3.2.3  and  Section  3.2.4)  section  to  explain  our  data  of  changes  in 
hippocampal neurogenesis in CII immunized mice at the same time point.  
10 DBA1 mice were immunized by intradermal injection of type II collagen in 
complete  Freund’s  adjuvant  on  day  0.  On  day  21,  mice  were  given  an  i.p. 
booster  injection  of  type  II  collagen  dissolved  in  PBS.  6  DBA1  sex   and  age Chapter 6    293 
matched  DBA1  mice  were  used  as  the  antigen naïve  control  group  and  were 
neither  immunized  nor  challenged  with  type  II  collagen.  Groups  of  both  CII 
immunized and naïve control mice were sacrificed on day 42 and the brain of 
each mouse was fixed in formalin and cryoprotected in 30% sucrose buffer. Serial 
sections throughout the hippocampus were cut at 60 um and immunostained for 
DCX using the free floating technique (Figure 6.7). 
 
Figure 6.7 The experimental procedure of collagen II induced experimental arthritis model 
for hippocampal neurogenesis analysis 
DBA1 mice at 6 8 weeks of age were separated into two groups: i) naïve control, n=6 naïve 
control; ii) immunized mice, n=10 immunized mice.  Mice were immunized with 100       g type II 
bovine collagen + complete Freund’s adjuvant (CFA) at day 0 and then challenged on day 21 
with 200       g type II collagen. A group of 6 naïve DBA1 mice which were not immunized and 
not treated with type II collagen was use as a control group.  Serum and brains from control 
and CII immunized mice were harvested at Day 42. The brain of each mouse from all 
experimental groups was fixed in formalin and cryoprotected in 30% sucrose buffer. Serial 
sections throughout the hippocampus were cut into 60 um sections and immunostained for 
DCX using the free floating technique.  
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6.3.2   Clinical response 
 
Some of CII immunized mice started to showed clinical signs of arthritis from day 
20  onwards  and  there  were  6  out  of  the  total  10  CII  immunized  mice  that 
developed arthritis (60% incidence) on day 42 (Figure 6.8A). 4 of the 10 mice did 
not  develop  arthritis  after  immunization  and  challenge,  and  these  formed  a 
separate immunised but non arthritis study group. CII immunized mice showed a 
significant  increase  in  paw  thickness  compared  to  the  naïve  control  mice 
(P<0.0001). The mean paw thickness and the mean arthritis score for the whole 
group of CII immunized mice (n=10) on day 42 were 2.0 ± 0.08 mm and 3.9 ± 1.4 
respectively (Figure 6.8B), (Figure 6.8C).  
 
Figure 6.8 Development and severity of arthritis disease in CII immunized mice over 42 days 
of experimental arthritis course 
The signs of arthritis in CII immunized mice were monitored from day 16 after immunization 
onwards. (A) shows the percent incidence of arthritis in CII immunized mice, which was 
calculated from number of CII immunized mice with arthritis/total number of CII immunized 
mice used. The signs of arthritis were observed in CII immunized mice from day 20 onwards 
and there were 6 out of total 10 CII immunized mice developed arthritis on day 42. The mean 
clinical arthritis score and mean paw thickness were used as a clinical evaluation to 
measure the severity of joint inflammation in arthritic mice. (B) shows mean paw thickness 
of CII immunized mice which was calculated from the sum of the paw thickness of all mice 
divided by the number of mice. (C) shows mean clinical of CII immunized mice which was 
calculated from the sum of the clinical scores of all mice divided by the number of mice. 
Mean paw thickness, mean clinical score and %incidence in CII immunised mice (n= 10 CII 
immunised mice; filled squares) were compared with those values of naïve control mice (n = 
6 naïve control mice; open circles). Data represented as mean ± SEM. (n=10 CII immunized Chapter 6    295 
mice). Statistical analysis of data was performed using two way ANOVA for multiple 
comparison, compared with a group of control naïve mice; *P<0.05, ** P<0.01, *** P<0.001.  
6.4   Changes in number of DCX positive neurons in 
the dentate gyrus in CII immunized mice 
To  investigate  whether  peripheral  inflammation  affects  changes  in  the 
neurogenesis, quantitative immuno histochemistry of DCX positive neurons was 
performed in the brain sections containing the hippocampus region from mice of 
all experimental groups to determine changes in the number and the morphology 
of DCX positive neurons in dentate gyrus of immunized mice compared to those 
in the control mice.   
6.4.1  Changes in number of DCX positive neurons in 
the dentate gyrus in arthritic mice 
In this CIA experiment, there were 6 mice that developed arthritis. DCX positive 
cells  were  detected  in  the  dentate  gyrus  of  both  naïve  control  and  arthritic 
mice. However, the light microscopy image showed that there were differences 
in the number of DCX positive neurons between arthritic mice and naïve control 
mice (Figure 6.9A   Figure 6.9H and Figure 6.10A   Figure 6.10D). A reduction in 
the number of DCX positive cells was observed in dentate gyrus of arthritic mice 
compared to those in naïve control mice. Figures 9A 9H and 10A 10D show the 
representative  images  of  DCX immuno histochemistry  in  the  dentate  gyrus  of 
arthritic  mice  with  different  arthritis  scores.  This  was  confirmed  by  the  cell 
count  data  showing  that  the  number  of  DCX positive  neurons  in  the  dentate 
gurus of arthritic mice was significantly decreased; the mean number of DCX 
positive neurons in the dentate gyrus (arthritic versus naïve control) was 1322 ± 
285 cells versus 5417 ± 1673 cells (P = 0.0001) (Figure 6.11A). However, the 
reduction in DCX positive neurons did not correlate with the arthritis score (r²= 
0.06948; P = 0.6138) (Figure 6.11B).  
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Figure 6.9 Changes in hippocampal neurogenesis in arthritic mice on day 42 
DCX immuno histochemistry in dentate gyrus of arthritic mice were randomly compared to 
those of naïve control mice. (A), (C), (E) and (G) show representative images of DCX 
immuno histochemistry in the dentate gyrus of naïve control mice no 1, 2, 3 and 4 
respectively. (B), (D), (F) and (H) show representative images of DCX immuno 
histochemistry in the dentate gyrus of different arthritic mice (No. 24, 21, 30 and 28) with 
different arthritis scores (score 1, 6, 9 and 3 respectively). Clinical scores (RA scores) were 
calculated on the cull day 42. All images were at 10X magnification.  
Naïve control No. 1 
A. 
Arthritic mouse No. 24 (RA score 6) 
B. 
C. 
Naïve control No. 2 
D. 
Arthritic mouse No.21 (RA score 1) 
E. 
Naïve control No. 3  Arthritic mouse No. 30 (RA score 9 ) 
Naïve control No. 4 
F. 
G.  H. 
Arthritic mouse No. 28 (RA score 3) Chapter 6    297 
 
Figure 6.10 Changes in hippocampal neurogenesis in arthritic mice on day 42 
DCX immuno histochemistry images in the dentate gyrus of arthritic mice were randomly 
compared to those of naïve mice. (A) and (C) show representative images of DCX immuno 
histochemistry in the dentate gyrus of naïve control mice no 5 and 6 respectively. (B) and 
(D) show representative images of DCX immuno histochemistry in the dentate gyrus of 
different arthritic mice (No. 22 and 27) with different arthritis scores (score 8 and 12 
respectively). Clinical scores (RA scores) were calculated on the cull day 42. All images 
were at 10X magnification. 
 
 
Figure 6.11 Changes in number of DCX positive cells in dentate gyrus of arthritic mice on 
day 42  
(A) The dots represent the number of DCX positive cells in the hippocampus of individual 
naïve control mice (filled squares; n=6 naïve control mice) and arthritic mice (filled triangles; 
n=6 arthritic mice). The number of DCX positive cells in the hippocampus of mice from both 
naïve control and arthritic groups all experimental groups was determined by counting 
DCX positive cells in every sixth serial brain section containing DCX immuno 
histochemistry in the dentate gyrus. Bars represent the mean values (***P < 0.01 by 
Student’s t test). (B) Correlations of the number of DCX positive cells and clinical (RA) 
score. Plots show relationships between the number of DCX positive cells in the dentate 
gyrus of arthritic mice and their arthritic score (RA score) on day 42 analysed by Pearson’s 
correlation coefficient analysis.  
 
A. 
Naïve control No. 5  Arthritic mouse No. 22 (RA score 8) 
B. 
Naïve control No. 6  Arthritic mouse No 27 (RA score 12) 
C.  D. Chapter 6    298 
6.4.2  Changes in number of DCX positive neurons in the 
dentate gyrus in non arthritic mice 
Interestingly, immunized mice that did not develop arthritis (non arthritic mice) 
also  showed  differences  in  the  number  of  DCX positive  neurons  compared  to 
those in the naïve control mice. Figure 12A – 12I show the representative images 
of  DCX immuno histochemistry  in  the  dentate  gyrus  of  non arthritic  mice 
compared to those in the control mice (Figure 6.12A – Figure 6.12I). Similar to 
arthritic mice, a reduction in hippocampal neurogenesis was also observed in 
non arthritic mice. The mean number of DCX positive  neurons in the dentate 
gyrus (non arthritic versus naïve control mice) was 1668 ± 329 cells versus 5417 ± 
1673 cells (P = 0.0025) (Figure 6.13).  
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Figure 6.12 Changes in hippocampal neurogenesis in non arthritic mice on day 42 
DCX immuno histochemistry images of the dentate gyrus of non arthritic mice were 
randomly compared to those of naïve control mice. (A), (C), (F) and (H) show representative 
images of DCX immuno histochemistry in the dentate gyrus of naïve control mice no 1, 2, 3 
and 4 respectively. (B), (D), (G) and (I) show representative images of DCX immuno 
histochemistry in the dentate gyrus of different non arthritic mice (No. 23, 25, 26 and 29) 
with clinical (RA) score 0. Clinical scores (RA scores) were calculated on the cull day 42. All 
images were at 10X magnification.  
A. 
Naïve control No. 1 
B. 
Non arthritic mouse No.23 (RA score 0) 
Naïve control No. 2 
C. 
Non arthritic mouse No.25 (RA score 0) 
F. 
D. 
Naïve control No. 3  Non arthritic mouse No.26 (RA score 0) 
G. 
Naïve control No. 4 
H. 
Non arthritic mouse No.29 (RA score 0) 
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Figure 6.13 Change in number of DCX positive cells in dentate gyrus of non arthritic mice 
on day 42 
The dots represent the number of DCX positive cells in the hippocampus of individual naïve 
control mice (filled squares; n=6 naïve control mice) and arthritic mice (filled triangles; n=4 
arthritic mice). The number of DCX positive cells in the hippocampus of mice from both 
naïve control and non arthritic groups was determined by counting DCX positive cells in 
every sixth serial brain section containing DCX immuno histochemistry in the dentate 
gyrus. Bars represent the mean values (*P < 05; **P < 01; ***P < 001 by Student’s t test) 
6.4.3  Comparison of changes in number of DCX positive 
neurons in the dentate gyrus between naïve control, arthritic 
and non arthritic mice  
A reduction in hippocampal neurogenesis indicated by decrease in number of 
DCX positive neurons was observed in the dentate gyrus of both arthritic and 
non arthritic mice compared to those of control naïve mice. One way ANOVA 
followed  by  Bonferroni's  post hoc  comparison  tests  demonstrated  that  there 
were  significant  differences  in  the  number  of  DCX positive  neurons  in  the 
dentate gyrus among the three groups of mice (P < 0.0001) (Figure 6.14). The 
mean  number  of  DCX positive  neurons  in  the  dentate  gyrus  (arthritic  versus 
naïve control) was 1322 ± 285 cells versus 5417 ± 1673 cells (P = 0.0001), while 
the mean number of DCX positive neurons in the dentate gyrus (non arthritic 
versus naïve control) was 1668 ± 329 cells versus 5417 ± 1673 cells (P = 0.0025). 
However, there was no significant difference in number of DCX positive cells 
between arthritic and non arthritic mice (Figure 6.14). This finding suggests that 
the immunization with CII/CFA may itself affect Hippocampal neurogenesis in a 
different mechanism of that affecting the joint in CII immunized mice.  
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Figure 6.14Changes in number of DCX positive cells in dentate gyrus of arthritic and non 
arthritic mice on day 42 
The dots represent the number of DCX positive cells in the hippocampus of individual naïve 
control mice (filled squares; n=6 naïve control mice), non arthritic mice (filled triangles; n=4 
non arthritic mice) and arthritic mice (filled circles; n=6 arthritic mice). The number of DCX 
positive cells in the hippocampus of mice from all experimental groups was determined by 
counting DCX positive cells in every sixth serial brain section containing DCX immuno 
histochemistry in the dentate gyrus. Bars represent the mean values (*P < 05; **P < 01; ***P 
< 001 by one way ANOVA.) 
6.5  Effect of etanercept on hippocampal 
neurogenesis in CII immunized mice  
Data  from  the  previous  section  of  this  Chapter  6  (section  6.4)  showed  a 
reduction of neurogenesis, indicated by a decrease in number of DCX positive 
cells in the dentate gyrus of CII immunized mice on day 42. In Chapter 3 (Section 
3.2.3  and  Section  3.2.4),  we  demonstrated  up regulation  of  several 
inflammatory  mediators,  including  of  IL 1α,  IL 2,  IL 5,  IL 10,  IL 13,  CXCL1, 
CXCL10, VEGF and FGF2 in the brain of CII immunized mice at the same time 
point (day 42). This data from Chapter 3 combined with data in this chapter 
suggested  that  the  reduction  in  neurogenesis  in  CII  immunized  mice  may  be 
associated  with  up regulation  of  inflammatory  mediators  in  the  brain  of  CII 
immunized  mice.  In  Chapter  5  (Section  5.2.3  and  Section  5.2.4),  we 
demonstrated that peripheral administration of etanercept treatment profoundly 
inhibited the production of inflammatory mediators, including TNF α, IL 12 in 
brains  of  CII  immunized  mice  during  the  period  of  clinical  manifestation  of 
arthritis.  We  hypothesized  that  the  inhibitory  effect  of  etanercept  on 
inflammatory  mediator  production  in  the  brain  may  also  contribute  to  the 
protective  effect  against  a  reduction  in  hippocampal  neurogenesis  in  CII 
immunized mice. We therefore conducted another CIA experiment, similar to 
the  CIA  experiment  in  Chapter  5  (Section  5.2.1).  In  this  third  stage  of  this 
chapter,  we  analysed  changes  in  hippocampal  neurogenesis  in  etanercept 
treated immunized mice compared to those of PBS treated immunized mice and Chapter 6    302 
control  naïve  mice  on  day  14  (pre onset  and  pre etanercept  treatment  time 
point), day 32 and day 35 (2 time points during the period of development of 
arthritis).  
6.5.1   Administration of etanercept and induction of arthritis 
in DBA1 mice; CIA experimental procedure 
Nineteen DBA1 mice were immunized by intradermal injection of type II collagen 
in  Freund’s  complete  adjuvant  on  day  0.  On  day  14,  3  CII  (collagen  type  II) 
immunized mice (Group 1) were sacrificed and the brains and serum of these 
mice  were  harvested  for  the  measurement  of  inflammatory  mediator  levels 
before the second immunization on day 21. There was no CII immunized mice in 
Group 1 that developed arthritis on day 14. The other 16 CII immunized mice 
were randomly divided into 2 groups of 8, namely the treatment and placebo 
groups.  From  day  18  onwards,  CII  immunized  mice  of  the  treatment  group 
received Etanercept (300  g/mice, i.p.) every 3 days, while the placebo group 
received PBS (i.p.) every 3 days. The signs of arthritis in CII immunized mice 
were monitored from day 16 after immunization onwards and arthritis severity 
scores in this experiment were verified independently by Dr. Bernard Leng. CII 
immunized  mice  from  both  groups  were  re challenged  by  intraperitoneal 
injection of collagen II in PBS on day 21. CII immunized mice in the placebo 
group  started  to  show  sign  of  arthritis  earlier  (day  19)  than  those  of  the 
treatment group (day 21). 3 CII immunized mice of the treatment group (Group 
2) and 3 CII immunized mice of the placebo group (Group 3) were sacrificed and 
serum and brains of these CII immunized mice were harvested on day 32. CII 
immunized mice of both treatment and placebo groups (Group 4 and Group 5; 5 
CII immunized mice/group) were sacrificed and serum and brains of these CII 
immunized mice were harvested on day 35; which is the peak day of disease. 
Another 11 sex  and age matched untreated DBA1 mice were used as antigen 
naïve control mice. These naïve control mice were neither sensitized with type II 
collagen nor given etanercept treatment. 3 naïve control mice were sacrificed 
on day 14, and a further 3 and 5 naïve control mice were sacrificed on day 32 
and day 35 respectively. The brains of all experimental groups of mice were 
harvested and fixed in formalin and cryoprotected in 30% sucrose buffer. Serial 
60 um sections throughout the hippocampus were cut and immunostained for 
DCX using the free floating technique (Figure 6.15). Chapter 6    303 
 
 
Figure 6.15 Administration of etanercept and CIA experimental procedure for hippocampal 
neurogenesis analysis 
19 DBA1 mice at 6 8 weeks of age were immunized with 100       g type II bovine collagen + 
complete Freund’s adjuvant (CFA) at day 0. On day 14, 3 CII immunized mice in Group 1 
were culled and brains and serum of these CII immunized mice from group 1 (3 mice/group) 
were harvested. At this time point, another 3 naïve control mice, which were given neither 
sensitized with type II collagen, were also culled and their brains and serum samples were 
used as controls to compared changes in brain inflammatory mediators with those of CII 
immunized mice culled on day 14. On day 18, CII immunized mice were randomly divided 
into 2 groups (8 CII immunized mice/group), which were a treatment group and a placebo 
group.  From this day onwards, 300        g/mouse etanercept was administrated (i.p.) to CII 
immunized mice of the treatment group every 3 days, while PBS was injected to CII 
immunized mice of the placebo group every 3 days. CII immunized mice of both groups 
were challenged on day 21 with 200       g type II collagen. From day 21 onwards, etanercept 
treated CII immunized mice of etenercept group were randomly divided into 2 groups, 
namely Group 2 and Group 4. etanercept treated CII immunized mice in Group 2 (3 CII 
immunized mice/group) were culled and brains of these CII immunized mice were harvested 
on day 32, while etanercept treated CII immunized mice in Group 4 (5 CII immunized 
mice/group) were culled and brains of these CII immunized mice were harvested on day 35. 
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groups, namely Group 3 and Group 5. PBS treated CII immunized mice in Group 2 (3 CII 
immunized mice/group) were culled and brains of these CII immunized mice were harvested 
on day, while PBS treated CII immunized mice in Group 4 (5 CII immunized mice/group) were 
culled and brains of these CII immunized mice were harvested on day 35. Another 8 naïve 
control mice were culled on the day indicated (3 naïve mice for day 32 and 5 naïve mice for 
day 35) and their serum and brain were used as controls. Brains from mice of all 
experimental groups were collected and brains processed for DCX immuno histochemistry. 
6.5.2   Effect of etanercept on the development of collagen 
induced arthritis (CIA) 
6.5.2.1  Effect of etanercept on the severity of arthritis in CII immunized 
mice on day 32 
CII immunized mice in the treatment Group 2 (n=3) and the placebo Group 3 
were  given  etanercept  (300   g/mouse  every  3  day)  and  PBS  (placebo) 
respectively from day 18 after immunization onwards. Mice of both Group 2 and 
Group 3 were sacrificed on day 32. Some CII immunized mice in both Group 2 
and Group 3 started to show signs of arthritis from day 18 onwards. In addition, 
by day 32, there were 2 etanercept treated CII immunized in Group 2 (66.66 % 
incidence), and 2 PBS treated CII immunized mice in Group 3 (66.66 % incidence) 
developed  arthritis.  In  this  very  small  study  sub group,  this  suggests  that 
etanercept treatment did not have an effect on the onset of disease and the 
incidence of disease in CII immunized mice in treatment Group 2 (Figure 6.16A). 
However,  a  significant  reduction  in  mean  paw  thickness  was  observed  in 
etanercept treated  mice  in  Group  2  compared  to  those  in  PBS treated  CII 
immunized mice (Figure 6.16B). The mean paw thickness of mice in Group 2 and 
3 (etanercept treated versus PBS treated) was 2.0 ± 0.1 mm versus 2.3 ± 0.3 mm 
(P = 0.084), while the mean clinical score of mice in Group 2 and 3 (etanercept 
treated versus PBS treated) was 4 ± 2.1 versus 8 ± 4.2 (P = 0.029) (Figure 6.16C). 
However,  the  mean  paw  thickness  and  mean  arthritis  score  of  etanercept 
treated immunized mice was also significantly higher than those in naïve control 
mice. The mean paw thickness of mice (etanercept treated versus control naïve) 
was  2.0  ±  0.1  mm  versus  1.8  ±  0.0  mm  (P  =  0.0008).  This  suggests  that 
etanercept treatment seemed to ameliorate joint inflammation in CII immunized 
mice, but not completely inhibit the onset and progression of arthritis on day 32, 
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Figure 6.16 Effect of etanercept on severity of arthritis in CII immunized mice on day 32  
CII immunized mice in Group 2 (n=3 CII immunized mice/group blue line) were given 
injections from days 18 onwards before collagen immunization with 300  g etanercept every 
3 days. 3 CII immunized mice in Group 3 were given PBS as placebo (n=3 CII immunized 
mice/group red line). Mice in both Group 2 and Group 3 were sacrificed on day 32. The signs 
of arthritis in CII immunized mice were monitor from day 16 after immunization onwards. (A) 
shows the percent of incidence of arthritis in etanercept treated and PBS treated CII 
immunized mice, which was calculated from number of CII immunized mice with arthritis per 
group/total number of CII immunized mice used per group. Mean clinical arthritis score and 
mean paw thickness were used as a clinical evaluation to measure the severity of joint 
inflammation in arthritic mice. (B) shows mean paw thickness of etanercept treated and 
PBS treated CII immunized mice which was calculated from the sum of the paw thickness of 
all mice in each group divided by the number of mice per group. (C) shows mean clinical 
score of etanercept treated and PBS treated CII immunized mice which was calculated from 
the sum of the clinical scores of all mice in the each group divided by the number of mice 
per group. Mean paw thickness, mean clinical score and %incidence in CII immunised mice 
(n= 3/group) were compared with those values of naïve control mice (n = 3 naïve control 
mice; green line). These naïve control mice were neither sensitized with type II collagen nor 
given etanercept treatment. Data represented as mean ± SEM. (n=6 CII immunized mice). 
Statistical analysis of data was performed using two way ANOVA for multiple comparison, 
compared with a group of control naïve mice; *P<0.05, ** P<0.01, *** P<0.001. 
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6.5.2.2   Effect of etanercept on severity of arthritis in CII immunized 
mice on day 35. 
By day 35, the etanercept treatment seemed to prevent the arthritis disease 
progression in the etanercept treated CII immunized mice in Group 4.  
Firstly, etanercept treatment delayed the disease onset and significantly 
reduced  disease  incidence  compared  with  the  PBS treated  arthritis  controls 
(P=0.0002). Mice in Group 4 (n=5) started to develop arthritis on day 19 days 
after  immunization  in  the  PBS treated  group,  compared  with  33  days  after 
immunization in the etanercept treated Group 5 (n=5) (Figure 6.17A). There was 
only 1 etanercept treated CII immunized mouse that  developed arthritis (20% 
incidence),  compared  with  3  arthritic  mice  in  the  PBS treated  group  (60% 
incidence).  
Secondly,  etanercept  significantly  decreased  mean  paw  thickness  of 
etanercept treated  CII  immunized  mice  compared  to those  of PBS treated  CII 
immunized mice. The mean paw thickness of mice in Group 4 and 5 (etanercept 
treated versus PBS treated) was 2.1 ± 0.2 mm versus 2.8 ± 2.1 mm (P < 0.0001) 
(Figure 6.17B).  
Thirdly,  a  significant  reduction  in  mean  clinical  score  was  observed  in 
etanercept treated  CII  immunized  mice  compared  to those  of PBS treated  CII 
immunized mice. The mean clinical score of mice in Group 4 and 5 (etanercept 
treated versus PBS treated) was 2.8 ± 2.1 versus 0.4 ± 0.4 (P < 0.0001) (Figure 
6.17C).  There  was  no  significant  difference  in  mean  clinical  score  between 
etanercept treated  mice  and  naïve  control  mice.  There  was  no  significant 
difference in mean paw thickness and mean clinical score between etanercept 
treated CII immunized mice Group 4 and naïve control mice on day 35.  Chapter 6    307 
 
Figure 6.17 Effect of etanercept on severity of arthritis in CII immunized mice on day 35 
CII immunized mice in Group 4 (n=5 CII immunized mice/group blue line) were given 
injections from days 18 onwards before collagen immunization with 300  g etanercept every 
3 days. 5 CII immunized mice in Group 5 were given PBS as placebo (n=5 CII immunized 
mice/group red line). Mice in both Group 4 and Group 5 were sacrificed on day 35. The signs 
of arthritis in CII immunized mice were monitor from day 16 after immunization onwards. (A) 
shows the percent incidence of arthritis in etanercept treated and PBS treated CII 
immunized mice, which was calculated from number of CII immunized mice with arthritis per 
group/total number of CII immunized mice used per group. Mean clinical arthritis score and 
mean paw thickness were used as a clinical evaluation to measure the severity of joint 
inflammation in arthritic mice. (B) shows mean paw thickness of etanercept treated and 
PBS treated CII immunized mice which was calculated from the sum of the paw thickness of 
all mice in each group divided by the number of mice per group. (C) shows mean clinical of 
etanercept treated and PBS treated CII immunized mice which was calculated from the sum 
of the clinical scores of all mice in the each group divided by the number of mice per group. 
Mean paw thickness, mean clinical score and %incidence in CII immunised mice (n= 5 CII 
immunized mice/group) were compared with those values of naïve control mice (n = 5; 
green line). These naïve control mice were neither sensitized with type II collagen nor given 
etanercept treatment. Data represented as mean ± SEM. (n=10 CII immunised mice). 
Statistical analysis of data was performed using two way ANOVA for multiple comparison, 
compared with a group of control naïve mice; *P < 05; **P < 01; ***P < 001. 
6.5.2.3   Overall severity of arthritis in etanercept treated groups to 
PBS treated groups 
Overall, there were 5 out of 8 PBS treated CII immunized mice from Group 3 and 
Group 5 (~62.5 % incidence) that showed clinical signs of arthritis from day 18. 
Etanercept  treated CII  immunized  mice  showed  a  lower  disease  incidence 
compared to those in PBS treated CII immunized mice. 3 out of 8 Etanercept 
treated CII immunized mice from Group 2 and 4 developed arthritis from day 18 Chapter 6    308 
(~37.5 % incidence) (Figure 6.18A). Clinical signs of arthritis were observed in 
PBS treated  CII  immunized  mice  from  Group  3  and  5  from  day  19  after 
immunization onward and there were 5 out of 8 PBS treated CII immunized mice 
developed  arthritis  (62.5%  incidence).  The  cumulative  mean  paw swelling 
diameter of all PBS treated CII immunized mice from Group 3 and Group 5 (n=8) 
was 2.1 ± 0.2 mm, which was significantly higher than those in naïve control 
mice (1.8 ± 0.0 mm; P< 0.0001). Etanercept treated CII immunized mice showed 
significantly less swelling than PBS treated CII immunized mice (2.1 ± 0.2 mm; P 
<0.0001). Two way ANOVA analysis also indicated that the cumulative mean of 
swelling  diameter  of Etanercept treated  CII  immunized  mice  was  significantly 
higher than those in control mice (1.8 ± 0.0 mm; P= P <0.0001) (Figure 6.18B). 
The cumulative mean arthritis score of Etanercept treated CII immunized mice 
was significantly lower than those of PBS treated CII immunized mice (2.25 ± 
1.21 versus 3.75 ± 1.35) (Figure 6.18C). A summary of number of arthritic mice, 
mean  arthritis  score,  maximum  arthritis  score,  mean  paw  diameter  of 
etanercept treated and PBS treated CII immunized mice is presented in Table 1. 
Overall, our data suggest that etanercept treatment before the onset of disease 
attenuated arthritis disease severity in CII immunized mice. 
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Figure 6.18 Effect of etanercept on severity of arthritis in all CII immunized mice in Group 2, 
3, 4 and 5 
CII immunized mice in Group 2 and Group 4 (n=8 CII immunized mice for both groups; blue 
line) were given injections of 300  g etanercept every 3 days from days 18 onwards, before 
collagen immunization. 3 CII immunized mice in Group 3 and Group 5 were given PBS as 
placebo treatment (n=8 CII immunized mice for both groups; red line). Mice in both Group 4 
and Group 5 were sacrificed on day 32, while mice in both Group 4 and Group 5 were 
sacrificed on day 35. The signs of arthritis in CII immunized mice were monitored from day 
16 after immunization onwards. (A) shows the cumulative percent of incidence of arthritis in 
all etanercept treated and all PBS treated CII immunized mice, which was calculated from 
number of CII immunized mice with arthritis per group/total number of CII immunized mice 
used per group. Cumulative mean clinical arthritis score and cumulative mean paw 
thickness were used as a clinical evaluation to measure the severity of joint inflammation in 
arthritic mice. (B) shows cumulative mean paw thickness of all etanercept treated and all 
PBS treated CII immunized mice which was calculated from the sum of the paw thickness of 
all mice in each group divided by the number of mice per group. (C) shows cumulative mean 
clinical of all etanercept treated and all PBS treated CII immunized mice which was 
calculated from the sum of the clinical scores of all mice in the each group divided by the 
number of mice per group. Cumulative mean paw thickness, cumulative mean clinical score 
and cumulative %incidence in CII immunised mice (n= 8 CII immunized mice/group) were 
compared with those values of naïve control mice (n = 8; green line). These naïve control 
mice were neither sensitized with type II collagen nor given etanercept treatment. Data 
represented as mean ± SEM. (n=16 CII immunized mice). Statistical analysis of data was 
performed using two way ANOVA for multiple comparison, compared with a group of 
control naïve mice; *P < 05; **P < 01; ***P < 001. 
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Group 
 
Treatment 
 
 
Day of 
harvesting 
 
Arthritic/total 
number of 
mice 
 
Mean 
Arthritis 
scores 
 
Maximum 
Arthritis 
scores 
 
Mean 
Paw    
Diameter 
(mm) 
 
2 
 
Etanercept 
 
32 
 
2/3 
 
4.0 ± 2.1 
 
7 
 
2.1 ± 0.1 
 
3 
 
PBS 
 
32 
 
2/3 
 
4.7 ± 2.4 
 
8 
 
2.1 ± 0.3 
 
4 
 
Etanercept 
 
35 
 
1/5 
 
0.4 ± 0.4 
 
2 
 
1.9 ± 0.0 
 
5 
 
PBS 
 
35 
 
3/5 
 
2.8 ± 2.1 
 
11 
 
2.1 ± 0.2 
Table 6.1 Numbers of arthritic mice, mean arthritis scores, and mean swelling scores of CIA 
mice in etanercept treated and PBS treated groups 
Etanercept treated mice and PBS treated mice (Group 2 and 3) were sacrificed on day 32, 
while etanercept treated mice and PBS treated mice (Group 4 and 5) were sacrificed on day 
35. Numbers of immunized mice developed arthritis from each time point group were 
counted on the harvesting day. Mean arthritis scores (total arthritis score/number of mice in 
the group), maximum arthritis score and mean swelling of immunized mice from each 
treatment time point group were calculated on the cull day. 
6.5.3  Changes in hippocampal neurogenesis in CII 
immunized mice before the onset of arthritis on day 14. 
Data  from  the  previous  section  of  this  Chapter  6  (Section  6.4)  showed  a 
reduction in neurogenesis in CII immunized mice on day 42; during the period of 
clinical  disease.  However,  it  still  remained  unclear  whether  the  reduction  in 
neurogenesis is actually associated with peripheral inflammation. We therefore 
analysed the change in neurogenesis in CII immunized mice compared to those in 
naïve  control  mice  before  the  disease  onset.  14  days  after  the  primary 
immunization on day 1, there were no CII immunized mice (n=19) that developed 
arthritis. We randomly sacrificed 3 CII immunized mice and the brains of these Chapter 6    311 
mice were processed for DCX immuno histochemistry to investigate any change 
in  hippocampal  neurogenesis  compared  to  brains  from  3  naïve  control  mice 
harvested on the same day. Etanercept treatment (300 ug/animal i.p., every 3 
days)  was  not  administrated  to  CII  immunized  mice  until  day  18  after 
immunization. Therefore, day 14 is also the control time point before etanercept 
treatment. The quantitative immuno histochemistry of DCX positive neurons was 
performed on the brain sections from CII immunized mice and naïve control mice 
harvested on day 14 to investigate changes in hippocampal neurogenesis before 
etanercept treatment which was started on day 18. The microscopy images of 
stained brain sections showed no changes in the number of DCX positive neurons 
in the hippocampus of immunized mice compared to those of control untreated 
mice (Figure 6.19A   Figure 6.19F). This was confirmed by the cell count data 
showing  that  the  number  of  DCX positive  neurons  in  the  dentate  gurus  of 
arthritic mice was not significantly different from those in naïve control mice on 
day  14.  The  mean  number  of  DCX positive  neurons  in  the  dentate  gyrus  (CII 
immunized versus control) was 9528 ± 2040 cells versus 10938 ± 2244 cells (P = 
0.4643;  n=3)  (Figure  6.20).  These  data  suggested  that  the  changes  in  the 
hippocampal neurogenesis seen at day 42 may be associated with the subsequent 
peripheral  inflammation.  This  also  corresponded  with  data  from  Chapter  5 
(Section  5.2.3  and  Section  5.2.4)  also  showing  that  there  was  no  significant 
difference in brain inflammatory mediator concentrations in CII immunized mice 
on day 14 compared to those in naïve control mice. Our data from the previous 
chapter  (Chapter  5  ;  Section  5.2.3  and  Section  5.2.4)  combined  with  this 
hippocampal neurogenesis data of CII immunized mice on day 14 in this section 
suggest that brain inflammatory mediators in CII immunized mice may contribute 
to the reduction in hippocampal neurogenesis.  Chapter 6    312 
 
Figure 6.19 DCX immuno histochemistry in the dentate gyrus of control untreated mice and 
CII immunized mice on day 14 
Control and CII immunized mice (3 mice/group) were sacrificed on day 14 and the brains of 
these were processed for DCX immuno histochemistry. (A), (C) and (E) show representative 
images of DCX immuno histochemistry in the dentate gyrus of control mice (numbers 1, 2 
and 3 respectively). (B), (D), (F) show representative images of DCX immuno histochemistry 
in the dentate gyrus of CII Immunized mice. All images were 10X magnification.  
A. 
Naïve Control No. 1 
B. 
CII immunized mice No.1 
C. 
Naïve Control No. 2  CII immunized mice No.2 
D. 
E. 
Naïve Control No. 3  CII immunized mice No.3 
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Figure 6.20 Changes in number of DCX positive cells in dentate gyrus of CII immunized 
mice on day 14 
The dots represent the number of DCX positive cells in the hippocampus of individual naïve 
control mice (filled squares; n=3 naïve control mice) and CII immunized mice (filled 
triangles; n=3 CII immunized mice) on day 14. Numbers of DCX positive cells in the 
hippocampus of mice from both naïve control and CII immunized groups were determined 
by counting DCX positive cells in every sixth serial brain section containing hippocampal 
tissue. Bars represent the mean values. (*P < 05; **P < 01; ***P < 001 by Student’s t test). 
 
6.5.4   Effect of etanercept on hippocampal neurogenesis 
during period of clinical manifestation of arthritis  
Data from Chapter 3 (section 3.2.3 and section 3.2.4) suggest that a reduction in 
hippocampal neurogenesis may be associated with peripheral joint inflammation 
that may due to inflammatory mediators that are up regulated in brains of CII 
immunized mice during the period of clinical manifestation of arthritis on day 
42.  In  Chapter  5  (Section  5.2.3  and  Section  5.2.4),  we  demonstrated  that 
peripheral  administration  of  etanercept  resulted  in  decreases  in  brain 
inflammatory  mediators,  including  TNF α,  IL 12  and  IL 5.  We  therefore 
hypothesised  that  the  reductions  of  these  brain  inflammatory  mediators 
resulting from peripheral etanercept treatment may have the protective effect 
against the impairment of hippocampal neurogenesis in CII immunized mice.  
To determine whether the reduction in hippocampus neurogenesis in CII 
immunized  mice  could  be  prevented  by  anti inflammatory  drug  therapy, 
etanercept (300 ug/animal i.p., every 3 days) was peripherally administrated to 
CII immunized mice from day 18 onwards. Etanercept treated immunized mice 
(Group 2 and 4), PBS treated CII immunized mice (Group 3 and 5), and naïve 
control mice were sacrificed on day 32 and day 35, which is typically during the 
period of clinical manifestation of arthritis. Brains of mice from all experimental 
groups were processed and immuno histochemistry stained for DCX. In order to Chapter 6    314 
compare  the  DCX  staining  pattern  we  used  a  strategy  to  compare  subgroups 
using random images from one mouse in each group of naïve control mice, PBS 
treated and Etanercept treated CII immunized mice at each of the time points 
on day 32 and day 35. Each subgroup was labelled study groups A, B, C etc. A 
summary of the data showing arthritis score, paw diameter and number of DCX 
positive cells of individual mouse from each subgroup on each day is added at 
the end. 
6.5.4.1   Effect of etanercept on hippocampal neurogenesis in CII 
immunized mice on day 32 
There  were  2  etanercept treated  CII  immunized  mice  from  Group  2  that 
developed  arthritis  on  day  32.  At  that  time  point,  there  was  1  etanercept 
treated CII immunized mouse with no arthritis in that group. In Group 3, there 
were 2 PBS treated CII immunized mice developed arthritis and 1 PBS treated CII 
immunized  mice  that  did  not  develop  arthritis.  We  compared  subgroups  of 
images from one mouse in each group of naïve control mice, PBS treated and 
etanercept treated  CII  immunized  mice.  Each  subgroup  was  labelled  study 
groups as Set A, Set B and Set C. Since we had the same number of PBS treated 
and etanercept treated  CII immunized  mice  that  developed  arthritis  (n=2)  on 
day 32, we decided to compare DCX immuno histochemistry images from PBS 
treated  mice  with  arthritis  and  etanercept treated  CII  immunized  mice  that 
developed arthritis. Therefore, Set A and Set B consisted of DCX staining images 
from etanercept treated and PBS treated CII immunized mice with arthritis and 
naïve control mice. Set C consisted of DCX staining images from one etanercept 
treated mouse and one PBS treated CII immunized mouse with arthritis and one 
naïve control mouse. The analysis plan of DCX immuno histochemistry images of 
mice from all experimental groups is shown in Figure 6.21. Chapter 6    315 
 
Figure 6.21 Analysis plan to compare DCX staining pattern in brains of PBS treated, 
etanercept treated CII immunized mice and naïve control mice on day 32 
DCX staining images from one mouse in each group of PBS treated mice (n=3 PBS treated 
mice; red mouse), naïve control mouse (n=3 naïve control mouse; green mouse) and 
etanercept treated mice (n=3 etanercept treated mice; blue mouse) were compared. DCX 
staining images of one PBS treated mouse (red), one naïve control mouse (green) and one 
etanercept treated mouse (blue) and were organized as subgroups, namely Set A, B and C. 
Set A and B consisted of DCX staining images from PBS treated, etanercept treated CII 
immunized mice with arthritis and naïve control mice. Set C consisted of DCX staining 
images from PBS treated, etanercept treated CII immunized mice without arthritis and a 
naïve control mouse.  
6.5.4.1.1   Effect of etanercept on the number of DCX-positive cells 
in CII immunized mice with arthritis on day 32 
Set  A  consisted  of  control  mouse  No.1,  the  PBS treated  arthritis  mouse  No.2 
(clinical score 8), and an etanercept treated arthritis mouse No.1 (clinical score 
1). The microscopy images in Figure 6.22 showed differences in the number of 
DCX positive  neurons  between  the  hippocampi  of  treated,  untreated  arthritic 
mice  and  control  mice.  A  result  from  the  cell  count  demonstrated  that  the 
hippocampus of the PBS treated arthritis mouse No. 2 (clinical score 8) showed 
fewer DCX positive cells compared to those of the naïve control mouse No. 1 
(4176  versus  8310  cells).  Interestingly,  the  etanercept treated  mouse  No.1 
showed a higher number of DCX positive cells (10416 cells) compared to those of 
a naïve control mouse No.1 and PBS treated arthritis mouse No.2 (Figure 6.22A   
Figure 6.22C).  Chapter 6    316 
 
Figure 6.22 DCX immuno histochemistry in the dentate gyrus of one naïve control, one PBS 
treated and one etanercept treated CII immunized mouse in set A 
All the mouse brains from mice of set A were harvested on day 32. (A) shows a 
representative image of DCX immuno histochemistry in the dentate gurus of control mice 
No.1. (B) shows a representative image of DCX of PBS treated CII immunized mice No.2 
(clinical score 8). (C) shows a representative image of DCX of Etanercept treated CII 
immunized mice No.1 (clinical score 1). RA score = clinical score. All images at 10X 
magnification. 
A similar pattern of changes in the number of DCX positive cells in the dentate 
gyrus was observed in DCX staining images from naïve control, PBS treated and 
etanercept treated arthritic mice in Set B.  The PBS treated arthritic mouse No 
3 (clinical score 6) had less number of DCX positive cells in the dentate gyrus 
compared those of naïve control mouse No 2 (Figure 6.23A and Figure 6.23B). 
The number of DCX positive cells in dentate gyrus of the naïve control mouse 
was 9222 cells, while the number of DCX positive cells in the dentate gyrus of 
the  PBS treated arthritis  mouse No.3  was  2310  cells.  The  etanercept  treated 
arthritic mouse No 3 (clinical score 6) showed a similar number of DCX positive 
cells in the dentate gyrus (n=9204) compared to the naïve control mouse No.2, 
which  higher than those  of the  PBS treated  CII immunized  mice  No.3  (Figure 
6.23A and Figure 6.23C). 
Naïve Control No.1  Placebo (PBS) 
Etanercept 
No.2 RA score 8 
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Figure 6.23 DCX immuno histochemistry in the dentate gyrus of one naïve control, one PBS 
treated arthritic and one etanercept treated arthritic mouse in set B 
All mouse brains from mice of set B were harvested on day 32 and processed for DCX 
immuno histochemistry. (A) shows a representative image of DCX immuno histochemistry  
in the dentate gurus of the naïve control mice No.2. (B) shows a representative image of 
DCX immuno histochemistry  in the dentate gurus of untreated CII immunized mice No.3 
(clinical  score 6). (C) shows a representative image of DCX immuno histochemistry  in the 
dentate gurus of the etanercept treated CII immunized mice No.3, (clinical score 6). RA 
score = clinical score. All images 10X magnification. 
A  summary  of  the  number  of  DCX positive  neurons  in  the  hippocampus  of 
individual naïve control mice, PBS treated arthritic mice and etanercept treated 
arthritic mice and their arthritis scores is presented in Table 6.2. 
 
 
 
 
 
Naïve Control No.2 
Placebo (PBS) 
No.3 RA score 6 
Etanercept 
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Individual  Individual  Number   
Mouse  Clinical 
scores 
paw 
diameter 
(mm) 
of DCX 
positive 
neurons 
 
 Set A mice 
 
Naïve control mouse No.1 
 
0 
 
1.8 
 
8310 
 
 PBS treated mouse No.2      
 
8 
 
2.5 
 
4176 
 
Etanercept treated mouse No.1        
 
1 
 
2.2 
 
10416 
 
Set B mice 
 
Naïve control mouse No.2 
 
0 
 
1.8 
 
9222 
 
 PBS treated mouse No.3     
 
6 
 
2.6 
 
2310 
 
Etanercept treated mouse No.3        
 
6 
 
2.5 
 
9204 
Table 6.2 Individual arthritis score, individual paw swelling scores and number of DCX 
positive neurons of arthritic mice in etanercept treated and PBS treated groups 
Each set of mice (set A and set B) consisted of a naïve control mouse, a PBS treated 
arthritic mouse and an etanercept treated arthritic mouse, which were sacrificed on day 32. 
DCX immuno histochemistry and number of DCX positive neurons in the dentate gyrus of 
mice in each set were compared. Individual arthritis score, paw diameter (sum of all 4 paws 
of each mouse divided by 4) and number of DCX positive neurons in the dentate gyrus of 
mice were calculated and measured on the cull day. 
6.5.4.1.2   Effect of etanercept on hippocampal neurogenesis of 
non- arthritic mice on day 32 
Set  C  of  mice  consisted  of  a  naïve  control  mouse  No.  3,  a  PBS treated  CII 
immunized mouse No.1 and an etanercept treated CII immunized mouse No. 2. 
Both the PBS treated and the etanercept treated CII immunized mice did not 
develop arthritis by day 32. Despite this, there was a difference in the number 
of DCX positive neurons observed in the dentate gyrus of both PBS treated and 
etanercept treated CII immunized mice with no arthritis compared to those of 
the naive control mouse (Figure 6.24A   Figure 6.24B). PBS treated non arthritic 
mouse No 1 had less DCX positive cells in its dentate gyrus as compared with 
DCX positive cells in the dentate gyrus of the naïve control mouse No 3 (n=2136 
cells  versus  8904  cells).  Interestingly,  the  dentate  gyrus  of  the  etanercept 
treated  non  arthritic  mouse  No  2  had  a  higher  number  of  DCX positive  cells 
(n=7428) than those of the PBS treated non arthritic mouse No 1 (Figure 6.24B   
Figure 6.24C). A summary of number DCX positive neurons in the dentate gyrus 
of  individual  mice  PBS treated  non  arthritic  mouse,  etanercept treated  non Chapter 6    319 
arthritic mouse and the naïve control mouse in Set C and their clinical scores 
and paw diameters is presented in Table 6.3. 
 
Figure 6.24 DCX immuno histochemistry in the dentate gyrus of one control, one PBS 
treated and one etanercept treated CII immunized mouse in Set C (neither developed 
arthritis) 
All the mouse brains from the mice of Set C were harvested on day 32 and processed for 
DCX immuno histochemistry. (A) shows a representative image of DCX immuno 
histochemistry  in the dentate gurus of the naïve control mice No.3. (B) shows a 
representative image of DCX immuno histochemistry  in the dentate gurus of PBS treated 
CII immunized mice No.1 (clinical score 0). (C) shows a representative image of DCX 
immuno histochemistry  in the dentate gurus of the etanercept treated CII immunized mice 
No.2 (clinical score 0). RA score = clinical score. All images at 10X magnification. 
    Number   
Mouse  clinical 
scores 
paw 
diameter 
(mm) 
of DCX 
positive 
neurons 
 
Naïve control mouse No.3 
 
0 
 
1.8 
 
8904 
 
 PBS treated mouse No.1      
 
0 
 
1.8 
 
2136 
 
Etanercept treated mouse No.2       
 
0 
 
1.8 
 
7428 
Table 6.3 Individual arthritis score, individual paw swelling scores and number of DCX 
positive neurons of non arthritic mice in etanercept treated and PBS treated CII immunized 
groups on day 32 
Set C consisted of a naïve control mouse No.3, PBS treated non arthritic mouse No.1 and 
etanercept treated non arthritic mouse No.2, which were sacrificed on day 32. DCX immuno 
histochemistry and number of DCX positive neurons in the dentate gyrus of mice in each 
Naïve Control No.3  Placebo (PBS) 
Etanercept 
No.1 RA score 0 
No.2 RA score 0 Chapter 6    320 
set were compared. Individual arthritis score, paw diameter (sum of all 4 paws of each 
mouse divided by 4) and number of DCX positive neurons in the dentate gyrus of mice were 
calculated and measured on the cull day 32. 
6.5.4.1.3  Comparison of numbers of DCX-positive cells between 
etanercept-treated and PBS-treated groups on day 32 
Overall, the cell count data showed that DCX positive neurons in the dentate 
gyrus of PBS treated CII immunized mice on day 32 were significantly decreased 
compared  to  those  in  the  naïve  control  mice  on  day  32.  One way  ANOVA 
followed  by  Bonferroni's  post hoc  comparison  tests  demonstrated  that  there 
were  significant  differences  in  the  number  of  DCX positive  neurons  in  the 
dentate gyrus among the three groups of mice culled on day 32 (P = 0.0008) 
(Figure 6.25). The mean number of DCX positive neurons in the dentate gyrus 
(PBS treated CII immunized versus naïve control) was 2874 ± 1128 cells versus 
8814 ± 462 cells (P =0.0011) (Figure 6.25). The number of DCX positive neurons 
in the dentate gyrus of etanercept treated CII immunized mice was significantly 
increased compared to those in the PBS treated arthritic mice on day 32. The 
mean number of DCX positive neurons in the dentate gyrus (etanercept treated 
CII immunized versus PBS treated CII immunized) was 9018 ± 1218 cells versus 
2874 ± 1128  cells (P = 0.0048) (Figure 6.25). However, there was no significant 
difference between the numbers of DCX positive neurons in the dentate gyrus of 
etanercept treated CII immunized compared to those of naïve control mice on 
day 32 (Figure 6.25). This finding suggests that etanercept treatment may have a 
protective  effect  against  the  impairment  of  hippocampal  neurogenesis  in  CII 
immunized mice on day 32 
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Figure 6.25 Number of DCX positive cells in dentate gyrus of PBS treated and etanercept 
treated CII immunized mice on day 32 
The dots represent the number of DCX positive cells in the hippocampus of individual 
control untreated mice (filled squares; n=3 control untreated mice), CII immunized mice 
treated with PBS as the placebo group (filled triangles; n=3 CII immunized mice), and 
immunised etanercept treated mice (filled circles; n=3 immunised etanercept treated mice) 
on day 32. The number of DCX positive cells in the hippocampus of mice from all 
experimental groups was determined by counting DCX positive cells in every sixth serial 
brain section containing DCX immuno histochemistry in the dentate gyrus. Bars represent 
the mean values: Statistical analysis of data was performed using one way ANOVA (*P<0.05, 
**P<0.01, ***P<0.001). 
6.5.4.2  Effect of Etanercept on hippocampal neurogenesis of CII 
immunized mice on day 35 
Quantitative immuno histochemistry of DCX positive neurons was performed in 
the  brain  sections  from  immunized  mice  of  the  etanercept treated  Group  4 
(n=5), the PBS treat Group 5 (n=5) and the naïve control roup (n=5) on day 35 to 
investigate the effect of etanercept on changes in hippocampal neurogenesis. At 
this time point, there were 3 out of 5 immunized mice from the PBS treated 
Group 5 that developed arthritis. There was one out of 5 Etanercept treated 
mouse  that  developed  arthritis.  Again,  to  compare  DCX staining  pattern  the 
dentate  gyrus  between  PBS treated,  etanercept treated  and  antigen naïve 
control  mice.  Images  of  DCX  immuno histochamistry  from one mouse  in  each 
group of naïve control, etanercept treated and PBS treated mice were randomly 
organized as subgroups, namely Set D, E, F, G and H. A summary of the data 
showing  arthritis  score,  paw  diameter  and  number  of  DCX positive  cells  of 
individual  mouse  from  each  subgroup  on  each  day  is  added  at  the  end.  The 
analysis plan for images of DCX staining of mice from all experimental groups on 
day 35 is shown in Figure 6.26. Chapter 6    322 
 
Figure 6.26 Analysis plan to compare DCX staining pattern in brains of PBS treated, 
etanercept treated CII immunized mice and naïve control mice on day 35 
DCX staining images from one mouse in each group of PBS treated mice (n=5 PBS treated 
mice; red mouse), naïve control mouse (n=5 naïve control mouse; green mouse) and 
etanercept treated mice (n=5 etanercept treated mice; blue mouse) were compared. DCX 
staining images of one PBS treated mouse (red), one naïve control mouse (green) and one 
etanercept treated mouse (blue) and were randomly organized as subgroups, namely Set D, 
E, F, G and H.  
Brain slices containing hippocampus from mice of all experimental groups on day 
35 were stained for DCX, and the differences in numbers of DCX positive cells 
between control, treated and untreated mice compared. The microscopy images 
showed  that  there  were  differences  in  the  numbers  of  DCX positive  neurons 
between  dentate  gyrus  of  PBS treated arthritic  mice  and  naïve  control  mice 
(Figure 6.27A   Figure 6.31A and Figure 6.27B   Figure 6.31B). PBS treated CII 
immunized mice were likely to have less DCX positive cells in their dentate gyrus 
compared to those of naïve control mice. Interestingly, PBS treated immunized 
mice,  which  did  not  develop  arthritis  also  showed  reduced  numbers  of  DCX 
positive neurons compared to those of the naïve control mice (Figure 6.27A   
Figure 6.31A and Figure 6.27B   Figure 6.31B). In comparison to PBS treated CII 
immunized  mice,  etanercept treated  mice  had a  trend  for  more  DCX positive 
cells in their dentate gyrus (Figure 6.27B   Figure 6.31C). However, the number 
DCX positive neurons in dentate gyrus of some etanercept treated immunized 
mice  were  less  than  those  of  the  naïve  control  mice  (Figure  6.27A     Figure 
6.31C). 
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Figure 6.27 DCX immuno histochemistry in the dentate gyrus of one naïve control, one PBS 
treated arthritic and one etanercept non arthritic mouse in set D 
All the mouse brains from mice of Set D were harvested on day 35 and processed for DCX 
immuno histochemistry. (A) shows a representative image of DCX immuno histochemistry  
in the dentate gurus of a naïve control mouse No.4. (B) shows a representative image of 
DCX immuno histochemistry  in the dentate gurus of the PBS treated arthritic CII immunized 
mouse No.4, (clinical score 1). (C) shows a representative image of DCX immuno 
histochemistry  in the dentate gurus of the Etanercept treated non arthritic mouse No.4, 
(clinical score 0). RA score = clinical score. All images at 10X magnification. 
Naïve Control No.4  Placebo (PBS) 
No.4 RA score 1 
Etanercept 
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Figure 6.28 DCX immuno histochemistry in the dentate gyrus of one naïve control, one PBS 
treated arthritic and one etanercept treated non arthritic mouse in Set E  
All the mouse brains from mice of Set E were harvested on day 35 and processed for DCX 
immuno histochemistry. (A) shows a representative image of DCX immuno histochemistry  
in the dentate gurus of the naïve control mice No.5. (B) shows a representative image of 
DCX immuno histochemistry  in the dentate gurus of the PBS treated arthritic untreated 
mouse No.6 (clinical score 11). (C) shows a representative image of DCX immuno 
histochemistry in the dentate gurus of etanercept treated non arthritic mouse No.5, (clinical 
arthritis score 0). RA score = clinical score. All images 10X magnification. 
 
 
Naïve Control No.5  Placebo (PBS) 
No.6 RA score 11 
No.5 RA score 0 
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Figure 6.29 DCX immuno histochemistry in the dentate gyrus of one naïve control, one PBS 
treated arthritic and one etanercept arthritic mice in Set F 
All the mouse brains from mice of Set F were harvested on day 35 and processed for DCX 
immuno histochemistry. (A) shows a representative image of DCX immuno histochemistry  
in the dentate gurus of the naïve control mouse No.7. (B) shows a representative image of 
DCX immuno histochemistry  in the dentate gurus of the PBS treated arthritic mouse No.8, 
(clinical score 4). (C) shows a representative image of DCX immuno histochemistry in the 
dentate gurus of the etanercept treated arthritic mouse No.7, (clinical score 2). RA score = 
clinical score. All images at 10X magnification. 
 
Naïve Control No.7  Placebo (PBS) 
No.8 RA score 4 
No.7 RA score 2 
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Figure 6.30 DCX immuno histochemistry in the dentate gyrus of one naïve control, one PBS 
treated non arthritic and one etanercept non arthritic mouse in Set G 
All the mouse brains from mice of Set G were harvested on day 35 and processed for DCX 
immuno histochemistry. (A) shows a representative image of DCX immuno histochemistry  
in the dentate gurus of the naïve control mouse No.6. (B) shows a representative image of 
DCX immuno histochemistry  in the dentate gurus of PBS treated non arthritic mouse No.5, 
(clinical score 0). (C) shows a representative image of DCX immuno histochemistry  in the 
dentate gurus of the etanercept treated non arthritic mouse No.6, (clinical score 0). RA 
score = clinical score. All images at 10X magnification. 
 
 
 
Naïve Control No.6  Placebo (PBS) 
No.5 RA score 0 
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Figure 6.31 DCX immuno histochemistry in the dentate gyrus of one naïve control, one PBS 
treated non arthritic and one etanercept non arthritic mouse in Set H 
All the mouse brains from mice of Set H were harvested on day 35 and processed for DCX 
immuno histochemistry. (A) shows a representative image of DCX immuno histochemistry  
in the dentate gurus of the naïve control mice No.8. (B) shows a representative image of 
DCX immuno histochemistry  in the dentate gurus of the PBS treated non arthritic mouse 
No.7, (clinical score 0). (C) shows a representative image of DCX immuno histochemistry in 
the dentate gurus of the etanercept treated non arthritic mouse No.8, (clinical score 0). RA 
score = clinical score. All images at 10X magnification. 
A  summary  of  the  number  of  DCX positive  neurons  in  the  dentate  gyrus  of 
individual naïve control mice, PBS treated arthritic mice and etanercept treated 
CII  immunized  mice,  their  clinical  scores  and  paw  diameters  is  presented  in 
Table 6.4.  
 
 
 
 
 
Naïve Control No.8  Placebo (PBS) 
No.7 RA score 0 
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Individual  Individual  Number   
Mouse  clinical 
scores 
paw 
diameter 
(mm) 
of DCX 
positive 
neurons 
 
 Set D mice 
 
Naïve control mouse No.4 
 
0 
 
1.8 
 
7422 
 
PBS treated mouse No.4   
 
1 
 
1.8 
 
4638 
 
Etanercept treated mouse No. 4   
 
0 
 
1.8 
 
5556 
 
Set E mice 
 
Control mouse No.2 
 
0 
 
1.8 
 
13860 
 
 Untreated mouse No.2   
 
11 
 
2.9 
 
2640 
 
Etanercept treated mouse No. 2   
 
0 
 
1.8 
 
5034 
 
Set F mice 
 
Control mouse No.3 
 
0 
 
1.8 
 
7146 
 
 Untreated mouse No.5   
 
0 
 
1.8 
 
1680 
 
Etanercept treated mouse No. 3   
 
0 
 
1.8 
 
3438 
 
Set G mice 
 
Control mouse No.1 
 
0 
 
1.8 
 
9276 
 
 Untreated mouse No. 5  
 
4 
 
2.1 
 
3414 
 
Etanercept treated mouse No. 4   
 
2 
 
1.9 
 
7422 
 
Set H mice 
 
Control mouse No.1 
 
0 
 
1.8 
 
10998 
 
 Untreated mouse No.3   
 
0 
 
1.8 
 
3108 
 
Etanercept treated mouse No.3.1 
 
0 
 
1.8 
 
7056 
Table 6.4 Inividual arthritis score, individual swelling scores and number of DCX positive 
neurons of CII immunized mice in etanercept treated and PBS treated groups on day 35 
Each set of mice (Set D to H) consisted of one antigen naïve control mouse, one PBS 
treated CII immunized mouse and one etanercept treated CII immunized mouse, which were 
sacrificed on day 35. DCX immuno histochemistry and number of DCX positive neurons in 
the dentate gyrus of mice in each set were compared. Individual arthritis scores, paw 
diameters (sum of all 4 paws of each mouse divided by 4) and numbers of DCX positive 
neurons in the dentate gyrus of mice were calculated and measured on the cull day. Chapter 6    329 
6.5.4.2.1   Comparison of numbers of DCX-positive cells between 
etanercept-treated and PBS-treated groups on day 35 
Overall,  the  cell  count  data  demonstrated  that  DCX positive  neurons  in  the 
dentate gyrus of PBS treated CII immunized mice were significantly decreased 
compared to those in of naïve control mice on day 35. One way ANOVA followed 
by  Bonferroni's  post hoc  comparison  tests  demonstrated  that  there  were 
significant  differences  in  the  number  of  DCX positive  neurons  in  the  dentate 
gyrus among the three groups of mice on day 35 (P = 0.0005). The mean number 
of DCX positive neurons in the dentate gyrus (PBS treated CII immunized versus 
naïve control) was 516 ± 181 cells versus 1631 ± 456 cells (P < 0.001) (Figure 
6.32). The number of DCX positive neurons in the dentate gyrus of etanercept 
treated CII immunized mice tended to be higher compared to those in the PBS 
treated CII immunized mice. The mean number of DCX positive neurons in the 
dentate  gyrus  (etanercept treated  CII  immunized  versus  PBS treated  CII 
immunized)  was  5700  ±  1614  cells  versus  3096  ±  1086  cells  (Figure  6.32). 
However,  post  hoc  analysis  with  Bonferroni  correction  showed  that  the 
difference  in  mean  number  of  DCX positive  neurons  in  the  dentate  gyrus 
between etenercept treated CII immunized and PBS treated CII immunized was 
not statistically significant. Interestingly, the number of DCX positive neurons in 
the dentate gyrus of etanercept treated CII immunized mice was significantly 
lower compared to those in the naïve control mice. The mean number of DCX 
positive neurons in the dentate gyrus (etanercept treated CII immunized versus 
control) was 5700 ± 1614 cells versus 9786 ± 2736 cells (P < 0.05) (Figure 6.32). 
This  data  suggest  that  TNF blockade  therapy  using  etanercept  showed  no 
preventative effect on the impairment of hippocampal neurogenesis in the group 
of CII immunized mice on day 35. Chapter 6    330 
 
Figure 6.32 Number of DCX positive cells in the dentate gyrus of PBS treated and 
etanercept treated CII immunized mice on day 35, compared with antigen naïve control mice 
The dots represent the number of DCX positive cells in the hippocampus of individual naïve 
control mice (filled squares; n=5), CII immunized mice treated with PBS as the placebo 
(filled triangles; n=5), and etanercept treated mice (filled circles; n=5) on day 35. The 
number of DCX positive cells in the hippocampus of mice from all experimental groups was 
determined by counting of DCX positive cells in every sixth serial brain section containing 
DCX immuno histochemistry in the dentate gyrus. Bars represent the means values: 
Statistical analysis of data was performed using one way ANOVA (*P<0.05, **P<0.01, 
***P<0.001). 
6.5.4.2.2  Correlation between hippocampal neurogenesis and 
arthritis score of PBS-treated CII immunized mice on day 35 
We investigated whether there was an association between the numbers of DCX 
positive neuron in the dentate gyrus of arthritic mice and their clinical score (RA 
score) on day 35. Using Pearson's correlation coefficient, we showed that the 
reduction in DCX positive neurons did not correlated with the arthritis score (r²= 
0.868;  P  =  0.236)  (Figure  6.33).  This  data  is  consistent  with  our  data  in  the 
previous  section  of  this  Chapter  6  (section  6.4)  showing  that  there  was  no 
significant  correlation  between  the  number  of  DCX positive  neurons  in  the 
dentate gyrus of arthritic mice and their RA score on day 42. We recognise that 
the  low  numbers  of  mice  used  in  these  experiments  is  likely  to  be  a  major 
limiting factor to this interpretation and would recommend that this is repeated 
with a sufficient number. Chapter 6    331 
 
Figure 6.33 Correlation of the number of DCX positive cells and RA score  
Plot showing the relationship between the number of DCX positive cells in the dentate 
gyrus of arthritic mice and their clinical score (RA score) on day 35 analysed by Pearson’s 
correlation coefficient analysis. 
6.5.5   Longitudinal changes of hippocampal neurogenesis in 
PBS treated CII immunized mice. 
We compared the number of DCX positive cells in the dentate gyrus of untreated 
CII  immunized  mice  and  control  mice  at  different  time  points  in  order  to 
investigate  the  association  between  the  development  of  inflammatory  joint 
disease and changes in hippocapal neurogenesis. Significant reductions in the 
number of DCX positive cells were observed in PBS treated CII immunized mice 
compared to those in the naïve control mice on day 32 and day 35. The mean 
numbers  of  DCX positive  cells  in  mice  on  day  32  (PBS treated  CII immunized 
versus naïve control mice) were 2850 ± 1128 cells versus 8814 ± 462 cells (P = 
0.0011), while the mean numbers of DCX positive cells on day 35 (PBS treated 
CII immunized versus naïve control mice) was 3096 ± 1086 cells versus 9786 ± 
2736  cells  (P  =  0.0009)  (Figure  6.34).This  suggests  that  the  impairment  in 
hippocampal neurogenesis occurred during the period of clinical manifestation of 
arthritis disease in CII immunized mice, but not during the period prior to the 
onset of disease.  Chapter 6    332 
 
Figure 6.34 Time course of the number of DCX positive neurons in the dentate gyrus of CII 
immunized mice  
Mice immunized with type II collagen (filled squares) were sacrificed on days 14 (n = 3 CII 
immunized mice), 32 (n = 3 CII immunized mice) and 35 (n = 5 CII immunized mice) and 
brains from CII immunized mice at all time points were harvested. Brain samples collected 
from untreated naïve mice (open circle) sacrificed on the days indicated were used as 
controls. Immuno histochemistry of DCX was performed in brain tissue containing the 
hippocampus, and the number of DCX positive cells in the hippocampus of mice from all 
experimental groups was determined by counting DCX positive cells in every sixth serial 
brain section containing DCX immuno histochemistry in the dentate gyrus. Data represent 
means ± S.E.M. (n = 3 5 mice/group). Statistical analysis of data was performed using two 
way ANOVA compared with naïve control mice: (*P < 05; **P < 01; ***P < 001).   
We  compared  the  number  of  DCX positive  cells  in  the  dentate  gyrus  of  CII 
immunized mice to investigate longitudinal changes in hippocampal neurogenesis 
with  in  the  group  of  CII  immunized  mice.  One way  ANOVA  followed  by 
Bonferroni's post hoc comparison tests demonstrated that there were significant 
differences in the number of DCX positive neurons in the dentate gyrus among 
the  three  groups  of  mice  culled  on  day  14,  day  32  and  day  35  (P  =  0.0004) 
(Figure 6.35). A decrease in the number of DCX positive cells  in the dentate 
gyrus was observed in CII immunized mice on day 32 and day 35 compared to 
those on day 14. The mean number of DCX positive cells in CII immunized mice 
(day  32  versus  day  14)  was  2874  ±  1128  cells  versus  9528  ±  2040  cells  (P  = 
0.0078), while the mean number of DCX positive cells in CII immunized mice 
(day 35 versus day 14) was 3108 ± 1086 cells versus 9528 ± 2040 cells (P = 0.001) 
(Figure 6.35). There was a significant reduction in hippocampus neurogenesis on 
day 32 and day 35, which correspond to the development stage and the peak of 
arthritis in the CIA model respectively. There was no significant difference in the 
hippocampal neurogenesis between control mice and CII immunized mice on day 
14, suggesting that the reduction of hippocampus neurogenesis occurred after Chapter 6    333 
the onset of  arthritis  and that  this  may  be  associated  with  the  development 
peripheral joint inflammation. 
 
Figure 6.35 Longitudinal changes of DCX positive neurons in dentate gyrus of CII 
immunized mice sacrificed on the day 14, 32 and 35 
Bars represent mean values: Statistical analysis of data was performed using one way 
ANOVA (*P<0.05, **P<0.01, ***P<0.001). 
6.5.6 Longitudinal changes of hippocampal neurogenesis in 
antigen naïve control mice. 
Time course experiments of doublecortin (DCX) expression in immature neurons 
of mouse adult dentate gyrus showed that hippocampal neurogenesis decreases 
with age (Kuhn et al., 1996). The detate gyrus of mice sacrificed on day 28 after 
administration  of  bromodeoxyuridine    (BrdU),  a  synthetic  thymidine  analogue 
which can be used as a marker of proliferation showed a significant reduction in 
BrdU positive neurons compared to those on day 14 (Couillard Despres et al., 
2005). In addition, a study by Brown et al., 2003 showed a transient expression 
of  DCX positive  neurons  during  adult  neurogenesis,  and  the  number  of  DCX 
positive neurons was also decreased over time (Brown et al., 2003).  
The expression of DCX in neurons persists for up to 3 weeks (Brown et al., 
2003),  which  could  be  a  limitation  of  using  DCX  as  the  neuronal  marker  for 
testing  changes  in  hippocampal  neurogenesis  and  the  effect  of  etanercept 
treatment on hippocampal neurogenesis in a chronic inflammatory disease like 
CIA  model.  We  therefore  compared  the  number  of  DCX positive  cells  in  the 
dentate gyrus of control mice to investigate the effect of age on hippocampal 
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We found no significant difference in the number of DCX positive cells in 
the dentate gyrus of control mice at different time points (P = 0.5361 by one 
way ANOVA analysis) (Figure 6.36). This suggests that there was no effect of age 
on number of DCX positive cells in the dentate gyrus, and therefore hippocampal 
neurogenesis of naïve control mice.  This also confirms that the reduction in 
numbers of DCX positive neurons observed in the dentate gyrus of PBS treated 
CII  immunized  mice  may  be  due  the  effect  of  peripheral  inflammation. 
Therefore we conclude that there is likely to be no effect of age affecting the 
result showing the impairment in hippocampal neurogesis in CII immunized mice 
in the previous sections of this Chapter 6 (Section 6.4 and Section 6.5.4). 
 
Figure 6.36 Longitudinal changes of DCX positive neurons in dentate gyrus of control mice 
sacrificed on the day 14, 32 and 35  
Bars represent mean values: there were no significant differences. 
6.6  Result chapter 6: Summary of major findings.  
This aim of the chapter is to investigate changes in hippocampal neurogenesis in 
a  murine  chronic  inflammatory  disease  model  of  rheumatoid  arthritis,  the 
collagen induced  arthritis  (CIA)  model.  To  investigate  whether  changes  in 
hippocampal neurogenesis in collagen II (CII) immunized mice is associated with 
peripheral inflammation, we tested the effects of anti inflammatory treatment, 
using therapeutic TNF blockade using recombinant human soluble TNF receptor 
(etanercept) on changes of hippocampal neurogenesis in CII immunized mice. We 
found; 
1. An impairment in hippocampal neurogenesis was observed in CII immunized 
mice. This was observed by a reduction in number of DCX positive cells in the 
dentate gurus compared with healthy age matched antigen naïve control mice. Chapter 6    335 
2. This reduction in the number of DCX positive cells in the dentate gurus was 
observed  in  CII  immunized  mice  irrespective  of  whether  they  developed 
arthritis. In addition, there was no significant different in the reduced number of 
DCX positive cells in the dentate gurus between arthritis and non arthritis mice.  
3. There was no significant correlation between the number of DCX positive cells 
in the dentate gurus and clinical scores of the CII immunized mice.  
4. There was no significant changes in hippocampal neurogenesis as estimated by 
the number of DCX positive cells in the dentate gurus in CII immunized mice 
before the onset of arthritis (day 14) compared to those in antigen naïve control 
mice. 
5. In the first of two experiments, etanercept treatment did not delay the onset 
of arthritis nor reduce the incidence at day 32, but attenuated the severity of 
arthritis by reducing the mean paw thickness and the clinical score compared to 
PBS treated CII immunized mice. At this time point the ertanercept treatment 
protected  against  impairment  of  neurogenesis;  there  was  no  significant 
difference in the number  of  DCX positive  cells  in  the  dentate  gyrus  between 
etanercept treated CII immunized mice and antigen naïve control mice. 
  In the second experiment, etanercept treatment did delay the onset of 
arthritis and reduced the incidence at day 35, as well as attenuating the severity 
of arthritis by reducing the mean paw thickness and the clinical score compared 
to PBS treated CII immunized mice. At this time point the etanercept treatment 
did  not  protect  against  impairment  of  neurogenesis;  there  was  a  significant 
decrease  in  the  number  of  DCX positive  cells  in  the  dentate  gyrus  between 
etanercept treated  CII  immunized  mice  and  antigen naïve  control  mice. 
However, a difference in the number of DCX positive cells in the dentate gyrus 
between etanercept treated CII immunized mice and PBS treated CII immunized 
mice was not statistically significant. 
6. Etanercept treatment seemed to have a protective effect on the brain and on 
the joints that appeared to be different at days 32 and 35. It may be that the 
disease  process  changes  between  these  two  time  points.  This  aspects  will 
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8.  There  was  no  effect  of  age  involved  in  the  reduction  of  hippocampal 
neurogenesis in CII immunized mice.  
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6.7  Discussion 
For clarity, I will set out the discussion in logical sections interpreting the results 
in sequence. I will summarise and draw conclusions from these at the end. 
6.7.1  The role of Doublecortin (DCX) in neuronal maturation 
in the adult hippocampus 
Doublecortin  (DCX)  is  widely  used  as  a  marker  in  studies  of  hippocampal 
neurogenesis in both rodents and humans. Our data demonstrated the presence 
of  DCX positive  cells  with  a  neuronal like  morphology  in  the  hippocampus  of 
both antigen naïve control and CII immunized mice. Triple immunofluorescent 
staining demonstrated a lack of co localization of DCX with NeuN, a neuronal 
marker of maturity, indicated an undifferentiated or immature phenotype, and 
this suggests that DCX positive neurons are immature. These immature neurons 
developed  during  the  process  of  hippocampus  neurogenesis  and  have  been 
demonstrated to play major roles in the induction of synaptic plasticity, leading 
to  the  encoding  of  new  hippocampus dependent  memories.  DCX  is  a 
microtubule associated protein which is considered to be an important regulator 
of several steps in the process of neuronal maturation during neurogenesis.  
Neurogenesis  in  the  dentate  gyrus  involves  neural  progenitor  proliferation, 
neural cell production/differentiation/maturation, and final integration into the 
neuronal  circuit  network  in  the  hippocampus  (Li  and  Pleasure,  2010).  The 
duration of the development of hippocampal granule neurons is usually about 
one or two months. Neuronal precursor cells are generated from neural stem 
cells in the subgranular zone of the dentate gyrus and continue to proliferate for 
a  few  more  days.  These  neuronal  precursor  cells  are  characterized  by  the 
expression of the intermediate filament proteins glial fibrillary acidic protein 
(GFAP)  and  nestin.  At  approximately  two  weeks  after  mitosis,  progenitors 
develop into either neuroblast or non neuronal cells. Neuroblasts continue to 
elongate  neurites  and  axons,  and  migrate  from  the  subgranular  zone  to  the 
granular layer of the dentate gyrus. Migrating neurons no longer express nestin, 
but the expression of DCX is up regulated (Perera et al., 2008). DCX functions to 
regulate  neuronal  migration  during  development.  DCX  expression  has  been 
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(Rao  and  Shetty,  2004).  DCX  gene deficient  mice  showed  morphological 
abnormalities  in  migrating  neurons,  including  neuronal  branching  defects  and 
shorter  length  of  neuronal  processes  (Kappeler  et  al.,  2006).  At  this  stage, 
immature  neurons  develop  primary  apical  dendrites  and  GABAergic  synapses 
expressed  on  apical  dendrite  become  excitatory.  GABAergic  synapses  initially 
depolarize immature neurons and then gradually convert to hyperpolarization 
over a period of 2–3 weeks (Perera et al., 2008). Excitatory dendritic GABAergic 
synaptic activation during hippocampal neurogenesis plays a major role in the 
neuronal maturation and the encoding of new memory. The level of excitatory 
GABA signal indicates of the dynamic neuronal network activity, while GABAergic 
activation encodes input specific information (Ming and Song, 2005). In addition, 
GABAergic activation is also thought to be the initial step of immature neurons 
to  integrate  into  the  hippocampal  neuronal  circuit  and  extend  their  axonal 
projections along mossy fiber pathways to the CA3 pyramidal cell layer (Lledo et 
al.,  2006).  This  is  considered  to  be  the  most  critical  period  of  hippocampal 
neurogenesis  since  these  immature  neurons  are  selected  for  activation  by 
external stimuli including environmental enrichment and spatial learning. These 
excitable immature neurons up regulate NMDA receptors with the NR2B subunit 
and the presence of T type Ca2+ channels and thus develop stronger electrical 
property  for  long term  potentiation  (LTP),  which  is  essential  for  encoding 
memory. DCX has been demonstrated to play a role in regulating the electrical 
property  in  the  hippocampal  immature  neurons  (Perera  et  al.,  2008).  DCX 
deficient  mice  showed  a  reduction  in  GABA mediated  synaptic  activity  in 
hippocampus  neurons  (Kerjan  et  al.,  2009).  This  also  suggests  that  DCX 
deficiency may also affect hippocampal dependent memory function. Nyffeler et 
al demonstrated that an increase in the numbers of doublecortin (DCX) positive 
neurons  in  both  subgranular  zone  and  granule  cell  layers  (SGZ GCL)  was 
associated  with  improvement  in  the  working  memory  performance  in  rats 
(Nyffeler et al., 2010). This evidence suggests that DCX could be an efficient 
neuronal  marker  to  analyse  the  absolute  number  and  dendritic  growth  of 
immature  neuron  in  the  dentate  gurus  in  the  adult  brain  which  reflects 
neurogenesis, memory formation, and cognitive function of the hippocampus. 
This is supported by several publications suggesting that DCX is a reliable and 
specific marker that reflects levels of adult neurogenesis and its modulation, 
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(Brown et al., 2003); (Rao and Shetty, 2004); (Couillard Despres et al., 2005). 
Using DCX immuno staining also provides the absolute number, the distribution 
and the differences in dendritic features of these immature neurons, which can 
reflect the pattern and dynamics of dendrite development (Plumpe et al., 2006). 
Several studies report the expression patterns of DCX in numerous combinations 
with  markers  of  proliferation  such  as  BrdU  incorporation  in  the  hippocampal 
dentate gyrus (DG) of animals. The in-vivo BrdU injection is the most commonly 
used  method  to  study  cell  proliferation  and  survival  in  neurogenesis  studies. 
However, there are several limitations using this approach to detect changes in 
neurogenesis. Firstly, the administration of BrdU can be toxic to animals since 
BrdU can interfere with DNA replication. Secondly, BrdU can be incorporated 
during DNA repair, resulting in inconsistent or partial labelling of proliferating 
cells (Ming and Song, 2005). Thirdly, BrdU can be non specific to all types of 
proliferative  cells,  including  neural  stem  cells,  glial  precursors  or  glial  cells 
(Couillard Despres  et  al.,  2005).  Thus,  it  is  necessary  to  use  other  specific 
marker  for  the  neuronal  lineage  to  identify  granular  neurons  in  the 
hippocampus.  This  could  be  another  advantage  of  using  DCX immuno 
histochemistry to study hippocampal neurogenesis in comparison of the in vivo 
BrdU staining. This is because DCX specifically labels immature neurons in the 
dentate gyrus, which allows us to see the clear morphology of pyramidal neurons 
without co staining with other markers. 
6.7.2  Reduction in hippocampal neurogenesis in CII 
immunized mice. 
An impairment in hippocampal neurogenesis has been implicated in mood and 
cognition disorders (Sahay and Hen, 2007); (Sahay et al., 2007). Several studies 
have demonstrated that antidepressants increase hippocampal neurogenesis in 
both animals and humans (Wang et al., 2008);  (Malberg et al., 2000); (Boldrini 
et  al.,  2009);  (Jacobs  et  al.,  2000).  In  addition,  impairment  in  hippocampal 
neurogenesis  may  underlie  the  cognitive  deficits  seen  in  depression.  Several 
animal behavioural studies showed that reduction or  ablation of hippocampal 
neurogenesis  in  rodents  had  detrimental  effects  on  hippocampus dependent 
forms  of  cognition  such  as  fear  conditioning,  long term  spatial  memory  and 
working  memory  (Saxe  et  al.,  2006);  (Winocur  et  al.,  2006);  (Snyder  et  al., 
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might  be  associated  with  inflammation.  Depression  is  common  in  chronic 
inflammatory  diseases  such  as  RA,  multiple  sclerosis  (MS)  and  psoriasis.  In 
addition, increases of pro inflammatory cytokines including interleukin (IL) 1, IL 
6, IL 8, IL 12, interferon (IFN) γ and tumor necrosis factor (TNF) α have been 
reported  in  patients  with  depression  (Schiepers  et  al.,  2005);  (Raison  et  al., 
2006).  In  animal  models,  peripheral  inflammation  induced  by  LPS  has  been 
shown to activate microglia to produce various brain inflammatory mediators, 
including IL 1β and IL 10 (Henry et al., 2009). The activation of microglia in the 
LPS induced  inflammation  model  has  been  reported  to  induce  a  reduction  in 
hippocampal  neurogenesis,  which  is  associated  with  a  cognitive  decline  in 
learning and memory (Ekdahl et al., 2003); (Monje et al., 2003). Taken together, 
this  evidence  suggests  that  suppression  of  hippocampal  neurogenesis  by 
inflammation may underlie the depression in chronic inflammatory disease.  
The data in this chapter demonstrated a significant reduction in a number of 
DCX positive  neurons  in  the  dentate  gyrus  of  collagen  (CII) immunized  mice 
compared  to  those  in  antigen naïve  control  mice on  day  42.  In  addition,  our 
longitudinal  study  showed  that  the  reduction  in  hippocampal  neurogenesis  in 
these CII immunized mice occurred during the period of clinical manifestation of 
arthritis (day 32 and day 35), but not before the onset of disease on day 14. 
These findings suggest that the reduction in hippocampal neurogenesis may be 
associated with the peripheral inflammation associated with joint disease. The 
reduction in DCX positive cells in the dentate gyrus was described in several 
autoimmune disease models, including type II diabetic rats (Hwang et al., 2008) 
and  autoimmune prone  cytokine  B cell activating  factor  (Capuzzi  et  al.) 
transgenic mice (Crupi et al., 2010). However, our findings contrast with one 
previous study which demonstrated a transient increased in DCX positive cells in 
the dentate gyrus of antigen induced arthritis (AIA) mice (Wolf et al., 2009b). In 
that  study,  an  increase  in  hippocampal  neurogenesis  was  observed  during  a 
particularly marked infiltration of inflammatory cells into the knee joint and the 
author suggested that this may be associated with the systemic activation of 
CD4 positive cells during the course of arthritis (Wolf et al., 2009b). There are 
several possible explanations that might underlie this contradictory data. Firstly, 
differences in the procedure for inducing arthritis and immuno pathogenesis may 
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(AIA) is an arthritis model, induced by a single intradermal injection of complete 
Freund’s  adjuvant  (CFA)  consisting  of  heat killed  Mycobacterium  tuberculosis 
(Mt)  in  an  oil in  water  emulsion  (Hossain  et  al.,  2001).  Unlike  CIA,  AIA  is  a 
transient  model  of  arthritis  in  which  antigens  activate  acute  inflammation, 
leading to joint destruction. Polyarthritis rapidly develops around 10 days after 
immunization using adjuvant and the whole course of the disease lasts for 21 
days  (Bendele,  2001).  In  addition,  the  AIA  model  is  Th1 cell  and  neutrophil 
dependent, and complement independent. There is no evidence demonstrating 
that  B cells  play  a  role  in  the  pathogenesis  of  AIA.  By  contrast,  the immune 
response  of  CIA  involves  both  CII specific  T cells  and  B cells,  which  produce 
antibodies  to  type  II  collagen.  The  difference  in  humoral  immune  response 
between the 2 arthritis models can be another explanation of the contradictory 
data. This is supported by evidence showing a reduction in DCX positive cells in 
the  dentate  gyrus  of  transgenic  mice  over expressing  BAFF,  which  develop 
autoantibodies  leading  to  an  autoimmune  syndrome  of  systemic  lupus 
erythematosus, rheumatoid arthritis and Sjögren’s syndrome (Crupi et al., 2010).  
However, the role of B cells in neurogenesis needs to be further investigated. In 
addition,  the  precise  effect  of  T  cells  on  hippocampal  neurogenesis  is  still 
controversial. A study by Wolf et al., suggeted that T cells enhance hippocapal 
neurogenesis in AIA model (Wolf et al., 2009b), which is supported by a study in 
transgenic  mice  lacking  T  cells  (Ziv  et  al.,  2006).  However,  it has  also  been 
reported that T cells could support and inhibit hippocampal neurogenesis (Wang 
et al., 2010). Secondly, the differences in the immuno pathological mechanism 
of both arthritic models may cause different peripheral inflammatory mediator 
profiles. TNF, IFN γ, IL 1, IL 6 and IL 17A are dominant in the circulation of AIA 
model, while several pro  and anti inflammatory cytokines, including TNF α and 
IL 1β, IL 6, IL 12, IL 1Ra, IL 10 and TGF β, are highly expressed in the periphery 
of mice with CIA (Hegen et al., 2008).  Different inflammatory mediator profiles 
may cause different effects on hippocampal neurogenesis, therefore the effect 
of peripheral inflammation inducing changes in hippocampal neurogenesis may 
be contradictory in different arthritis models. 
Inflammation and inflammatory cytokines can affect hippocampal neurogenesis 
directly (Vallieres et al., 2002); (Monje et al., 2003); (Ekdahl et al., 2003). Our 
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including TNF α, IL 1α, IL 1β, IFN γ, IL 2, IL 4, IL 5, IL 10, IL 13, CXCL1, CXCL10, 
VEGF and FGF2 in brains of CII immunized mice. It is possible that the reduction 
of neurogenesis observed in the CIA mice may be the result of the up regulation 
of  brain  inflammatory  mediators  during  the  course  of  arthritis.  Some  of  the 
inflammatory  mediators,  including  IL 1α  and  IL 1β,  that  are  increased  in  the 
brains of CII immunized mice in our study have been reported to have different 
regulatory effects on hippocampal neurogenesis. TNF α (Seguin et al., 2009), IL 
1β (Kaneko et al., 2006) and IL 2 (Beck et al., 2005) have been demonstrated to 
be  inhibitors  of  neurogenesis.  CXCL10  not  only  exaggerates  the  brain 
inflammation by recruiting activated T cells into the brain, but also functions as 
a neuromodulator for immature neurons in the hippocampus (Muzio et al., 2010). 
CXCL10 has been shown to suppress hippocampal neurogenesis by inhibiting long 
term  potentiation  (LTP)  in  immature  hippocampal  neurons,  probably  via 
changing expression levels of synaptic proteins involved in synaptic transmission 
such as GABA receptor and NMDA receptor (Vlkolinsky et al., 2004); (Cho et al., 
2009). In contrast, IL 1α (Greco and Rameshwar, 2007), IL 4, IFN γ (Butovsky et 
al.,  2006),  VEGF  (Wang  et  al.,  2007)  and  FGF2  (Jin  et  al.,  2005)  have  been 
reported  to  support  hippocampal  neurogenesis.  Therefore,  the  reduction  in 
hippocampal neurogenesis observed in our CIA model may be due to the complex 
interplay  between  activated  immune  cells  and  inflammatory  mediators.  For 
example, an increase in hippocampal neurogenesis was observed in IL 2 deficient 
mice, along with up regulation of brain IL 15, IL 12, CXCL10 and CCL2 (Beck et 
al.,  2005).  This  finding  suggests  that  IL 2  may  either  suppress  hippocampal 
neurogenesis directly or via the production of other cytokines such as IL 15, IL 
12, CXCL10 and CCL2. Likewise, the detrimental effect of IL 1β on hippocampal 
neurogenesis may be regulated by IFN α (Kaneko et al., 2006). However, it is not 
clear to what extent each individual cytokine contributes to the overall reduced 
hippocampal  neurogenesis  in  CII  immunized  mice.  Different  concentrations  of 
the  same  cytokines  in  the  brain  may  also  result  in  different  effects  on 
hippocampal  neurogenesis.  IFN γ  has  been  associated  with  pathology  of  CNS 
inflammation.  IFN γ  (1000  ng/ml)  activates  the  production  of  CXCL10  in 
microglia which could be detrimental to hippocampal neurogenesis (Ellis et al., 
2010). In contrast, activation of microglia by low concentrations of IFN γ (20 
ng/ml)  has  been  shown  to  support  neurogenesis  (Butovsky  et  al.,  2006). 
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neuronal progenitor cell culture and test the effects of different concentrations 
of cytokines on the differentiation and maturation of these cells.  
The  mechanism,  function  and  significance  of  the  modulation  of 
neurogenesis during inflammatory processes remain to be elucidated. It has been 
hypothesized that the same CNS immune response that blocks neurogenesis in 
the adult CNS under neurodegenerative conditions can also paradoxically support 
neurogenesis. This is supported by a study showing that neurogenesis is inhibited 
by LPS activated microglia, but induced by the same microglia activated by IL 4 
or low concentration of IFN γ (Butovsky et al., 2006). This could be a protective 
mechanism of the CNS against excessive inflammation in the brain, which may 
eventually cause irreversible neuronal loss or damage. In addition, peripheral 
and central cytokine signals have been shown to have different influences on 
hippocampal neurogenesis. A study has shown that peripheral administration of 
TNF α resulted in suppression of neurogenesis, while intra hippocampal injection 
of IL 1β and IL 6 caused increased neurogenesis (Seguin et al., 2009). This data 
suggest  that  cytokines  produced  locally  in  the  brain  under  the  condition  of 
neuro inflammation  may  play  a  protective  role  against  excessive  brain 
inflammation.  Therefore,  it  is  important  to  know  the  cellular  source  of 
inflammatory  mediators  up regulated  in  brains  of  CII  immunized  mice  in  our 
study  since  cytokines  from  different  sources  (either  peripheral  circulation  or 
CNS) may regulate neurogenesis differently.  
6.7.3   Effect of etanercept on impairment of hippocampal 
neurogenesis in CII immunized mice 
TNF α  has  been  implicated  in  the  development  of  depressive  disorders.  A 
significant increase in serum TNF α has been reported in depression patients. 
Etenercept is an anti TNF agent that has been associated with the improvement 
of mood and anxiety disorders in patients with chronic inflammatory diseases 
such as psoriasis and RA (Uguz et al., 2009); (Tyring et al., 2006). In addition, 
one  well  known  study  by  Tobinick  et  al  demonstrated  an  immediate  effect 
improving  cognition  in  Alzheimer's  disease  (Tobinick  and  Gross,  2008).  The 
mechanism that underlies the effects of etanercept on neurobiological functions 
that  contribute  to  the  improvement  in  psychiatric  and  cognitive  problems  in 
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Terrando  et  al.,  showed  that  TNF blockade  can  improve  a  hippocampal 
dependent form of cognitive decline induced by surgery induced Inflammation 
(Terrando et al., 2010). In that study, etanercept  also reduced IL 1β protein 
levels in both brain and periphery (Terrando et al., 2010). This suggests that 
etanercept  can  improve  cognitive  decline  by  inhibiting  IL 1β,  which  may  be 
associated with the improvement of hippocampal function. However, that study 
did  not  address  the  issue  of  the  effects  of  etanercept  on  hippocampal 
neurogenesis, which may be associated with the improvement of the cognitive 
function of the hippocampus. To date, there are no animal studies that report 
the molecular mechanism of etanercept on hippocampal neurogenesis. We first 
demonstrated  that  peripheral  etanercept  treatment  reversed  impairment  of 
neurogenesis  in  CII  immunized  mice.  Our  findings  may  help  explain  the 
mechanism  by  which  etanercept  improves  cognitive  decline  observed  in  both 
human and animal studies.  
The  combination  of  our  data  in  Chapter  3  (Section  3.2.3  and  Section  3.2.4), 
Chapter  4  (Section  4.2.3,  Section  4.2.4  and  Section  4.2.5)  and  this  chapter 
suggests  that  the  reduction  in  neurogenesis  in  CII  immunized  mice  may  be 
associated with increases in brain inflammatory mediators. Our data also showed 
that etanercept treated CII immunized mice had more DCX positive cells in their 
hippocampus compared to untreated CII immunized mice during the peak of the 
disease, whereas the severity of arthritic disease of these etanercept treated CII 
immunized  mice  was  lower  compared  to  control  PBS treated  CII  immunized 
mice.  This  suggests  that  the  neuro protective  effect  of  etanercept  on 
hippocampal neurogenesis during disease development of inflammatory arthritis 
could  be  due  to  its  anti inflammatory  effect on  peripheral  inflammation.  We 
could not address the mechanism of how peripheral etanercept treatment could 
prevent the reduction of hippocampal neurogenesis in CII immunized mice during 
the period of clinical manifestation of arthritis. Etanercept may directly inhibit 
the  peripheral  inflammatory  signal  of  TNF α,  which  has  been  shown  to  be 
detrimental to neurogenesis (Seguin et al., 2009). This is also supported by a 
study  by  Jiang  et  al  showing  that  the  effect  of  peripheral  treatment  of 
etanercept  on  sickness  behaviour  induced  centrally  by  IL 1β  did  not  require 
transportation of the etanercept molecules across the blood brain barrier into 
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behaviour in mice by suppressing the expression of IL 1β in the peripheral organs 
(Jiang et al., 2008). Another possibility is that peripheral etanercept treatment 
may prevent the reduction of hippocampal neurogenesis via the suppression of 
brain cytokine production. This possibility is supported by our data in Chapter 5 
(Section  5.2.3  and  Section  5.2.4)  showing  that  peripheral  treatment  of 
etanercept reduced brain inflammatory mediators, including TNF α, IL 1β, IL 12 
and IL 5 in brains of CII immunized mice. As discussed previously, some of these 
inflammatory mediators including TNF α, IL 1β and IL 12 have been reported to 
have detrimental effects on hippocampus neurogenesis.  Some of our data in 
that section is consistent with a recent report showing that peripheral treatment 
using etanercept reduced IL 1β protein levels in brains of the mouse model of 
surgery induced brain inflammation (Terrando et al., 2010). A study by the same 
group  also  showed  that  IL 1β  is  a  potent  regulator  of  the  hippocampus 
dependent form of cognition. Taken together, data from recent reports suggest 
that  IL 1β  may  be  the  target  for  the  action  of  etanercept  to  improve  the 
function of the hippocampus.  
Interestingly,  our  data  also  demonstrated  that  the  suppression  of  brain 
inflammatory mediators by etanercept may not be the only mechanism by which 
etanercept  treatment  protects  against  the  reduction  of  hippocampal 
neurogenesis. In this chapter, we had 2 etanercept treated CII immunized mice 
and PBS treated CII immunized mice sacrificed on day 32 and day 35. On day 32, 
etanercept treatment attenuated severity of arthritis and prevented impairment 
of  hippocampal  neurogenesis  in  CII  immunized  mice.  In  contrast,  etanercept 
treatment  inhibited  the  progression  of  arthritis  in  etanercept treated  CII 
immunized  mice,  but  the  effect  to  prevent  the  impairment  of  hippocampus 
neurogenesis seemed to be weaker compared to those etanercept treated CII 
immunized mice on day 35. Etanercept treatment only attenuated, but did not 
prevent  the  reduction  of  hippocampal  neurogenesis  in  etanercept treated  CII 
immunized mice on day 35.  These data suggest that the effect of etanercept 
treatment on impairment of hippocampal neurogenesis may not be associated 
with the therapeutic effect of etanercept on peripheral joint inflammation of 
arthritis. Considering the brain inflammatory mediator profiles of etanercept 
treated CII immunized mice on day 35 and day 32 (Chapter 5; Section 5.2.3 and 
Section 5.2.4), we found that etanercept treatment reduced TNF α, IL 5 and IL Chapter 6    346 
12, which have detrimental effects on hippocampal neurogenesis in etanercept 
treated CII immunized mice on day 32. We could not measure changes in brain 
inflammatory mediators and hippocampal neurogenesis in the same brain since 
brain samples for both analyses were processed differently. However, data of 
both  brain  inflammatory  mediator  profiles  and  hippocampal  neurogenesis  in 
etanercept treated CII immunized mice on the same time point (day 32 and day 
35  after  immunization)  seemed  to  correspond  and  support  each  other.  It  is 
possible that the prevention of the reduction of hippocampal neurogenesis by 
etanercept may be due to the reduction of these brain inflammatory mediators. 
Surprisingly, brains of etanercept treated CII immunized mice on day 35 not only 
showed a reduction of IL 1β, CXCL1 and IL 12, but also showed increases in IL 2, 
VEGF  and  FGF2.  VEGF  and  FGF2  have  been  reported to  support  hippocampal 
neurogenesis.  These  inflammatory  mediators  may  enhance  the  action  of 
etanercept, leading the greater effects of etanercept to prevent impairment of 
hippocampal neurogenesis. However, we found that etanercept did not prevent 
hippocampal neurogenesis in etanercept treated CII immunized mice on day 35. 
These  data  suggest  that  changes  in  hippocampal  neurogenesis  may  not  only 
depend  on  direct  effects  of  cytokines  in  the  brain.  There  may  be  several 
explanations for this observation. Firstly, we do not know the actual function of 
these inflammatory mediators in the brain. Although VEGF and FGF2 have been 
shown  to  play  neuroprotective  roles,  they  could  also  have  detrimental 
immunological effects on neurogenesis. For example, VEGF has been report to 
be a neuronal growth factor supporting growth of neurons (Rosenstein et al., 
2003). However, it is also an angiogenic factor and has been implicated in BBB 
breakdown  (Sasaki  et  al.,  2010)  that  is  associated  with  more  recruitment  of 
immune cells into the brain, which could suppress hippocampal neurogenesis. 
Secondly,  the  effect  of  etanercept  on  hippocampal  neurogenesis  may  be 
transient. This hypothesis is supported by a study in Alzheimer's disease showing 
that etanercept can improve mood within minutes (Tobinick and Gross, 2008). 
This  could  be  the  reason  why  the  effect  of  etanercept  on  impairment  of 
hippocampal neurogenesis was observed at the earlier time point (day 32) but 
not the later (day 35). However, this hypothesis needs to be further investigated 
by determining changes of hippocampal neurogenesis in etanercept treated CII 
immunized  mice  in  more  time  points  across  the  CIA  experimental  period. 
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systems that regulate systemic inflammation such as HPA axis. The hypothalamo–
pituitary–adrenal  (HPA)  system  is  a  combined  regulatory  system  between  the 
endocrine  system  and  the  immune  system  (Heiser  et  al.,  2008).  Peripheral 
inflammatory signals activate the HPA axis by stimulating the anterior pituitary 
gland  to  release  adrenocorticotropic  hormone  (ACTH)  into  the  circulation. 
Adrenocorticotropic  hormone  (ACTH)  in  turn  activates  the  production  of 
glucocorticoid producing cortex cells in adrenal glands to release corticosteroid 
hormones  including  cortisol  (in  humans)  (Lanfumey  et  al.,  2008).  These 
corticosteroids  function  as  anti inflammatory  hormones  and  their  levels  are 
normally  upregulated  during  inflammation  and infection  (Hadid  et  al.,  1999). 
Chronic  administration  of  corticosteroid  hormones  was  shown  to  inhibit 
hippocampal  neurogenesis  and  reduce  hippocampal  volume,  along  with 
increased anxiety (light dark box test) and depression (forced swim test) like 
behaviour, suggesting that corticosterone not only induces depression via the 
serotonergic system, but also via neurogenesis (Murray et al., 2008). A recent 
study  showed  that  after  TNF blockade,  a  rapid  increase  in  corticosteroid 
hormones in RA patients during the first 12 week period of treatment, following 
by the reduction of corticosteroid hormones in the later period as the result of 
HPA adaptation (Straub et al., 2003). Based on this evidence, we hypothesized 
that  etanercept  may  effect  the  level  of  peripheral  corticosteroid  hormones, 
which  eventually  effect  changes  in  hippocampal  neurogenesis.  To  test  this 
hypothesis we could measure the level of corticosteroid hormones during the 
treatment of etanercept that may provide additional information underlying the 
protective  effect  of  etanercept  against  impairment  of  hippocampal 
neurogenesis.  
6.7.4  Severity of arthritis was not associated changes in 
hippocampal neurogenesis in arthritic mice, and the 
reduction in hippocampal neurogenesis in non arthritic 
mice 
Our data also showed that there was no significant correlation between clinical 
score  and  the  number  of  DXC positive  cells  in  both  untreated  arthritic  CII 
immunized mice and etanercept treated arthritic CII immunized mice. Our data 
suggest that the reduction in hippocampal neurogenesis in arthritic mice and the 
preventive effect of etanercept against impairment in hippocampal neurogenesis Chapter 6    348 
were not associated with severity of arthritis. This observation also contrasts 
with a previous study using AIA mice showing a significant correlation between 
degree of joint swelling and cell proliferation indicated by the number of BrdU 
positive cells (Wolf et al., 2009b). However, there was no significant correlation 
between the number of DCX positive cells and joint swelling reported in that 
study, suggesting that the increase in proliferative brain immune cells such as 
microglia and astrocytes may reflect the increase inflammatory cells in the joint 
that may distribute to the brain. Our data also showed significant reduction in 
neurogenesis  in  immunized  mice  that  did  not  develop  arthritis  (non arthritic 
mice).  In  addition,  the  etanercept  treatment  also  showed  similar  effects 
preventing  the  reduction  in  hippocampal  neurogenesis  in  these  non arthritic 
mice  as  well  as  arthritic  mice.  This  finding  suggests  that  the  impairment  in 
hippocampal neurogenesis may be independent to inflammatory joint disease. 
There may be ongoing immune activation in the peripheral of non arthritic mice 
that could signal the suppression of neurogenesis, but could not initiate joint 
inflammation due to difference in immune tolerance mechanisms in individual 
mice.  This  premis  is  supported  by  our  data  in  Chapter  3  (Section  3.2.3  and 
Section 3.2.4) and Chapter 4 (Section 4.2.3, Section 4.2.4 and Section 4.2.5) 
showing that there was no significant difference in brain inflammatory mediator 
concentrations  between  arthritic  and  non arthritic  mice.  There  are  several 
explanation underlying these observations. One possible explanation is that the 
CFA given to the non arthritic mice during the immunization may itself cause a 
reduction  in  hippocamapal  neurogenesis  without  development  of  arthritis. 
Peripheral  administration  of  CFA  alone  has  been  reported  to  activate  brain 
immune response (Raghavendra et al., 2004), suggesting that the inhibition of 
hippocampal neurogenesis in non arthritic mice may be the result of CFA itself 
that  can  induce  brain  inflammation.  Our  data  also  suggests  that  brain 
inflammation  can  cause  a  reduction  in  neurogenesis  even  at  the  subclinical 
level.  So  the  presence  of  inflammatory  phenotypes  in  terms  of  illness 
[manifestation  of  frank  arthritis  or  not  (sub clinical)  in  CIA  model]  is  not 
necessary directly connected with the depression (Tyring et al., 2006), where 
there  is  a  separation  of  the  effect  of  anti inflammatory  drug  (TNF blokadge) 
between the arthritis and the depression. So inflammatory mediators can impact 
on neurogenesis negatively eventhough the illness is not manifested. In addition, 
peripheral administration of CFA has also been reported to reduce hippocampal Chapter 6    349 
neurogenesis via suppressing the gene expression of brain derived growth factor 
(BDNF) in the hippocampus (Duric and McCarson, 2006). BDNF is a nerve growth 
factor that is constitutively expressed across subregions of the hippocampus and 
the adult forebrain (Lu et al., 2008) that has been implicated in the regulation 
of hippocampal neurogenesis. Interestingly, ablation of BDNF in the hippocampus 
resulted  in  a  reduction  in  hippocampus  neurogenesis,  along  with  increased 
behaviour  associated  with  depression,  suggesting  a  role  for  BDNF induced 
neurogenesis in the psychological aspect of depression (Taliaz et al., 2010). The 
production of BDNF in the brain could be suppressed by cytokines such as IL β or 
LPS (Guan and Fang, 2006). This evidence suggests another indirect pathway of 
peripheral  inflammation  to  modulate  hippocampal  neurogenesis  via  the 
production of brain neurotrophic factors. Therefore, it would be of interest to 
determine  the  concentrations  of  BDNF  in  the  hippocampus  in  brains  of  CII 
immunized mice, which may be associated with brain cytokine concentrations 
and number of DCX positive cells in dentate gyrus. 
Summary  
We  demonstrated  a  reduction  in  hippocampal  neurogenesis  in  CII  immunized 
mice that may be induced by peripheral inflammation, which may/ may not be 
directly  associated  with  peripheral  joint  inflammation.  In  addition,  we  also 
showed that peripheral treatment with etanercept prevented / attenuated the 
impairment of hippocampal neurogenesis in CII immunized mice. This could be 
important evidence suggesting that the reduction in hippocampal neurogenesis 
may be caused by peripheral inflammation in this chronic inflammatory disease 
model of arthritis. However, it would be of interest to conduct behavioural tests 
of  hippocampal dependent  forms  of  cognition  for  the  functional  analysis  of 
changes in hippocampal neurogenesis in both treated and etanercept treated CII 
immunized mice. Our findings could also help explain the cognitive decline and 
depression associated with chronic inflammatory diseases like RA. In addition our 
findings could help explain the underlying mechanism of etanercept in transient 
improvement of mood in patients with chronic inflammatory diseases. 
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7  General discussion and conclusion 
Several lines of evidence have demonstrated that peripheral inflammation could 
induce  neuro inflammation,  indicated  by  up regulation  of  inflammatory 
mediator profiles. The model of systemic challenge with LPS showed increases in 
expression of several cytokines, including IL 1β, IL 6 and TNF α in various regions 
of the brain (Henry et al., 2009); (Datta and Opp, 2008). These pro inflammatory 
cytokines have been reported to be up regulated in the spinal cord and brains of 
animal  models  of  chronic  inflammatory  disease  such  as  adjuvant induced 
arthritis (Bao et al., 2001); (del Rey et al., 2008). IL 1β was increased in the 
hippocampus in a model of surgery induced peripheral inflammation (Terrando 
et al., 2010a). Other inflammatory mediators such as CCL2 were shown to be up 
regulated  in  the  brain  of  mice  with  liver  injury  (D'Mello  et  al.,  2009). 
Importantly, this neuro inflammation induced by peripheral inflammation may 
also contribute to changes in neurobiology, resulting in psychological disorder 
such  as  depression  and  cognitive  dysfunction.  A  high  rate  of  depression  is 
commonly found in patients with RA (Isik et al., 2007), psoriasis (Biljan et al., 
2009)  and  MS  (Lo  Fermo  et  al.,  2010),  which  is  presumably  associated  with 
chronic inflammation. A reduction in serotonin transporter (SERT) density and an 
improvement in physical and mental function were observed in RA patients after 
receiving  anti TNF α  treatment  (Cavanagh  et  al.,  2010).  Animal  studies  also 
showed  that  up regulation  of  cytokines  induced  by  peripheral  inflammation 
caused a decline in hippocampal neurogenesis, resulting in cognitive decline and 
changes  in  emotional  behaviour  (Crupi  et  al.,  2010);  (Ekdahl  et  al.,  2003), 
(Kaneko et al., 2006); (Terrando et al., 2010b); (Ziv et al., 2006). Interestingly, 
peripheral  administration  of  anti inflammatory  drugs  and  the  blockade  of 
cytokines can inhibit production of some of the brain inflammatory mediators 
such as IL 1β that is generated during peripheral inflammation (Terrando et al., 
2010). Clinical and animal studies also showed that anti inflammatory therapy 
and  TNF–blockade  can  result  in  a reduction  in  hippocampal  neurogenesis  and 
improve cognitive impairment and depression symptoms in patients with chronic 
inflammatory diseases (Monje et al., 2003); (Tyring et al., 2006); (Tobinick and 
Gross,  2008);  (Tobinick  and  Gross,  2008b).  These  data  provide  important 
evidence  showing  that  the  impairment  of  hippocampal  neurogenesis  and Chapter 7    352 
cognition  may  be  associated  with  and  regulated  by  increases  in  brain 
inflammatory mediators during peripheral inflammation. 
Based  on  this  evidence  we  hypothesized  that  the  peripheral 
immune/inflammatory  response  during  arthritis  can  affect  the  brain 
inflammatory mediator profiles and hippocampal neurogenesis which might help 
explain the psychological illness associated with RA. To explore this possibility, 
firstly,  we  determined  changes  in  brain  inflammatory  mediators  and  the 
interplay  between  production  of  cytokines,  chemokines  and  growth  factors 
during experimental arthritis induced by type II collagen (CIA mice), a model of 
arthritis. Secondly, we investigate changes in hippocampal neurogenesis in this 
arthritis  model.  Finally,  to  confirm  that  all  changes  in  brain  inflammatory 
mediators and hippocampal neurogenesis are associated with inflammation, the 
effect  of  Etanercept,  a  recombinant  humanised  soluble  TNF receptor,  on 
peripheral  inflammation induced  neuro inflammation  and  impairment  in 
hippocampal neurogenesis in this CIA model was also investigated.  
The major findings from this thesis are summarised in Figure 7.1 
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Figure 7.1 Summary of the major findings from this thesis entitled; ‘Peripheral autoimmunity 
induces central neuro inflammation and hippocampal neurogenesis impairment in a murine 
model of collagen induced Rheumatoid Arthritis’.  
Peripheral joint inflammation was induced by type II collagen in a mouse model of 
Rheumatoid Arthritis (CIA mice). Several inflammatory mediators were detected in the 
periphery (serum) during the course of arthritis and they may be transported through the 
blood brain barrier (BBB) into the brain by unknown mechanisms and induced neuro 
inflammation. Up regulation of both gene and protein expression of inflammatory mediators 
observed in the brain of these collagen II immunized mice may be associated with 
impairment in hippocampal neurogenesis.  Peripheral TNF blockade treatment with 
Etanercept attenuated the arthritis in arthritic mice, along with a reduction of several 
inflammatory cytokines (including IL 1β, TNF α, IL 12), chemokine (including CXCL1), and 
an increase of some inflammatory and remodelling mediators (including IL 2, FGF2, VEGF) 
in the brain of arthritic mice. Etanercept treatment was also associated with a reversal of the 
disease associated reduction in hippocampal neurogenesis. The anti inflammatory effect of 
Etanercept on neuro inflammation may contribute to neuroprotection against impairment of 
hippocampal neurogenesis.  
We demonstrated that changes in inflammatory mediator profiles in brains of CII 
immunized  mice  may  be  associated  with  peripheral  inflammation.  Our  time 
course data showed that there was no significant difference in levels of brain 
inflammatory mediators in CII immunized mice compared to those in the control 
mice  on  day  14,  which  is  the  time  point  typically  just  before  the  onset  of 
arthritis  which  usually  starts  on  day  19.  However,  changes  in  various 
inflammatory mediator profiles were observed after the onset of arthritis; on 
day 22, and towards the end of the course of arthritis disease at day 42. In 
addition,  our  time course  experiment  showed  longitudinal  changes  in  various Chapter 7    354 
inflammatory mediator gene/protein concentrations including IL 1β, TNF α, IL 4, 
IL 2, CXCX1, CXCL10, VEGF and FGF2 in brains of CII immunized mice during the 
whole period of onset and clinical manifestation of arthritis disease. In addition, 
prolonged increases in protein concentrations of IL 12 and IL 4 were observed in 
brains of CII immunized mice during the onset and disease development periods 
of  experimental  arthritis.  These  data  suggest  that  there  may  be  immune 
activation and inflammation occurring in the brain of CII immunized mice during 
the developmental process of peripheral joint inflammatory disease. A previous 
study by del Rey et al is consistent with our findings by showing longitudinal 
changes in brain cytokines such as IL 1β, IL 6 and TNF α and the up regulation of 
some  cytokines  such  as  IL 6  during  the  ongoing  stage  and  the  peak  of  the 
arthritic disease in an adjuvant induced arthritis model (AIA) (del Rey et al., 
2008). Importantly, our data also showed that the anti inflammatory effect of 
Etanercept  could  also  suppress  the  up regulations  of  some  inflammatory 
mediators, including TNF α, IL 1β, IL 12 and CXCL1 in the brain of CII immunized 
mice.  These  inflammatory  mediators  play  important  roles  in  initiating  the 
immune  response  and  the  development  of  joint  inflammation  in  RA.  Similar 
findings  were  reported  recently  by  Terrando  et  al.,  showing  that  anti TNF α 
could  suppress  up regulation  of  brain  IL 1β  during  peripheral  inflammation 
induced by surgery in a model of surgical trauma (Terrando et al., 2010a).  
Up regulation of inflammatory mediators in the brain of CII immunized mice may 
reflect immune activation and neuro inflammatory processes. Increases in the 
levels  of  pro inflammatory cytokines  TNF α  and IL 1β  may indicate  microglial 
activation and innate immune responses in the brain of CII immunized mice. Up 
regulation of Th1 cytokines (IL 12, IL 2, IFN γ) and Th2 cytokines may suggest 
the  potential  for  adaptive  immunity  in  the  brain  of  CII  immunized  mice. 
Increases  in  chemokines,  including  CXCL1,  CCL2  and  CXCL10,  and  angiogenic 
factors such as FGF and VEGF may implicate trafficking of immune cells and 
blood brain barrier leakage in the brain of CII immunized mice. One of the most 
striking findings in this study is the up regulation of CXCL10 in CII immunized 
mouse brains during the ongoing stage and peak of arthritis. Interestingly, mRNA 
levels  of  brain  CXCL10  were  higher  in  arthritic  mice  compared  to  those  in 
similarly CII immunized mice but with no arthritis. The CXCL10 is thought to play 
an important role in neuro inflammatory diseases because, during CNS neuro Chapter 7    355 
inflammation,  expression  of  CXCL10  is  elevated  several  fold  (Bajova  et  al., 
2008). In the CNS, CXCL10 regulates trafficking of Th1 cells into the CNS, which 
is  thought  to  be  the  initiation  of  the  development  of  inflammatory 
demyelination  in  MS  and  EAE  (Klein,  2004).  The  lesions  of  CNS  inflammatory 
demyelination  have  also  been  reported  in  brains  of  RA  patients  (Tsai  et  al., 
2008); (Tajima et al., 2004). It is possible that peripheral Th1 cells are recruited 
into  the  CNS  by  CXCL10  chemotactic  signals  which  can  then  induce  the 
development of inflammatory demyelination in the brain during the course of 
arthritis  in  these  RA  patients.  This  rational  is  feasible  because  of  several 
similarities in pathological mechanisms of MS and RA. Particularly, CD4
+T cells 
are thought to have a crucial role in both MS and RA pathogenesis (Zozulya and 
Wiendl, 2008); (McInnes and Schett, 2007). Therefore, the elevation of CXCL10 
in arthritic mouse brains may be the most important indicator of the presence of 
neuro inflammation  in  the  brain  of  arthritic  mice,  and  this  may  be  strongly 
associated with peripheral joint inflammation.  
Our longitudinal data of inflammatory mediators in the brain of CII immunized 
mice demonstrated some interesting observations about brain immune system 
joint communication. The concentrations of brain inflammatory mediators such 
as  TNF α  and  IL 13  increased  in  parallel  with  arthritis  development,  while 
prolonged expressions of some brain inflammatory mediators such as IL 6, IL 10, 
IL 13, IL 12 and CXCL2 were observed over the course of arthritis. These data 
seem  to  suggest  that  inflammatory  mediators  can  access  the  brain  from  the 
periphery  during  the development  of  “peripheral”  chronic  joint  inflammatory 
diseases. However, our data of serum inflammatory mediators showed that the 
concentrations of several inflammatory mediators such as IL 5, IL 1β, CCL2 and 
FGF were elevated in serum immediately after the onset of arthritis and the 
concentrations then decreased in parallel with disease development. These data 
suggest a disruption in communication between the peripheral immune system 
and CNS during the course of arthritis. We cannot define a precise mechanism of 
how the inflamed joint signalled to the brain in order to produce inflammatory 
mediators. A similar finding was reported by del Rey et al in CIA rats. In that 
study, there were no significant serum cytokines detected, but the brains of 
these CIA rats showed elevations of IL 1β and IL 6 during the course of arthritis 
(del  Rey  et  al.,  2008).  Two  main  questions  remain:  first,  how  can  these Chapter 7    356 
inflammatory  mediators  access  the  brain,  and  second,  what  are  the  cellular 
sources in the brain that produce these inflammatory mediators? Several studies 
suggest various mechanisms of how peripheral inflammation signals the CNS to 
produce inflammatory mediators. One putative mechanism is that the trafficking 
of  the  peripheral  immune  cells  into  the  brain  occurs  during  the  blood  brain 
barrier breakdown that is induced by the peripheral inflammation (Carson et al., 
2006). Our data showed that various inflammatory mediators were up regulated 
in the brain of CII immunized mice, including IL 1β, TNF α, IL 4, IL 10, IL 12 and 
CXCL1, on day 22, whereas VEGF and FGF, which are angiogenic factors that 
could be indicators of blood brain barrier damage,  are elevated in the brain 
later on day 28. These data suggest that the brains of these CII immunized mice 
may be signalled to produce inflammatory mediators before the integrity of the 
blood  brain  barrier  is  compromised.  Several  pieces  of  experimental  evidence 
supported this observation by showing that blood brain barrier breakdown during 
neuro inflammation is not a simple case of increase recruitment of peripheral 
immune cells into the brain (Carson et al., 2006); (D'Mello et al., 2009); (Shaftel 
et al., 2007) . Brains of transgenic mice over expressing IL 1β showed blood– 
brain barrier leakage, along with elevations of CXCL1 and CCL2, and dramatic 
infiltration of CD45
+ leukocytes. However, transgene induction of IL 1β in brains 
of  mice  lacking  CXCR2,  a  chemokine  receptor  that  regulates  neutrophil 
recruitment, showed disruption in neutrophil infiltration into the brain but failed 
to reduce leakage of the blood– brain barrier (Shaftel et al., 2007). The data of 
this  study  suggest  that  blood  brain  barrier  breakdown  is  not  associated  with 
increased rate of leukocyte accumulation in the brain.  
We also found prolonged expression of Th2 cytokines including IL 4 and IL 10 in 
the brains of CII –immunized mice throughout the onset of disease (day 22), the 
ongoing stage of the disease (day 28) and during the peak of the disease (day 
35). However, in the periphery, during the onset of disease (day 19 to day 22) 
and on to the peak of the disease (day 35), the course of the arthritis in the CIA 
model is thought to be regulated predominantly by Th1 cells, whereas the Th2 
response is dominant during the remission phase (day 35 – day 42). This finding 
suggests there may be local production of IL 4 and IL 10 by CNS immune cells 
such  as  astrocytes  and  microglia.  Several  studies  reported  that  inflamed 
peripheral  organs  can  signal  brain  microglia  and  astrocytes  to  produce Chapter 7    357 
inflammatory mediators in the brain by an unknown mechanism (D'Mello et al., 
2009); (Riazi et al., 2008). A study using a model of liver inflammation showed 
that microglia were activated to produce CCL2 before monocytes could migrate 
into the brain. This study also demonstrated that the inflamed liver signalled to 
the  brain  microglia  to  produce  CCL2  and  as  a  consequence  cause  monocyte 
trafficking to the brain via systemic TNFR signalling (D'Mello et al., 2009). We 
also  showed  similar  observation  in  our  study;  systemic  administration  of 
Etanercept, which effectively induced TNF blockade, demonstrated reductions in 
various inflammatory mediators, including TNF α, IL 1β, IL 12 and CXCL1 in the 
brain of CII immunized mice. 
Taken together, our data combined with findings from previous reports suggest 
that peripheral joint inflammation may provide a signal to the brain to produce 
inflammatory  mediators  by  local  CNS  immune  cells  such  as  microglia  and 
astrocytes.  This  is  shown  in  the  brains  of  CII  immunized  mice  during  the 
elevation  of  serum  inflammatory  mediators  at  the  onset  and  clinical 
manifestation stages of the disease (day 22 – day 28 after immunization). The 
initial  signal  from  the  periphery  may  further  activate  the  immune  and 
inflammation response in the brain and recruit more peripheral immune cells 
into the brain.  
We also demonstrated that these inflammatory mediators that were elevated in 
the brains of CII immunized mice may contribute to neurobiological changes in 
the brain. This is demonstrated by the impairment in hippocampal neurogenesis, 
characterized by a decline in DCX positive cells in the dentate gyrus that was 
observed  in  brains  of  CII  immunized  mice.  This  was  reversed  by  the  anti 
inflammatory  effect  of  TNF  blockade  using  Etanercept.  Our  data  raised  an 
important question; does neuro inflammation in brains of CII –immunized mice 
contribute to neuron loss in the dentate gyrus by suppression of hippocampal 
neurogenesis, or by enhancing neurodegeneration? Several experimental studies 
reported  various  roles  of  innate  immunity,  adaptive  immunity,  cytokines, 
chemokines  and  growth  factors,  which  contribute  to  different  aspects  of  the 
regulation  of hippocampal  neurogenesis.  For  example,  TLR2  agonists  enhance 
neurogenesis, while TLR4 agonists suppress hippocampal neuronal proliferation 
(Rolls et al., 2007). T cells have been reported to maintain neurogenesis (Ziv et 
al., 2006), whereas B cells  were shown to inhibit neurogenesis (Crupi et al., Chapter 7    358 
2010).  Chemokines  such  as  CXCL12  acts  as  a  neuromodulator  to  support 
maturation  and  neutrite  extension  of  hippocampal  neurons  (Chalasani  et  al., 
2003). In contrast, IFN α has been reported to inhibit neuronal proliferation in 
the dentate gyrus via IL 1β signalling (Kaneko et al., 2006). Therefore, brain 
inflammatory  mediators  up regulated  in  brains  of  CII  –immunized  mice  may 
function  in  a  complex  network  to  regulate  hippocampal  neurogenesis. 
Interestingly,  a  recent  study  by  Julie  Anne  Seguin  2009  et  al  demonstrated 
different  regulation  of  various  pro inflammatory  cytokines  on  hippocampal 
neurogenesis depending upon the route and duration of administration. Systemic 
administration  of  TNF α  reduces  hippocampal  neurogenesis,  while  intra 
hippocampal infusion of IL 6 and IL 1β enhances neuronal proliferation. These 
data suggest that the inflammatory signals from the periphery are detrimental to 
hippocampal  neurogenesis,  whereas  local  inflammatory  signals  paradoxically 
play a protective role in hippocampal neurogenesis (Seguin et al., 2009). This 
would  also  explain  our  finding  showing  that  peripheral  treatment  using  TNF 
blockade  could  reverse  the  impairment  of  hippocampus  neurogenesis  in  CII 
immunized mice, probably via the inhibition of inflammatory signals from the 
periphery.  Preventing  the  TNF induced  apoptosis  pathway  could  be  another 
mechanism by which Etanercept could inhibit neuronal loss in the hippocampus. 
However,  it  is  difficult  to  conclude  the  precise  effect  of  TNF  blockade  on 
apoptosis induced  neuronal  death  in  this  study.  This  is  because  the  two  TNF 
receptor chains; p55 TNFR and p75 TNFR can play divergent roles in hippocampal 
neurogenesis. p55 TNFR (TNFR1) contains an intracellular “death domain” and 
activation of this receptor leads to apoptosis and neuronal death. In contrast, 
p75  TNFR  (TNFR2)  can  be  either  neuroprotective  (Marchetti  et  al.,  2004)  or 
induce  apoptosis  (Depuydt  et  al.,  2005).  Therefore,  blocking  TNFR  signal  by 
Etanercept can possibly prevent apoptosis and neuronal death as well as reduced 
neuroprotection.            
Our study has a number of strengths. Firstly, we used a CIA mouse model of 
arthritis, which shares similar immunopathology with human RA. This is also one 
of the best validated models of a chronic inflammatory disease. Secondly, we 
employed a novel high throughput screening method, Luminex, to detect protein 
expression of multiple inflammatory mediators which allows analysis of the small 
volumes obtained from serum and brain homogenate samples. We also used a Chapter 7    359 
highly sensitive real time PCR for specific detection and quantification of mRNA 
levels of brain inflammatory mediators. Thirdly, we  chose DCX as a neuronal 
marker  for  hippocampal  neurogenesis  because  it  specifically  labels  immature 
neurons in the dentate gyrus. It also allows us to see the clear morphology of 
pyramidal neurons without co staining with other markers. However, it also had 
several important limitations.  
1.  There were apparent inconsistencies in several concentrations of 
brain inflammatory mediators in the CII immunized mice. Part of 
this was because we used different number of mice and measured 
levels of brain inflammatory mediators in experimental time points 
in different CIA experiments. Therefore, increase statistical power 
by increasing number of mice per group per time point would have 
helped to improve the consistency of the data.  
2.  The etanercept experiments in chapter 5 and 6, conducted using 
small  sample  size  (3 5  mice/  group),  are  considered  to  be  pilot 
studies  which  belongs  to  the  exploratory  phase  of  the  research 
project. The preliminary data generated from small groups of mice 
may affect the power of statistical analysis and thus impact the 
ability to interpret the results. However, these pilot data can be 
very  valuable  and  can  guide  to  a  more  extensive  experiment. 
Therefore, it is worthwhile to repeat these experiments using the 
larger numbers of animals.   
3.  Most of our data, particularly in Chapter 3 and 4, demonstrated 
that there was a significant difference in increased inflammatory 
mediator  gene/protein  levels  in  arthritic  compared  with  non 
arthritic mouse brains; both groups received CFA. In addition, we 
also  found  that  there  was  no  significant  correlation  between 
inflammatory mediator gene/protein levels and arthritis scores of 
arthritic  mice,  suggesting  that  the  subclinical  systemic 
inflammation  may  also  be  important  in  neurological  response  as 
seen in psoriasis (Tyring et al., 2006). Our neurogenesis study also 
showed  that  there  was  no  significant  different  in  the  reduced 
number of DCX positive cells in the dentate gurus between arthritis Chapter 7    360 
and  non arthritis  mice.  Again,  there  is  no  correlation  between 
number of DCX positive cells in the dentate gyrus of arthritic mice 
and  their  arthritis  score.  Based  on  our  data,  it  is  difficult  to 
conclude whether or not up regulations of inflammatory mediator 
gene/protein levels and the reduction in neurogenesis are directly 
associated with clinical manifestations of rheumatoid arthritis. We 
hypothesized that the CFA given to the non arthritic mice during 
the  immunization  may  itself  cause  a  reduction  in  hippocamapal 
neurogenesis and the activation of brain immune response in the 
subclinical level of rheumatoid arthritis. Therefore, it is important 
to include another control consisting of DBA1 mice that recive only 
CFA  in  the  future  study  to  investigate  the  extent  of  CFA  in 
induction of inflammatory mediator gene/protein expression and of 
the reduction in neurogenesis in the subclinical level in this CIA 
model.  
4.   In  an  attempt  to  investigate  the  inflammatory  signals  from  the 
periphery, we measured inflammatory mediator proteins in serum 
of  CII  immunized  mice.  However,  we  only  detected  increases  in 
serum  inflammatory  mediator  proteins  during  the  earlier  time 
points  of  the  disease  progression  period  (day  22 day  28  after 
immunization)  but  not  during  the  period  that  the  arthritis  was 
manifested (day 35 day 42 afther immunization) in CII imminized 
mice.  Our  results  were  consistent  with  previous  studies  showing 
that serum cytokine concentrations in CIA model were inconsistent 
and in many cases undetectable at the arthritis phase (Harnett et 
al., 2008); (Lu et al., 2010); (del Rey et al., 2008). This may be 
explained by several studies showing that rheumatiod arthritis is a 
tissue specific autoimmune disease where inflammatory mediators 
are  generated  locally  and  induce  bone  and  cartilage  destructive 
process, but may not circulate in the bloodstream (Lu et al., 2010); 
(Palmblad et al., 2001). In addition, clinical evidence also suggests 
that the localization of inflammatory mediators from the inflamed 
sites to other peripheral organs may be mainly via the lymphatic 
system rather than the bloodstream (Olszewski et al., 2001). This Chapter 7    361 
was also supported by several CIA studies revealling increases of 
various inflammatory mediators in several peripheral organs such 
as  paws,  draining  lymph  nodes  and  spleen  during  the  peiod  of 
clinical manifestation of arthritis (Thornton et al., 1999);(Rioja et 
al., 2004);(Mauri et al., 1996). Therefore, to futher investigate the 
communication between peripheral inflammatory signal and brain 
inflammation  in  CIA  model,  it  would  be  important  to  measure 
expression  of  inflammatory  mediators  in  other  peripheral  organs 
such  as  paws,  draining  lymph  nodes  and  spleen  which  may  be 
associated with the expression of these inflammatory mediators in 
the brain of CIA mice.  
                                                                                                                                               
In  summary,  our  study  demonstrated  that  peripheral  inflammation  in  CII 
immunized mice induced changes in brain inflammatory mediator profiles and 
impairment  in  hippocampal  neurogenesis.  We  also  showed  that  peripheral 
treatment of TNF blockade using Etanercept could inhibit cytokine production 
and activity within the brain of CII immunized mice, resulting in the reversal of 
the  arthritis associated  impairment  in  hippocampal  neurogenesis.  These 
observations suggest that inflammatory signals from the periphery can activate 
immune  and  inflammatory  responses  in  the  brain,  which  may  contribute  to 
neurobiological  changes  such  as  alterations  in  hippocampal  function.  This 
scenario may help explain the clinical observations of psychiatric disorders such 
as depression and cognitive impairment in chronic inflammatory diseases such as 
RA and psoriasis. Our findings also suggest that TNF blockade may be a possible 
novel  strategy  to  alleviate  symptoms  of  depression  and  cognitive  impairment 
associated  with  chronic  inflammatory  diseases.  Studies  have  shown  that 
depression  in  rheumatoid  arthritis  has  an important  impact  on health related 
quality  of  life.  Therefore,  further  investigations  of  Etanercept  as  a  novel 
approach  to  both  the  anti inflammatory  and  antidepressant  treatments  are 
worthy.   
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7.1  Suggestions for future studies 
Based  on  the  results  of  this  thesis  we  propose  the  following  hypotheses  and 
studies that might address them: 
7.1.1   Hypothesis; there is migration of immune cells from 
the periphery into the brain of CII immunized mice.  
We found up regulation of inflammatory mediators in the brain of CII immunized 
mice, which may be produced from immune cells migrating from the periphery.  
7.1.1.1  Investigate the migration of immune cells from the periphery 
into the brain of the CIA mouse model of arthritis.  
The  questions  of  how  peripheral  joint  inflammation  signals  to  the  brain  to 
produce  inflammatory  mediators,  and  does  that  process  involve  migration  of 
immune cells from the periphery into the brain remains unresolved. We suggest 
using an ex vivo technique called ‘adaptive transfer’ to track the migration of 
labelled immune cells from the periphery into the CNS (D'Mello et al., 2009). 
This technique is commonly used to study the pathological mechanism of MS, in 
which  inflammatory  demyelination  is  thought  to  be  induced  by  peripheral 
immune cells. The principle of this technique involves isolation of monocytes 
from peripheral blood and/or leukocyes from lymph nodes in the donor animals. 
Each type of peripheral immune cell is isolated and purified by magnetic beads 
linked to cell specific antibodies. For example, beads with anti CD11b can be 
used to purify monocytes (D'Mello et al., 2009), while CD45 and TCR can be used 
for the isolation of T cells (Lees et al., 2008). These CD11b
+ monocytes and/or 
CD45
+  T  cells  are  then  labelled  with  florescent  dyes.  These  labelled  immune 
cells are then adoptively transferred by i.v. injection into the recipient animals. 
The presence of these adoptively transferred immune cells is then detected in 
the brains of these recipient animals using fluorescent immunohistochemistry. 
This  technique  can  also  be  used  for  measuring  the  cytokine  production 
capabilities  of  immune  cells  present  within  the  CNS  at  various  time  points 
following adoptive transfer. Chapter 7    363 
7.1.2   Hypothesis; there is local production of inflammatory 
mediators by astrocytes and microglia in the brain of CII 
immunized mice.  
We found up regulation of protein and gene of inflammatory mediators in the 
brain of CII immunized mice, which may be produced from CNS immune cells 
such as astrocytes and micoglia.  
7.1.2.1  Investigate the local production of inflammatory mediators by 
CNS immune cells such as astrocytes and microglia.  
Previous  reports  suggest  that  peripheral  inflammation  can  signal  to  the  local 
immune cells in the brain to produce inflammatory mediators by an unknown 
mechanism. Although we demonstrated an increase of both protein and mRNA 
levels of some inflammatory mediators in the brain of CII immunized mice, it is 
still difficult to conclude the cellular sources of these inflammatory mediators. 
The  activation  of  astrocytes  and  microglia  and  their  cytokine  production 
capabilities during the peripheral inflammatory process can be investigated by 
double staining for each cytokine and the microglia or astrocytic markers. We 
can  use  GFAP  to  label  astrocytes  and  determine  any  increase  in  astrocyte 
number  in the  brain (Sofroniew  and  Vinters,  2010).  Studies  also  showed  that 
peripheral inflammation can induce cytokine production via microglial activation 
in  the brain  (D'Mello  et  al.,  2009);  (Riazi et  al.,  2008).  CD11b  and  CD45  are 
commonly used as markers for microglia (Yang et al., 2010). Microglia activation 
is indicated by the change in morphology of microglia from inactive ramified 
microglia to active ameboid microglia (Riazi et al., 2008).  
7.1.3   Hypothesis; difference inflammatory mediators play 
different role in hippocampal neurogenesis.  
Up regulation of protein and genes of various inflammatory mediators including 
IL 1α, IL 5, CXCL1, CXCL10, IL 10, IL 13, FGF2 and VEGF in brains of CII 
immunized mice on day 42. At that time point, we also found an impairment in 
hippocampal neurogenesis in the brains of CII immunized mice. Different 
inflammatory mediators play different roles in regulation of hippocampal 
neurogensis. Therefore, it is interesting to define the extent to which 
inflammatory mediators regulate hippocampal neurogenesis.  Chapter 7    364 
7.1.3.1  Investigate roles of inflammatory mediators in hippocampal 
neurogenesis using in vitro experiments.  
Different  regulations  of  various  inflammatory  mediators  on  hippocampal 
neurogenesis are also worth investigating. We can generate an in vitro model of 
hippocampal  neurogenesis  by  deriving  and  culturing  neuronal  progenitor  cells 
from  the  adult  hippocampal  dentate  gyrus.  Single  or  multiple  inflammatory 
mediators can be add into the culture of neuronal progenitor cells to determine 
the effect of individual or combined inflammatory mediators on the proliferation 
and maturation of dentate gyrus neurons. The hippocampal neurogenesis after 
the cytokine treatment can be analysed by labelling these dentate gyrus neurons 
with various neuronal markers identifying different stages of neurogenesis. For 
example, DCX is used to label neurons in the immature stage, while NeuN is used 
to  label  neurons  in  the  immature  stage.  FACS  (fluorescence  activated  cell 
sorting) can then be used to  determine the level of neurogenesis by analysing 
the number of neurons that are positive to immature neuronal markers such as 
DCX and Brdu (Ming and Song, 2005). 
7.1.4  Hypothesis; the reduction in the number of neurons in 
the hippocampus of CII immunized mice could be the result 
of neurodegeneration.  
We demonstrated that the reduction in the number of neurons in dentate gyrus 
of CII iimmunized mice was the result of the inhibition of neurogenesis using 
neuronal marker DCX. However, the neuronal loss in dentate gyrus of CII 
iimmunized mice may possibly the result of neurodegeneration process such as 
apoptosis. 
7.1.4.1  Investigate neurodegenerative effects of peripheral 
inflammation on neurons in the hippocampal dentate gyrus.  
We demonstrated the suppression in hippocampal neurogenesis in CII immunized 
mice  using  DCX,  a  neuronal  marker  for  immature  neurons  in  the  maturation 
stage. This was indicated by a reduction in the number of DCX positive neurons 
in the dentate gyrus. However, it is also possible that peripheral inflammation 
can  induce  neuronal  loss  in  the  hippocampal  dentate  gyrus  via 
neurodegenerative  pathways.  We  showed  that  TNF blockade  can  reverse  this 
neurogenesis impairment. The neuroprotective effect of Etanercept may involve Chapter 7    365 
blocking  the  apoptosis  pathway  induced  by  TNF  receptor.  Therefore,  using 
markers  for  apoptosis  such  as  TUNEL  may  lead  to  better  understanding  of 
another mechanism underlying the process of neuronal loss in the hippocampal 
dentate gyrus by peripheral inflammation. 
7.1.5  Hypothesis; Peripheral inflammation has effects on 
neurotransmitter and neurotropic factors in brains of CII 
immunized mice, that are associated with the pathological 
mechanism of depression.  
We demonstrated that peripheral inflammation had a detrimental effect o 
hippocampal neurogenesis. Inflammatory mediators up regulated in brains of CII 
immunized mice may have actions on neurochemical or neurotropic factors, 
which may be associated with the development of depression. 
7.1.5.1  Investigate effects of peripheral inflammation in other 
pathological mechanisms of depression.  
Animal  studies  suggest  that  peripheral  inflammation  can  induce  cognitive 
impairment  and  depressive like  symptoms  via  suppression  of  hippocampal 
neurogenesis.  However,  the  implication  of  neurogenesis  and  neural  network 
disturbance in the patho physiology of depression is still a novel theory. The 
effect of peripheral inflammation on other classical pathological mechanisms, 
monoamine (eg., serotonin, dopamine), HPA axis, and neuronal growth factors 
(eg., BDNF) should not be ignored. A study by del Rey et al., showed an increase 
in serotonin levels in the hypothalamus of the CIA rat model. Interestingly, that 
study also showed an increase in noradrenaline (NA), corresponding to reduced 
glucocorticoid levels in the hypothalamus of CIA rat. The author suggests that 
this data demonstrated a reduction in HPA axis activity, which has also been 
reported in RA patients (del Rey et al., 2008). However, an increase in HPA axis 
activity and a decrease in brain serotonin level have been reported in depression 
patients  (Lanfumey  et  al.,  2008).  Therefore,  it  is  better  to  use  anatomical 
analysis such as in situ hybridization and autoradiography to determine changes 
in  monoamine  levels  and  neurotransmitter  receptors  in  various  areas  in  the 
brain. It may also be interesting to study changes in animal behaviour in the CIA 
mouse model using animal behavioural tests to investigate changes in cognition Chapter 7    366 
and  depressive like  behaviour  during  different  phases  of  disease;  to  quantify 
associated inflammatory mediators and to test the effects of TNF blockade.                                                                                                                                                 367 
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9  Appendices 
 
Appendix 1A; Standard curves of the Luminex assay  
Validations of assay performance as assessed by Standard curves of IL 1α (A), IL 2 (B), IL 
10 (C) and IL 5 (D), IL 13 proteins obtained from Luminex cytokine 20 Plex assay. Standards 
were prepared according to manufacturer’s instructions, and all standards were run in 
triplicate. Readings were obtained using BioPlex 200 hardware running BioPlex Manager 
software. 
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Appendix 1B; Standard curves of the Luminex assay  
Validations of assay performance as assessed by Standard curves of IL 13 (E), CXCL 1 (F), 
CXCL10 (G) and FGF2 (H) proteins obtained from Luminex cytokine 20 Plex assay. 
Standards were prepared according to manufacturer’s instructions, and all standards were 
run in triplicate. Readings were obtained using BioPlex 200 hardware running BioPlex 
Manager software. 
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Appendix 2; Real time PCR standard curve of inflammatory mediators 
Real time PCR standard curves of IFN γ (A), CXCL1 (B), CXCL10 (C), VEGF (D) were 
generated by amplifications of serial dilutions of known quantities of plasmids containing 
the target sequences. Plasmid containing IFN γ, CXCL1, CXCL10, and VEGF genes was 10 
fold serially diluted to obtain dilutions ranging from 106 to 102 copies amplified by real time 
PCR. These standard curves plotting each Ct value against the log quantity of each 
standard mRNA copy number were used to extrapolate absolute mRNA copy numbers of 
inflammatory mediator gene expressions in brain samples. Each dot plot on the standard 
curve linear dynamic range represents gene expression value (copy number) of each 
standard, while each point in the graph represents gene expression value (copy number) of 
each sample.                                                                                                                                    417 
 
Appendix 3 Melting curves of IFN γ (A), CXCL1 (B), CXCL10 (C), VEGF (D) confirm 
specificity of PCR amplification                                                                                                                                   418 
 